

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22638 A1

(51) International Patent Classification⁷: C07H 21/04,
21/02, C07K 5/00, 14/00, C12Q 1/68, C12N 1/21, 15/63,
15/85, 15/86

(21) International Application Number: PCT/US01/01386

(22) International Filing Date: 17 January 2001 (17.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/232,104 12 September 2000 (12.09.2000) US

(71) Applicant (for all designated States except US): HUMAN
GENOME SCIENCES, INC. [US/US]; 9410 Key West
Avenue, Rockville, MA 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROSEN, Craig,
A. [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD
20882 (US). KOMATSOUKIS, George, A. [US/US];
9518 Garwood Steet, Silver Spring, MD 20901 (US).
BAKER, Kevin, P. [GB/US]; 14006 Indian Run Drive,
Darnestown, MD 20878 (US). BIRSE, Charles, E.
[GB/US]; 13822 Saddlevue Drive, North Potomac,
MD 20878 (US). SOPPET, Daniel, R. [US/US]; 15050
Stillfield Place, Centreville, VA 22020 (US). OLSEN,
Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithers-
burg, MD 20878 (US). MOORE, Paul, A. [GB/US];
19005 Leatherbark Drive, Germantown, MD 20874 (US).
WEI, Ping [CN/US]; 19100 Baltimore Raod, Brookeville,
MD 20833 (US). EBNER, Reinhard [DE/US]; 9906

Shelburne Terrace #316, Gaithersburg, MD 20878 (US).
DUAN, D., Roxanne [US/US]; 5515 Northfield Road,
Bethesda, MD 20817 (US). SHI, Yanggu [CN/US]; 437
West Side Drive, Apartment 102, Gaithersburg, MD 20878
(US). CHOI, Gil, H. [KR/US]; 11429 Potomac Oaks
Drive, Rockville, MD 20850 (US). FISCELLA, Michele
[IT/US]; 6308 Redwing Road, Bethesda, MD 20817 (US).
NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD
20853 (US).

(74) Agents: HOOVER, Kenley, K. et al.; Human Genome
Science, Inc., 9410 Key West Avenue, Rockville, MD
20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/22638 A1

(54) Title: 22 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

22 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides, polypeptides
5 encoded by these polynucleotides, antibodies that bind these polypeptides, uses of
such polynucleotides, polypeptides, and antibodies, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a
10 membrane, human cells and other eucaryotes are subdivided by membranes into many
functionally distinct compartments. Each membrane-bounded compartment, or
organelle, contains different proteins essential for the function of the organelle. The
cell uses "sorting signals," which are amino acid motifs located within the protein, to
target proteins to particular cellular organelles.

15 One type of sorting signal, called a signal sequence, a signal peptide, or a
leader sequence, directs a class of proteins to an organelle called the endoplasmic
reticulum (ER). The ER separates the membrane-bounded proteins from all other
types of proteins. Once localized to the ER, both groups of proteins can be further
directed to another organelle called the Golgi apparatus. Here, the Golgi distributes
20 the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes,
and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the
extracellular space as a secreted protein. For example, vesicles containing secreted
proteins can fuse with the cell membrane and release their contents into the
25 extracellular space - a process called exocytosis. Exocytosis can occur constitutively
or after receipt of a triggering signal. In the latter case, the proteins are stored in
secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly,
proteins residing on the cell membrane can also be secreted into the extracellular
space by proteolytic cleavage of a "linker" holding the protein to the membrane.

30 Despite the great progress made in recent years, only a small number of genes
encoding human secreted proteins have been identified. These secreted proteins

include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA

preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig

analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard,
5 Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to
10 sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon
15 sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower
20 percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE,
25 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress
30 background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking

reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA⁺ sequences (such as any 3' terminal polyA⁺ tract of a cDNA shown in the sequence listing), or to a
5 complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any
10 polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA
15 that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for
20 example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide
25 isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications
30 can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in

a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or
5 may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of
10 covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
15 (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)
20 "SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.
"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the
25 present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not
30 more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Polynucleotides and Polypeptides of the Invention**FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

5 The translation product of this gene shares sequence homology with human
alpha-1-B-glycoprotein (see, e.g. Genbank accession No. P04217; all references
available through this accession are hereby incorporated in their entirety by reference
herein) which is thought to be important in immune modulation. "Amino acid
sequence of human plasma alpha 1B-glycoprotein: homology to the immunoglobulin
10 supergene family". Proc. Natl. Acad. Sci. U.S.A. 83 (8), 2363-2367 (1986) This
protein contains 5 immunoglobulin-like V-type domains.

 This gene is expressed primarily in human liver and to a lesser extent in lung,
brain and colon.

 Polynucleotides and polypeptides of the invention are useful as reagents for
15 differential identification of the tissue(s) or cell type(s) present in a biological sample
and for diagnosis of diseases and conditions which include but are not limited to liver
diseases. Similarly, polypeptides and antibodies directed to these polypeptides are
useful in providing immunological probes for differential identification of the
tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,
20 particularly of the hepatic system, expression of this gene at significantly higher or
lower levels may be routinely detected in certain tissues or cell types (e.g., liver,
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, bile,
lymph, synovial fluid and spinal fluid) or another tissue or sample taken from an
individual having such a disorder, relative to the standard gene expression level, i.e.,
25 the expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

 Preferred polypeptides of the present invention comprise, or alternatively
consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 61 as
residues: Gly-85 to Gly-96, Pro-162 to Val-168, Pro-177 to Gly-188, Arg-254 to Asp-
30 260, Leu-283 to Asp-293, Glu-310 to Gly-318, Arg-338 to Arg-345, Ala-387 to Leu-
392, Gly-398 to Gln-404, His-464 to Trp-475. Polynucleotides encoding said
polypeptides are also encompassed by the invention.

The tissue distribution almost exclusively in liver and homology to alpha-1-B-glycoprotein indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1684 of SEQ ID NO:11, b is an integer of 15 to 1698, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The translation product of this gene shares homology with the murine G1RP (see, e.g., Genbank Accession No. gb|AAF05310.1|AF171875_1 (AF171875); all references available through this accession are hereby incorporated in their entirety by reference herein). Northern blot analysis using RNAs derived from 32Dcl3 cells that have been grown in the absence of IL-3 demonstrated that the murine G1RP message

is upregulated in these cells following the removal of IL-3, suggesting that this gene may regulate growth factor withdrawal-induced apoptosis of myeloid precursor cells (see, e.g., Baker and Reddy Gene 248:33-40 (2000), hereby incorporated in its entirety by reference herein). Based on the sequence similarity, the translation product
5 of this gene is expected to share at least some biological activities with the murine G1RP.

Moreover, the polypeptide encoded by this gene has been determined to have transmembrane domains at about amino acid position 195 to about 211 and at about 388 to about 404 of the amino acid sequence referenced in Table 1 for this gene.
10 Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

This gene is expressed primarily in immune, reproductive and developing tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for
15 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the immune or reproductive system, or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell
20 type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or reproductive system(s) or developing fetus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, fetal, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, amniotic fluid, synovial fluid and spinal
25 fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 62 as
30 residues: Ala-27 to Glu-33, Asp-57 to Glu-69, Asn-134 to Thr-143, Met-185 to Arg-192, Ile-221 to Leu-234, Thr-249 to Asp-260, Ser-270 to Asp-275, Pro-366 to Gly-

376. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates and homology to G1RP that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the tissue distribution in reproductive and developing tissues and homology to murine G1RP indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the treatment, prevention, detection, and/or diagnosis of disorders of reproductive system organs, including cancers, disorders affecting fertility, and/or developmental disorders. Specifically, expression in prostate indicates that polynucleotides and/or polypeptides of the invention would

be useful for diagnosis, treatment and/or prevention of the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. Likewise, expression in breast tissue indicates that polynucleotides and/or polypeptides of the invention would be useful for diagnosis, treatment and/or prevention of breast neoplasia and breast cancers, such as fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. Similarly, expression in ovarian tissue, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and diagnosis of conditions concerning proper ovarian function (e.g., egg maturation, endocrine function), as well as cancer. The expression in ovarian tissue may indicate the gene or its products can be used to treat, prevent, detect and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis (e.g., caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, Ovarian Krukenberg tumor).

Furthermore, expression in testicular tissue indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, polynucleotides and/or polypeptides of the invention would be useful in the treatment of male infertility and/or impotence. Polynucleotides and/or polypeptides of the invention would be also useful in assays designed to identify binding agents, as such agents (antagonists) would be useful as male contraceptive agents. Similarly, polynucleotides and/or polypeptides of the invention are believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene

expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that polypeptides and/or polynucleotides corresponding to this gene may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1475 of SEQ ID NO:12, b is an integer of 15 to 1489, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

The translation product of this gene shares sequence homology with a family of secreted cyteine rich proteins including a Drosophila protein called sprouty which acts as a FGF antagonist (see, e.g., GeneSeq Accession No. W48794; all references available through this accession are hereby incorporated in their entirety by reference herein). The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 1 to about 23 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 24 to about 159 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

This gene is expressed primarily in testes and epididymus.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: male reproductive disorders, vascular disorders, and wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system, the vascular and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell
5 types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, semen, lymph, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 63 as residues: Gly-25 to Leu-30, Pro-40 to Ser-49, Pro-74 to Ser-91, Asn-97 to Cys-104, Pro-115 to Phe-123, Ser-125 to Ser-132. Polynucleotides encoding said polypeptides are also encompassed by the invention.

15 The tissue distribution in testes and homology to an fibroblast growth factor antagonist indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment of testicular cancer, male sterility, impotence and potentially in the regulation of testoserone production and the induction and maintenance of male characteristics; in addition there is potential for this molecule in
20 would healing, anti-angiogenesis and tumor treatment, angiogenesis and the treatment of cardiac arrest, stroke and other vascular disorders. In addition, expression in testicular tissue indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm
25 maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) would be useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene
30 expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as

hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 965 of SEQ ID NO:13, b is an integer of 15 to 979, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

20 FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The gene encoding the disclosed cDNA is believed to reside on chromosome 22, specifically at interval D22S420-D22S1144. Accordingly, polynucleotides related to this invention would be useful as a marker in linkage analysis for chromosome 22.

Moreover, the polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 26 to about 42 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 1 to about 25 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in monocytes and dendritic cells and to a lesser extent in other immune cell types.

Polynucleotides and polypeptides of the invention would be useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders. Similarly, polypeptides and antibodies directed to these

5 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, dendritic, cancerous and wounded tissues) or bodily fluids (e.g.,

10 lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively

15 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 64 as residues: Gly-100 to Pro-105, Pro-111 to Lys-116. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention

20 and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including

25 blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma,

30 immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity;

immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and

5 tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the predicted

10 membrane localization indicates that polynucleotides and/or polypeptides corresponding to this gene would be a good target for antagonists, particularly small molecules or antibodies, which block functional activity (such as, for example, binding of the receptor by its cognate ligand(s); transport function; signalling function). Accordingly, preferred are antibodies and or small molecules which

15 specifically bind an extracellular portion of the translation product of this gene. The extracellular regions can be ascertained from the information regarding the transmembrane domains as set out above. Also provided is a kit for detecting immune disorders such as cancer. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also

20 provided is a method of detecting immune disorders, including but not limited to, cancer, in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is

25 serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

30 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1079 of SEQ ID NO:14, b is an integer of 15 to 1093, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in brain and during early development.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: developmental disorders and neurological diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., nervous, neural, neuronal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 65 as residues: Ser-53 to Thr-59, Lys-65 to Glu-70, Pro-80 to Gly-91, Ser-94 to Pro-100, Ala-116 to Asn-124, Pro-135 to Trp-151, Asn-172 to Phe-189, Asn-191 to Trp-196,

Pro-201 to Trp-223, Gly-234 to Gly-245, Thr-251 to Asn-260, Arg-340 to Lys-357, Gly-428 to Tyr-454, Phe-458 to Tyr-464. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and/or polypeptides
5 corresponding to this gene would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,
10 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, toxic neuropathies induced by neurotoxins, peripheral neuropathies, multiple sclerosis, neoplasia of neuroectodermal origin, ischemia and infarction,
15 aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.
20 Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,
25 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2628 of SEQ ID NO:15, b is an integer of 15 to 2642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene is expressed primarily in the salivary gland and in the palate.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: digestive and salivary gland disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., digestive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, saliva, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 66 as residues: Pro-28 to Asp-41, Thr-107 to Tyr-114, Glu-158 to Pro-164. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of digestive disorders and salivary gland disorders including salivary gland carcinoma, dental caries, oral candidiasis, Sjorgens syndrome and xerostomia. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 681 of SEQ ID NO:16, b is an integer of 15 to 695, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

This gene is expressed primarily in fetal spleen and immune cell populations and to a lesser extent in testes.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders and male reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the

expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 67 as
5 residues: Met-1 to Ala-11, Leu-20 to Gly-26, Leu-51 to Ser-61, Phe-82 to Leu-87, Gln-94 to Pro-99. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention
10 and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including
15 blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma,
20 immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility,
25 lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the
30 expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

In addition, expression in testicular tissue indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer, male sterility, impotence and potentially in the regulation of testosterone production and the induction and maintenance of male characteristics. Therefore, polynucleotides and/or polypeptides of the invention would be useful in the treatment of male infertility and/or impotence. Polynucleotides and/or polypeptides of the invention would also be useful in assays designed to identify binding agents, as such agents (antagonists) would be useful as male contraceptive agents. Similarly, polynucleotides and/or polypeptides of the invention are believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2507 of SEQ ID NO:17, b is an integer of 15 to 2521, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

The translation product of this gene shares sequence homology with
5 polyadenylate binding proteins of several organisms (see, e.g., Genbank Accession
No. gb|AAB88449.1| (AF032896) and/or emb|CAA88401.1|; all references available
through these accessions are hereby incorporated in their entirety by reference herein)
and may represent a fragment of a novel protein with similar function.

In specific embodiments, polypeptides of the invention comprise, or
10 alternatively consist of, the following amino acid sequence:
PGSTHANXGRVGPXVHIPGQEPLTASMLAAAPLHEQKQMIGTCYLVLKRW
DWMVLSFLPLLLSCDFEGSVSTPLSMMSTPSWLARSRACCWRLTTXSCCSCW
SLQNPSMPR (SEQ ID NO: 111). Moreover, fragments and variants of these
polypeptides (such as, for example, fragments as described herein, polypeptides at
15 least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these
polypeptides, or polypeptides encoded by a polynucleotide which hybridizes, under
stringent conditions, to the polynucleotide encoding these polypeptides) are
encompassed by the invention. Antibodies that bind polypeptides of the invention and
polynucleotides encoding these polypeptides are also encompassed by the invention.

20 This gene is expressed primarily in kidney and to a lesser extent in the
developing embryo.

Polynucleotides and polypeptides of the invention are useful as reagents for
differential identification of the tissue(s) or cell type(s) present in a biological sample
and for diagnosis of diseases and conditions which include but are not limited to:
25 renal disorders and/or developmental disorders. Similarly, polypeptides and
antibodies directed to these polypeptides are useful in providing immunological
probes for differential identification of the tissue(s) or cell type(s). For a number of
disorders of the above tissues or cells, particularly of the developing fetus, and/or
renal system, expression of this gene at significantly higher or lower levels may be
30 routinely detected in certain tissues or cell types (e.g., fetal, renal, reproductive,
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph,
amniotic fluid, synovial fluid and spinal fluid) or another tissue or sample taken from

an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively
5 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 68 as residues: His-8 to Met-13. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in kidney indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful in the treatment, prevention,
10 diagnosis and/or detection of kidney diseases including renal failure, nephritis, renal colic, renal diabetes, renal hypertension, renal osteodystrophy, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe
15 kidney, polycystic kidney, and Falconi's syndrome. Moreover, the expression within embryonic tissue and homology to polyadenylate binding proteins indicates that polypeptides and/or polynucleotides corresponding to this gene may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other
20 proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure
25 to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type
30 specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein

may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1262 of SEQ ID NO:18, b is an integer of 15 to 1276, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

The translation product of this gene shares sequence homology with DOCK180 protein (see, e.g., Genbank Accession No. dbj|BAA09454.1|, all references available through this accession are hereby incorporated in their entirety by reference herein), a new effector molecule which transduces signals from tyrosine kinases through the CRK adaptor protein, which is thought to be important in detection and/or treatment of tumors.

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

IHHPIPSALLEVMLTAVKMFRLSAVTLCAFSLLHSGVQLCEQLVLRALFQN
CRAEDGFGLRVCWRRLMRSFCRSAKFWGSNDLRTWGSRFLWKDCT (SEQ
ID NO: 112). Moreover, fragments and variants of these polypeptides (such as, for
example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%,
5 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides
encoded by a polynucleotide which hybridizes, under stringent conditions, to the
polynucleotide encoding these polypeptides) are encompassed by the invention.
Antibodies that bind polypeptides of the invention and polynucleotides encoding
these polypeptides are also encompassed by the invention.

10 This gene is expressed primarily in colon and to a lesser extent in chronic
lymphocytic leukemia.

Polynucleotides and polypeptides of the invention are useful as reagents for
differential identification of the tissue(s) or cell type(s) present in a biological sample
and for diagnosis of a variety of diseases and conditions which include but are not
15 limited to: disorders of the digestive system, particularly diseases of the colon,
including but not limited to, cancer; and/or disorders of the immune system. Similarly,
polypeptides and antibodies directed to these polypeptides are useful in providing
immunological probes for differential identification of the tissue(s) or cell type(s). For
a number of disorders of the above tissues or cells, particularly of the digestive tract
20 and immune system expression of this gene at significantly higher or lower levels
may be routinely detected in certain tissues or cell types (e.g., digestive, immune,
cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,
synovial fluid and spinal fluid) or another tissue or sample taken from an individual
having such a disorder, relative to the standard gene expression level, i.e., the
25 expression level in healthy tissue or bodily fluid from an individual not having the
disorder.

Preferred polypeptides of the present invention comprise, or alternatively
consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 69 as
residues: Asn-71 to Trp-76. Polynucleotides encoding said polypeptides are also
30 encompassed by the invention.

The tissue distribution in colon and immune tissues and homology to
DOCK180 indicates that polynucleotides and polypeptides corresponding to this gene

would be useful for diagnosis, detection, prevention and/or treatment of a variety of conditions including cancer. The tissue distribution in colon indicates that polynucleotides and polypeptides corresponding to this gene would be useful for diagnosis, treatment, prevention and/or detection of tumors, especially of the intestine, such as, carcinoid tumors, lymphomas, non-neoplastic polyps, adenomas, familial syndromes, colorectal carcinogenesis, colorectal carcinoma, cancer of the colon, cancer of the rectum and carcinoid tumors, as well as cancers in other tissues where expression has been indicated. The expression in the colon tissue may indicate the gene or its products can be used to treat, detect, prevent and/or diagnose disorders of the colon, including inflammatory disorders such as, congenital abnormalities, such as atresia and stenosis, Meckel diverticulum, congenital aganglionic megacolon-Hirschsprung disease; enterocolitis, such as diarrhea and dysentery, infectious enterocolitis, including viral gastroenteritis, bacterial enterocolitis, necrotizing enterocolitis, antibiotic-associated colitis (pseudomembranous colitis), and collagenous and lymphocytic colitis, miscellaneous intestinal inflammatory disorders, including parasites and protozoa, amoebic colitis, acquired immunodeficiency syndrome, transplantation, drug-induced intestinal injury, radiation enterocolitis, neutropenic colitis, diverticular colon disease (DCD), inflammatory colonic disease, idiopathic inflammatory bowel disease, such as Crohn's disease (CD), non-inflammatory bowel disease (non-IBD) colonic inflammation; ulcerative disorders such as, ulcerative colitis (UC); eosinophilic colitis; noncancerous tumors, such as, polyps in the colon, adenomas, leiomyomas, lipomas, and angiomas.

Similarly, the tissue distribution in B cells indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the

natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1201 of SEQ ID NO:19, b is an integer of 15 to 1215, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 12 to about 28 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail
5 encompassing about amino acids 29 to about 122 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

This gene is expressed primarily in immune system.

Polynucleotides and polypeptides of the invention are useful as reagents for
10 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above
15 immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in
20 healthy tissue or bodily fluid from an individual not having the disorder.

Expression of this gene primarily in immune cells suggests a role for the encoded protein in the treatment, prevention, diagnosis and/or detection of immune disorders including autoimmune disease, asthma, and cancer. Moreover, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this
25 gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or
30 activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune

responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1615 of SEQ ID NO:20, b is an integer of 15 to 1629, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 38 to about 54 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail
5 encompassing about amino acids 55 to about 184 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

This gene is expressed specifically expressed in normal and diseased pancreas.

Polynucleotides and polypeptides of the invention are useful as reagents for
10 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to digestive diseases, particularly, disorders of the pancreas. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of
15 disorders of the above tissues or cells, particularly of the pancreas, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., digestive, cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the
20 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 71 as residues: Arg-128 to Tyr-134. Polynucleotides encoding said polypeptides are also
25 encompassed by the invention.

The tissue distribution in pancreas indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention and/or diagnosis of disorders of the pancreas, including inflammatory disorders, such as chronic or acute pancreatitis; diabetes mellitus; pancreatic cancer. Furthermore, the
30 protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1001 of SEQ ID NO:21, b is an integer of 15 to 1015, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 12

This gene is expressed primarily in brain and to a lesser extent in liver and immune cell types.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neurological and/or immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, nervous and hepatic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neural, neuronal, nervous, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 72 as residues: Gly-4 to Glu-9, Asp-22 to Cys-28, Glu-39 to Leu-44, Phe-88 to Phe-94. Polynucleotides encoding said polypeptides are also encompassed by the invention.

5 The tissue distribution in brain indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,
10 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, toxic neuropathies induced by neurotoxins, peripheral neuropathies,
15 multiple sclerosis, neoplasia of neuroectodermal origin, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene
20 product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. In addition, the tissue distribution in immune tissues indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection,
25 prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including
30 blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the

natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1226 of SEQ ID NO:22, b is an integer of 15 to 1240, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 75 to about 91 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 1 to about 74 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in immune cell types.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 73 as residues: Ser-34 to Ile-39. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including

blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be

5 also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and

10 graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to

15 sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

20 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

25 related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

30 general formula of a-b, where a is any integer between 1 to 555 of SEQ ID NO:23, b is an integer of 15 to 569, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

5

The translation product of this gene shares sequence homology with dishevelled gene products which are involved in signal transduction during development. The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention would be

10 useful as a marker in linkage analysis for chromosome 17.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

RPESYLVNLSLNDNDGSSGASDQDTLAPLPGATPWPLLPTFSYQYPAPHPYSP
QPPPYHELSSYTYGGGSASSQHSEGSRSSGSTRSDGGAGRTGRPEERAPESKS

15 GSGSESEPSSRGGSLRRGGEASGTSDGGPPPSRGSTGGAPNLRHPGLHPYGP
PPGMALPYNPMMVMMPPPPPPVPPAVQPPGAPPVRDLGSVPPELTASRQSF
HGHGQSQRVLCGCYVAHCGARLGRALLVCDWVSWPSCACSYSAWAQPTSC
CHTGDCGHCDSHQQCLVPPPSLRGRQGTFDYF (SEQ ID NO: 113). Moreover,

fragments and variants of these polypeptides (such as, for example, fragments as
20 described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% identical to these polypeptides and polypeptides encoded by the polynucleotide
which hybridizes, under stringent conditions, to the polynucleotide encoding these
polypeptides, or the complement thereof are encompassed by the invention.

Antibodies that bind polypeptides of the invention are also encompassed by the
25 invention. Polynucleotides encoding these polypeptides are also encompassed by the
invention.

This gene is expressed primarily in reproductive tissues, such as placenta and to a lesser extent in the brain.

Polynucleotides and polypeptides of the invention are useful as reagents for
30 differential identification of the tissue(s) or cell type(s) present in a biological sample
and for diagnosis of diseases and conditions which include but are not limited to:
reproductive and/or immune system(s) disorders, and/or neurological disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous systems and/or the reproductive system, expression of this gene at

5 significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, nervous, neural, neuronal, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, vaginal pool, amniotic fluid, lymph, semen, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

10 the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 74 as residues: Pro-39 to Leu-44, Gln-80 to Pro-93, Pro-153 to Pro-158. Polynucleotides

15 encoding said polypeptides are also encompassed by the invention.

The tissue distribution in reproductive and developing tissues indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the treatment, prevention, detection, and/or diagnosis of disorders of reproductive system organs, including cancers, disorders affecting fertility, and/or developmental

20 disorders. Specifically, expression in prostate indicates that polynucleotides and/or polypeptides of the invention would be useful for diagnosis, treatment and/or prevention of the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell

25 carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. Likewise, expression in breast tissue indicates that polynucleotides and/or polypeptides of the invention would be useful for diagnosis, treatment and/or prevention of breast neoplasia and breast cancers, such as fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's disease, medullary

30 carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases.

Similarly, expression in ovarian tissue, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and diagnosis of conditions concerning proper ovarian function (e.g., egg maturation, endocrine function), as well as cancer.

5 The expression in ovarian tissue may indicate the gene or its products can be used to treat, prevent, detect and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis (e.g., caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, endometrioid
10 carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, Ovarian Krukenberg tumor). Furthermore, expression in testicular tissue indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm
15 maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) would be useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene
20 expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

25 In addition, the tissue distribution in nervous system tissues and homology to the dishevelled family of signaling proteins indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the
30 "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,

Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, toxic neuropathies induced by neurotoxins, peripheral neuropathies, multiple sclerosis, neoplasia of neuroectodermal origin, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1240 of SEQ ID NO:24, b is an integer of 15 to 1254, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The translation product of this gene shares sequence homology with type-2 phosphatidic acid phosphatase-gamma (see, e.g., Genbank Accession Nos.

gb|AAC15968.1| (AF035959) and gb|AAD24061.1|AF123611_1; all references available through these accession are hereby incorporated in their entirety by reference herein).

In specific embodiments, polypeptides of the invention comprise, or
 5 alternatively consist of, an amino acid sequence selected from the group:
 YAVTYTAMYVTLVFRVKGSRLLVKPSLCLALLCPAFLVGVRVAEYRNHWSD
 VLAGFLTGAALATFLVTCVVH (SEQ ID NO: 114);
 AALCAYAVTYTAMYVTLVFRVKGSRLLVKPSLCLALLCPAFLVGVRVAEYR
 NHWSDVLAGFLTGAALATFLVTCVVHNFQXR (SEQ ID NO: 115) and/or
 10 AALCAYAVTYTAMYVTLVFRVKGSRLLVKPSLCLALLCPAFLVGVRVAEYR
 NHWSDVLAGFLTGAALATFLVTCVVHNFQXRPPSGRXLSPQSAYPRLPGPXF
 PHLHNGGDHPCPAGCRXGCESSAWMQPGGSHRAAFTGLALPWAGGRPHPKR
 (SEQ ID NO: 116). Moreover, fragments and variants of these polypeptides (such as,
 for example, fragments as described herein, polypeptides at least 80%, 85%, 90%,
 15 95%, 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides
 encoded by a polynucleotide which hybridizes, under stringent conditions, to the
 polynucleotide encoding these polypeptides) are encompassed by the invention.
 Antibodies that bind polypeptides of the invention and polynucleotides encoding
 these polypeptides are also encompassed by the invention.

20 Contact of human T cells with supernatant expressing the product of this gene
 was shown to increase the expression of a the surface molecule, CD152. Thus it is
 likely that the product of this gene is involved in the activation of T cells, in addition
 to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides related
 to this gene have uses which include, but are not limited to, activating immune cells,
 25 such as during an inflammatory response.

This gene is expressed primarily in brain and to a lesser extent in reproductive
 and immune tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for
 differential identification of the tissue(s) or cell type(s) present in a biological sample
 30 and for diagnosis of diseases and conditions which include but are not limited to:
 neurological disorders, immune system disorders, and disorders of the reproductive
 system. Similarly, polypeptides and antibodies directed to these polypeptides are

useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, reproductive system, and immune system, expression of this gene at significantly higher or lower levels may be routinely
5 detected in certain tissues or cell types (e.g., nervous, neural, neuronal, immune, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the
10 disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 75 as residues: Glu-37 to Trp-42, Phe-67 to Gly-88, Pro-101 to Leu-110. Polynucleotides encoding said polypeptides are also encompassed by the invention.

15 The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the detection, diagnosis, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,
20 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, toxic neuropathies induced by neurotoxins, peripheral neuropathies,
25 multiple sclerosis, neoplasia of neuroectodermal origin, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene
30 product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

Similarly, the tissue distribution in immune tissues indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere

5 Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the

10 treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis,

15 acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis,

20 Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell

25 types. Moreover, the tissue distribution in reproductive and developing tissues indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the treatment, prevention, detection, and/or diagnosis of disorders of reproductive system organs, including cancers, disorders affecting fertility, and/or developmental disorders. Specifically, expression in prostate indicates that

30 polynucleotides and/or polypeptides of the invention would be useful for diagnosis, treatment and/or prevention of the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia,

prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. Likewise, expression in breast tissue indicates that polynucleotides and/or polypeptides of the invention would be useful for diagnosis, treatment and/or prevention of breast neoplasia and breast cancers, such as fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases.

Similarly, expression in ovarian tissue, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and diagnosis of conditions concerning proper ovarian function (e.g., egg maturation, endocrine function), as well as cancer. The expression in ovarian tissue may indicate the gene or its products can be used to treat, prevent, detect and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis (e.g., caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, Ovarian Krukenberg tumor).

Furthermore, expression in testicular tissue indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) would be useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used

to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets
 5 for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
 10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1970 of SEQ ID NO:25, b is an integer of 15 to 1984, where both a and b correspond to the positions of
 15 nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

20 The translation product of this gene shares sequence homology with a portion of renal specific transporter proteins from several different species (see, e.g., Genbank Accession Nos. dbj|BAA23875.1| (AB005451) and gb|AAC70004.1| (AF057039); all references available through these accession numbers are hereby incorporated in their entirety by reference herein) which are thought to be involved in the cellular transport
 25 of anionic and cationic compounds (see, e.g., Mori, et al., FEBS Lett. 417:371-374 (1997), hereby incorporated in its entirety by reference herein).

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence selected from the group:
 MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCWTH
 30 MLDNGSAVSTNMTPKALLTISIPPGPNQGPHQCRRFRQPQWQLLDPNATATS
 WSEADTEPCVDGWVYD (SEQ ID NO: 117) and
 MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCWTH

MLDNGSAVSTNMTPKALLTISIPPGPNQGPHQCRRFRQPQWQLLDPNATATS
WSEADTEPCVDGWVYXRRSSPPPSWPSGTWCAAPRLEXP (SEQ ID NO:).

Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,
5 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides encoded by a polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention and polynucleotides encoding these polypeptides are also encompassed by the invention.

10 The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 21 to about 37 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 1 to about 20 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of
15 this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in placenta.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to
20 developmental disorders and reproductive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of developing or proliferating tissues, expression of this gene at significantly higher or lower levels may be
25 routinely detected in certain tissues or cell types (e.g., fetal, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 76 as

residues: Pro-45 to Trp-50, Pro-76 to Trp-93. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in placenta and homology to a transporter protein indicates that polynucleotides and/or polypeptides corresponding to this gene would
5 be useful for the treatment, prevention, detection, and/or diagnosis of disorders of reproductive system organs, including cancers, disorders affecting fertility, developmental disorders, placenta abruptio, placenta previa, placental failure, and placental insufficiency.

In addition, the specific expression in placental tissue and predicted membrane
10 localization indicates that polynucleotides and/or polypeptides corresponding to this gene would be a good target for antagonists, particularly small molecules or antibodies, which block functional activity (e.g., transport function). Accordingly, preferred are antibodies and or small molecules which specifically bind an extracellular portion of the translation product of this gene. The extracellular regions
15 can be ascertained from the information regarding the transmembrane domains as set out above. Also provided is a kit for detecting developmental disorders or cancer. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting developmental disorders or cancer in an individual which comprises a step of
20 contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described
25 elsewhere herein.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically
30 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 2086 of SEQ ID NO:26, b is an integer of 15 to 2100, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

10 MRQEVHGCFAQMDRSLALPKIRARVLLQQFQTAWREAQEFVKLDQAVAAPEL
 QQQSKVRKSRSSKSKGELLKKCIEDKIHLCQEQASEDLVEKVRGELLRERVQ
 RMEAQEGGFAQSLVALQFQKASRVTTLSAYTALLSIQDLLLLLEELSASEMLTK
 SACTQILESHSRELQELERKLEDQLVQQEAAQQQQALASWQQWVADGPGIL
 NEPGEVDSESRQVSTVLHQALSKSQTLLEQHQQLREEQQNSVVLEDLLENME
 15 ADTFATLCSQELRLASYLARMAMVPGATLRRLSVVLPTASQPQLLALLDSA
 TERHVDHAAESDGGAEQADVGRRRKHQSWWQALDGKLRGDLISRGLEKML
 WARKRKQSILKKTCLPLRERMIFSGKGSWPHLSLEPIGELXPVPIVGAETIDLL
 NTGEKLFIFRNPKEPEISLHVPPRKKKNFLNAKKAMRAXGMD (SEQ ID NO:
 118) and
 20 MAMVPGATLRRLSVVLPTASQPQLLALLDSATERHVDHAAESDGGAEQAD
 VGRR
 RKHQSWWQALDGKLRGDLISRGLEKMLWARKRKQSILKKTCLPLRERMIFS
 GKGSWPHLSLEPIGELXPVPIVGAETIDLLNTGEKLFIFRNPKEPEISLHVPPR
 KKNFLNAKKAMRAXGMD (SEQ ID NO:). Moreover, fragments and variants of
 25 these polypeptides (such as, for example, fragments as described herein, polypeptides
 at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these
 polypeptides, or polypeptides encoded by a polynucleotide which hybridizes, under
 stringent conditions, to the polynucleotide encoding these polypeptides) are
 encompassed by the invention. Antibodies that bind polypeptides of the invention and
 30 polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in immune and reproductive tissues and to a lesser extent in epithelial cells and connective tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to immune or reproductive system disorders. Similarly, polypeptides and antibodies
5 directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or reproductive system(s), expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, reproductive, cancerous and
10 wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively
15 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 77 as residues: Val-52 to Trp-61, Leu-65 to Gly-71, Lys-86 to Leu-92. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention
20 and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including
25 blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma,
30 immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity;

immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and
5 tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

10 Moreover, the tissue distribution in reproductive tissues indicates that polynucleotides and/or polypeptides corresponding to this gene would be useful for the treatment, prevention, detection, and/or diagnosis of disorders of reproductive system organs, including cancers, disorders affecting fertility, and/or developmental disorders. Specifically, expression in prostate indicates that polynucleotides and/or
15 polypeptides of the invention would be useful for diagnosis, treatment and/or prevention of the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors
20 with systemic or reproductive functions. Likewise, expression in breast tissue indicates that polynucleotides and/or polypeptides of the invention would be useful for diagnosis, treatment and/or prevention of breast neoplasia and breast cancers, such as fibroadenoma, pipillary carcinoma, ductal carcinoma, Paget's disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and
25 apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. Furthermore, expression in testicular tissue indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm
30 maturation), as well as cancer. Therefore, polynucleotides and/or polypeptides of the invention would be useful in the treatment of male infertility and/or impotence. Polynucleotides and/or polypeptides of the invention would be also useful in assays

designed to identify binding agents, as such agents (antagonists) would be useful as male contraceptive agents. Similarly, polynucleotides and/or polypeptides of the invention are believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1122 of SEQ ID NO:27, b is an integer of 15 to 1136, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

25

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The translation product of this gene shares sequence homology with human heat shock protein hsp40 and homologs thereof (see, e.g., Genbank accession Nos. gb|AAB07346.1| and gb|AAC14483.2|; all references available through these accessions are hereby incorporated in their entirety by reference herein) which are

30

thought to be important in maintaining the structure and activity of labile proteins through direct interactions.

The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 36 to about 52 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 1 to about 35 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome 12, specifically at interval D12S325-D12S1691. Accordingly, polynucleotides related to this invention would be useful as a marker in linkage analysis for chromosome 12.

The polynucleotide of this clone encodes a 412aa protein with at least one transmembrane domain at the 5'. It shows strong homology to a fragment of the Bovine viral diarrhea virus-2 viral nonstructural protein NS2-3 and to pestivirus type 1 viral nonstructural protein p125.

This gene is expressed primarily in immune/hematopoietic tissues and to a lesser extent in lung and ovarian cancers. The tissue distribution also shows some enrichment in digestive, reproductive, and immune/hematopoietic organs.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to immune disorders and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 78 as residues: Leu-66 to Lys-71, Arg-92 to Trp-97, Lys-115 to Gly-122, Pro-182 to Glu-192, Ala-207 to Glu-212, Asn-221 to Val-227, Leu-234 to Lys-239, Cys-250 to Arg-255, Asp-260 to Ala-266, Pro-336 to Pro-349, Ser-387 to Arg-412. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution and homology to human heat shock proteins hsp40 indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention, and/or treatment of conditions or disorders associated with heat shock protein expression. They are also useful as antagonists for prevention or treatment of cancer (e.g. lung cancer, ovarian cancer, adenocarcinoma, breast and skin cancers). They are also useful for drug screening using libraries of compounds.

In addition, the tissue distribution in immune tissues indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis,

Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2265 of SEQ ID NO:28, b is an integer of 15 to 2279, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The translation product of this gene shares sequence homology with mitochondrial transcription factor A (see, e.g., Genbank accession Nos. gb|AAC52815.1| and gb|AAA59849.1|; all references available through these accessions are hereby incorporated in their entirety by reference herein).

This gene is expressed primarily in ovarian cancer tissue.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to

cancer and disorders of the reproductive system, particularly diseases of the ovary (for example, ovarian cancer). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above

5 tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, ovarian, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, vaginal pool, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to

10 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 79 as residues: Thr-45 to Leu-54, Gln-71 to Asn-77, Glu-90 to Ile-98, Lys-111 to Thr-122,

15 Lys-131 to Lys-140, Gly-153 to Ala-161, Arg-169 to Ser-178, Thr-184 to Gln-198, Glu-214 to Glu-220, Thr-234 to Tyr-246. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in ovarian cancer tissue, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment,

20 prevention, detection and diagnosis of tumors, especially ovarian cancer, as well as cancers of other tissues where expression has been indicated.

The expression in ovarian cancer tissue may indicate that polynucleotides and/or polypeptides of the invention can be used to treat, prevent, detect and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis

25 (e.g., caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, Ovarian Krukenberg tumor). Furthermore, the protein may also be used to determine biological activity, to raise

30 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1579 of SEQ ID NO:29, b is an integer of 15 to 1593, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The gene encoding the disclosed cDNA is believed to reside on chromosome 13, specifically at interval D13S153-D13S163. Accordingly, polynucleotides related to this invention would be useful as a marker in linkage analysis for chromosome 13.

The polypeptide encoded by this gene has been determined to have a transmembrane domain at about amino acid position 55 to about 71 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing about amino acids 72 to about 490 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

The translated gene has homology to neurofilament protein NF-220 (gi|161292|gb|AAA29991.1).

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

30 MLKDFSNNLLVVLCDYVLGEAEYLLLRPGHVALSNDTVYVDFQYFDGANG
TLRNVSVLLLEANTNQTVTTKYLLTNQSQGTLKFECFYFKEAGDYWFTMTPE
ATDNSTPFPWWEKSAFLKVEWPVFHVDLNRSAKAAEGTFQVGLFTSQPLCPF

PVDKPNIVVDVIFTNSLPEARNSRQPLEIRTSKRTELAQGQWVEFGCAPLGPE
AYVTVVLKLLGRDSVITSTGPIDLAQKFGYKLVMPELTCESGVEVTVLPPPC
TFVQGVVTVFKEAPRYPGKRTHLAENSLPWERRGGQFLTVLCLTWGRISTALT
LAFQAEAIFLQRRSAC (SEQ ID NO: 119). Moreover, fragments and variants of
5 this polypeptide (such as, for example, fragments as described herein, polypeptides at
least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides
and polypeptides encoded by the polynucleotide which hybridize, under stringent
conditions, to the polynucleotide encoding this polypeptide are encompassed by the
invention. Antibodies that bind polypeptides of the invention are also encompassed by
10 the invention. Polynucleotides encoding this polypeptide are also encompassed by the
invention.

This gene is expressed primarily in lung and fetal tissues and to a less extent
in colon and pancreas tumors.

Polynucleotides and polypeptides of the invention are useful as reagents for
15 differential identification of the tissue(s) or cell type(s) present in a biological sample
and for diagnosis of diseases and conditions which include but are not limited to
developmental disorders and diseases or conditions associated with proliferating cells.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
20 type(s). For a number of disorders of the above tissues or cells, particularly of the
developing fetus, and proliferating tissues or cells, expression of this gene at
significantly higher or lower levels may be routinely detected in certain tissues or cell
types (e.g., fetal, cancerous and wounded tissues) or bodily fluids (e.g., amniotic
fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or
25 sample taken from an individual having such a disorder, relative to the standard gene
expression level, i.e., the expression level in healthy tissue or bodily fluid from an
individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively
consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 80 as
30 residues: Pro-35 to Ser-49, Thr-85 to Ile-92, Pro-95 to Glu-103, Ser-110 to Thr-130,
Val-142 to Gly-150, Glu-152 to Ala-158, Gln-173 to Leu-183, Gly-238 to Leu-245,
Gly-272 to His-282, Arg-298 to Met-308, Ala-318 to Gly-339, Ala-353 to Leu-360,

Pro-362 to Tyr-367, Pro-372 to Asp-380, Glu-390 to Ser-414, Ile-416 to Arg-424, Ser-429 to Gln-439, Gly-472 to Thr-480. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in lung and fetal tissues indicates that polynucleotides
5 and polypeptides corresponding to this gene would be useful for the diagnosis and treatment of lung diseases and developmental disorders. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that polypeptides and/or polynucleotides corresponding to this gene may play a role in the regulation of cellular division, and may show utility in the diagnosis,
10 treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in
15 inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the
20 treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention would be useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection,
25 treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise
30 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2652 of SEQ ID NO:30, b is an integer of 15 to 2666, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

15 FEATURES OF PROTEIN ENCODED BY GENE NO: 21

The translation product of this gene shares sequence homology with three isoforms of rat tomosyn (see, e.g., Genbank Accession Nos. gb|AAD27818.1|AF118889_1 (AF118889), gb|AAD27819.1|AF118890_1 (AF118890), and gb|AAD04756.1|; all references available through these accessions are hereby incorporated in their entirety by reference herein). Tomosyn is a neural tissue-specific syntaxin-1-binding protein which is capable of dissociating Munc18/n-Sec1/rbSec1 from syntaxin-1 to form a 10S tomosyn complex, an intermediate complex converted to the 7S SNARE complex.

The three isoforms (m-tomosyn, b-tomosyn, and s-tomosyn) bind to syntaxin-1, but not to syntaxin-2, -3, or -4, and have a region highly homologous to VAMP, another syntaxin-binding protein. This region is necessary but not sufficient for high-affinity binding of tomosyn to syntaxin-1. See, e.g., Yokoyama, et al., Biochem. Biophys. Res. Commun. 256 (1), 218-222 (1999), incorporated herein by reference.

Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with any one of the three isoforms of the tomosyn proteins.

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

MDWWFLAIA MALLWLTTSRKQCCSTWALLNYMALMILIGENPDLLVNLDL
QEPVCVILVKGLLFQRIAANLQPLQRCQGS (SEQ ID NO: 120) and

5 MVDYLQKAVLLNLGTIELYGSNDPYRREPRSPRKSQRQPSGAGLCDISEGTVVP
EDRCKSPTSAKMSRKLSLPTDLKPDLDVKDNSFSRSRSSSVTSIDKESREISA
LHFCETFTRKTDSSPCLWVGTTLTGTVLVIALNLPPGGEXLLQPVIVSPSGTI
LRLKGAILRMAFLDTTGCLIPPAYEPWREHNVPEEKDEKEKXKKRRPVSVSPS
SSQEISENQYAVICSEKQAKVISLPTQNCA YKQNTTETSFVLRGDIVALSNSICL
10 ACFCANGHIMTFSLPSLRPLLXVYYLPLTNMRXARTFCFTNNGQALYLVSPTE
IQRLTYSQETCENLQEMLGELFTPVETPEAPNRGFFKGLFGGGAQSLDREELF
GESSGKASRSLAQHIPGGGIEGVKGAASGVV GELARARLALDERGQKLGD
LEERTAAMLSSAESFSKHAHEIMLKYKDKK WYQF (SEQ ID NO: 121).

Moreover, fragments and variants of this polypeptide (such as, for example,
15 fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,
97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the
polynucleotide which hybridize, under stringent conditions, to the polynucleotide
encoding this polypeptide are encompassed by the invention. Antibodies that bind
polypeptides of the invention are also encompassed by the invention. Polynucleotides
20 encoding this polypeptide are also encompassed by the invention.

This gene is expressed primarily in immune tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for
differential identification of the tissue(s) or cell type(s) present in a biological sample
and for diagnosis of diseases and conditions which include but are not limited to
25 immune system disorders. Similarly, polypeptides and antibodies directed to these
polypeptides are useful in providing immunological probes for differential
identification of the tissue(s) or cell type(s). For a number of disorders of the above
tissues or cells, particularly of the immune system, expression of this gene at
significantly higher or lower levels may be routinely detected in certain tissues or cell
30 types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum,
plasma, urine, lymph, synovial fluid and spinal fluid) or another tissue or sample
taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 81 as
5 residues: Thr-17 to Cys-23, Gln-76 to Ser-81. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution in immune tissues and homology to the rat tomosyn protein indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety
10 of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in
15 the regulation of cytokine production, antigen presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such
20 as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus
25 erythematosus, drug induced hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of
30 various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify

agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2687 of SEQ ID NO:31, b is an integer of 15 to 2701, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

15

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

This gene is expressed primarily in B-cell leukemia and to a lesser extent in ovarian cancer.

20 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders and disorders of the reproductive system, including, but not limited to ovarian cancer. Similarly, polypeptides and antibodies directed to these
25 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune,
30 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, lymph, vaginal pool, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level,

i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 82 as
5 residues: Thr-35 to Gly-48. Polynucleotides encoding said polypeptides are also encompassed by the invention.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis, detection, prevention and/or treatment of a variety of immune system disorders. Representative uses are
10 described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen
15 presentation, or other processes indicates a usefulness in the treatment of cancer (e.g., by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis,
20 granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced
25 hemolytic anemia, Hodgkin's rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in
30 the differentiation and/or proliferation of various cell types. Similarly, the tissue distribution in ovarian cancer tissue, indicates that polynucleotides and polypeptides corresponding to this gene would be useful for the treatment, prevention, detection

and diagnosis of tumors, especially ovarian cancer, as well as cancers of other tissues where expression has been indicated. The expression in ovarian cancer tissue may indicate the gene or its products can be used to treat, prevent, detect and/or diagnose disorders of the ovary, including inflammatory disorders, such as oophoritis (e.g.,
5 caused by viral or bacterial infection), ovarian cysts, amenorrhea, infertility, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, Ovarian Krukenberg tumor). Furthermore, the protein may also be used to determine biological activity, raise
10 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention
20 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 514 of SEQ ID NO:32, b is an integer of 15 to 528, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HLDAB75	PTA-2076 06/09/00	pCMVSPor t 3.0	11	1698	1	1698	32	32	61	1	21	22	495
1	HLDAB75	PTA-2076 06/09/00	pCMVSPor t 3.0	33	1710	1	1710	37	37	83	1	21	22	495
2	HDPGT25	PTA-2076 06/09/00	pCMVSPor t 3.0	12	1489	1	1489	30	30	62	1	27	28	419
2	HDPGT25	PTA-2076 06/09/00	pCMVSPor t 3.0	34	1546	45	1509	57	57	84	1	27	28	419
3	HEEBI05	PTA-2076 06/09/00	Uni-ZAP XR	13	979	88	979	226	226	63	1	22	23	159
4	HLTIP27	PTA-2076 06/09/00	Uni-ZAP XR	14	1093	1	1093	148	148	64	1	40	41	122
4	HLTIP27	PTA-2076 06/09/00	Uni-ZAP XR	35	1604	493	1604	705	705	85	1	16	17	112
5	HAHFU44	PTA-2076 06/09/00	Uni-ZAP XR	15	2642	1	2642	24	24	65	1	29	30	464
5	HAHFU44	PTA-2076 06/09/00	Uni-ZAP XR	36	757	1	757	17	17	86	1	29	30	206

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
5	HAHFU44	PTA-2076 06/09/00	Uni-ZAP XR	37	807	1	652		377	87	1	1	2	107
6	HNKCO80	PTA-2076 06/09/00	pSport1	16	695	1	695	26	26	66	1	22	23	178
6	HNKCO80	PTA-2076 06/09/00	pSport1	38	1518	183	1518	152	152	88	1	22	23	66
7	HEEBB55	PTA-2076 06/09/00	Uni-ZAP XR	17	2521	1	2521	70	70	67	1	47	48	110
7	HEEBB55	PTA-2076 06/09/00	Uni-ZAP XR	39	696	1	696	63	63	89	1	47	48	110
7	HEEBB55	PTA-2076 06/09/00	Uni-ZAP XR	40	1397	7	714		1374	90	1	1	2	382
8	HOCPM23	PTA-2076 06/09/00	pSport1	18	1276	1	1091	80	80	68	1	39	40	86
8	HOCPM23	PTA-2076 06/09/00	pSport1	41	1323	1	1091	80	80	91	1	39	40	86
9	HWMGN33	PTA-2076 06/09/00	pSport1	19	1215	1	862	176	176	69	1	44	45	86
9	HWMGN33	PTA-2076 06/09/00	pSport1	42	813	1	813	176	176	92	1	44	45	86
10	HWMLN52	PTA-2076 06/09/00	pSport1	20	1629	1	1629	298	298	70	1	25	26	376

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
10	HWMMLN52	PTA-2076 06/09/00	pSport1	43	817	1	817	298	298	93	1	25	26	122
10	HWMMLN52	PTA-2076 06/09/00	pSport1	44	643	1	630		566	94	1	1	2	121
11	HVARW53	PTA-2076 06/09/00	pSport1	21	1015	1	1015	111	111	71	1	34	35	186
11	HVARW53	PTA-2076 06/09/00	pSport1	45	1006	1	1006	96	96	95	1	34	35	164
12	HLTIP94	PTA-2076 06/09/00	Uni-ZAP XR	22	1240	1	1170	226	226	72	1	26	27	97
12	HLTIP94	PTA-2076 06/09/00	Uni-ZAP XR	46	647	1	647	226	226	96	1	26	27	65
12	HLTIP94	PTA-2076 06/09/00	Uni-ZAP XR	47	1321	113	452		1319	97	1	1	2	299
13	HEGCL11	PTA-2076 06/09/00	Uni-ZAP XR	23	569	11	569	79	79	73	1	35	36	156
13	HEGCL11	PTA-2076 06/09/00	Uni-ZAP XR	48	725	244	725	224	224	98	1	35	36	167
14	HCOOS80	PTA-2076 06/09/00	pSport1	24	1254	1	1254	36	36	74	1	26	27	158
14	HCOOS80	PTA-2076 06/09/00	pSport1	49	869	15	869	40	40	99	1	26	27	158

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
14	HCOOS80	PTA-2076 06/09/00	pSport1	50	692	187	354		692	100	1	1	2	106
15	HLCND09	PTA-2076 06/09/00	Uni-ZAP XR	25	1984	1	1984	146	146	75	1	38	39	110
15	HLCND09	PTA-2076 06/09/00	Uni-ZAP XR	51	465	1	465	38	38	101	1	38	39	142
16	HLWBT09	PTA-2076 06/09/00	pCMVSPor t3.0	26	2100	1	2100	54	54	76	1	37	38	515
16	HLWBT09	PTA-2076 06/09/00	pCMVSPor t3.0	52	546	1	546	54	54	102	1	37	38	143
17	HKAEL28	PTA-2076 06/09/00	pCMVSPor t2.0	27	1136	1	1136	195	195	77	1	21	22	200
17	HKAEL28	PTA-2076 06/09/00	pCMVSPor t2.0	53	1861	694	1833	888	888	103	1	21	22	178
18	HNTPB82	PTA-2076 06/09/00	pSport1	28	2279	1	2279	36	36	78	1	1	2	412
18	HNTPB82	PTA-2076 06/09/00	pSport1	54	884	205	884	272	272	104	1	43	44	204
19	HOFMM69	PTA-2076 06/09/00	pCMVSPor t2.0	29	1593	1	1593	141	141	79	1	18	19	246
19	HOFMM69	PTA-2076 06/09/00	pCMVSPor t2.0	55	572	1	572	148	148	105	1	18	19	122

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
20	HKACC80	PTA-2076 06/09/00	pCMVSPor t 2.0	30	2666	273	2666	932	932	80	1	2	3	490
20	HKACC80	PTA-2076 06/09/00	pCMVSPor t 2.0	56	464	1	464	5	5	106	1	19	20	153
20	HKACC80	PTA-2076 06/09/00	pCMVSPor t 2.0	57	729	7	680		494	107	1	1	2	78
21	HHEDN80	PTA-2076 06/09/00	pCMVSPor t 3.0	31	2701	123	803	155	155	81	1	19	20	81
21	HHEDN80	PTA-2076 06/09/00	pCMVSPor t 3.0	58	1325	674	1325	706	706	108	1	19	20	88
21	HHEDN80	PTA-2076 06/09/00	pCMVSPor t 3.0	59	2878	300	979	332	332	109	1	19	20	81
22	HPDWP28	PTA-2076 06/09/00	pSport1	32	528	1	528	143	143	82	1	29	30	49
22	HPDWP28	PTA-2076 06/09/00	pSport1	60	510	1	500	133	133	110	1	29	30	49

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related
5 DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits
10 contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq."
15 and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is
20 identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal
25 peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

30 SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also
5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the
15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the
20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.
25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

Table 2 provides predicted epitopes contained in certain embodiments of the invention and polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column refers to each "Gene #" described above in Table 1. The second column provides the sequence identifier, "NT SEQ ID NO:X", for polynucleotide sequences disclosed in Table 1. The third column provides the sequence identifier, "AA SEQ ID NO:Y", for polypeptide sequences disclosed in Table 1. The fourth column provides a unique integer "ntA" where "ntA" is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer "ntB" where "ntB" is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both ntA and ntB correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where ntB is greater than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf ((1988) CABIOS, 4; 181-186); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE (Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This

method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 2 as "Predicted epitopes".

Polypeptides of the invention may possess one, two, three, four, five or more
5 antigenic epitopes comprising residues described in Table 2. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

Table 3 summarizes the expression profile of polynucleotides corresponding to the clones disclosed in Table 1. The first column provides a unique clone
10 identifier, "Clone ID", for a cDNA clone related to each contig sequence disclosed in Table 1. Column 2, "Library Code(s)" shows the expression profile of tissue and/or cell line libraries which express the polynucleotides of the invention. Each Library Code in column 2 represents a tissue/cell source identifier code corresponding to the Library Code and Library description provided in Table 5. Expression of these
15 polynucleotides was not observed in the other tissues and/or cell libraries tested. One of skill in the art could routinely use this information to identify tissues which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue expression.

20 Table 4, column 1, provides a nucleotide sequence identifier, "SEQ ID NO:X," that matches a nucleotide SEQ ID NO:X disclosed in Table 1, column 5. Table 4, column 2, provides the chromosomal location, "Cytologic Band or Chromosome," of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences
25 contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD)
30 and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). If the putative chromosomal location of the Query overlapped with the chromosomal

location of a Morbid Map entry, the OMIM reference identification number of the morbid map entry is provided in Table 4, column 3, labelled "OMIM Reference(s)."

A key to the OMIM reference identification numbers is provided in Table 6.

5 Table 5 provides a key to the Library Code disclosed in Table 3. Column 1 provides the Library Code disclosed in Table 3, column 2. Column 2 provides a description of the tissue or cell source from which the corresponding library was derived. Library codes corresponding to diseased Tissues are indicated in column 3 with the word "disease".

10 Table 6 provides a key to the OMIM reference identification numbers disclosed in Table 4, column 3. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web
15 URL: <http://www.ncbi.nlm.nih.gov/omim/>). Column 2 provides diseases associated with the cytologic band disclosed in Table 4, column 2, as determined using the Morbid Map database.

Table 2

Gene #	NT SEQ ID NO: X	AA SEQ ID NO: Y	nt A	nt B	Predicted Epitopes
1	11	61	1 - 1684	15 - 1698	Gly-85 to Gly-96 Pro-162 to Val-168 Pro-177 to Gly-188 Arg-254 to Asp-260 Leu-283 to Asp-293 Glu-310 to Gly-318 Arg-338 to Arg-345 Ala-387 to Leu-392 Gly-398 to Gln-404 His-464 to Trp-475.
1	33	83	1 - 1696	15 - 1710	Gly-85 to Gly-96 Glu-163 to Val-168 Pro-177 to Gly-188 Arg-254 to Asp-260 Leu-283 to Asp-293 Glu-310 to Gly-318.
2	12	62	1 - 1475	15 - 1489	Ala-27 to Glu-33 Asp-57 to Glu-69 Asn-134 to Thr-143 Met-185 to Arg-192 Ile-221 to Leu-234 Thr-249 to Asp-260 Ser-270 to Asp-275 Pro-366 to Gly-376.
2	34	84	1 - 1532	15 - 1546	Ala-27 to Glu-33 Asp-57 to Glu-69 Asn-134 to Thr-143 Met-185 to Arg-192 Ile-221 to Leu-234 Thr-249 to Asp-260 Ser-270 to Asp-275 Pro-366 to Gly-376.
3	13	63	1 - 965	15 - 979	Gly-25 to Leu-30 Pro-40 to Ser-49 Pro-74 to Ser-91 Asn-97 to Cys-104 Pro-115 to Phe-123 Ser-125 to Ser-132.
4	14	64	1 - 1079	15 - 1093	Gly-100 to Pro-105 Pro-111 to Lys-116.
4	35	85	1 - 1590	15 - 1604	
5	15	65	1 - 2628	15 - 2642	Ser-53 to Thr-59 Lys-65 to Glu-70 Pro-80 to Gly-91 Ser-94 to Pro-100 Ala-116 to Asn-124 Pro-135 to Trp-151 Asn-172 to Phe-189 Asn-191 to Trp-196 Pro-201 to Trp-223

					Gly-234 to Gly-245 Thr-251 to Asn-260 Arg-340 to Lys-357 Gly-428 to Tyr-454 Phe-458 to Tyr-464.
5	36	86	1 - 743	15 - 757	Ser-53 to Thr-59 Lys-65 to Glu-70 Pro-80 to Gly-91 Ser-94 to Pro-100 Ala-116 to Asn-124 Pro-135 to Trp-151 Asn-172 to Phe-189 Asn-191 to Trp-196.
5	37	87	1 - 793	15 - 807	His-1 to His-18 Pro-36 to Gly-44.
6	16	66	1 - 681	15 - 695	Pro-28 to Asp-41 Thr-107 to Tyr-114 Glu-158 to Pro-164.
6	38	88	1 - 1504	15 - 1518	Pro-28 to Asp-41.
7	17	67	1 - 2507	15 - 2521	Met-1 to Ala-11 Leu-20 to Gly-26 Leu-51 to Ser-61 Phe-82 to Leu-87 Gln-94 to Pro-99.
7	39	89	1 - 682	15 - 696	Met-1 to Ala-11 Leu-20 to Gly-26 Leu-51 to Ser-61 Phe-82 to Leu-87 Gln-94 to Pro-99.
7	40	90	1 - 1383	15 - 1397	Gly-1 to Asn-14 Lys-80 to Phe-88 Gly-139 to Lys-147 Gly-174 to Thr-179 Ala-198 to Ser-208 Asn-210 to Leu-223 Gln-226 to Arg-253 Ser-260 to Asn-270 Ser-289 to Asp-296 Met-303 to Pro-310 Arg-332 to Thr-340 Asn-353 to Asn-361.
8	18	68	1 - 1262	15 - 1276	His-8 to Met-13.
8	41	91	1 - 1309	15 - 1323	His-8 to Met-13.
9	19	69	1 - 1201	15 - 1215	Asn-71 to Trp-76.
9	42	92	1 - 799	15 - 813	Asn-71 to Trp-76.
10	20	70	1 - 1615	15 - 1629	
10	43	93	1 - 803	15 - 817	Ser-42 to Asn-50.
10	44	94	1 - 629	15 - 643	Ser-8 to Glu-14 Tyr-23 to Ala-28 Glu-42 to Trp-51 Glu-107 to Glu-121.
11	21	71	1 - 1001	15 - 1015	Arg-128 to Tyr-134.
11	45	95	1 - 992	15 - 1006	
12	22	72	1 - 1226	15 - 1240	Gly-4 to Glu-9 Asp-22 to Cys-28 Glu-39 to Leu-44

					Phe-88 to Phe-94.
12	46	96	1 - 633	15 - 647	Gly-4 to Glu-9.
12	47	97	1 - 1307	15 - 1321	Gly-1 to Glu-8 Gly-37 to Gly-61 Gln-71 to Phe-81 Asp-95 to Gly-103 Leu-126 to Ile-131 Val-166 to Glu-171.
13	23	73	1 - 555	15 - 569	Ser-34 to Ile-39.
13	48	98	1 - 711	15 - 725	Ser-34 to Ile-39 Leu-120 to Glu-128.
14	24	74	1 - 1240	15 - 1254	Pro-39 to Leu-44 Gln-80 to Pro-93 Pro-153 to Pro-158.
14	49	99	1 - 855	15 - 869	Pro-39 to Leu-44 Gln-80 to Pro-93 Pro-153 to Pro-158.
14	50	100	1 - 678	15 - 692	Pro-12 to His-25.
15	25	75	1 - 1970	15 - 1984	Glu-37 to Trp-42 Phe-67 to Gly-88 Pro-101 to Leu-110.
15	51	101	1 - 451	15 - 465	Glu-37 to Trp-42.
16	26	76	1 - 2086	15 - 2100	Pro-45 to Trp-50 Pro-76 to Trp-93.
16	52	102	1 - 532	15 - 546	Pro-45 to Trp-50 Pro-76 to Trp-93.
17	27	77	1 - 1122	15 - 1136	Val-52 to Trp-61 Leu-65 to Gly-71 Lys-86 to Leu-92.
17	53	103	1 - 1847	15 - 1861	Val-52 to Trp-61 Leu-65 to Gly-71 Lys-86 to Leu-92.
18	28	78	1 - 2265	15 - 2279	Leu-66 to Lys-71 Arg-92 to Trp-97 Lys-115 to Gly-122 Pro-182 to Glu-192 Ala-207 to Glu-212 Asn-221 to Val-227 Leu-234 to Lys-239 Cys-250 to Arg-255 Asp-260 to Ala-266 Pro-336 to Pro-349 Ser-387 to Arg-412.
18	54	104	1 - 870	15 - 884	Leu-52 to Lys-57 Arg-78 to Trp-83 Lys-101 to Gly-108 Pro-168 to Glu-178.
19	29	79	1 - 1579	15 - 1593	Thr-45 to Leu-54 Gln-71 to Asn-77 Glu-90 to Ile-98 Lys-111 to Thr-122 Lys-131 to Lys-140 Gly-153 to Ala-161 Arg-169 to Ser-178 Thr-184 to Gln-198 Glu-214 to Glu-220

					Thr-234 to Tyr-246.
19	55	105	1 - 558	15 - 572	Thr-45 to Leu-54 Gln-71 to Asn-77 Glu-90 to Ile-98.
20	30	80	1 - 2652	15 - 2666	Pro-35 to Ser-49 Thr-85 to Ile-92 Pro-95 to Glu-103 Ser-110 to Thr-130 Val-142 to Gly-150 Glu-152 to Ala-158 Gln-173 to Leu-183 Gly-238 to Leu-245 Gly-272 to His-282 Arg-298 to Met-308 Ala-318 to Gly-339 Ala-353 to Leu-360 Pro-362 to Tyr-367 Pro-372 to Asp-380 Glu-390 to Ser-414 Ile-416 to Arg-424 Ser-429 to Gln-439 Gly-472 to Thr-480.
20	56	106	1 - 450	15 - 464	Asn-64 to Thr-70 Glu-103 to Pro-110.
20	57	107	1 - 715	15 - 729	Ser-1 to Arg-12 Ser-17 to Gln-27 Gly-60 to Thr-68.
21	31	81	1 - 2687	15 - 2701	
21	58	108	1 - 1311	15 - 1325	Thr-17 to Cys-23.
21	59	109	1 - 2864	15 - 2878	Thr-17 to Cys-23 Gln-76 to Ser-81.
22	32	82	1 - 514	15 - 528	Thr-35 to Gly-48.
22	60	110	1 - 496	15 - 510	Thr-35 to Gly-48.

Table 3

Clone ID	Library Code(s)
HLDAB75	H0509
HDPGT25	H0038 H0042 H0051 H0124 H0163 H0170 H0318 H0328 H0341 H0355 H0376 H0400 H0416 H0427 H0428 H0438 H0441 H0445 H0484 H0486 H0510 H0521 H0522 H0539 H0546 H0551 H0552 H0553 H0555 H0574 H0586 H0591 H0615 H0616 H0619 H0624 H0638 H0639 H0641 H0644 H0648 H0659 H0662 H0663 H0676 H0683 H0689 H0696 H0711 L1290 S0002 S0010 S0031 S0051 S0052 S0142 S0144 S0242 S0276 S0278 S0300 S0328 S0330 S0344 S0346 S0358 S0360 S0388 S0418 S0420 S0422 S0426 S0444 S0460 S0474 T0003 T0004 T0006 T0041 T0049
HEEBI05	H0150 H0549 L1290
HLTIP27	H0040 H0050 H0087 H0090 H0255 H0318 H0506 H0521 H0522 H0581 H0591 H0597 H0599 H0640 H0650 H0672 H0689 H0710 L1290 S0031 S0116 S0142 S0358 S0360 S0378 S0426 S0458 T0023
HAHFU44	H0333 H0520 H0539 H0599 H0622 L1290 S0312 S0330
HNKCO80	H0032 H0096 H0263 H0402 H0478 H0542 H0593 H0696 L1290 S0150 S0328 S0330 S0380 S0392
HEEBB55	H0038 H0090 H0120 H0135 H0144 H0166 H0170 H0310 H0331 H0423 H0494 H0506 H0519 H0520 H0538 H0543 H0545 H0549 H0616 H0632 H0657 H0661 H0673 L1290 S0016 S0051 S0310 S0358 S0364 S0420 S0448 S0624
HOCPM23	H0660 L1290
HWMGN33	L1290 S0358
HWMLN52	H0393 H0551 H0638 L1290 S0358
HVARW53	S0378 S0380
HLTIP94	H0170 H0591 S0626
HEGCL11	H0267 H0457 H0497 H0550 H0586 L1290 S0028 S0152 S0344
HCOOS80	H0014 H0033 H0052 H0100 H0290 H0333 H0352 H0402 H0436 H0521 H0543 H0545 H0546 H0550 H0574 H0580 H0618 H0643 H0660 L1290 S0280 S0354 S0404 S0406 S0418
HLCND09	H0009 H0100 H0123 H0144 H0179 H0266 H0271 H0327 H0435 H0438 H0545 H0551 H0575 H0594 H0615 H0628 H0696 L1290 S0007 S0028 S0038 S0210 S0212 S0300 S0376 S0418 S0420 S0464
HLWBT09	H0031 H0553 H0620 L1290
HKAEL28	H0255 H0494 H0556 H0587 H0618 L1290 S0132
HNTPB82	H0003 H0059 H0081 H0090 H0144 H0265 H0428 H0543 H0547 H0555 H0594 H0599 H0600 H0662 H0670 H0684 L1290 S0046 S0050 S0344 S0358 S0406 S0408 S0444 S0462
HOFMM69	H0415
HKACC80	H0013 H0039 H0494 H0586 H0644 L1290 S0037 S0346 S0354 S0356 S0420
HHEDN80	H0036 H0038 H0042 H0100 H0130 H0267 H0272 H0486 H0542 H0616 H0625 H0634 H0637 H0666 L1290 S0051 S0212 S0214 S0222 S0276 S0346 S0358 S0430 S3012
HPDWP28	H0658 L1290

Table 4

SEQ ID NO: X	Cytologic Band or Chromosome:	OMIM Reference(s):
11	19cen-q13.2	
23	6p21.3	106300 108800 120290 120810 120820 142857 142858 150270 167250 170261 177900 179450 201910 217000 222100 233100 235200 248611 256550 600202 600261 601868 602280 602475
24	17	

Table 5

Library Code	Library Description	Disease
H0003	Human Adult Liver	
H0009	Human Fetal Brain	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0031	Human Placenta	
H0032	Human Prostate	
H0033	Human Pituitary	
H0036	Human Adult Small Intestine	
H0038	Human Testes	
H0039	Human Pancreas Tumor	disease
H0040	Human Testes Tumor	disease
H0042	Human Adult Pulmonary	
H0050	Human Fetal Heart	
H0051	Human Hippocampus	
H0052	Human Cerebellum	
H0059	Human Uterine Cancer	disease
H0081	Human Fetal Epithelium (Skin)	
H0087	Human Thymus	
H0090	Human T-Cell Lymphoma	disease
H0096	Human Parotid Cancer	disease
H0100	Human Whole Six Week Old Embryo	
H0120	Human Adult Spleen, subtracted	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0130	LNCAp untreated	
H0135	Human Synovial Sarcoma	
H0144	Nine Week Old Early Stage Human	
H0150	Human Epididymus	
H0163	Human Synovium	
H0166	Human Prostate Cancer, Stage B2 fraction	disease
H0170	12 Week Old Early Stage Human	
H0179	Human Neutrophil	
H0255	breast lymph node CDNA library	
H0263	human colon cancer	disease
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0267	Human Microvascular Endothelial Cells, fract. B	
H0271	Human Neutrophil, Activated	
H0272	HUMAN TONSILS, FRACTION 2	
H0290	Human OB HOS treated (1 nM E2) fraction I	
H0310	human caudate nucleus	
H0318	HUMAN B CELL LYMPHOMA	disease
H0327	human corpus colosum	
H0328	human ovarian cancer	disease
H0331	Hepatocellular Tumor	disease
H0333	Hemangiopericytoma	disease
H0341	Bone Marrow Cell Line (RS4,11)	

H0352	wilm's tumor	disease
H0355	Human Liver	
H0376	Human Spleen	
H0393	Fetal Liver, subtraction II	
H0400	Human Striatum Depression, re-rescue	
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision	
H0415	H. Ovarian Tumor, II, OV5232	disease
H0416	Human Neutrophils, Activated, re-excision	
H0423	T-Cell PHA 24 hrs	
H0427	Human Adipose	
H0428	Human Ovary	
H0435	Ovarian Tumor 10-3-95	
H0436	Resting T-Cell Library,II	
H0438	H. Whole Brain #2, re-excision	
H0441	H. Kidney Cortex, subtracted	
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0457	Human Eosinophils	
H0478	Salivary Gland, Lib 2	
H0484	Breast Cancer Cell line, angiogenic	
H0486	Hodgkin's Lymphoma II	disease
H0494	Keratinocyte	
H0497	HEL cell line	
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0510	Human Liver, normal	
H0519	NTERA2, control	
H0520	NTERA2 + retinoic acid, 14 days	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells,frac 2	
H0538	Merkel Cells	
H0539	Pancreas Islet Cell Tumor	disease
H0542	T Cell helper I	
H0543	T cell helper II	
H0545	Human endometrial stromal cells-treated with progesterone	
H0546	Human endometrial stromal cells-treated with estradiol	
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)	
H0549	H. Epididymus, caput & corpus	
H0550	H. Epididymus, cauda	
H0551	Human Thymus Stromal Cells	
H0552	Signal trap,Femur Bone Marrow,pooled	
H0553	Human Placenta	
H0555	Rejected Kidney, lib 4	disease
H0556	Activated T-cell(12h)/Thiouridine-re-excision	
H0574	Hepatocellular Tumor, re-excision	disease
H0575	Human Adult Pulmonary,re-excision	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	
H0586	Healing groin wound, 6.5 hours post incision	disease
H0587	Healing groin wound, 7.5 hours post incision	disease
H0591	Human T-cell lymphoma,re-excision	disease
H0593	Olfactory epithelium,nasalcavity	
H0594	Human Lung Cancer,re-excision	disease
H0597	Human Colon, re-excision	

H0599	Human Adult Heart, re-excision	
H0600	Healing Abdomen wound, 70&90 min post incision	disease
H0615	Human Ovarian Cancer Reexcision	disease
H0616	Human Testes, Reexcision	
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart	
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0624	12 Week Early Stage Human II, Reexcision	
H0625	Ku 812F Basophils Line	
H0628	Human Pre-Differentiated Adipocytes	
H0632	Hepatocellular Tumor, re-excision	
H0634	Human Testes Tumor, re-excision	disease
H0637	Dendritic Cells From CD34 Cells	
H0638	CD40 activated monocyte dendritic cells	
H0639	Ficoll Human Stromal Cells, 5Fu treated	
H0640	Ficoll Human Stromal Cells, Untreated	
H0641	LPS activated derived dendritic cells	
H0643	Hep G2 Cells, PCR library	
H0644	Human Placenta (re-excision)	
H0648	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot	disease
H0650	B-Cells	
H0657	B-cells (stimulated)	
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	disease
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0661	Breast, Cancer: (4004943 A5)	disease
H0662	Breast, Normal: (4005522B2)	
H0663	Breast, Cancer: (4005522 A2)	disease
H0666	Ovary, Cancer: (4004332 A2)	disease
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	
H0672	Ovary, Cancer: (4004576 A8)	
H0673	Human Prostate Cancer, Stage B2, re-excision	
H0676	Colon, Cancer: (9808C064R)-total RNA	
H0683	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0684	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0689	Ovarian Cancer	
H0696	Prostate Adenocarcinoma	
H0710	Patient #6 Acute Myeloid Leukemia/SGAH	
H0711	Ovarian Cancer Cell Line(Xenograft) ES-2	
L1290	NCI CGAP Sub4	
S0002	Monocyte activated	
S0007	Early Stage Human Brain	
S0010	Human Amygdala	
S0016	Kidney Pyramids	
S0028	Smooth muscle, control	
S0031	Spinal cord	
S0037	Smooth muscle, IL1b induced	
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0046	Endothelial-induced	
S0050	Human Frontal Cortex, Schizophrenia	disease

S0051	Human Hypothalamus,Schizophrenia	disease
S0052	neutrophils control	
S0116	Bone marrow	
S0132	Epithelial-TNF α and INF induced	
S0142	Macrophage-oxLDL	
S0144	Macrophage (GM-CSF treated)	
S0150	LNCAP prostate cell line	
S0152	PC3 Prostate cell line	
S0210	Mesangial cell, frac 2	
S0212	Bone Marrow Stromal Cell, untreated	
S0214	Human Osteoclastoma, re-excision	disease
S0222	H. Frontal cortex,epileptic,re-excision	disease
S0242	Synovial Fibroblasts (II/TNF), subt	
S0276	Synovial hypoxia-RSF subtracted	
S0278	H Macrophage (GM-CSF treated), re-excision	
S0280	Human Adipose Tissue, re-excision	
S0300	Frontal lobe,dementia,re-excision	
S0310	Normal trachea	
S0312	Human osteoarthritic,fraction II	disease
S0328	Palate carcinoma	disease
S0330	Palate normal	
S0344	Macrophage-oxLDL, re-excision	
S0346	Human Amygdala,re-excision	
S0354	Colon Normal II	
S0356	Colon Carcinoma	disease
S0358	Colon Normal III	
S0360	Colon Tumor II	disease
S0364	Human Quadriceps	
S0376	Colon Tumor	disease
S0378	Pancreas normal PCA4 No	
S0380	Pancreas Tumor PCA4 Tu	disease
S0388	Human Hypothalamus,schizophrenia, re-excision	disease
S0392	Salivary Gland	
S0404	Rectum normal	
S0406	Rectum tumour	
S0408	Colon, normal	
S0418	CHME Cell Line,treated 5 hrs	
S0420	CHME Cell Line,untreated	
S0422	Mo7e Cell Line GM-CSF treated (1ng/ml)	
S0426	Monocyte activated, re-excision	
S0430	Aryepiglottis Normal	
S0444	Colon Tumor	disease
S0448	Larynx Normal	
S0458	Thyroid Normal (SDCA2 No)	
S0460	Thyroid Tumour	
S0462	Thyroid Thyroiditis	
S0464	Larynx Normal	
S0474	Human blood platelets	
S3012	Smooth Muscle Serum Treated, Norm	
S6024	Alzheimers, spongy change	disease
S6026	Frontal Lobe, Dementia	
T0003	Human Fetal Lung	
T0004	Human White Fat	

T0006	Human Pineal Gland	
T0023	Human Pancreatic Carcinoma	disease
T0041	Jurkat T-cell G1 phase	
T0049	Aorta endothelial cells + TNF-a	

Table 6

OMIM Reference	Description
106300	Ankylosing spondylitis
108800	Atrial septal defect, secundum type
120290	OSMED syndrome, 215150 Stickler syndrome, type II, 184840
120810	C4 deficiency
120820	C4 deficiency
142857	Pemphigoid, susceptibility to
142858	Beryllium disease, chronic, susceptibility to
150270	Laryngeal adductor paralysis
167250	Paget disease of bone
170261	Bare lymphocyte syndrome, type I, due to TAP2 deficiency
177900	Psoriasis susceptibility-1
179450	Ragweed sensitivity
201910	Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency
217000	C2 deficiency
222100	Diabetes mellitus, insulin-dependent-1
233100	[Renal glucosuria]
235200	Hemochromatosis
248611	Maple syrup urine disease, type Ib
256550	Sialidosis, type I Sialidosis, type II
600202	Dyslexia, specific, 2
600261	Ehlers-Danlos-like syndrome
601868	Deafness, autosomal dominant 13
602280	Retinitis pigmentosa-14, 600132
602475	Ossification of posterior longitudinal ligament of spine

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides
5 are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification ,
10 such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially
15 purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

20 The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides
25 encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

Signal Sequences

30 The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature

forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretary leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty.

Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the

nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).
5 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or
10 alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

15 By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In
20 other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire
25 sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally
30 using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined

using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base

subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1,

Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal

ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding
5 regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or
10 added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of
15 several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

20 Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988
25 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

30 Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational

analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule
5 could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or
10 C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular
15 polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions,
20 inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

25 The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these
30 positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

- 5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification or (v) fusion of the polypeptide with another compound, such as albumin (including, but not limited to, recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,

and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40,

41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5 In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope
10 of the invention.

Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide
30 encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies

described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays
5 described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985),
10 further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30
15 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,
20 that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

25 Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any
30 combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to

an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very
5 least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-
10 2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS),
15 while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an
20 immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the
25 peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention (e.g., those comprising an immunogenic or antigenic epitope) can be fused to heterologous polypeptide sequences. For example,
30 polypeptides of the present invention (including fragments or variants thereof), may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof,

resulting in chimeric polypeptides. By way of another non-limiting example, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused with albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). In a preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1 – 585 of human serum albumin as shown in Figures 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. In another preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-z of human serum albumin, where z is an integer from 369 to 419, as described in U.S. Patent 5,766,883 herein incorporated by reference in its entirety. Polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused to either the N- or C-terminal end of the heterologous protein (e.g., immunoglobulin Fc polypeptide or human serum albumin polypeptide). Polynucleotides encoding fusion proteins of the invention are also encompassed by the invention.

Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can

also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines
5 (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are
10 loaded onto Ni²⁺ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to
15 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol.
20 Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA
25 segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections,
30 parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as
5 determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a
10 Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The
15 immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

20 Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s)
25 alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human,
30 murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from

human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific,
5 trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol.
10 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be
15 specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

20 Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at
25 least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less
30 than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present

invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity

or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent
5 ligand binding and receptor activation as well as antibodies that recognize the
receptor-ligand complex, and, preferably, do not specifically recognize the unbound
receptor or the unbound ligand. Likewise, included in the invention are neutralizing
antibodies which bind the ligand and prevent binding of the ligand to the receptor, as
well as antibodies which bind the ligand, thereby preventing receptor activation, but
10 do not prevent the ligand from binding the receptor. Further included in the invention
are antibodies which activate the receptor. These antibodies may act as receptor
agonists, i.e., potentiate or activate either all or a subset of the biological activities of
the ligand-mediated receptor activation, for example, by inducing dimerization of the
receptor. The antibodies may be specified as agonists, antagonists or inverse agonists
15 for biological activities comprising the specific biological activities of the peptides of
the invention disclosed herein. The above antibody agonists can be made using
methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.
5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.
58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu
20 et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-
3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J.
Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241
(1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al.,
Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998);
25 Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference
herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited
to, to purify, detect, and target the polypeptides of the present invention, including
both in vitro and in vivo diagnostic and therapeutic methods. For example, the
30 antibodies have use in immunoassays for qualitatively and quantitatively measuring
levels of the polypeptides of the present invention in biological samples. See, e.g.,

Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and

potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the

hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods* 182:41-50 (1995); Ames et al., *J. Immunol. Methods* 184:177-186 (1995); Kettleborough et al., *Eur. J. Immunol.* 24:952-958 (1994); Persic et al., *Gene* 187 9-18 (1997); Burton et al., *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies,

including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using
5 methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and
10 antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule
15 in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol.*
20 *Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule.
25 Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence
30 comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., *Nature* 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be

humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation.

Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

30

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that
5 encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the
10 nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then
15 amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized
20 or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe
25 specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the
30 antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for

example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their
5 entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the
10 art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally
15 occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid
20 substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other
25 alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes
30 from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are

derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain
5 antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the
10 assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the
15 art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an
20 expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using
25 techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include,
30 for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or

light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of
5 the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a
10 polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

15 A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the
20 invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems
25 infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO,
30 BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the

vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary
5 cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously
10 selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression
15 vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign
20 polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the
25 GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in
Spodoptera frugiperda cells. The antibody coding sequence may be cloned
individually into non-essential regions (for example the polyhedrin gene) of the virus
30 and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., *Cell* 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, *Proc. Natl. Acad. Sci. USA* 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., *Cell* 22:817 (1980)) genes can be employed in tk-, hgp^rt- or ap^rt- cells, respectively.

Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., *Natl. Acad. Sci. USA* 77:357 (1980); O'Hare et al., *Proc. Natl. Acad. Sci. USA* 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, *Proc. Natl. Acad. Sci. USA* 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (*Clinical Pharmacy* 12:488-505; Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hyg^r, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993);

Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

5 The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in
10 culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

 The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second
15 vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic
20 free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

 Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any
25 method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or
30 fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., *supra*, and PCT publication WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.* 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., *PNAS* 89:1428-1432 (1992); Fell et al., *J. Immunol.* 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., *Proc. Natl. Acad. Sci. USA* 88:10535-10539 (1991);

Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide,
5 polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins
10 consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in
15 binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been
20 expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58
25 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA,
30 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags

useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof
5 conjugated to a diagnostic or therapeutic agent. The antibodies can be used
diagnostically to, for example, monitor the development or progression of a tumor as
part of a clinical testing procedure to, e.g., determine the efficacy of a given
treatment regimen. Detection can be facilitated by coupling the antibody to a
detectable substance. Examples of detectable substances include various enzymes,
10 prosthetic groups, fluorescent materials, luminescent materials, bioluminescent
materials, radioactive materials, positron emitting metals using various positron
emission tomographies, and nonradioactive paramagnetic metal ions. The detectable
substance may be coupled or conjugated either directly to the antibody (or fragment
thereof) or indirectly, through an intermediate (such as, for example, a linker known
15 in the art) using techniques known in the art. See, for example, U.S. Patent No.
4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics
according to the present invention. Examples of suitable enzymes include horseradish
peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase;
examples of suitable prosthetic group complexes include streptavidin/biotin and
20 avidin/biotin; examples of suitable fluorescent materials include umbelliferone,
fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine
fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material
includes luminol; examples of bioluminescent materials include luciferase, luciferin,
and aequorin; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{111}In
25 or ^{99}Tc .

Further, an antibody or fragment thereof may be conjugated to a therapeutic
moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or
a radioactive metal ion, e.g., alpha-emitters such as, for example, ^{213}Bi . A cytotoxin
or cytotoxic agent includes any agent that is detrimental to cells. Examples include
30 paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin,
etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin,
dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-

dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld

et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to

prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

5 *Assays For Antibody Binding*

 The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent
10 assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular
15 Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

 Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium
20 deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or
25 more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing
30 the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ^{32}P or ^{125}I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., ^3H or ^{125}I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., ^3H or ^{125}I) in the presence of increasing amounts of an unlabeled second antibody.

Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the

antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC).

Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or

prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded
5 protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991);
10 Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and
15 Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains
20 thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a
25 desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy
30 and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or

indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered
5 in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct
10 injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see,
15 e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for
20 cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al.,
25 Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral
30 genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can

be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be

carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, 5 e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. 10 The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or 15 progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to 20 epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

25 In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then 30 administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of

the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

5 In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

Demonstration of Therapeutic or Prophylactic Activity

10 The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect
15 of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient
20 tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by
25 administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses,
30 chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above;

additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein

and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliet et al., *Proc. Natl. Acad. Sci. USA* 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term

"pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry

lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art

(e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody
5 assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium (^{99}Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or
10 disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval
15 following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject
20 has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging
25 system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor
30 imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:

The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,
Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode
of administration, the time interval following the administration for permitting the
5 labeled molecule to preferentially concentrate at sites in the subject and for unbound
labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or
6 to 12 hours. In another embodiment the time interval following administration is 5
to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by
10 repeating the method for diagnosing the disease or disease, for example, one month
after initial diagnosis, six months after initial diagnosis, one year after initial
diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods
known in the art for in vivo scanning. These methods depend upon the type of label
15 used. Skilled artisans will be able to determine the appropriate method for detecting a
particular label. Methods and devices that may be used in the diagnostic methods of
the invention include, but are not limited to, computed tomography (CT), whole body
scan such as position emission tomography (PET), magnetic resonance imaging
(MRI), and sonography.

20 In a specific embodiment, the molecule is labeled with a radioisotope and is
detected in the patient using a radiation responsive surgical instrument (Thurston et
al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with
a fluorescent compound and is detected in the patient using a fluorescence responsive
scanning instrument. In another embodiment, the molecule is labeled with a positron
25 emitting metal and is detected in the patent using positron emission-tomography. In
yet another embodiment, the molecule is labeled with a paramagnetic label and is
detected in a patient using magnetic resonance imaging (MRI).

Kits

30 The present invention provides kits that can be used in the above methods. In
one embodiment, a kit comprises an antibody of the invention, preferably a purified
antibody, in one or more containers. In a specific embodiment, the kits of the present

invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present
5 invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

10 In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically
15 immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide
20 antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this
embodiment, binding of the antibody to the polypeptide antigen can be detected by
25 binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of
30 the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled

monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

25

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target

30

cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).) Polynucleotides comprising or alternatively consisting of nucleic acids which encode these fusion proteins are also encompassed by the invention.

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a

fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if
5 the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).)

10 Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available.
15 As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., *Cell* 37:767 (1984).)

20 Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of
25 the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

30 The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the

vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac
5 promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a
10 translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin
15 resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as
20 CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and
25 ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph,
30 pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic
5 Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or
10 ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

15 Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,
20 insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine
25 encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

30 In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A

main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an

expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and
5 immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example,
10 techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650,
15 published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using
20 techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid
25 analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine,
30 norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino acids, designer amino acids such as β -methyl amino acids, Ca-methyl amino

acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used,

depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an
5 average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000,
10 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug.*
15 *Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those
20 skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated
25 polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for
30 therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ($\text{ClSO}_2\text{CH}_2\text{CF}_3$). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The polypeptides of the invention may be in monomers or multimers (*i.e.*, dimers, trimers, tetramers and higher multimers). Accordingly, the present invention

relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least
5 dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and
10 fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing
15 polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at
20 least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional
25 embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as,
30 for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed

when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al.,

Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described
5 in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

10 Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by
15 reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations
20 proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers
25 of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues
30 located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely

modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers,

since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety)..

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g., Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London

(1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

5 Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins
10 University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

 Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.
15 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide
20 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

 Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using
25 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

 Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the
30 present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression

level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test
5 subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand
10 containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present
15 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the
20 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard
25 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

30 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples

include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art.

5 Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a
10 "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying
15 disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or
20 according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain
25 components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and
30 tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide

backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ($T_{sub.m}$) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of
5 HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl.
10 Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

15 In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al.,
20 Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix -
25 see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while
30 antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information

disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective
5 gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute
10 biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of
15 "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions
20 of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from
25 extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or
30 surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR

Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be
5 used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the
10 present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a
15 specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

20

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a
25 biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay
30 (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and

technetium (^{99m}Tc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo
5 imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for
10 the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , ^{99m}Tc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or
15 intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc . The labeled antibody or antibody fragment will then
20 preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

25 Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is
30 indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for

detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

5 Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair
10 proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune
15 response to proliferative cells or tissues).

 Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can
20 activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

 At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also
25 be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations,

lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and
5 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3,
10 pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters
15 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters,
20 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the
25 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver,
30 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular,

fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph
5 fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated
10 cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20
15 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

20 The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the
25 procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

30 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a
5 tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated
10 by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are
15 particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

20 Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.
25 Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol,
30 phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP

starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC),
dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine
5 (DOPE) can be used in various combinations to make conventional liposomes, with or
without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be
prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas
into a sonication vial. The sample is placed under a vacuum pump overnight and is
hydrated the following day with deionized water. The sample is then sonicated for 2
10 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an
inverted cup (bath type) probe at the maximum setting while the bath is circulated at
15EC. Alternatively, negatively charged vesicles can be prepared without sonication
to produce multilamellar vesicles or by extrusion through nucleopore membranes to
produce unilamellar vesicles of discrete size. Other methods are known and available
15 to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar
vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.
The various liposome-nucleic acid complexes are prepared using methods well known
in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983),
20 which is herein incorporated by reference. For example, MLVs containing nucleic
acid can be prepared by depositing a thin film of phospholipid on the walls of a glass
tube and subsequently hydrating with a solution of the material to be encapsulated.
SUVs are prepared by extended sonication of MLVs to produce a homogeneous
population of unilamellar liposomes. The material to be entrapped is added to a
25 suspension of preformed MLVs and then sonicated. When using liposomes containing
cationic lipids, the dried lipid film is resuspended in an appropriate solution such as
sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and
then the preformed liposomes are mixed directly with the DNA. The liposome and
DNA form a very stable complex due to binding of the positively charged liposomes
30 to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are
prepared by a number of methods, well known in the art. Commonly used methods
include Ca^{2+} -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*,

394:483 (1975); Wilson et al., Cell , 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA , 76:145 (1979)); and
5 reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA , 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the
10 ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469
15 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

20 In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis
25 virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-
30 19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any

means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

5 The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

 In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with
10 polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional
15 mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991);
20 Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

 Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);
25 Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and
30 constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other

varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or
5 packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

10 In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base
15 pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will
20 include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells
25 which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.
30 These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

5 The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor
10 factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.
15 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

20 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available
25 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the
30 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is

administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide
5 construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include
10 recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection,
15 aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present
20 invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

25 Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of
30 polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of

the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

5 **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological
10 activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

Polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis, prognosis, prevention, and/or treatment of diseases and/or disorders associated with the following systems.

15

Immune Activity

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing
20 diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of
25 these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

30 In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to treat diseases and disorders of the immune system and/or to inhibit or enhance an

immune response generated by cells associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1, column 8 (Tissue Distribution Library Code).

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing, and/or prognosing immunodeficiencies, including both congenital and acquired immunodeficiencies. Examples of B cell immunodeficiencies in which immunoglobulin levels B cell function and/or B cell numbers are decreased include: X-linked agammaglobulinemia (Bruton's disease), X-linked infantile agammaglobulinemia, X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, X-linked lymphoproliferative syndrome (XLP), agammaglobulinemia including congenital and acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, unspecified hypogammaglobulinemia, recessive agammaglobulinemia (Swiss type), Selective IgM deficiency, selective IgA deficiency, selective IgG subclass deficiencies, IgG subclass deficiency (with or without IgA deficiency), Ig deficiency with increased IgM, IgG and IgA deficiency with increased IgM, antibody deficiency with normal or elevated Igs, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), common variable immunodeficiency (CVID), common variable immunodeficiency (CVI) (acquired), and transient hypogammaglobulinemia of infancy.

In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are treated, prevented, diagnosed, and/or prognosing using the polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof.

Examples of congenital immunodeficiencies in which T cell and/or B cell function and/or number is decreased include, but are not limited to: DiGeorge anomaly, severe combined immunodeficiencies (SCID) (including, but not limited to, X-linked SCID, autosomal recessive SCID, adenosine deaminase deficiency, purine nucleoside phosphorylase (PNP) deficiency, Class II MHC deficiency (Bare lymphocyte syndrome), Wiskott-Aldrich syndrome, and ataxia telangiectasia), thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic

mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia, immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity.

In specific embodiments, DiGeorge anomaly or conditions associated with
5 DiGeorge anomaly are treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

Other immunodeficiencies that may be treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, include, but are not limited to, chronic granulomatous disease,
10 Chédiak-Higashi syndrome, myeloperoxidase deficiency, leukocyte glucose-6-phosphate dehydrogenase deficiency, X-linked lymphoproliferative syndrome (XLP), leukocyte adhesion deficiency, complement component deficiencies (including C1, C2, C3, C4, C5, C6, C7, C8 and/or C9 deficiencies), reticular dysgenesis, thymic
15 alymphoplasia-aplasia, immunodeficiency with thymoma, severe congenital leukopenia, dysplasia with immunodeficiency, neonatal neutropenia, short limbed dwarfism, and Nezelof syndrome-combined immunodeficiency with Igs.

In a preferred embodiment, the immunodeficiencies and/or conditions associated with the immunodeficiencies recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or
20 agonists or antagonists of the present invention.

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among immunodeficient individuals. In specific
25 antagonists of the present invention could be used as an agent to boost immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing autoimmune disorders. Many autoimmune disorders result from
30 inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of

the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Autoimmune diseases or disorders that may be treated, prevented, diagnosed
5 and/or prognosed by polynucleotides, polypeptides, antibodies, and/or agonists or
antagonists of the present invention include, but are not limited to, one or more of the
following: systemic lupus erythematosus, rheumatoid arthritis, ankylosing
spondylitis, multiple sclerosis, autoimmune thyroiditis, Hashimoto's thyroiditis,
autoimmune hemolytic anemia, hemolytic anemia, thrombocytopenia, autoimmune
10 thrombocytopenia purpura, autoimmune neonatal thrombocytopenia, idiopathic
thrombocytopenia purpura, purpura (e.g., Henloch-Schoenlein purpura),
autoimmunocytopenia, Goodpasture's syndrome, Pemphigus vulgaris, myasthenia
gravis, Grave's disease (hyperthyroidism), and insulin-resistant diabetes mellitus.

Additional disorders that are likely to have an autoimmune component that
15 may be treated, prevented, and/or diagnosed with the compositions of the invention
include, but are not limited to, type II collagen-induced arthritis, antiphospholipid
syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing
polychondritis, rheumatic heart disease, neuritis, uveitis ophthalmia,
polyendocrinopathies, Reiter's Disease, Stiff-Man Syndrome, autoimmune pulmonary
20 inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus,
and autoimmune inflammatory eye disorders.

Additional disorders that are likely to have an autoimmune component that
may be treated, prevented, diagnosed and/or prognosed with the compositions of the
invention include, but are not limited to, scleroderma with anti-collagen antibodies
25 (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed
connective tissue disease (often characterized, e.g., by antibodies to extractable
nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by
nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell,
microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often
30 characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility
(often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often
characterized, e.g., by glomerular basement membrane antibodies or immune

complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic
5 drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional disorders that may have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized,
10 e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondria antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by
15 myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

20 In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention. In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed
25 using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred
30 embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

5 In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention

In preferred embodiments, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a immunosuppressive agent(s).

10 Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, prognosing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells, including but not limited to, leukopenia, neutropenia, anemia, and thrombocytopenia. Alternatively, Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with an increase in certain (or many) types of hematopoietic cells, including but not limited to, histiocytosis.

25 Allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, diagnosed and/or prognosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, prognose, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

30 Additionally, polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, may be used to treat, prevent, diagnose and/or prognose

IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

5 Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention have uses in the diagnosis, prognosis, prevention, and/or treatment of inflammatory conditions. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells
10 involved in an inflammatory response, these molecules can be used to prevent and/or treat chronic and acute inflammatory conditions. Such inflammatory conditions include, but are not limited to, for example, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection,
15 nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines (e.g., TNF or IL-1.), respiratory disorders (e.g., asthma and allergy); gastrointestinal disorders (e.g., inflammatory bowel disease); cancers (e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (e.g., multiple sclerosis; ischemic brain injury and/or stroke, traumatic brain
20 injury, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's disease); AIDS-related dementia; and prion disease); cardiovascular disorders (e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma,
25 pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection).

Because inflammation is a fundamental defense mechanism, inflammatory disorders can effect virtually any tissue of the body. Accordingly, polynucleotides,
30 polypeptides, and antibodies of the invention, as well as agonists or antagonists thereof, have uses in the treatment of tissue-specific inflammatory disorders, including, but not limited to, adrenalitis, alveolitis, angiocholecystitis, appendicitis,

balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chorditis, cochlitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myositis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis.

10 In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat organ transplant rejections and graft-versus-host disease. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues.

Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD. In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing experimental allergic and hyperacute xenograft rejection.

25 In other embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat immune complex diseases, including, but not limited to, serum sickness, post streptococcal glomerulonephritis, polyarteritis nodosa, and immune complex-induced vasculitis.

30 Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected,

and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of
5 application listing infectious agents, etc), without necessarily eliciting an immune response.

In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a vaccine adjuvant that enhances immune responsiveness to an antigen. In a specific embodiment,
10 polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance tumor-specific immune responses.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be
15 enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In
20 another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, respiratory syncytial virus, Dengue, rotavirus, Japanese B encephalitis, influenza A and B, parainfluenza, measles, cytomegalovirus, rabies, Junin, Chikungunya, Rift Valley Fever, herpes simplex, and
25 yellow fever.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as
30 an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune

response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B.

In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meissneria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, and *Borrelia burgdorferi*.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria) or Leishmania.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat infectious diseases including silicosis, sarcoidosis, and idiopathic pulmonary fibrosis; for example, by preventing the recruitment and activation of mononuclear phagocytes.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

In one embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production and

immunoglobulin class switching (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B
5 cell responsiveness to pathogens.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an activator of T cells.

In another specific embodiment, polypeptides, antibodies, polynucleotides
10 and/or agonists or antagonists of the present invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to induce
15 higher affinity antibodies.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to increase serum immunoglobulin concentrations.

In another specific embodiment, polypeptides, antibodies, polynucleotides
20 and/or agonists or antagonists of the present invention are used as an agent to accelerate recovery of immunocompromised individuals.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among aged populations and/or neonates.

25 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to,
30 concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment,

compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

In another specific embodiment, polypeptides, antibodies, polynucleotides
5 and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone
10 marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or
15 treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, and recovery from surgery.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one
20 embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonism of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to direct
30 an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to
5 virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or
10 Common Variable Immunodeficiency.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect. In another specific embodiment, polypeptides, antibodies,
15 polynucleotides and/or agonists or antagonists of the present invention are used in the pretreatment of bone marrow samples prior to transplant.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-
20 incompetence/immunodeficiency such as observed among SCID patients.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania.

25 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the
30 applications described herein, as they may apply to veterinary medicine.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of

blocking various aspects of immune responses to foreign agents or self. Examples of diseases or conditions in which blocking of certain aspects of immune responses may be desired include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and
5 diseases/disorders associated with pathogens.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus
10 and multiple sclerosis.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and
15 blocking sepsis.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related
20 idiopathic monoclonal gammopathies, and plasmacytomas.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated
25 and CD8 cytotoxic T cells and natural killer cells, in certain autoimmune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes.

The polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat idiopathic hyper-eosinophilic
30 syndrome by, for example, preventing eosinophil production and migration.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit complement mediated cell lysis.

5 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit antibody dependent cellular cytotoxicity.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery
10 wall.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed to treat adult respiratory distress syndrome (ARDS).

15 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be useful for stimulating wound and tissue repair, stimulating angiogenesis, and/or stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

In a specific embodiment, polynucleotides or polypeptides, and/or agonists
20 thereof are used to diagnose, prognose, treat, and/or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne
25 infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes
30 zoster), and/or pneumocystis carinii. Other diseases and disorders that may be prevented, diagnosed, prognosed, and/or treated with polynucleotides or

polypeptides, and/or agonists of the present invention include, but are not limited to, HIV infection, HTLV-BLV infection, lymphopenia, phagocyte bactericidal dysfunction anemia, thrombocytopenia, and hemoglobinuria.

5 In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

10 In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to diagnose, prognose, prevent, and/or treat cancers or neoplasms including immune cell or immune tissue-related cancers or neoplasms. Examples of cancers or neoplasms that may be prevented, diagnosed, or treated by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, acute
15 myelogenous leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL) Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, and/or diseases and disorders described in the section entitled "Hyperproliferative Disorders" elsewhere herein.

20 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of
25 decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

In specific embodiments, the compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete
30 splenectomy.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, ribozymes or soluble forms of the polypeptides of

the present invention (e.g., Fc fusion protein; see, e.g., Example 9). Agonists of the invention include, for example, binding or stimulatory antibodies, and soluble forms of the polypeptides (e.g., Fc fusion proteins; see, e.g., Example 9). polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention
5 may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (including, but not limited to, those listed above, and also including transgenic
10 animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741).
15 Administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention to such animals is useful for the generation of monoclonal antibodies against the polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention in an organ system listed above.

20 **Blood-Related Disorders**

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hemostatic (the stopping of bleeding) or thrombolytic (clot dissolving) activity. For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists
25 or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, hemophilia), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or
30 antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be

important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, diagnose, prognose, and/or treat thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to prevent, diagnose, prognose, and/or treat diseases and disorders of the blood and/or blood forming organs associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1, column 8 (Tissue Distribution Library Code).

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hematopoietic activity (the formation of blood cells). For example, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to increase the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis

and/or treatment of anemias and leukopenias described below. Alternatively, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to decrease the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g.,
5 basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets.. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of leukocytoses, such as, for example eosinophilia.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists
10 of the present invention may be used to prevent, treat, or diagnose blood dyscrasia.

Anemias are conditions in which the number of red blood cells or amount of hemoglobin (the protein that carries oxygen) in them is below normal. Anemia may be caused by excessive bleeding, decreased red blood cell production, or increased red blood cell destruction (hemolysis). The polynucleotides, polypeptides, antibodies,
15 and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias. Anemias that may be treated prevented or diagnosed by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include iron deficiency anemia, hypochromic anemia, microcytic anemia, chlorosis, hereditary sideroblastic anemia, idiopathic
20 acquired sideroblastic anemia, red cell aplasia, megaloblastic anemia (e.g., pernicious anemia, (vitamin B12 deficiency) and folic acid deficiency anemia), aplastic anemia, hemolytic anemias (e.g., autoimmune hemolytic anemia, microangiopathic hemolytic anemia, and paroxysmal nocturnal hemoglobinuria). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may
25 be useful in treating, preventing, and/or diagnosing anemias associated with diseases including but not limited to, anemias associated with systemic lupus erythematosus, cancers, lymphomas, chronic renal disease, and enlarged spleens. The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias
30 arising from drug treatments such as anemias associated with methyl dopa, dapson, and/or sulfadiazine. Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing,

and/or diagnosing anemias associated with abnormal red blood cell architecture including but not limited to, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase deficiency, and sickle cell anemia.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists
5 of the present invention may be useful in treating, preventing, and/or diagnosing
hemoglobin abnormalities, (e.g., those associated with sickle cell anemia, hemoglobin
C disease, hemoglobin S-C disease, and hemoglobin E disease). Additionally, the
polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the
present invention may be useful in diagnosing, prognosing, preventing, and/or treating
10 thalassemias, including, but not limited to major and minor forms of alpha-
thalassemia and beta-thalassemia.

In another embodiment, the polynucleotides, polypeptides, antibodies, and/or
agonists or antagonists of the present invention may be useful in diagnosing,
prognosing, preventing, and/or treating bleeding disorders including, but not limited
15 to, thrombocytopenia (e.g., idiopathic thrombocytopenic purpura, and thrombotic
thrombocytopenic purpura), Von Willebrand's disease, hereditary platelet disorders
(e.g., storage pool disease such as Chediak-Higashi and Hermansky-Pudlak
syndromes, thromboxane A2 dysfunction, thromboasthenia, and Bernard-Soulier
syndrome), hemolytic-uremic syndrome, hemophelias such as hemophelia A or Factor
20 VII deficiency and Christmas disease or Factor IX deficiency, Hereditary
Hemorrhagic Telangiectasia, also known as Rendu-Osler-Weber syndrome, allergic
purpura (Henoch Schonlein purpura) and disseminated intravascular coagulation.

The effect of the polynucleotides, polypeptides, antibodies, and/or agonists or
antagonists of the present invention on the clotting time of blood may be monitored
25 using any of the clotting tests known in the art including, but not limited to, whole
blood partial thromboplastin time (PTT), the activated partial thromboplastin time
(aPTT), the activated clotting time (ACT), the recalcified activated clotting time, or
the Lee-White Clotting time.

Several diseases and a variety of drugs can cause platelet dysfunction. Thus, in
30 a specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists
or antagonists of the present invention may be useful in diagnosing, prognosing,
preventing, and/or treating acquired platelet dysfunction such as platelet dysfunction

accompanying kidney failure, leukemia, multiple myeloma, cirrhosis of the liver, and systemic lupus erythematosus as well as platelet dysfunction associated with drug treatments, including treatment with aspirin, ticlopidine, nonsteroidal anti-inflammatory drugs (used for arthritis, pain, and sprains), and penicillin in high doses.

5 In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders characterized by or associated with increased or decreased numbers of white blood cells. Leukopenia occurs when the number of white blood cells decreases below normal. Leukopenias
10 include, but are not limited to, neutropenia and lymphocytopenia. An increase in the number of white blood cells compared to normal is known as leukocytosis. The body generates increased numbers of white blood cells during infection. Thus, leukocytosis may simply be a normal physiological parameter that reflects infection. Alternatively, leukocytosis may be an indicator of injury or other disease such as cancer.
15 Leukocytoses, include but are not limited to, eosinophilia, and accumulations of macrophages. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukopenia. In other specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or
20 antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukocytosis.

Leukopenia may be a generalized decreased in all types of white blood cells, or may be a specific depletion of particular types of white blood cells. Thus, in specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists
25 or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating decreases in neutrophil numbers, known as neutropenia. Neutropenias that may be diagnosed, prognosed, prevented, and/or treated by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, infantile genetic agranulocytosis,
30 familial neutropenia, cyclic neutropenia, neutropenias resulting from or associated with dietary deficiencies (e.g., vitamin B 12 deficiency or folic acid deficiency), neutropenias resulting from or associated with drug treatments (e.g., antibiotic

regimens such as penicillin treatment, sulfonamide treatment, anticoagulant treatment, anticonvulsant drugs, anti-thyroid drugs, and cancer chemotherapy), and neutropenias resulting from increased neutrophil destruction that may occur in association with some bacterial or viral infections, allergic disorders, autoimmune diseases, conditions
5 in which an individual has an enlarged spleen (e.g., Felty syndrome, malaria and sarcoidosis), and some drug treatment regimens.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating lymphocytopenias (decreased numbers of B and/or T lymphocytes),
10 including, but not limited lymphocytopenias resulting from or associated with stress, drug treatments (e.g., drug treatment with corticosteroids, cancer chemotherapies, and/or radiation therapies), AIDS infection and/or other diseases such as, for example, cancer, rheumatoid arthritis, systemic lupus erythematosus, chronic infections, some viral infections and/or hereditary disorders (e.g., DiGeorge syndrome, Wiskott-
15 Aldrich Syndrome, severe combined immunodeficiency, ataxia telangiectasia).

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with macrophage numbers and/or macrophage function including, but not limited to, Gaucher's disease, Niemann-Pick
20 disease, Letterer-Siwe disease and Hand-Schuller-Christian disease.

In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with eosinophil numbers and/or eosinophil function including, but not limited to,
25 idiopathic hypereosinophilic syndrome, eosinophilia-myalgia syndrome, and Hand-Schuller-Christian disease.

In yet another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukemias and lymphomas including, but not
30 limited to, acute lymphocytic (lymphoblastic) leukemia (ALL), acute myeloid (myelocytic, myelogenous, myeloblastic, or myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., B cell leukemias, T cell leukemias, Sezary syndrome, and

Hairy cell leukemia), chronic myelocytic (myeloid, myelogenous, or granulocytic) leukemia, Hodgkin's lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and mycosis fungoides.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or
5 agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders of plasma cells including, but not limited to, plasma cell dyscrasias, monoclonal gammaopathies, monoclonal gammopathies of undetermined significance, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, cryoglobulinemia, and
10 Raynaud's phenomenon.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing myeloproliferative disorders, including but not limited to, polycythemia vera, relative polycythemia, secondary polycythemia, myelofibrosis,
15 acute myelofibrosis, agnogenic myelod metaplasia, thrombocythemia, (including both primary and secondary thrombocythemia) and chronic myelocytic leukemia.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as a treatment prior to surgery, to increase blood cell production.

20 In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to enhance the migration, phagocytosis, superoxide production, antibody dependent cellular cytotoxicity of neutrophils, eosinophils and macrophages.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or
25 agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to stem cells pheresis. In another specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to platelet pheresis.

30 In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase cytokine production.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in preventing, diagnosing, and/or treating primary hematopoietic disorders.

5 **Hyperproliferative Disorders**

In certain embodiments, polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder
10 through direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating,
15 differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

20 Examples of hyperproliferative disorders that can be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and
25 peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: Acute
30 Childhood Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, Adult (Primary) Hepatocellular Cancer, Adult (Primary) Liver Cancer, Adult Acute

Lymphocytic Leukemia, Adult Acute Myeloid Leukemia, Adult Hodgkin's Disease,
 Adult Hodgkin's Lymphoma, Adult Lymphocytic Leukemia, Adult Non-Hodgkin's
 Lymphoma, Adult Primary Liver Cancer, Adult Soft Tissue Sarcoma, AIDS-Related
 Lymphoma, AIDS-Related Malignancies, Anal Cancer, Astrocytoma, Bile Duct
 5 Cancer, Bladder Cancer, Bone Cancer, Brain Stem Glioma, Brain Tumors, Breast
 Cancer, Cancer of the Renal Pelvis and Ureter, Central Nervous System (Primary)
 Lymphoma, Central Nervous System Lymphoma, Cerebellar Astrocytoma, Cerebral
 Astrocytoma, Cervical Cancer, Childhood (Primary) Hepatocellular Cancer,
 Childhood (Primary) Liver Cancer, Childhood Acute Lymphoblastic Leukemia,
 10 Childhood Acute Myeloid Leukemia, Childhood Brain Stem Glioma, Childhood
 Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Extracranial
 Germ Cell Tumors, Childhood Hodgkin's Disease, Childhood Hodgkin's Lymphoma,
 Childhood Hypothalamic and Visual Pathway Glioma, Childhood Lymphoblastic
 Leukemia, Childhood Medulloblastoma, Childhood Non-Hodgkin's Lymphoma,
 15 Childhood Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood
 Primary Liver Cancer, Childhood Rhabdomyosarcoma, Childhood Soft Tissue
 Sarcoma, Childhood Visual Pathway and Hypothalamic Glioma, Chronic
 Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Colon Cancer, Cutaneous
 T-Cell Lymphoma, Endocrine Pancreas Islet Cell Carcinoma, Endometrial Cancer,
 20 Ependymoma, Epithelial Cancer, Esophageal Cancer, Ewing's Sarcoma and Related
 Tumors, Exocrine Pancreatic Cancer, Extracranial Germ Cell Tumor, Extragonadal
 Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Female Breast
 Cancer, Gaucher's Disease, Gallbladder Cancer, Gastric Cancer, Gastrointestinal
 Carcinoid Tumor, Gastrointestinal Tumors, Germ Cell Tumors, Gestational
 25 Trophoblastic Tumor, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular
 Cancer, Hodgkin's Disease, Hodgkin's Lymphoma, Hypergammaglobulinemia,
 Hypopharyngeal Cancer, Intestinal Cancers, Intraocular Melanoma, Islet Cell
 Carcinoma, Islet Cell Pancreatic Cancer, Kaposi's Sarcoma, Kidney Cancer,
 Laryngeal Cancer, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer,
 30 Lymphoproliferative Disorders, Macroglobulinemia, Male Breast Cancer, Malignant
 Mesothelioma, Malignant Thymoma, Medulloblastoma, Melanoma, Mesothelioma,
 Metastatic Occult Primary Squamous Neck Cancer, Metastatic Primary Squamous

Neck Cancer, Metastatic Squamous Neck Cancer, Multiple Myeloma, Multiple Myeloma/Plasma Cell Neoplasm, Myelodysplastic Syndrome, Myelogenous Leukemia, Myeloid Leukemia, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin's

5 Lymphoma During Pregnancy, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Occult Primary Metastatic Squamous Neck Cancer, Oropharyngeal Cancer, Osteo-/Malignant Fibrous Sarcoma, Osteosarcoma/Malignant Fibrous Histiocytoma, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic

10 Cancer, Paraproteinemias, Purpura, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Primary Central Nervous System Lymphoma, Primary Liver Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Renal Pelvis and Ureter Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoidosis Sarcomas, Sezary

15 Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Neck Cancer, Stomach Cancer, Supratentorial Primitive Neuroectodermal and Pineal Tumors, T-Cell Lymphoma, Testicular Cancer, Thymoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Renal Pelvis and Ureter Cancer, Trophoblastic Tumors, Ureter and Renal

20 Pelvis Cell Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma, Vulvar Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumor, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

In another preferred embodiment, polynucleotides or polypeptides, or agonists

25 or antagonists of the present invention are used to diagnose, prognose, prevent, and/or treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described above. Such uses are indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia,

30 metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79.)

Hyperplasia is a form of controlled cell proliferation, involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Hyperplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, angiofollicular mediastinal lymph node hyperplasia, angiolymphoid hyperplasia with eosinophilia, atypical melanocytic hyperplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cementum hyperplasia, congenital adrenal hyperplasia, congenital sebaceous hyperplasia, cystic hyperplasia, cystic hyperplasia of the breast, denture hyperplasia, ductal hyperplasia, endometrial hyperplasia, fibromuscular hyperplasia, focal epithelial hyperplasia, gingival hyperplasia, inflammatory fibrous hyperplasia, inflammatory papillary hyperplasia, intravascular papillary endothelial hyperplasia, nodular hyperplasia of prostate, nodular regenerative hyperplasia, pseudoepitheliomatous hyperplasia, senile sebaceous hyperplasia, and verrucous hyperplasia.

Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, agnogenic myeloid metaplasia, apocrine metaplasia, atypical metaplasia, autoparenchymatous metaplasia, connective tissue metaplasia, epithelial metaplasia, intestinal metaplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, myeloid metaplasia, primary myeloid metaplasia, secondary myeloid metaplasia, squamous metaplasia, squamous metaplasia of amnion, and symptomatic myeloid metaplasia.

Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation. Dysplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, anhidrotic

ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, atriodigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphysial dysplasia, craniocarpotarsal dysplasia, 5 craniometaphysial dysplasia, dentin dysplasia, diaphysial dysplasia, ectodermal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, dysplasia epiphysialis hemimelia, dysplasia epiphysialis multiplex, dysplasia epiphysialis punctata, epithelial dysplasia, faciodigitogenital dysplasia, familial fibrous dysplasia of jaws, familial white folded dysplasia, fibromuscular dysplasia, fibrous dysplasia of bone, 10 florid osseous dysplasia, hereditary renal-retinal dysplasia, hidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, mucoepithelial dysplasia, multiple epiphysial dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, 15 oculovertbral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous dysplasia, pseudoachondroplastic spondyloepiphysial dysplasia, retinal dysplasia, septo-optic dysplasia, spondyloepiphysial dysplasia, and ventriculoradial dysplasia.

Additional pre-neoplastic disorders which can be diagnosed, prognosed, 20 prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps, colon polyps, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, Farmer's Skin, solar cheilitis, and solar keratosis.

25 In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1, column 8 (Tissue Distribution Library Code).

30 In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat cancers and neoplasms, including,

but not limited to those described herein. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat acute myelogenous leukemia.

5 Additionally, polynucleotides, polypeptides, and/or agonists or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be diagnosed, prognosed, prevented, and/or treated
10 by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma,
15 lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related
20 glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

 In preferred embodiments, polynucleotides, polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis
25 of cancers, in particular those listed above.

 Additional diseases or conditions associated with increased cell survival that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such
30 as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic

(granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, emangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, neoplasms located in the liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

Similarly, other hyperproliferative disorders can also be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Another preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention

inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for

polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some

of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

5 In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

10 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example., which serve to increase the number or activity of effector cells which interact with the antibodies.

 It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or
15 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments
20 thereof. Preferred binding affinities include those with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.

 Moreover, polypeptides of the present invention are useful in inhibiting the
25 angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl
30 Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,

Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, anti-inflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide

antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

10

Renal Disorders

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the renal system. Renal disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, kidney failure, nephritis, blood vessel disorders of kidney, metabolic and congenital kidney disorders, urinary disorders of the kidney, autoimmune disorders, sclerosis and necrosis, electrolyte imbalance, and kidney cancers.

Kidney diseases which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, acute kidney failure, chronic kidney failure, atheroembolic renal failure, end-stage renal disease, inflammatory diseases of the kidney (e.g., acute glomerulonephritis, postinfectious glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, familial nephrotic syndrome, membranoproliferative glomerulonephritis I and II, mesangial proliferative glomerulonephritis, chronic glomerulonephritis, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, acute post-streptococcal glomerulonephritis (PSGN), pyelonephritis, lupus nephritis, chronic nephritis, interstitial nephritis, and post-streptococcal glomerulonephritis), blood vessel disorders of the kidneys (e.g., kidney infarction, atheroembolic kidney disease, cortical necrosis, malignant nephrosclerosis, renal vein thrombosis, renal underperfusion, renal retinopathy, renal ischemia-reperfusion, renal

30

artery embolism, and renal artery stenosis), and kidney disorders resulting from urinary tract disease (e.g., pyelonephritis, hydronephrosis, urolithiasis (renal lithiasis, nephrolithiasis), reflux nephropathy, urinary tract infections, urinary retention, and acute or chronic unilateral obstructive uropathy.)

- 5 In addition, compositions of the invention can be used to diagnose, prognose, prevent, and/or treat metabolic and congenital disorders of the kidney (e.g., uremia, renal amyloidosis, renal osteodystrophy, renal tubular acidosis, renal glycosuria, nephrogenic diabetes insipidus, cystinuria, Fanconi's syndrome, renal fibrocystic osteosis (renal rickets), Hartnup disease, Bartter's syndrome, Liddle's syndrome,
- 10 polycystic kidney disease, medullary cystic disease, medullary sponge kidney, Alport's syndrome, nail-patella syndrome, congenital nephrotic syndrome, CRUSH syndrome, horseshoe kidney, diabetic nephropathy, nephrogenic diabetes insipidus, analgesic nephropathy, kidney stones, and membranous nephropathy), and autoimmune disorders of the kidney (e.g., systemic lupus erythematosus (SLE),
- 15 Goodpasture syndrome, IgA nephropathy, and IgM mesangial proliferative glomerulonephritis).

- Compositions of the invention can also be used to diagnose, prognose, prevent, and/or treat sclerotic or necrotic disorders of the kidney (e.g., glomerulosclerosis, diabetic nephropathy, focal segmental glomerulosclerosis
- 20 (FSGS), necrotizing glomerulonephritis, and renal papillary necrosis), cancers of the kidney (e.g., nephroma, hypernephroma, nephroblastoma, renal cell cancer, transitional cell cancer, renal adenocarcinoma, squamous cell cancer, and Wilm's tumor), and electrolyte imbalances (e.g., nephrocalcinosis, pyuria, edema, hydronephritis, proteinuria, hyponatremia, hypernatremia, hypokalemia,
- 25 hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia).

- Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle
- 30 accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the

art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

5 **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose cardiovascular disorders, including, but not limited to, peripheral artery disease, such as limb ischemia.

10 Cardiovascular disorders include, but are not limited to, cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include, but are not limited to, aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia,
15 patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilog of Fallot, ventricular heart septal defects.

20 Cardiovascular disorders also include, but are not limited to, heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy,
25 right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar
30 Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include, but are not limited to, sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-

branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular
5 rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve diseases include, but are not limited to, aortic valve insufficiency, aortic valve stenosis, heart murmurs, aortic valve prolapse, mitral valve prolapse,
10 tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include, but are not limited to, alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular
15 stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include, but are not limited to, coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis,
20 coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive
25 diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena
30 cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include, but are not limited to, dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include, but are not limited to, arteriosclerosis,
5 intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric
vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery
occlusion, and thromboangiitis obliterans.

Cerebrovascular disorders include, but are not limited to, carotid artery
diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral
10 arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases,
cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis,
Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural
hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia
(including transient), subclavian steal syndrome, periventricular leukomalacia,
15 vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include, but are not limited to, air embolisms, amniotic fluid
embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary
embolisms, and thromboembolisms. Thrombosis include, but are not limited to,
coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery
20 thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemic disorders include, but are not limited to, cerebral ischemia, ischemic
colitis, compartment syndromes, anterior compartment syndrome, myocardial
ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes, but
is not limited to, aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome,
25 mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity
vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's
granulomatosis.

Polypeptides may be administered using any method known in the art,
including, but not limited to, direct needle injection at the delivery site, intravenous
30 injection, topical administration, catheter infusion, biolistic injectors, particle
accelerators, gelfoam sponge depots, other commercially available depot materials,
osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or

topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

5

Respiratory Disorders

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases and/or disorders of the respiratory system.

- 10 Diseases and disorders of the respiratory system include, but are not limited to, nasal vestibulitis, nonallergic rhinitis (e.g., acute rhinitis, chronic rhinitis, atrophic rhinitis, vasomotor rhinitis), nasal polyps, and sinusitis, juvenile angiofibromas, cancer of the nose and juvenile papillomas, vocal cord polyps, nodules (singer's nodules), contact ulcers, vocal cord paralysis, laryngoceles, pharyngitis (e.g., viral and
15 bacterial), tonsillitis, tonsillar cellulitis, parapharyngeal abscess, laryngitis, laryngoceles, and throat cancers (e.g., cancer of the nasopharynx, tonsil cancer, larynx cancer), lung cancer (e.g., squamous cell carcinoma, small cell (oat cell) carcinoma, large cell carcinoma, and adenocarcinoma), allergic disorders (eosinophilic pneumonia, hypersensitivity pneumonitis (e.g., extrinsic allergic alveolitis, allergic
20 interstitial pneumonitis, organic dust pneumoconiosis, allergic bronchopulmonary aspergillosis, asthma, Wegener's granulomatosis (granulomatous vasculitis), Goodpasture's syndrome)), pneumonia (e.g., bacterial pneumonia (e.g., *Streptococcus pneumoniae* (pneumococcal pneumonia), *Staphylococcus aureus* (staphylococcal pneumonia), Gram-negative bacterial pneumonia (caused by, e.g., *Klebsiella* and
25 *Pseudomas spp.*), *Mycoplasma pneumoniae* pneumonia, *Hemophilus influenzae* pneumonia, *Legionella pneumophila* (Legionnaires' disease), and *Chlamydia psittaci* (Psittacosis)), and viral pneumonia (e.g., influenza, chickenpox (varicella).

- Additional diseases and disorders of the respiratory system include, but are not limited to bronchiolitis, polio (poliomyelitis), croup, respiratory syncytial viral
30 infection, mumps, erythema infectiosum (fifth disease), roseola infantum, progressive rubella panencephalitis, german measles, and subacute sclerosing panencephalitis), fungal pneumonia (e.g., Histoplasmosis, Coccidioidomycosis, Blastomycosis, fungal

infections in people with severely suppressed immune systems (e.g., cryptococcosis, caused by *Cryptococcus neoformans*; aspergillosis, caused by *Aspergillus spp.*; candidiasis, caused by *Candida*; and mucormycosis)), *Pneumocystis carinii* (pneumocystis pneumonia), atypical pneumonias (e.g., *Mycoplasma* and *Chlamydia* spp.), opportunistic infection pneumonia, nosocomial pneumonia, chemical pneumonitis, and aspiration pneumonia, pleural disorders (e.g., pleurisy, pleural effusion, and pneumothorax (e.g., simple spontaneous pneumothorax, complicated spontaneous pneumothorax, tension pneumothorax)), obstructive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis, black lung (coal workers' pneumoconiosis), asbestosis, berylliosis, occupational asthma, byssinosis, and benign pneumoconioses), Infiltrative Lung Disease (e.g., pulmonary fibrosis (e.g., fibrosing alveolitis, usual interstitial pneumonia), idiopathic pulmonary fibrosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, histiocytosis X (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma), idiopathic pulmonary hemosiderosis, sarcoidosis and pulmonary alveolar proteinosis), Acute respiratory distress syndrome (also called, e.g., adult respiratory distress syndrome), edema, pulmonary embolism, bronchitis (e.g., viral, bacterial), bronchiectasis, atelectasis, lung abscess (caused by, e.g., *Staphylococcus aureus* or *Legionella pneumophila*), and cystic fibrosis.

Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization

including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and

Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists
5 may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in
10 treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular
15 glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations;
20 ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a
25 polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists of the invention are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This
30 therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress

(approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and

administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the

compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, disorders and/or states, which can be treated, prevented, diagnosed, and/or prognosed with the the polynucleotides, polypeptides, agonists and/or antagonists of the invention include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals,

arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation
5 controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (Helicobacter pylori), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and
10 fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

15 Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present
20 invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat
25 tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized
30 during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl

complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten
5 oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its
10 hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and
15 sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan
20 Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin;
25 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum;
30 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-

316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolimidazole; and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

5 Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors,
10 pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's
15 syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

20 In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or
25 antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic
30 lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and

carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include, but are not limited to, AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to

stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical

5 wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications
10 associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

Polynucleotides or polypeptides, as well as agonists or antagonists of the
15 present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown
20 grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or
25 antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach,
30 small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes,

mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

5 Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides,
10 as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat
15 glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides,
20 as well as agonists or antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly.

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large
25 intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the
30 production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Neural Activity and Neurological Diseases

The polynucleotides, polypeptides and agonists or antagonists of the invention may be used for the diagnosis and/or treatment of diseases, disorders, damage or injury of the brain and/or nervous system. Nervous system disorders that can be

5 treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian

10 patients) according to the methods of the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including

15 lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of

20 the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, or syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to, degeneration

25 associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including, but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia,

30 Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy),

systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human
5 immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In one embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects
10 of hypoxia. In a further preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one non-exclusive aspect of this embodiment, the
15 polypeptides, polynucleotides, or agonists or antagonists of the invention, are used to treat or prevent neural cell injury associated with cerebral ischemia. In another non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction.

20 In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a stroke.

25 In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a heart attack.

30 The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of

limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture either in the presence or absence of hypoxia or hypoxic conditions; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, in Zhang *et al.*, *Proc Natl Acad Sci USA* 97:3637-42 (2000) or in Arakawa *et al.*, *J. Neurosci.*, 10:3507-15 (1990); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk *et al.*, *Exp. Neurol.*, 70:65-82 (1980), or Brown *et al.*, *Ann. Rev. Neurosci.*, 4:17-42 (1981); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists

or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such

5 neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition,

10 compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage,

15 disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus

20 thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

25 In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be

30 used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral

encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, 5 encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden- 10 Spatz Syndrome.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral 15 malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine 20 Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis 25 which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uveomeningoencephalitic syndrome, myelitis such as 30 transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as

Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention

5 include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral

10 scleritis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue

15 Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's

20 Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett

25 Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

30 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie

- Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia,
- 5 apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia,
- 10 broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia,
- 15 myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic
- 20 Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism,
- 25 spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy,
- 30 Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia,

- amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes
- 5 Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis,
- 10 Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.
- 15 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial
- 20 neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies
- 25 which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Endocrine Disorders

- Polynucleotides or polypeptides, or agonists or antagonists of the present
- 30 invention, may be used to treat, prevent, diagnose, and/or prognose disorders and/or diseases related to hormone imbalance, and/or disorders or diseases of the endocrine

system.

Hormones secreted by the glands of the endocrine system control physical growth, sexual function, metabolism, and other functions. Disorders may be classified in two ways: disturbances in the production of hormones, and the inability of tissues
5 to respond to hormones. The etiology of these hormone imbalance or endocrine system diseases, disorders or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy, injury or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular
10 disease or disorder related to the endocrine system and/or hormone imbalance.

Endocrine system and/or hormone imbalance and/or diseases encompass disorders of uterine motility including, but not limited to: complications with pregnancy and labor (e.g., pre-term labor, post-term pregnancy, spontaneous abortion, and slow or stopped labor); and disorders and/or diseases of the menstrual
15 cycle (e.g., dysmenorrhea and endometriosis).

Endocrine system and/or hormone imbalance disorders and/or diseases include disorders and/or diseases of the pancreas, such as, for example, diabetes mellitus, diabetes insipidus, congenital pancreatic agenesis, pheochromocytoma--islet cell tumor syndrome; disorders and/or diseases of the adrenal glands such as, for example,
20 Addison's Disease, corticosteroid deficiency, virilizing disease, hirsutism, Cushing's Syndrome, hyperaldosteronism, pheochromocytoma; disorders and/or diseases of the pituitary gland, such as, for example, hyperpituitarism, hypopituitarism, pituitary dwarfism, pituitary adenoma, panhypopituitarism, acromegaly, gigantism; disorders and/or diseases of the thyroid, including but not limited to, hyperthyroidism,
25 hypothyroidism, Plummer's disease, Graves' disease (toxic diffuse goiter), toxic nodular goiter, thyroiditis (Hashimoto's thyroiditis, subacute granulomatous thyroiditis, and silent lymphocytic thyroiditis), Pendred's syndrome, myxedema, cretinism, thyrotoxicosis, thyroid hormone coupling defect, thymic aplasia, Hurthle cell tumours of the thyroid, thyroid cancer, thyroid carcinoma, Medullary thyroid
30 carcinoma; disorders and/or diseases of the parathyroid, such as, for example, hyperparathyroidism, hypoparathyroidism; disorders and/or diseases of the hypothalamus.

In addition, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases of the testes or ovaries, including cancer. Other disorders and/or diseases of the testes or ovaries further include, for example, ovarian cancer, polycystic ovary syndrome, Klinefelter's syndrome, 5 vanishing testes syndrome (bilateral anorchia), congenital absence of Leydig's cells, cryptorchidism, Noonan's syndrome, myotonic dystrophy, capillary haemangioma of the testis (benign), neoplasias of the testis and neo-testis.

Moreover, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases such as, for example, 10 polyglandular deficiency syndromes, pheochromocytoma, neuroblastoma, multiple Endocrine neoplasia, and disorders and/or cancers of endocrine tissues.

In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose, prognose, prevent, and/or treat endocrine diseases and/or disorders 15 associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1, column 8 (Tissue Distribution Library Code).

Reproductive System Disorders

20 The polynucleotides or polypeptides, or agonists or antagonists of the invention may be used for the diagnosis, treatment, or prevention of diseases and/or disorders of the reproductive system. Reproductive system disorders that can be treated by the compositions of the invention, include, but are not limited to, reproductive system injuries, infections, neoplastic disorders, congenital defects, and 25 diseases or disorders which result in infertility, complications with pregnancy, labor, or parturition, and postpartum difficulties.

Reproductive system disorders and/or diseases include diseases and/or disorders of the testes, including testicular atrophy, testicular feminization, cryptorchism (unilateral and bilateral), anorchia, ectopic testis, epididymitis and 30 orchitis (typically resulting from infections such as, for example, gonorrhea, mumps, tuberculosis, and syphilis), testicular torsion, vasitis nodosa, germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, yolk sac

tumors, and teratomas), stromal tumors (e.g., Leydig cell tumors), hydrocele, hematocele, varicocele, spermatocele, inguinal hernia, and disorders of sperm production (e.g., immotile cilia syndrome, aspermia, asthenozoospermia, azoospermia, oligospermia, and teratozoospermia).

5 Reproductive system disorders also include disorders of the prostate gland, such as acute non-bacterial prostatitis, chronic non-bacterial prostatitis, acute bacterial prostatitis, chronic bacterial prostatitis, prostatodystonia, prostatosis, granulomatous prostatitis, malacoplakia, benign prostatic hypertrophy or hyperplasia, and prostate neoplastic disorders, including adenocarcinomas, transitional cell carcinomas, ductal
10 carcinomas, and squamous cell carcinomas.

 Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases of the penis and urethra, including inflammatory disorders, such as balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, syphilis, herpes simplex virus, gonorrhea, non-
15 gonococcal urethritis, chlamydia, mycoplasma, trichomonas, HIV, AIDS, Reiter's syndrome, condyloma acuminatum, condyloma latum, and pearly penile papules; urethral abnormalities, such as hypospadias, epispadias, and phimosis; premalignant lesions, including Erythroplasia of Queyrat, Bowen's disease, Bowenoid paplosis, giant condyloma of Buscke-Lowenstein, and verrucous carcinoma; penile cancers,
20 including squamous cell carcinomas, carcinoma in situ, verrucous carcinoma, and disseminated penile carcinoma; urethral neoplastic disorders, including penile urethral carcinoma, bulbomembranous urethral carcinoma, and prostatic urethral carcinoma; and erectile disorders, such as priapism, Peyronie's disease, erectile dysfunction, and impotence.

25 Moreover, diseases and/or disorders of the vas deferens include vasculitis and CBAVD (congenital bilateral absence of the vas deferens); additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the seminal vesicles, including hydatid disease, congenital chloride
30 diarrhea, and polycystic kidney disease.

 Other disorders and/or diseases of the male reproductive system include, for example, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes

mellitus, cystic fibrosis, Kartagener's syndrome, high fever, multiple sclerosis, and gynecomastia.

Further, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of
5 diseases and/or disorders of the vagina and vulva, including bacterial vaginosis, candida vaginitis, herpes simplex virus, chancroid, granuloma inguinale, lymphogranuloma venereum, scabies, human papillomavirus, vaginal trauma, vulvar trauma, adenositis, chlamydia vaginitis, gonorrhea, trichomonas vaginitis, condyloma acuminatum, syphilis, molluscum contagiosum, atrophic vaginitis, Paget's disease,
10 lichen sclerosus, lichen planus, vulvodynia, toxic shock syndrome, vaginismus, vulvovaginitis, vulvar vestibulitis, and neoplastic disorders, such as squamous cell hyperplasia, clear cell carcinoma, basal cell carcinoma, melanomas, cancer of Bartholin's gland, and vulvar intraepithelial neoplasia.

Disorders and/or diseases of the uterus include dysmenorrhea, retroverted
15 uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding (e.g., due to aberrant hormonal signals), and neoplastic disorders, such as adenocarcinomas, leiomyosarcomas, and sarcomas. Additionally, the polypeptides, polynucleotides, or
20 agonists or antagonists of the invention may be useful as a marker or detector of, as well as in the diagnosis, treatment, and/or prevention of congenital uterine abnormalities, such as bicornuate uterus, septate uterus, simple unicornuate uterus, unicornuate uterus with a noncavitary rudimentary horn, unicornuate uterus with a non-communicating cavitary rudimentary horn, unicornuate uterus with a
25 communicating cavitary horn, arcuate uterus, uterine didelphys, and T-shaped uterus.

Ovarian diseases and/or disorders include anovulation, polycystic ovary syndrome (Stein-Leventhal syndrome), ovarian cysts, ovarian hypofunction, ovarian insensitivity to gonadotropins, ovarian overproduction of androgens, right ovarian vein syndrome, amenorrhea, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, Sertoli-Leydig tumors, endometriod
30 carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, and Ovarian Krukenberg tumors).

Cervical diseases and/or disorders include cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, and cervical neoplasms (including, for example, cervical carcinoma, squamous metaplasia, squamous cell carcinoma, adenosquamous cell neoplasia, and columnar cell neoplasia).

Additionally, diseases and/or disorders of the reproductive system include disorders and/or diseases of pregnancy, including miscarriage and stillbirth, such as early abortion, late abortion, spontaneous abortion, induced abortion, therapeutic abortion, threatened abortion, missed abortion, incomplete abortion, complete abortion, habitual abortion, missed abortion, and septic abortion; ectopic pregnancy, anemia, Rh incompatibility, vaginal bleeding during pregnancy, gestational diabetes, intrauterine growth retardation, polyhydramnios, HELLP syndrome, abruptio placentae, placenta previa, hyperemesis, preeclampsia, eclampsia, herpes gestationis, and urticaria of pregnancy. Additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases that can complicate pregnancy, including heart disease, heart failure, rheumatic heart disease, congenital heart disease, mitral valve prolapse, high blood pressure, anemia, kidney disease, infectious disease (e.g., rubella, cytomegalovirus, toxoplasmosis, infectious hepatitis, chlamydia, HIV, AIDS, and genital herpes), diabetes mellitus, Graves' disease, thyroiditis, hypothyroidism, Hashimoto's thyroiditis, chronic active hepatitis, cirrhosis of the liver, primary biliary cirrhosis, asthma, systemic lupus eryematositis, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, appendicitis, ovarian cysts, gallbladder disorders, and obstruction of the intestine.

Complications associated with labor and parturition include premature rupture of the membranes, pre-term labor, post-term pregnancy, postmaturity, labor that progresses too slowly, fetal distress (e.g., abnormal heart rate (fetal or maternal), breathing problems, and abnormal fetal position), shoulder dystocia, prolapsed umbilical cord, amniotic fluid embolism, and aberrant uterine bleeding.

Further, diseases and/or disorders of the postdelivery period, including endometritis, myometritis, parametritis, peritonitis, pelvic thrombophlebitis,

pulmonary embolism, endotoxemia, pyelonephritis, saphenous thrombophlebitis, mastitis, cystitis, postpartum hemorrhage, and inverted uterus.

Other disorders and/or diseases of the female reproductive system that may be diagnosed, treated, and/or prevented by the polynucleotides, polypeptides, and agonists or antagonists of the present invention include, for example, Turner's syndrome, pseudohermaphroditism, premenstrual syndrome, pelvic inflammatory disease, pelvic congestion (vascular engorgement), frigidity, anorgasmia, dyspareunia, ruptured fallopian tube, and Mittelschmerz.

10 **Infectious Disease**

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papilloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial

virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

Similarly, bacterial and fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacteria, bacterial families, and fungi: Actinomyces (e.g., Norcardia), Acinetobacter, *Cryptococcus neoformans*, Aspergillus, Bacillaceae (e.g., *Bacillus anthracis*), Bacteroides (e.g., *Bacteroides fragilis*), Blastomycosis, Bordetella, Borrelia (e.g., *Borrelia burgdorferi*), Brucella, Candidia, Campylobacter, Chlamydia, Clostridium (e.g., *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Clostridium tetani*), Coccidioides, Corynebacterium (e.g., *Corynebacterium diphtheriae*), Cryptococcus, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacter (e.g., *Enterobacter aerogenes*), Enterobacteriaceae (Klebsiella, Salmonella (e.g., *Salmonella typhi*, *Salmonella enteritidis*, *Salmonella typhi*), Serratia, Yersinia, Shigella), Erysipelothrix, Haemophilus (e.g., *Haemophilus influenza* type B), Helicobacter, Legionella (e.g., *Legionella pneumophila*), Leptospira, Listeria (e.g., *Listeria monocytogenes*), Mycoplasma, Mycobacterium (e.g., *Mycobacterium leprae* and *Mycobacterium tuberculosis*), Vibrio (e.g., *Vibrio cholerae*), Neisseriaceae (e.g.,

Neisseria gonorrhea, *Neisseria meningitidis*), Pasteurellaceae, *Proteus*, *Pseudomonas* (e.g., *Pseudomonas aeruginosa*), Rickettsiaceae, *Spirochetes* (e.g., *Treponema* spp., *Leptospira* spp., *Borrelia* spp.), *Shigella* spp., *Staphylococcus* (e.g., *Staphylococcus aureus*), *Meningioccus*, *Pneumococcus* and *Streptococcus* (e.g., *Streptococcus pneumoniae* and Groups A, B, and C *Streptococci*), and *Ureaplasmas*. These

5 bacterial, parasitic, and fungal families can cause diseases or symptoms, including, but not limited to: antibiotic-resistant infections, bacteremia, endocarditis, septicemia, eye infections (e.g., conjunctivitis), uveitis, tuberculosis, gingivitis, bacterial diarrhea, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related

10 infections, dental caries, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, dysentery, paratyphoid fever, food poisoning, *Legionella* disease, chronic and acute inflammation, erythema, yeast infections, typhoid, pneumonia, gonorrhea, meningitis (e.g., meningitis types A and B), chlamydia, syphilis, diphtheria, leprosy, brucellosis,

15 peptic ulcers, anthrax, spontaneous abortions, birth defects, pneumonia, lung infections, ear infections, deafness, blindness, lethargy, malaise, vomiting, chronic diarrhea, Crohn's disease, colitis, vaginosis, sterility, pelvic inflammatory diseases, candidiasis, paratuberculosis, tuberculosis, lupus, botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases

20 (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections, nosocomial infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, diphtheria, botulism, and/or meningitis type B.

25 Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Schistosoma,

30 Theileriasis, Toxoplasmosis, Trypanosomiasis, and *Trichomonas* and Sporozoans (e.g., *Plasmodium virax*, *Plasmodium falciparum*, *Plasmodium malariae* and *Plasmodium ovale*). These parasites can cause a variety of diseases or symptoms,

including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be
5 used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an
10 effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

15

Regeneration

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997)). The regeneration of
20 tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs
25 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists
30 of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the

present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular
5 insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases,
10 neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic
15 lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

Gastrointestinal Disorders

20 Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose gastrointestinal disorders, including inflammatory diseases and/or conditions, infections, cancers (e.g., intestinal neoplasms (carcinoid tumor of the small intestine, non-Hodgkin's lymphoma of the small intestine, small bowel lymphoma)), and ulcers, such as peptic
25 ulcers.

Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers,
30 polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric stenosis, gastritis (bacterial, viral, eosinophilic, stress-induced, chronic erosive, atrophic, plasma cell, and Ménétrier's), and peritoneal diseases (e.g., chyloperitoneum,

hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, peritonitis, pneumoperitoneum, bubphrenic abscess,).

Gastrointestinal disorders also include disorders associated with the small
 5 intestine, such as malabsorption syndromes, distension, irritable bowel syndrome, sugar intolerance, celiac disease, duodenal ulcers, duodenitis, tropical sprue, Whipple's disease, intestinal lymphangiectasia, Crohn's disease, appendicitis, obstructions of the ileum, Meckel's diverticulum, multiple diverticula, failure of complete rotation of the small and large intestine, lymphoma, and bacterial and
 10 parasitic diseases (such as Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by Roundworms (*Ascariasis lumbricoides*), Hookworms (*Ancylostoma duodenale*), Threadworms (*Enterobius vermicularis*), Tapeworms (*Taenia saginata*, *Echinococcus granulosus*, *Diphyllobothrium spp.*, and *T. solium*).

Liver diseases and/or disorders include intrahepatic cholestasis (alagille
 15 syndrome, biliary liver cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome), hepatic vein thrombosis, hepatolenticular degeneration, hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome, portal hypertension (esophageal and gastric varices), liver abscess (amebic liver abscess), liver cirrhosis (alcoholic, biliary and experimental), alcoholic liver diseases (fatty liver, hepatitis, cirrhosis),
 20 parasitic (hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (hemolytic, hepatocellular, and cholestatic), cholestasis, portal hypertension, liver enlargement, ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced), toxic hepatitis, viral human hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E),
 25 Wilson's disease, granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, portal hypertension, varices, hepatic encephalopathy, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (hepatic encephalopathy, acute liver failure), and liver neoplasms (angiomyolipoma, calcified liver metastases, cystic liver metastases, epithelial
 30 tumors, fibrolamellar hepatocarcinoma, focal nodular hyperplasia, hepatic adenoma, hepatobiliary cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma, liver cancer, liver hemangioendothelioma, mesenchymal hamartoma, mesenchymal

- tumors of liver, nodular regenerative hyperplasia, benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal tumors [Mesenchymal hamartoma, Infantile hemangioendothelioma, Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor, Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular hyperplasia, Nodular regenerative hyperplasia)], malignant liver tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma, cholangiocellular, cholangiocarcinoma, cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Kaposi's sarcoma, hemangioendothelioma, other tumors, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma]), peliosis hepatis, erythrohepatic porphyria, hepatic porphyria (acute intermittent porphyria, porphyria cutanea tarda), Zellweger syndrome).
- 15 Pancreatic diseases and/or disorders include acute pancreatitis, chronic pancreatitis (acute necrotizing pancreatitis, alcoholic pancreatitis), neoplasms (adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma, gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors, pancreoblastoma), and other pancreatic diseases (e.g., cystic fibrosis, cyst (pancreatic pseudocyst, pancreatic
- 20 fistula, insufficiency)).
- Gallbladder diseases include gallstones (cholelithiasis and choledocholithiasis), postcholecystectomy syndrome, diverticulosis of the gallbladder, acute cholecystitis, chronic cholecystitis, bile duct tumors, and mucocele.
- Diseases and/or disorders of the large intestine include antibiotic-associated
- 25 colitis, diverticulitis, ulcerative colitis, acquired megacolon, abscesses, fungal and bacterial infections, anorectal disorders (e.g., fissures, hemorrhoids), colonic diseases (colitis, colonic neoplasms [colon cancer, adenomatous colon polyps (e.g., villous adenoma), colon carcinoma, colorectal cancer], colonic diverticulitis, colonic diverticulosis, megacolon [Hirschsprung disease, toxic megacolon]; sigmoid diseases
- 30 [proctocolitis, sigmoid neoplasms]), constipation, Crohn's disease, diarrhea (infantile diarrhea, dysentery), duodenal diseases (duodenal neoplasms, duodenal obstruction, duodenal ulcer, duodenitis), enteritis (enterocolitis), HIV enteropathy, ileal diseases

- (ileal neoplasms, ileitis), immunoproliferative small intestinal disease, inflammatory bowel disease (ulcerative colitis, Crohn's disease), intestinal atresia, parasitic diseases (anisakiasis, balantidiasis, blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic dysentery, giardiasis), intestinal fistula (rectal fistula), intestinal neoplasms
- 5 (cecal neoplasms, colonic neoplasms, duodenal neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms, rectal neoplasms), intestinal obstruction (afferent loop syndrome, duodenal obstruction, impacted feces, intestinal pseudo-obstruction [cecal volvulus], intussusception), intestinal perforation, intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers syndrome), jejunal diseases (jejunal neoplasms),
- 10 malabsorption syndromes (blind loop syndrome, celiac disease, lactose intolerance, short bowel syndrome, tropical sprue, whipple's disease), mesenteric vascular occlusion, pneumatosis cystoides intestinalis, protein-losing enteropathies (intestinal lymphagiectasis), rectal diseases (anus diseases, fecal incontinence, hemorrhoids, proctitis, rectal fistula, rectal prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic
- 15 esophagitis, hemorrhage, perforation, stomach ulcer, Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping syndrome), stomach diseases (e.g., achlorhydria, duodenogastric reflux (bile reflux), gastric antral vascular ectasia, gastric fistula, gastric outlet obstruction, gastritis (atrophic or hypertrophic), gastroparesis, stomach dilatation, stomach diverticulum, stomach neoplasms (gastric
- 20 cancer, gastric polyps, gastric adenocarcinoma, hyperplastic gastric polyp), stomach rupture, stomach ulcer, stomach volvulus), tuberculosis, visceroptosis, vomiting (e.g., hematemesis, hyperemesis gravidarum, postoperative nausea and vomiting) and hemorrhagic colitis.

- Further diseases and/or disorders of the gastrointestinal system include biliary
- 25 tract diseases, such as, gastroschisis, fistula (e.g., biliary fistula, esophageal fistula, gastric fistula, intestinal fistula, pancreatic fistula), neoplasms (e.g., biliary tract neoplasms, esophageal neoplasms, such as adenocarcinoma of the esophagus, esophageal squamous cell carcinoma, gastrointestinal neoplasms, pancreatic
- neoplasms, such as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the
- 30 pancreas, pancreatic cystic neoplasms, pancreatoblastoma, and peritoneal neoplasms), esophageal disease (e.g., bullous diseases, candidiasis, glycogenic acanthosis, ulceration, barrett esophagus varices, atresia, cyst, diverticulum (e.g., Zenker's

diverticulum), fistula (e.g., tracheoesophageal fistula), motility disorders (e.g., CREST syndrome, deglutition disorders, achalasia, spasm, gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave syndrome, Mallory-Weiss syndrome), stenosis, esophagitis, diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal
5 diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk virus infection), hemorrhage (e.g., hematemesis, melena, peptic ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g., congenital diaphragmatic hernia, femoral hernia, inguinal hernia, obturator hernia, umbilical hernia, ventral hernia), and intestinal diseases (e.g., cecal
10 diseases (appendicitis, cecal neoplasms)).

Chemotaxis

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotactic molecule attracts or
15 mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotactic activity of particular cells. These
20 chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by
25 attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or
30 polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit
5 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural
10 or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)). Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

15 Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or
20 inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

25 Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a
30 standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The

antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labeled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. *See generally*, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., *et al.*, *Curr. Opinion Biotechnol.* 8:724-

33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., *et al.*, *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and
5 corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior
10 to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments,
15 the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation
20 factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present
25 invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the
30 polypeptide of the present invention, the compound to be screened and $^3\text{[H]}$ thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be

screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of $^3\text{[H]}$ thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of $^3\text{[H]}$ thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Targeted Delivery

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

- 5 As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention
- 10 (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate
- 15 episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

- 20 By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes
- 25 known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a
- 30 non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of

benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

5 **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected
10 compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in
15 such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation
20 of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the
25 present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a
30 particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present

invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

10 This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Polypeptides of the Invention Binding Peptides and Other Molecules

The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the polypeptide of the invention binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

25 This method comprises the steps of: contacting a polypeptide of the invention with a plurality of molecules; and identifying a molecule that binds the polypeptide of the invention.

The step of contacting the polypeptide of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the polypeptide of the invention on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptide of the invention. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptide of the

invention. The molecules having a selective affinity for the polypeptide of the invention can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptide of the invention to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional
5 and well known to those of ordinary skill in the art.

Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of
10 polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be "probed" by the polypeptide of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptide of
15 the invention and the individual clone. Prior to contacting the polypeptide of the invention with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of
20 transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for a polypeptide of the invention. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptide of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be
25 determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

In certain situations, it may be desirable to wash away any unbound
30 polypeptide of the invention, or alternatively, unbound polypeptides, from a mixture of the polypeptide of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction.

Such a wash step may be particularly desirable when the polypeptide of the invention or the plurality of polypeptides is bound to a solid support.

The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide
5 libraries which can be screened for molecules that specifically bind to a polypeptide of the invention. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature*
10 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al.,
15 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R. B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157;
20 Kay et al., 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9022-9026.

25 By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically
30 transformed combinatorial library, is described by Ostresh et al. (1994, *Proc. Natl. Acad. Sci. USA* 91:11138-11142).

The variety of non-peptide libraries that are useful in the present invention is

great. For example, Ecker and Crooke, 1995, *Bio/Technology* 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, *Adv. Exp. Med. Biol.* 251:215-218; Scott and Smith, 1990, *Science* 249:386-390; Fowlkes et al., 1992; *BioTechniques* 13:422-427; Oldenburg et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:5393-5397; Yu et al., 1994, *Cell* 76:933-945; Staudt et al., 1988, *Science* 241:577-580; Bock et al., 1992, *Nature* 355:564-566; Tuerk et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:6988-6992; Ellington et al., 1992, *Nature* 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, *Science* 263:671-673; and CT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a molecule that binds a polypeptide of the invention can be carried out by contacting the library members with a polypeptide of the invention immobilized on a solid phase and harvesting those

library members that bind to the polypeptide of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

5 In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a polypeptide of the invention.

Where the polypeptide of the invention binding molecule is a polypeptide, the
10 polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

15 Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine.

20 Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

As mentioned above, in the case of a polypeptide of the invention binding
25 molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a polypeptide of the invention binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

30 The selected polypeptide of the invention binding polypeptide can be obtained by chemical synthesis or recombinant expression.

Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited
5 clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA
10 or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300
15 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These
20 experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is
25 heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA
30 oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense

RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non-translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, *e.g.*, PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, *e.g.*, Krol et al., *BioTechniques*, 6:958-976 (1988)) or intercalating agents. (See, *e.g.*, Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are

commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990)). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of

the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

Other Activities

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide

may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to

modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by
5 influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present
10 invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

15 Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous
20 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous
25 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of
30 contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5'

Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
5 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

10 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X
15 in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under
20 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which
25 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
30 sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA

Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected

from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least
5 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
10 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least
15 one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a
20 biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA
25 Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least
30 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as

defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid

sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone

identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 7, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 7 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 7. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 7. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 7

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HLDAB75	11	1138191	AI022193, AW139382, AA484435, AL118990, AI499684, AI936673, H94666, AA828353, AI500265, W25099, AI695809, T80683, AA773578, AA865715, T81364, AA703007, T72188, T62061, T72967, AA700860, T68210, T68646, and T71737.
1	HLDAB75	33	944248	AI022193, AW139382, AA484435, AL118990, AI499684, AI936673, H94666, AA828353, AI500265, W25099, AI695809, T80683, AA773578, AA865715, T81364, AA703007, T72188, T62061, T72967, AA700860, T68210, T68646, and T71737.
2	HDPGT25	12	1127875	AW131613, AI798698, AI659391, AI383966, AI301904, AI141050, AW051534, AI436572, AI423024, AI949462, AI765807, AI860169, AI361220, AA669355, AI917250, AI127630, AI206098, AI025741, AA102584, AI379587, AI660603, AI092712, AI445710, AA232806, AW195884, AI750128, AA773721, AI081798, AI858261, AI371779, AI379674, AA557338, AI246467, AW205857, AI085334, AA446521, AI275393, AI803647, AA534301, AI200736, AI275421, AA442342, AA677318, AW024979, AA780999, AI682250, AA890704, AA825312, AA354775, AA400736, W20040, AI492629, AI378226, AI623977, AI800704, AW130062,

				AW015559, AI751864, AW003455, AI751865, AI983914, AA885942, AA906852, AW051657, AA437265, AA773840, AI568957, AW190646, AI276712, N62947, AI278977, AA232534, AA233861, AI274077, AI222157, AA708681, AA232099, AA987704, W74448, AI559955, AA400461, AI024657, AW195372, R83674, AA235866, AW450241, R83686, AI241402, H27797, AI225079, AW193093, AA970287, AA358446, AI363499, H51031, AA928622, H28191, AA625934, AI916024, H52549, N63163, R83661, AA669356, N91378, N79850, AW103180, T86281, AI435315, AI769946, AI208326, AI784521, AI350985, R79809, R83660, T72660, T67465, R83685, R83673, H28234, AA296079, AI471621, AA315225, H51032, AA364922, AA430360, F32350, AA306937, R86312, T86380, D79226, AI268212, H26813, AI910377, R86311, R79909, AI567136, W72762, AI203285, H60248, AI869518, H88268, AA918002, H28014, R86296, H80916, AI567085, T72729, T96316, AA634691, AI471363, R86297, AI284210, D20230, D58181, H52153, T99806, AW299944, T39986, AI758516, T98500, T93486, AI244569, AA095338, T99911, AI432316, AI583987, AW054877, D57273, AF136411, T69498, AA082118, H88269, AI093819, AI458482, AA495794, AI091031, AI583515, AW194818, T98445, AA700194, AI719360, AI886968, AA236068, AA644472, AA358447, AI963920, AI342813, AA456230, T11390, AR030960, and AF171875.
2	HDPGT25	34	1042465	T39986, T93486, T96316, T67465, T69498, T72660, T72729, T86380, T86281, T98445, T98500, T99806, T99911, R79809, R79909, H26813, H27797, H28014, H28191, H28234, R83661, R83660, R83673, R83674, R83685, R83686, R86297, R86296, R86312, R86311, H51032, H51031, H52549, H60248, H80916, H88268, H88269, N62947, N63163, N79850, W20040, W72762, W74448, N91378, AA082118, AA102584, AA232099, AA232534, AA232806, AA233861, AA235866, AA236068, AA534301, AA557338, AA825312, AA885942, AA918002, AA928622, AA970287, AA987704, D79226, AA400461, AA400736, AA430360, AA437265, AA442342, AA446521, AA625934, AA644472, AA669356, AA669355, AA677318, AA708681, AA780999, AA890704, AA773721, AA906852, AI024657,

				AI025741, AI081798, AI092712, T11390, AA773840, AI244569, AI278977, AI301904, AI342813, AI361220, AI363499, AI371779, AI203285, AI206098, AI436572, AI445710, AI471363, AI471621, AI492629, AI559955, AI567085, AI567136, AI568957, AI423024, AI127630, AI141050, AI623977, AI222157, AI225079, AI241402, AI246467, AI659391, AI208326, AI268212, AI274077, AI275393, AI275421, AI276712, AI284210, AI350985, AI758516, AI765807, AI769946, AI858261, AI860169, AI886968, AI910377, AI916024, AI917250, AI949462, AW003455, AI983914, AW015559, AW024979, AW051534, AW051657, AW054877, AW130062, AW131613, AW205857, AW190646, AW193093, AW195372, AW299944, AW450241, AW612601, and AW613994.
3	HEEBIO5	13	1047700	AI150047.
4	HLTIP27	14	1135064	AW245446, AI572068, AA081788, AA706549, AI280779, AI679371, AW439535, AI033531, AI870982, AA494055, AI206492, AA444102, R98055, AI140510, AW016324, AA443923, AA084768, AA911833, AI591207, R98295, T46976, R50108, AA776108, AA834837, AA584489, W23510, AW021917, AW248861, AI917132, AA533176, AW168433, AA348023, AW237905, AW103383, AI336054, AA130647, AI291823, AI004591, AW157005, AI355587, AI312790, AA653139, AA878140, AI160786, AI569510, T50676, AL046746, AI039809, AA904275, AI216151, AI040051, AW193493, AI028510, AW327961, AW117740, AI755214, AI270476, AI754567, AA657835, AA992126, AA402129, AI754105, AA720732, AL079734, AI620585, AA904137, AL138265, AI590458, AA483606, AI499954, AA702539, AA862243, AW304971, AI354423, AA702080, AW157624, AI623563, F24728, AI635440, AA579427, AI653515, AA570740, AW029038, AI908093, AA879053, AW023672, AI783911, AI679782, AI368745, AW069227, AA832145, N55019, AW162442, AW162049, AI929531, AI445934, AI380617, AW263864, AC005300, Z97056, AL022316, AC005358, AL050318, AC009247, AL008582, AC005304, AC006001, AL035587, AC006120, AC004655, AC006208, AC006455, AL139054, AE000658, AB023052, AC009516, AF111168, AC006125, AC003029, AC005399, AC004895, U85195, AC006210, Z83840, AC007695, AC002072, AL049759,

				AC006057, AC004686, AC020663, AC005081, Z98742, AL049539, Z84467, Z97352, AL034549, Z82976, AC006126, AC006088, AP000513, AC005348, AC006111, AC005318, AL049643, AC000379, AF001549, AL121653, AC002312, AF196969, AC005365, AC005703, L29074, AL117352, AL031432, AL035461, AC005251, D88270, AL022336, Z82244, AC004253, AC005058, AC006449, AL080317, AC004477, AL133448, AP000558, AL023575, AC004408, AL024507, AC008372, AL049832, AC007993, AP000964, AC005233, AC003965, AC007227, AC005828, AC007055, AC005971, AC005520, AC004634, AC005332, AC004762, AC005901, AF045555, AC005837, AL021546, AC005899, AL022320, AC004741, AF107885, AL021155, AC007370, AC006153, AC007878, AC004887, AL096701, AC007461, AC005608, AL022322, AC000134, AC006013, AL109952, AD000092, Z97181, AL109758, AF205588, AC005411, AC006064, AL020997, AL031282, AL117337, AL023577, AL022165, M89651, AP000501, AL133245, AL133243, AC005821, AP000350, AC004000, AC005041, Z84480, AC006285, AC006509, AL121603, AC005523, D86992, AC007731, AC004106, AL035455, U91328, AC006960, AC004087, AP000692, Z98200, AF134726, AP001050, AL021918, AC005089, AF001548, AL033375, AC004999, AP000359, AP000045, AL078593, AL035659, AL109865, AC005778, AC006160, AC007546, AC005366, AC004491, A63032, AL021808, AC004019, AL035422, AF030876, AC002425, AC000353, AC006023, Z95152, AL023879, AC004913, AC006077, AC008119, AL133485, AL049776, AP000215, Z98884, AC006270, AL031680, AL031005, AF061032, AC005856, AC005480, AL035443, Z82214, AC004263, AL008630, AC006539, AC005291, AC007435, AC007091, AC002553, AC003982, AL022327, AL021397, U78027, AL079340, AP000212, AP000237, AF015167, AC005775, AL035086, AL035249, AL008726, Z86090, AL121655, AC002477, AC004552, AB020868, AC006036, AC005519, AF181896, AC004673, AP000030, AF015158, AL022323, AC006130, AC003957, AL121658, AC004890, X53550, AL078477, AC002544,
--	--	--	--	---

				AC005015, AL049712, AP000557, AL121825, AC002365, AC005036, and AC008055.
4	HLTIP27	35	1048173	AW245446, AI572068, AA081788, AA706549, AI280779, AI679371, AI613429, AW439535, AI033531, AI870982, AA494055, AI206492, AA444102, R98055, AI140510, AA776108, AW140116, AA443923, AW016324, AI342751, R98295, AA084768, AA911833, AI591207, T46976, R50107, R50108, AI422852, AA834837, AW248861, W23510, AA348023, AA584489, AA366535, AI270476, F24728, AA862243, AI791659, AI623563, F17312, AI917132, H71738, AA720732, AA482953, AC005300, AL079295, AC007298, AC009247, Z93930, AC005754, AL035249, AC005839, AC006285, AC004953, AC005551, AF196969, AC004019, AL031311, AL034420, AC005484, AL021154, AC006536, AL031255, AC005779, AL031657, AC006130, Z99716, AC005520, AC006011, AC005778, U80017, AC004999, AC005619, AC002072, AL139054, AF038458, AC007637, AC007878, AC004263, AF196779, AC006160, AC005899, AL133245, AC003982, AL031846, AL033392, AE000658, AL080243, AC005527, AC004656, AC016027, AC006057, Z83826, AC005005, AL022320, AF001549, AC005081, AC002310, AC002312, AC004983, AC007685, AC006449, AC005932, AL049757, U85195, Z84466, Z98884, AC002477, AC005015, AL022322, AF134726, AC004821, AL050318, AL121754, AC004813, AC005031, AC003101, Z86090, AC005041, Z95115, AL117352, AC009946, AL133246, AC007066, AC007676, AC004975, AC006211, AF129756, AL049832, AF003626, AL035422, AL132987, AC007193, AC005318, AC007182, AL009181, AC004448, AC004765, AC000025, AC004859, AL022311, AL022165, AC004991, AC006241, AC000085, AP000355, AC005211, AL035587, AC002565, AC005971, Z83840, AC000159, AF207550, AL050332, AL021391, AL031594, AC005730, U78027, AC005531, AC005913, AC004673, AC007461, AL022313, AC007868, AL109827, AC002070, Z85996, AC002126, and AI002841.
5	HAHFU44	15	1130777	AI886394, AI082824, AA633473, W07772, AA884248, W86073, R52250, W86257, AI191256, R44763, AI816793, R19947, and

				AL050320.
5	HAHFU44	36	1033579	AA884248, and AL050320.
5	HAHFU44	37	1044501	AI886394, AI082824, AA633473, W07772, R52250, W86073, AI191256, R44763, and AI816793.
6	HNKCO80	16	1091274	AA716150, AI559190, AI076929, AI027322, AI927434, AA722847, AA577045, AA559906, AA533247, AI916650, AA340605, AW167602, AI973046, AI671915, AA367486, and AC005361.
6	HNKCO80	38	1049168	AA513718.
7	HEEBB55	17	1160551	AL041746, AW245413, AI133458, AI829588, AI703136, AI681030, AW016897, AI261939, AA279731, T03663, AI911069, AA491271, AA492258, AA134948, T56959, AW193335, AA614026, AI828031, AI343416, W02121, AW364386, AW372936, AA235089, AA502166, AW364390, AW364385, AA804447, C75195, AA991910, AI765508, T62977, AA235216, AA811535, W32582, AI380924, AI654800, AI698651, AA970785, R50651, T56960, AW372360, AI204400, AI203095, AI799244, T56296, AI669719, AI537784, AI865063, AA917498, AA318751, AI492866, F30264, AI694519, F36518, AW188642, AI813548, AA608897, AI761282, AA995435, AI868917, AW450162, AA554272, AI918570, AA913227, AW250445, AI949550, D25867, AA494543, and AL050306.
7	HEEBB55	39	1038368	R50651.
7	HEEBB55	40	1047701	AL041746, AW245413, AI133458, AI829588, AI703136, AI681030, AW016897, AI261939, T03663, AI911069, AA491271, AA492258, AA134948, T56959, AW193335, AA614026, AI828031, W02121, AI343416, AW364386, AW372936, AA235089, AA502166, AW364390, AW364385, T63229, AA804447, C75195, AA991910, T62977, AA235216, AI765508, AI380924, W32582, AA811535, AI654800, AI698651, AA970785, T56960, AW372360, AI204400, AI799244, AI203095, T56296, AI669719, AI537784, AI865063, AA917498, AA318751, F30264, F36518, H23437, AW188642, AI813548, AA608897, AA995435, AI868917, AI918570, AA913227, AW250445, AI949550, D25867, AA314760, AA324262, and AL050306.
8	HOCPM23	18	1166556	AA740146, AA225896, AA411185, AA411260, AW027558, AI492574, AI435243, AI962727, AW264181, AI590823, AA578471, AW008383, AW013828, AI308942, AA813387, AA772448, AI652217, AA886735, AI351311, AA047652, AW243900, AA749059,

				AI123510, AI309550, AI123509, AW148364, W90707, AI633474, AI420780, AA824475, AI874384, AI263268, AW016584, T50370, AA301502, W95592, AI284727, AA250970, AI689512, AA732070, AA553396, AI597906, AA299869, and AL109839.
8	HOCPM23	41	1047693	W95592, AA225896, AA740146, AI351311, and AW148364.
9	HWMGN33	19	1054916	AW081162, AI380766, and AI752442.
9	HWMGN33	42	1027763	AI380766, and AI752442.
10	HWMLN52	20	1182071	AW411232, AW410448, W26135, AA128849, T55548, AI366140, AA406110, AI935492, AA804708, T55627, AI565184, AA413377, AW386009, AL119457, AL119324, AL134524, AL119399, AL042544, AW392670, AL119443, AW372827, AW384394, AW363220, Z99396, AL119497, AL119341, AL119391, U46346, AL119319, AL134920, AL119484, AL119363, AL119355, AL119522, AL119335, AL119496, U46341, U46349, AL119418, AL119396, AL119483, AL134902, U46350, U46345, U46351, AL119444, AL042614, U46347, AL119439, AL037205, AL134518, AL134528, AL042975, AL042965, AL042433, AL042984, AL119464, AL042970, AI142131, AL134529, AL134538, AL042551, AL042450, AL043019, AL043029, AL119488, AL042542, AL043003, AP001054, AP001053, Z65151, AR066494, AR060234, A81671, AR069079, AR054110, and AB026436.
10	HWMLN52	43	1033546	AA406110, W26135, AW392670, AW372827, AW384394, AW363220, Z99396, AL119497, AL119341, AL119391, U46346, AL119457, AL119319, AL119443, AL119324, AL119484, AL119363, AL119355, AL119522, AL119335, AL119496, U46341, U46349, AL119396, AL119483, U46350, U46345, U46351, AL119444, AL042614, U46347, AL119418, AL134920, AL134524, AL119439, AL037205, AL134518, AL134528, AL042975, AL134902, AL119399, AL042965, AL042433, AL042984, AL042970, AI142131, AL134529, AL134538, AL042551, AL042450, AL042544, AL043019, AL043029, AL119488, AL042542, AL043003, AL119464, AP001054, AP001053, Z65151, A81671, AR060234, AR066494, AR069079, AR054110, and AB026436.
10	HWMLN52	44	1045424	AW411232, AW410448, AA128849, T55548, AI366140, AI935492, AI565184, AA413377, AW386009, AI559670, and AP001054.

11	HVARW53	21	1194812	AI991013.
12	HLTIP94	22	1087335	AA552985, AA314716, AA228139, AI802948, and AC005325.
12	HLTIP94	47	1047690	AA552985, AA314716, AA372628, AI971282, AI686063, AI207633, AW054806, AW003937, AW027784, AI498100, AI933313, AA228139, AI802948, and AC005325.
13	HEGCL11	48	1045251	AI990714.
14	HCOOS80	24	1134974	AW016304, AI400000, AA639399, AW173281, AA805253, AI125734, AI656792, AW275025, AI561207, AI394693, AI095511, AI379330, AL036013, AI374641, AA905729, AA653313, AA807671, AI089517, AI863503, R76330, AA325249, AA812964, R79509, AA121257, AA527638, R38325, AA452283, AA779864, R39405, AA121256, AA236132, AI269580, AW192701, AI637584, AI478123, AI812107, AI921248, AW104056, AL037081, AI670009, AI433157, AI702073, AI590530, AI633125, AW148408, AL037104, AI582871, AI445025, AI874166, AL042745, AW192652, AI610690, AI619502, AI627988, AI580190, AI921464, AI653979, AI073952, AI564719, AI871923, AI288285, AW129916, AW129722, AI634345, AI612852, AW129659, AI249877, AI811192, AW087455, AL043070, AL119836, AI889376, AI681985, AW073865, AL119791, AL036631, AL121365, AI915291, AI241744, AI677796, AI611743, AI499393, AI912356, AI956080, AW104827, AI286256, AI500061, AW162118, AW059828, AA427700, AI916419, AI340603, AI334450, AL045500, AI866770, AI348854, AW268220, AI698391, AI688858, AW149311, AI889189, AI687362, AI812080, AI978703, AI567128, AI539771, AI696612, AL134259, AW090071, AI963193, AW190194, N71180, AW148457, AI872711, AW161579, AW151136, AI312428, AW265004, AI345613, AI669459, AW130134, AW088628, AW104724, AI349004, AI816010, AI345666, AA572758, AW105383, AI310575, AA176980, AI815232, AI923357, AW152182, AI254727, AW020693, AI582932, AA613907, AI587114, AI620003, AI340533, AI689420, AI925502, AI521560, AA814782, AI872064, AI801325, AI500588, AI590021, AI469532, AL039086, AI682725, AL036638, AI859464, AI963458, AI500662, AW302992, AL120853, AI340982, AA579232, AI366992, AA635382, AI818574, AI446373, AI802542, AA420722, AI471909, AI634682, AI702433, AI312542, AI954183, AI866162, AI925196,

				AW167918, AI499285, AI538885, AW090550, AI469112, AI583085, AW193530, AW073270, AI352376, AI866801, AI269862, AW075667, AI800440, AI499131, AW087207, AW132056, AW057937, AI280637, AI554186, AI567582, AI690480, AW152000, AI924971, AI887308, AI520785, AL121007, AI570884, AI499986, AI348897, AI349957, AI283760, AI697099, AW022808, AW026882, AI345745, AW192712, AI569583, AI872910, AI953562, AL045413, AI521012, AI520862, AI680435, AW198090, AW403717, AI500523, AI690930, AL037454, AL036396, AW080746, AI340627, AL038605, AI635478, AI564306, AI537677, AI572021, AI439087, AI335209, AI687376, AI611354, AL036274, AI538342, AL037030, AI440448, AW268302, AI862142, AI554821, AI798373, AL036802, AI950892, AI635942, AI281772, AI624548, AI590120, AI560030, AF006012, AC003688, U24160, I48978, AL050149, I89947, AL049938, A08916, A08910, A08909, AL137480, A08913, A77033, A77035, AL137271, AL050116, AL137459, AL133606, AL117435, AR038969, AF106862, I89931, I49625, AL096744, I48979, AF067790, AJ000937, AL137560, AF090901, AL137521, U42766, AF113019, AL133568, U35846, AL080124, I03321, Z72491, U42031, AL137527, AL137283, AL133640, AF090900, X65873, Z82022, AF177401, AL122110, Y16645, AL122050, AF111851, AL049452, AL122098, AL133113, AL050277, X82434, AL133557, AF125948, X98834, X72889, A58524, A58523, AF118094, AF097996, AF087943, AF113699, AF183393, A07647, U78525, A03736, AL137538, A65341, AL137550, AL110225, AF146568, U91329, AL049382, X63574, AL137463, AF091084, AL137292, AL049283, U67958, I33392, AL117460, U80742, AL133031, AL110280, AF113690, AL122049, X87582, AL049466, AL117583, I17767, AL117457, AF090896, AL122123, AL049464, E05822, AL133080, AL137523, AL122111, AL050108, AL133072, AL122093, AR038854, Y11254, AF090903, A12297, AL050146, AF090934, A08908, E07108, AL117440, S78214, AF113013, AL133560, AF078844, Y10655, AF113694, AF017437, AF113677, S36676, AF090943, AF067728, AF118070, AJ238278, X84990, AF026124, AL110221, AL133016, AF113676, L31396, AF158248, E15569, AL133565, L31397, AJ012755, X96540, AF061943, AR011880, AF111112,
--	--	--	--	---

				AL137526, AL050024, AL110196, AL049430, E02349, I42402, A93350, AF017152, AL133075, U00763, A08912, AL050393, AF085809, AF079765, AF104032, AF119337, AL080159, X70685, M30514, AL049314, AL110197, AL137648, AF125949, AL137476, AL080060, AF113689, I09360, AL137557, I26207, Y11587, AJ242859, AL050138, AF061573, AL122121, U72620, AF113691, AF026816, AB019565, AL137429, AL049300, AF118064, AL117585, AL133077, AF185576, AL117394, AL137294, AL117432, A93016, S61953, E03348, AL133093, AL133081, AR059958, U68233, I92592, Z37987, AL080127, S68736, AL080137, X93495, M92439, E07361, AF100931, AF022813, AL137555, AR000496, U39656, AL050280, AL133014, E08263, E08264, X72387, AL122118, AL137300, I41145, AF003737, AL137556, AL133645, AL050172, AF153205, AL080158, U96683, Y14314, S77771, E02152, AF132676, AF061836, AF026030, AF079763, A45787, AL110159, AL035458, U75932, A18777, AL133104, AF076464, L13297, and AF118090.
14	HCOOS80	49	1045182	R39405, R76330, R79509, and AI829007.
14	HCOOS80	50	1045183	AW016304, AI400000, AA639399, AW173281, AA805253, AI125734, AI656792, AW275025, AI561207, AI394693, AI095511, AI379330, AI374641, AA807671, AA653313, AI089517, AA905729, AI863503, AA812964, AA121257, AA527638, R38325, AA779864, AA121256, AL036013, AI269580, AW192701, AI637584, AL037081, AL037104, AL042745, AI812107, AI433157, AI702073, AI478123, AI633125, AI921248, AW087455, AI670009, AW148408, AL119791, AI688858, AI611743, AI582871, AW129722, AI445025, AI874166, AI634345, AI681985, AW192652, AI590530, AI288285, AW129659, AI610690, AI580190, AI249877, AW149311, AI921464, AI812080, AI872711, AI653979, AI471909, AI811192, N71180, AL119836, AI871923, AI866162, AI564719, AI619502, AW129916, AW104056, AI816010, AA420722, AI612852, AL043070, AW073865, AW105383, AI915291, AI241744, AL121365, AI889376, AI499393, AI925196, AI744449, AI702433, AI912356, AI340603, AI348854, AI627988, AI539771, AI500061, AW104827, AI570884, AI923357, AI286256, AW162118, AI520785, AW059828, AW161579, AI924971, AI916419, AI677796, AA814782, AI687376,

				AL036631, AI439087, AI698391, AI312428, AI560030, AI567802, AI569579, AI590021, AI889189, AI345666, AI498067, AI347701, AI963193, AI804585, AW068845, AI310575, AW073882, AA176980, AI669616, AI281772, AI815232, AI640700, AW151681, AI573032, AL037454, AI687362, AI978703, AI582932, AI334450, AI567128, AI340533, AW105431, AI312542, AA427700, AI521560, AW090071, AI311926, AW268220, AI590785, AI073952, AI800440, AI476046, AI633330, AW151136, AW190194, AL134259, AL040243, AI801325, AI269862, AW265004, AW148457, AI696612, AI859464, AL042744, AI499285, AW130134, AI345613, AI669459, AI500662, AI697099, AA579232, AI366992, AA259207, AA635382, AI955906, AI654750, AW104724, AW152182, AI224992, AI623682, AI690480, AI872910, AW020693, AI345415, AI349004, AI499986, AI587114, AI538829, AI689420, AI538885, AI434223, AW079159, AI560099, AA807352, N49165, AL038605, AL039086, AI925502, AW029329, AI469532, AI598061, AI620003, AI500588, F27788, AI872064, AW268122, AI682725, AI446373, AI500523, AI963068, AI963458, AI591228, AI340982, AI348897, AI634682, AI954183, AI634219, AA572758, AW193027, AI866573, AW084440, AW022682, H89138, AW403717, AL036396, AW090550, AI340627, AW084850, AI469112, AI418970, AI421903, AI860698, AW193530, AI889839, AW073270, AW190487, AI583085, AI818574, AI866801, AI828367, AI345745, AW087207, AI886124, AI570989, AI564306, AW169790, AW075667, AI924923, AI744525, AI798373, AI567582, AI587056, AI352376, AI499131, AI251221, AC003688, AF006012, U24160, AL049938, I48978, I89947, AL050149, AL050116, A08916, A08910, A08909, AF106862, A08913, AL137560, AL122098, AL133606, AL080124, A77033, A77035, AL137271, U67958, AR038969, AL137459, I89931, AL117435, AF067790, I49625, AL049452, AF125948, X72889, AF118094, AL096744, U78525, AF113019, U35846, I48979, AJ000937, AF090901, AL137527, AL137521, X63574, AL137538, AL137283, AL133568, AL110280, A65341, Z72491, I03321, U42031, AL137292, AL122123, AL137463, AL133640, X65873, AF090900, Z82022, AF177401, X98834, AL122110, Y16645, U42766, AL122050, AF111851, A07647, AL117440, AL133113, A03736,
--	--	--	--	---

				X82434, AL050277, S36676, AL117460, AL133557, AF113013, A58524, A58523, AF078844, AF097996, AF087943, AF113699, AF183393, AF017152, AL137550, AF091084, AL049283, I33392, AL050146, AL110225, AF146568, U80742, AL133031, U91329, AR013797, X87582, AL049382, AL117583, I17767, AL049466, AL117457, AF090896, AL122093, AJ012755, AR053103, AL049464, AL133080, AL122111, AJ238278, AL050108, AL133072, AR038854, AF113690, AL122049, AF158248, AF113694, AF090943, AL137557, E05822, A08908, AL137523, AF113676, AF185576, AL050393, AL122121, U72620, S78214, AL133560, AF090934, AF017437, AF113689, AF113677, AF067728, AF118070, Y11254, AL049314, AF026124, AL110221, AF090903, AL133016, A12297, AL133565, X96540, AF061943, E15569, AR011880, AL050024, AL110196, AL049430, E02349, I42402, AL137648, E07108, AL133075, A08912, AL050138, AF085809, AF079765, AF104032, A93016, AL137539, AB019565, AL080060, Y10655, U00763, AF119337, L13297, X70685, AR029490, M30514, X84990, A93350, Z37987, L31396, L31397, AF111112, AL137526, AL137480, I09360, Y11587, AL080159, A21625, AF019298, AF113691, AL137429, AL049300, AF118064, U83980, AL110197, AJ242859, AL117585, AF125949, AL133077, AL117394, S77771, AL137294, AL137476, S61953, E03348, AL133093, E03671, I26207, AR059958, U68233, I92592, E01963, AL080127, S68736, AL080137, X93495, AF061573, E07361, AF026816, AF100931, AF022813, AR000496, U39656, AL110228, AL133014, AL117432, E08263, E08264, E02152, AL133081, AL137658, AL122118, M92439, AL035067, AL137300, I41145, AF003737, AL137556, AL133645, Y13350, AL050172, AL050280, AF153205, AL080158, U96683, Y14314, I09499, AC006039, E12747, AF132676, AF061836, AF026030, AF079763, AL137281, A45787, X72387, AL035458, AC007458, and AW593997.
15	HLCND09	25	1172046	AI832149, AA253498, AA927669, AW136320, AA284897, AI341987, AI375638, AI141878, AA410733, AA724418, AI656580, AA626359, AA633990, AA210941, AA480438, AI499844, AI498056, AW135997, AA595691, AA209463, AI804771, AI199374, AI278733, W52189, AA602519,

				AA253394, AI189792, AI151483, AI242359, AI278938, AA456100, AI831279, N51328, AA455603, H22614, R55869, AA496421, W96552, AA284720, T16865, AI913942, AA904546, R55788, R87952, R87953, R25653, T16864, H20796, AI673432, AI954640, R90922, AI631375, AI380914, AA969376, AI123164, T06607, R90921, AI355743, R27502, AA338810, R90911, D51799, C14429, D80227, D80038, D80269, D80166, D59859, D58283, D51423, D59619, D80210, D80240, D80253, D80212, D81030, D80195, D80188, D80219, D80391, D59889, D59927, D80196, C14331, D80043, D80193, D80366, D80024, D80022, D80378, D59275, C75259, D80045, D50979, T03269, D50995, C14014, D57483, D59610, D59502, D80241, F13647, D80134, D59787, D80164, D80268, AA305409, D81026, D51250, C15076, C14389, D80949, D58253, D81111, D59467, D51060, D80168, AW178893, C14227, D51079, C14407, AI910186, AI557751, AW177440, D51022, AW179328, AA285331, AW178775, AW378532, AA305578, D80522, AA514188, AW352158, Z21582, D80251, D59695, AI905856, AW377671, D80248, AA514186, AW369651, D51097, AW178762, AW177501, D52291, AW177511, D80133, C14298, AW360834, D80064, AW243972, AW360811, C05695, AW352117, T11051, AW176467, AW375405, AW378540, D80014, T11417, AW366296, AW360844, AW360817, AW375406, AW378534, AW179332, AW377672, AW179023, AW178905, D80439, D80132, N71180, D59373, AW179220, D80302, AW352171, AW377676, AW178906, AW352170, AW177731, AW178907, AW179019, AW179024, D80247, AA809122, AW177505, AW360841, AW179020, T02974, AW178909, AW177456, AW179329, AW178980, AW177733, AW378528, AW178908, AW178754, AW179018, D51213, D51103, AW352174, AW179004, D80157, AW179012, AW178914, AW378525, AW378539, D51759, C06015, AW177722, AW177728, AI621341, AW179009, T03116, AW178774, AI670009, AW178911, AW378543, AW367967, AA585438, AW352163, AW131282, AW020710, AI336575, AA826625, AW178983, D58246, AW352120, AI540674, N71199, AW117652, AI524654, AI333104, AW193467, AI871703, AW178781, A62298, A84916, A62300, AJ132110, AR018138, X67155, A67220,
--	--	--	--	---

				A78862, A25909, D89785, Y17188, D26022, D34614, X68127, X82626, AR025207, D88547, Z82022, AF135125, AF058696, AR008278, AB012117, AB028859, A85396, AR066482, A85477, I19525, A86792, A30438, X93549, A82595, Y12724, A44171, U87250, U79457, A94995, AR060385, AB002449, Y17187, AR008443, I50128, I50133, I50126, I50132, S68736, AR064240, AR066488, AR016514, AR008277, AR008281, AR060138, A45456, A26615, AR052274, A07588, A12297, X59414, AL117432, I89947, AL117416, AF061795, AF151685, AL137480, Y09669, A43192, A43190, AR038669, AF026124, AL122123, AL110225, AR066487, AL133049, X64588, E01314, AL117435, U35846, AL050172, AF022857, AF022858, AL137627, AL137557, X79812, AR066490, S82852, AF185576, AR054175, AL133081, AL110296, AF068229, AL133113, AF111851, D88507, I48978, AL133054, I14842, S77771, AL137555, AL133072, AR038854, U46128, AL080074, AL110280, AF113019, AL122050, U02475, AL137459, AF026008, AR016691, AR016690, AR034821, A08910, Y14314, A08909, A08913, M85165, AF017790, AL031984, I18367, A18777, D50010, A08908, A08912, AL137267, A08911, A08907, L13297, AB025103, I32738, AF115410, AF077051, AF145233, A65340, AF079763, U68233, I92592, AL137533, U62966, S76508, M79462, AF087943, AF111849, U42031, X81464, AL133637, AL110218, I33392, AL050170, AF026816, AR068753, I89931, AL050277, A83556, AF151109, AB033111, I89934, I29004, X66417, X61970, I49625, U88966, AF082526, AL137478, I03321, AF177401, A63261, A03736, Z97214, Z30970, AL137476, AL110159, AF013214, L19437, S36676, E03671, AL117583, AL110197, AL122098, AF205861, E06743, AL122118, AL080129, E02221, AL137665, AF008439, AL137550, S56212, AL137705, E12580, AR060156, AC007458, AF022813, AL137523, Z13966, AF090900, AF199027, Z32749, AL133559, Y10655, A92311, AF100781, AL049339, Y10823, AL080159, AL049314, I46765, AL137529, AF125948, AL080140, AF194030, AL137641, AF106862, AF032666, AJ005690, AF055917, AC004227, AF091084, Y14634, A08456, E12806, AL137538, M84133, AF113676, U80742, AF038440, X72889, AF118070, AF111112, U75932, AR020905, AL049996, X82434, U67958, A77033, A77035,
--	--	--	--	---

				AL117587, AF115392, E12579, AF141289, and AW594694.
15	HLCND09	51	1035153	T06607.
16	HLWBT09	26	1226469	N54154, AI765950, R93383, R56658, H12876, R16970, AW205252, R25871, R93384, AA886432, AI242210, R16914, and AW612639.
17	HKAEL28	27	1194803	AW137166, AA810981, AI018305, AA234305, AA465650, AA993581, AI783662, AI420484, AA234395, AW235115, and AI805210.
17	HKAEL28	53	1042705	AA234305, AA234395, AA465650, AA810981, AA993581, AI018305, AI420484, AI783662, AI805210, AW137166, AW235115, and AW515646.
18	HNTPB82	28	1150030	AA460131, N50057, AA156470, AA461486, AI052764, AA224905, AA262535, R74136, AA513450, AA261898, AW132156, AA156132, AA312310, AA708287, AA224804, AW339474, AA908339, R17611, AI799274, H27799, W19833, AI828581, AI859438, AA503298, AI755214, AI754567, N90800, AI754105, AI635028, AW272294, AA225406, AW190484, AA652834, AI610737, AA904211, AW151935, AI371208, AA299589, AI565126, AA405726, AI249688, AI354333, AA470933, AW131356, AL135377, AA456924, AI038304, AI435045, AI569100, AA659333, AA541532, AW192599, AI870453, AI978718, AA745342, AA410788, H71678, AI056177, AA828592, AW338081, AW265688, T50061, AI587467, AL046782, AI473671, AI984168, AA714110, AI270476, AW238484, AI431513, N67313, AI570943, AA427636, AA524616, AI090334, AA084439, AW081610, AI923451, AI077941, AA779783, U95739, AC007314, AC005363, AL031447, AF129756, AL031311, AF149289, AF196969, AF196972, AL034548, AC002429, AL050308, Z98950, AC007308, AC004841, AL109827, AC007055, AL024498, AC004801, AC007731, AC005089, AC005500, AP000362, AC005058, AL035587, AL022320, AC006160, AC002551, AC006312, AF121781, AC005274, AC005726, AP000045, AP000113, AL050318, AC002470, Y14768, U47924, AC006538, AL021978, AC016830, AF196779, AC002565, AC004590, AC002395, AL035072, Z97054, AC005215, AL109798, AC005037, AC005393, AC006121, AC006512, AC005839, AP000300, AC006449, AC005622, AC005335, AD001527, AC008018, AC003077,

				AL050348, AC000041, AC004099, AC006211, AC005225, AC002301, AL049776, AP000505, AC004799, AF111168, AC006285, AL078596, AC002316, AC003043, AL049766, AC007792, AC005183, AC005291, AJ236701, AB023050, AB023049, AL122020, AC004686, AC005231, AC005368, L44140, AC005280, AL050307, AC003029, AL049758, AL022326, Z83838, AL133163, AC004929, AC005412, AL021154, U95742, AF190465, AL022315, AC008085, AL109622, AC004859, AC004492, AC002054, AC002407, AL035659, AC005972, AL109627, AC007686, AP000504, AC004148, AL021940, AL133246, AL022311, AC005620, AC004984, AL022316, AC005796, AC006080, AC003070, AC007695, AC012599, AC005763, AC011311, U91326, AC004510, Z82208, AL049830, Y18000, Z82244, AL022722, AC002400, AL109963, AL033524, Z82214, AC005592, AC005841, AC007191, AC005899, AL035681, L78810, AC004638, AC005736, AC005529, AL049872, AP000553, D87675, AL139054, AL031277, D79206, AP000102, AP000356, AC004785, AC002991, AC005175, Z98752, AC004820, AC005102, AF111167, Z98051, AC005476, AC005756, Z83845, AC002425, AC005086, AP000556, AC005261, AC007216, AC005237, AL022165, AL031257, AP000359, AL035458, AL023803, AC005519, AC005247, AC004079, AC005535, AC007050, AL049835, AC005874, AL031595, AF134471, AC005548, AC005015, AC008079, AC006064, AF111169, U80017, AL031133, AF002223, AL022476, AL022069, AC004655, AC005057, AC005253, AL049569, AC005971, AL109801, AL135744, AC004883, AC004169, AC006271, AC005004, AC009399, AC000111, AL121652, AC002430, AC004765, Z84466, AC004491, AC004990, AC005578, AL033521, AL034379, AC002312, Z93016, U89335, AL020996, AL096703, AC006137, AC005220, AC002091, AP000512, AC005755, AC000029, AC005793, AB022785, AB026899, U62317, AL022721, AP000959, AC007384, AC003030, AC007536, AC016027, AP000210, AP000132, and Z84480.
18	HNTPB82	54	1035148	R17611.
19	HOFMM69	29	1094390	AW340722, AA625849, AW303542,

				AA398622, AA758646, AW269796, AI928504, AA449551, AI090110, AI214404, AI921516, AI653196, AI637679, AW195686, AI769813, AA102499, AA216389, C02893, AI203433, AW089045, AA933956, AI473739, AI862124, C04410, AW176737, AW136263, AW176739, C04272, AA382285, AA229416, AA847971, AA150885, H18558, AW085017, AI138753, AA828857, and M62810.
19	HOFMM69	55	1036812	AI090110, C04410, AA102499, AI921516, C02893, AI637679, AI653196, AA449551, AW195686, C04272, AW089045, AA216389, AA229416, AA847971, AW303542, H18558, and M62810.
20	HKACC80	30	1138133	AI928201, AI698137, AI146819, AI703346, AW004965, AI701031, AI692542, AW150796, W22770, AA700658, AW449280, AI191866, AI083502, AI493779, AI193204, AI476648, AW341803, AI222353, AI246478, AI352013, W69588, AI222151, AI298880, AI371212, AA115259, AW194901, AA115280, AI017698, AI991559, AI140315, AA516386, AA897282, AA815370, AA927307, AW341804, AA783052, T03345, AA010468, AW023736, AI363733, AA035456, AA331773, C01820, AA027071, AA194849, AW452282, H79332, T77824, AA746955, AA035124, T77908, AI907818, AA905651, AI754363, AW151424, and AL137707.
20	HKACC80	57	1042695	AI928201, AI698137, AI703346, AW449280, AI701031, AI146819, AI692542, AI493779, AA700658, AI193204, AW341803, AI083502, AW004965, AI352013, AI222353, AI246478, AI222151, AI476648, AI298880, AI191866, AA115259, AW150796, AW194901, AI991559, AA115280, AI017698, AI140315, AI371212, AW341804, AA815370, AA927307, AA516386, AA783052, AA897282, H79332, AI363733, AA035456, AA010468, AW452282, AW023736, AA027071, T03345, AA746955, T77824, T77908, AA194849, AA035124, AI754363, C01820, AW151424, AA905651, AL137707, AW452602, and AW612800.
21	HHEDN80	31	1079531	AI825998, AA744373, AA732336, AW451096, AW370463, AA291321, AA291320, N74752, AA766450, R59259, AA844417, AA588329, AI122843, AI168449, AA215692, AI079651, AL044945, R19718, AA357760, AA029285, Z43800, AA855104, H93163, H92772, Z39868, N46928, N90519, R59201, AA215691, AI749837, D25990, F03066, AA770259, AA034362, W20097, AA037521, AA027067,

				R44274, R05650, R05649, AI784147, U92072, AF118889, and AF118890.
21	HHEDN80	58	1045311	AI025874, and AI038136.
21	HHEDN80	59	1046081	AI825998, AA744373, AA732336, AW451096, AW370463, AA291321, AA291320, N74752, AA766450, R59259, AA844417, AA588329, AI122843, AI168449, AA215692, AI079651, AL044945, R19718, AA357760, AA029285, Z43800, AA855104, H93163, H92772, Z39868, N46928, N90519, R59201, AA215691, AI749837, D25990, F03066, AA770259, AA034362, W20097, AA037521, AA027067, R44274, R05650, R05649, AI784147, U92072, AF118889, and AF118890.
22	HPDWP28	32	1094609	AI394037, AW303979, AW293101, AI827868, AA010190, AW006972, AI809548, AW138946, and AP000067.
22	HPDWP28	60	1047702	AI394037, AW138946, and AW293101.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
20	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
	pCMVSPORT 3.0	pCMVSPORT 3.0
25	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are

30

commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5 Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10 The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15 These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is
- 25 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30 the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers
5 used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a
10 bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified
fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at
15 the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and
20 confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG
25 (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic
30 agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from

QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or

Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

5

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

10 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution
15 containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

 The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by
20 centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

 The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree
25 C overnight to allow further GuHCl extraction.

 Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C
30 without mixing for 12 hours prior to further purification steps.

 To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area

(e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a
5 stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak
10 anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are
15 collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified
20 protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus

Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as
30 BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak

Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

5 Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-
10 39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does
15 not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

20 The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and
25 optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue
30 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by

gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and

cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of ^{35}S -methionine and 5 uCi ^{35}S -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment

then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector
5 are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 a pC4 is cotransfected with 0.5
10 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in
15 alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing
20 even higher concentrations of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

25 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see
30 also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a

specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by
5 modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These
10 primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with
15 BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted
20 protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

25 GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCCACC
GTGCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCC
AAAACCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCG
TGGTGGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC
GTGGACGGCGTGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC
30 AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG
GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCT
CCCAACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA

GAACCACAGGTGTACACCCTGCCCCATCCCGGGATGAGCTGACCAAGAA
 CCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCG
 CCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCAC
 GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCAC
 5 CGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGTCCGTGA
 TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT
 CCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Production of an Antibody from a Polypeptide

10 The antibodies of the present invention can be prepared by a variety of
 methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells
 expressing a polypeptide of the present invention is administered to an animal to
 induce the production of sera containing polyclonal antibodies. In a preferred
 method, a preparation of the secreted protein is prepared and purified to render it
 15 substantially free of natural contaminants. Such a preparation is then introduced into
 an animal in order to produce polyclonal antisera of greater specific activity.

 In the most preferred method, the antibodies of the present invention are
 monoclonal antibodies (or protein binding fragments thereof). Such monoclonal
 antibodies can be prepared using hybridoma technology. (Köhler et al.,
 20 Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al.,
 Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-
 Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures
 involve immunizing an animal (preferably a mouse) with polypeptide or, more
 preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in
 25 any suitable tissue culture medium; however, it is preferable to culture cells in Earle's
 modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at
 about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids,
 about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

 The splenocytes of such mice are extracted and fused with a suitable myeloma
 30 cell line. Any suitable myeloma cell line may be employed in accordance with the
 present invention; however, it is preferable to employ the parent myeloma cell line
 (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are

selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

5 Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a
10 mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of
15 further protein-specific antibodies.

 It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂
20 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

 For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced
25 using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson
30 et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

- 5 First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel).
- 10 Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

- Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine
- 15 (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

- The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an
- 20 expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem
- 25 I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

- Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates
- 30 of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells

first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130 mg/L CuSO₄-5H₂O; 0.050 mg/L of Fe(NO₃)₃-9H₂O; 0.417 mg/L of FeSO₄-7H₂O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄-H₂O; 71.02 mg/L of Na₂HPO₄; 4320 mg/L of ZnSO₄-7H₂O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H₂O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L

DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person
5 B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

10 It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant
15 characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the
20 Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six
25 members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in
30 tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are
5 generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-
10 12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- α , IFN- γ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn
15 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines
20 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>JAKs</u>					<u>STATS</u>	<u>GAS(elements) or ISRE</u>
	<u>Ligand</u>	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	IL-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
0	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)?	+	+	?	1,3		
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
5	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
0	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
5	IL-15	?	+	?	+	5	GAS
	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
0	GM-CSF (myeloid)	-	-	+	-	5	GAS
	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
5	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTT
CCCCGAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID
NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3'
15 (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following
20 sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCC
GAAATGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGT
CCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCA
TTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGC
25 CGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAG
GCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be
30 instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and
5 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-
10 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding
15 as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described
20 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the
30 GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152),

although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-
5 SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is
10 demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life
15 Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25
20 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of
25 the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100
30 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred
5 directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed
10 in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve
15 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,
20 stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.

25 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct
30 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing

10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM
5 KCl, 375 uM Na₂HPO₄·7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400
10 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in
15 the 96-well plate (or 1×10^5 cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the
20 supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes,
25 EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or
30 differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably

transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 µl per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 µg/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 µg/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

- 5 Add 200 μ l of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 μ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ μ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the
10 supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

- NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and
15 CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development; anti-viral and antimicrobial responses, and multiple stress responses.

- 20 In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- 25 Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid
30 arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-

KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCC
5 GGGACTTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in
10 the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

15 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTC
CGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATG
GCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTG
AGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGC
20 AAAAAGCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-
promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and
HindIII. However, this vector does not contain a neomycin resistance gene, and
25 therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP
cassette is removed from the above NF-KB/SEAP vector using restriction enzymes
SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,
the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the
30 GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are
created and maintained according to the protocol described in Example 13. Similarly,

the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

5 **Example 17: Assay for SEAP Activity**

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

- 10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- Cool the samples to room temperature for 15 minutes. Empty the dispenser
15 and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at
20 each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5

21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small

molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star
5 black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To
load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate
10 is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are
re-suspended to $2-5 \times 10^6$ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml
fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension.
15 The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

20 For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the
following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4
25 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

30 **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies.

- 5 In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation
10 of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

- 15 Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

- 20 Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or
25 polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar
30 Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen

Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyn plates (20,000/200ml/well) and cultured overnight in complete medium.

- 5 Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from
- 10 Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on
- 15 ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described

- 20 here.

- Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and
- 25 PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

- The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride,
- 30 pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the

components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

- 5 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish
- 10 peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

- Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound
- 15 peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

- 20 As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other
- 25 molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

- Specifically, assay plates are made by coating the wells of a 96-well ELISA
- 30 plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against

Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

- 5 A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.
- 10 After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard
- 15 procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

20 **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

- RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA
- 25 is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

- PCR products are then sequenced using primers labeled at their 5' end with T4
- 30 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring

suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

25

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

30

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in

5 Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled

10 water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

15 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).

20 Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulation

The invention also provides methods of treatment and/or prevention of

25 diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type

30 (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual

patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

5 As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 $\mu\text{g/kg/day}$ to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day , and most preferably for humans between about 0.01 and 1 mg/kg/day for
10 the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 $\mu\text{g/kg/hour}$ to about 50 $\mu\text{g/kg/hour}$, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears
15 to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray.

"Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid
20 filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-
25 release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or
30 formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials
5 (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al.,
10 J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990);
15 Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP
20 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

25 In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer
30 (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage

injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container

having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG (e.g., THERACYS®), MPL and nonviable preparations of *Corynebacterium parvum*. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture,

separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, and/or therapeutic treatments described below. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs). NRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). NNRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™

(ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent
5 or treat HIV infection.

Additional NRTIs include LODENOSINE™ (F-ddA; an acid-stable adenosine NRTI; Triangle/Abbott); COVIRACIL™ (emtricitabine/FTC; structurally related to lamivudine (3TC) but with 3- to 10-fold greater activity *in vitro*; Triangle/Abbott); dOTC (BCH-10652, also structurally related to lamivudine but retains activity
10 against a substantial proportion of lamivudine-resistant isolates; Biochem Pharma); Adefovir (refused approval for anti-HIV therapy by FDA; Gilead Sciences); PREVEON® (Adefovir Dipivoxil, the active prodrug of adefovir; its active form is PMEA-pp); TENOFOVIR™ (bis-POC PMPA, a PMPA prodrug; Gilead); DAPD/DXG (active metabolite of DAPD; Triangle/Abbott); D-D4FC (related to
15 3TC, with activity against AZT/3TC-resistant virus); GW420867X (Glaxo Wellcome); ZIAGEN™ (abacavir/159U89; Glaxo Wellcome Inc.); CS-87 (3'azido-2',3'-dideoxyuridine; WO 99/66936); and S-acyl-2-thioethyl (SATE)-bearing prodrug forms of β -L-FD4C and β -L-FddC (WO 98/17281).

Additional NNRTIs include COACTINON™ (Emivirine/MKC-442, potent
20 NNRTI of the HEPT class; Triangle/Abbott); CAPRAVIRINE™ (AG-1549/S-1153, a next generation NNRTI with activity against viruses containing the K103N mutation; Agouron); PNU-142721 (has 20- to 50-fold greater activity than its predecessor delavirdine and is active against K103N mutants; Pharmacia & Upjohn); DPC-961 and DPC-963 (second-generation derivatives of efavirenz, designed to be
25 active against viruses with the K103N mutation; DuPont); GW-420867X (has 25-fold greater activity than HBY097 and is active against K103N mutants; Glaxo Wellcome); CALANOLIDE A (naturally occurring agent from the latex tree; active against viruses containing either or both the Y181C and K103N mutations); and Propolis (WO 99/49830).

30 Additional protease inhibitors include LOPINAVIR™ (ABT378/r; Abbott Laboratories); BMS-232632 (an azapeptide; Bristol-Myers Squibb); TIPRANAVIR™

(PNU-140690, a non-peptic dihydropyrone; Pharmacia & Upjohn); PD-178390 (a nonpeptidic dihydropyrone; Parke-Davis); BMS 232632 (an azapeptide; Bristol-Myers Squibb); L-756,423 (an indinavir analog; Merck); DMP-450 (a cyclic urea compound; Avid & DuPont); AG-1776 (a peptidomimetic with *in vitro* activity
5 against protease inhibitor-resistant viruses; Agouron); VX-175/GW-433908 (phosphate prodrug of amprenavir; Vertex & Glaxo Welcome); CGP61755 (Ciba); and AGENERASE™ (amprenavir; Glaxo Wellcome Inc.).

Additional antiretroviral agents include fusion inhibitors/gp41 binders. Fusion inhibitors/gp41 binders include T-20 (a peptide from residues 643-678 of the
10 HIV gp41 transmembrane protein ectodomain which binds to gp41 in its resting state and prevents transformation to the fusogenic state; Trimeris) and T-1249 (a second-generation fusion inhibitor; Trimeris).

Additional antiretroviral agents include fusion inhibitors/chemokine receptor antagonists. Fusion inhibitors/chemokine receptor antagonists include CXCR4
15 antagonists such as AMD 3100 (a bicyclam), SDF-1 and its analogs, and ALX40-4C (a cationic peptide), T22 (an 18 amino acid peptide; Trimeris) and the T22 analogs T134 and T140; CCR5 antagonists such as RANTES (9-68), AOP-RANTES, NNY-RANTES, and TAK-779; and CCR5/CXCR4 antagonists such as NSC 651016 (a distamycin analog). Also included are CCR2B, CCR3, and CCR6 antagonists.
20 Chemokine receptor agonists such as RANTES, SDF-1, MIP-1 α , MIP-1 β , etc., may also inhibit fusion.

Additional antiretroviral agents include integrase inhibitors. Integrase inhibitors include dicaffeoylquinic (DFQA) acids; L-chicoric acid (a dicaffeoyltartaric (DCTA) acid); quinalizarin (QLC) and related anthraquinones;
25 ZINTEVIR™ (AR 177, an oligonucleotide that probably acts at cell surface rather than being a true integrase inhibitor; Arondex); and naphthols such as those disclosed in WO 98/50347.

Additional antiretroviral agents include hydroxyurea-like compounds such as BCX-34 (a purine nucleoside phosphorylase inhibitor; Biocryst); ribonucleotide
30 reductase inhibitors such as DIDOX™ (Molecules for Health); inosine monophosphate dehydrogenase (IMPDH) inhibitors such as VX-497 (Vertex); and mycopholic acids such as CellCept (mycophenolate mofetil; Roche).

Additional antiretroviral agents include inhibitors of viral integrase, inhibitors of viral genome nuclear translocation such as arylene bis(methylketone) compounds; inhibitors of HIV entry such as AOP-RANTES, NNY-RANTES, RANTES-IgG fusion protein, soluble complexes of RANTES and glycosaminoglycans (GAG), and
5 AMD-3100; nucleocapsid zinc finger inhibitors such as dithiane compounds; targets of HIV Tat and Rev; and pharmacoenhancers such as ABT-378.

Other antiretroviral therapies and adjunct therapies include cytokines and lymphokines such as MIP-1 α , MIP-1 β , SDF-1 α , IL-2, PROLEUKINTM (aldesleukin/L2-7001; Chiron), IL-4, IL-10, IL-12, and IL-13; interferons such as
10 IFN- α 2a; antagonists of TNFs, NF κ B, GM-CSF, M-CSF, and IL-10; agents that modulate immune activation such as cyclosporin and prednisone; vaccines such as RemuneTM (HIV Immunogen), APL 400-003 (Apollon), recombinant gp120 and fragments, bivalent (B/E) recombinant envelope glycoprotein, rgp120CM235, MN rgp120, SF-2 rgp120, gp120/soluble CD4 complex, Delta JR-FL protein, branched
15 synthetic peptide derived from discontinuous gp120 C3/C4 domain, fusion-competent immunogens, and Gag, Pol, Nef, and Tat vaccines; gene-based therapies such as genetic suppressor elements (GSEs; WO 98/54366), and intrakines (genetically modified CC chemokines targetted to the ER to block surface expression of newly synthesized CCR5 (Yang *et al.*, *PNAS* 94:11567-72 (1997); Chen *et al.*,
20 *Nat. Med.* 3:1110-16 (1997)); antibodies such as the anti-CXCR4 antibody 12G5, the anti-CCR5 antibodies 2D7, 5C7, PA8, PA9, PA10, PA11, PA12, and PA14, the anti-CD4 antibodies Q4120 and RPA-T4, the anti-CCR3 antibody 7B11, the anti-gp120 antibodies 17b, 48d, 447-52D, 257-D, 268-D and 50.1, anti-Tat antibodies, anti-TNF- α antibodies, and monoclonal antibody 33A; aryl hydrocarbon (AH) receptor
25 agonists and antagonists such as TCDD, 3,3',4,4',5-pentachlorobiphenyl, 3,3',4,4'-tetrachlorobiphenyl, and α -naphthoflavone (WO 98/30213); and antioxidants such as γ -L-glutamyl-L-cysteine ethyl ester (γ -GCE; WO 99/56764).

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered
30 with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with

PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial
5 infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases,
10 Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamethoxazole, and vancomycin.

In other embodiments, Therapeutics of the invention are administered in
15 combination with immunosuppressive agents. Immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.
20 Other immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, prednisolone, methotrexate, thalidomide, methoxsalen, rapamycin, leflunomide, mizoribine (BREDININ™), brequinar, deoxyspergualin, and azaspirane (SKF 105685), ORTHOCLONE OKT® 3 (muromonab-CD3), SANDIMMUNE™, NEORAL™,
25 SANGDYA™ (cyclosporine), PROGRAF® (FK506, tacrolimus), CELLCEPT® (mycophenolate mofetil, of which the active metabolite is mycophenolic acid), IMURAN™ (azathioprine), glucocorticosteroids, adrenocortical steroids such as DELTASONE™ (prednisone) and HYDELTRASOL™ (prednisolone), FOLEX™ and MEXATE™ (methotrexate), OXSORALEN-ULTRA™ (methoxsalen) and
30 RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, ATGAM™ (antithymocyte globulin), and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

10 In certain embodiments, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, corticosteroids (e.g. betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal anti-inflammatory drugs (e.g., diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin.), as well as antihistamines, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-angiogenic agent. Anti-angiogenic agents that may be administered with the compositions of the invention include, but are not limited to, Angiostatin (Entremed, Rockville, MD), Troponin-1 (Boston Life Sciences, Boston, MA), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor

of Metalloproteinase-2, VEGF, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition
5 metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium
10 metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten
15 oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its
20 hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and
25 sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, (1991)); Sulphated
30 Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline

analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., *J. Bio. Chem.* 267:17321-17326, (1992)); Chymostatin (Tomkinson et al., *Biochem J.* 286:475-480, (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., *Nature* 348:555-557, (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, *J. Clin. Invest.* 79:1440-1446, (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., *J. Biol. Chem.* 262(4):1659-1664, (1987)); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., *Agents Actions* 36:312-316, (1992)); and metalloproteinase inhibitors such as BB94.

Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, NJ); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman *J Pediatr. Surg.* 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., *J Clin. Invest.* 103:47-54 (1999)); carboxynaminimidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, MD); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, MA); Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, PA); TNP-470, (Tap Pharmaceuticals, Deerfield, IL); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM101; Dexrazoxane (ICRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purlitin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil.

Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic

inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, CA), BAY-12-9566 (Bayer, West Haven, CT), BMS-275291 (Bristol Myers Squibb, Princeton, NJ), CGS-27032A (Novartis, East Hanover, NJ), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the compositions of the invention include, but are not limited to, EMD-121974 (Merck KgaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, CA/Medimmune, Gaithersburg, MD). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, CO), Anti-VEGF antibody (Genentech, S. San Francisco, CA), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, CA), SU-5416 (Sugen/ Pharmacia Upjohn, Bridgewater, NJ), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the compositions of the invention include, but are not limited to, IM-862 (Cytran, Kirkland, WA), Interferon-alpha, IL-12 (Roche, Nutley, NJ), and Pentosan polysulfate (Georgetown University, Washington, DC).

In particular embodiments, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

In a particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis.

In another embodiment, the polynucleotides encoding a polypeptide of the present invention are administered in combination with an angiogenic protein, or polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins that may be administered with the compositions of the invention include, but are not
5 limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin-like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide
10 synthase.

In additional embodiments, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to alkylating agents such as nitrogen mustards (for example, Mechlorethamine,
15 cyclophosphamide, Cyclophosphamide Ifosfamide, Melphalan (L-sarcosine), and Chlorambucil), ethylenimines and methylmelamines (for example, Hexamethylmelamine and Thiotepa), alkyl sulfonates (for example, Busulfan), nitrosoureas (for example, Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl-CCNU), and Streptozocin (streptozotocin)), triazines (for example,
20 Dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)), folic acid analogs (for example, Methotrexate (amethopterin)), pyrimidine analogs (for example, Fluorouracil (5-fluorouracil; 5-FU), Floxuridine (fluorodeoxyuridine; FudR), and Cytarabine (cytosine arabinoside)), purine analogs and related inhibitors (for example, Mercaptopurine (6-mercaptopurine; 6-MP), Thioguanine (6-thioguanine;
25 TG), and Pentostatin (2'-deoxycoformycin)), vinca alkaloids (for example, Vinblastine (VLB, vinblastine sulfate)) and Vincristine (vincristine sulfate)), epipodophyllotoxins (for example, Etoposide and Teniposide), antibiotics (for example, Dactinomycin (actinomycin D), Daunorubicin (daunomycin; rubidomycin), Doxorubicin, Bleomycin, Plicamycin (mithramycin), and Mitomycin (mitomycin C),
30 enzymes (for example, L-Asparaginase), biological response modifiers (for example, Interferon-alpha and interferon-alpha-2b), platinum coordination compounds (for example, Cisplatin (cis-DDP) and Carboplatin), anthracenedione (Mitoxantrone),

substituted ureas (for example, Hydroxyurea), methylhydrazine derivatives (for example, Procarbazine (N-methylhydrazine; MIH), adrenocorticosteroids (for example, Prednisone), progestins (for example, Hydroxyprogesterone caproate, Medroxyprogesterone, Medroxyprogesterone acetate, and Megestrol acetate),
5 estrogens (for example, Diethylstilbestrol (DES), Diethylstilbestrol diphosphate, Estradiol, and Ethinyl estradiol), antiestrogens (for example, Tamoxifen), androgens (Testosterone propionate, and Fluoxymesterone), antiandrogens (for example, Flutamide), gonadotropin-releasing hormone analogs (for example, Leuprolide), other hormones and hormone analogs (for example, methyltestosterone, estramustine,
10 estramustine phosphate sodium, chlorotrianisene, and testolactone), and others (for example, dicarbazine, glutamic acid, and mitotane).

In one embodiment, the compositions of the invention are administered in combination with one or more of the following drugs: infliximab (also known as Remicade™ Centocor, Inc.), Trocade (Roche, RO-32-3555), Leflunomide (also
15 known as Arava™ from Hoechst Marion Roussel), Kineret™ (an IL-1 Receptor antagonist also known as Anakinra from Amgen, Inc.)

In a specific embodiment, compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or combination of one or more of the components of CHOP. In one
20 embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies, human monoclonal anti-CD20 antibodies. In another embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies and CHOP, or anti-CD20 antibodies and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or
25 prednisone. In a specific embodiment, compositions of the invention are administered in combination with Rituximab. In a further embodiment, compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the
30 invention are administered in combination with tositumomab. In a further embodiment, compositions of the invention are administered with tositumomab and CHOP, or tositumomab and any combination of one or more of the components of

CHOP, particularly cyclophosphamide and/or prednisone. The anti-CD20 antibodies may optionally be associated with radioisotopes, toxins or cytotoxic prodrugs.

In another specific embodiment, the compositions of the invention are administered in combination Zevalin™. In a further embodiment, compositions of the invention are administered with Zevalin™ and CHOP, or Zevalin™ and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. Zevalin™ may be associated with one or more radisotopes. Particularly preferred isotopes are ⁹⁰Y and ¹¹¹In.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993);

5 Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth

15 Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent

20 Number DE19639601. The above mentioned references are herein incorporated by reference in their entireties.

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but

25 are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention

30 include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF) (sargramostim, LEUKINE™, PROKINE™), granulocyte colony stimulating factor (G-CSF) (filgrastim, NEUPOGEN™), macrophage colony

stimulating factor (M-CSF, CSF-1) erythropoietin (epoetin alfa, EPOGEN™, PROCRIT™), stem cell factor (SCF, c-kit ligand, steel factor), megakaryocyte colony stimulating factor, PIXY321 (a GMCSF/IL-3 fusion protein), interleukins, especially any one or more of IL-1 through IL-12, interferon-gamma, or
5 thrombopoietin.

In certain embodiments, Therapeutics of the present invention are administered in combination with adrenergic blockers, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol.

10 In another embodiment, the Therapeutics of the invention are administered in combination with an antiarrhythmic drug (e.g., adenosine, amidoarone, bretylium, digitalis, digoxin, digitoxin, diltiazem, disopyramide, esmolol, flecainide, lidocaine, mexiletine, moricizine, phenytoin, procainamide, N-acetyl procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, and verapamil).

15 In another embodiment, the Therapeutics of the invention are administered in combination with diuretic agents, such as carbonic anhydrase-inhibiting agents (e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic diuretics (e.g., glycerin, isosorbide, mannitol, and urea), diuretics that inhibit $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ symport (e.g., furosemide, bumetanide, azosemide, piretanide, tripamide, ethacrynic acid, muzolimine, and torsemide), thiazide and thiazide-like diuretics (e.g.,
20 bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichormethiazide, chlorthalidone, indapamide, metolazone, and quinethazone), potassium sparing diuretics (e.g., amiloride and triamterene), and mineralcorticoid receptor antagonists
25 (e.g., spironolactone, canrenone, and potassium canrenoate).

In one embodiment, the Therapeutics of the invention are administered in combination with treatments for endocrine and/or hormone imbalance disorders. Treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, ^{127}I , radioactive isotopes of iodine such as ^{131}I and ^{123}I ; recombinant
30 growth hormone, such as HUMATROPE™ (recombinant somatropin); growth hormone analogs such as PROTROPIN™ (somatrem); dopamine agonists such as PARLODEL™ (bromocriptine); somatostatin analogs such as SANDOSTATIN™

(octreotide); gonadotropin preparations such as PREGNYL™, A.P.L.™ and PROFASI™ (chorionic gonadotropin (CG)), PERGONAL™ (menotropins), and METRODIN™ (urofollitropin (uFSH)); synthetic human gonadotropin releasing hormone preparations such as FACTREL™ and LUTREPULSE™ (gonadorelin hydrochloride); synthetic gonadotropin agonists such as LUPRON™ (leuprolide acetate), SUPPRELIN™ (histrelin acetate), SYNAREL™ (nafarelin acetate), and ZOLADEX™ (goserelin acetate); synthetic preparations of thyrotropin-releasing hormone such as RELEFACT TRH™ and THYPINONE™ (protirelin); recombinant human TSH such as THYROGEN™; synthetic preparations of the sodium salts of the natural isomers of thyroid hormones such as L-T₄™, SYNTHROID™ and LEVOTHROID™ (levothyroxine sodium), L-T₃™, CYTOMEL™ and TRIOSTAT™ (liothyroine sodium), and THYROLAR™ (liotrix); antithyroid compounds such as 6-*n*-propylthiouracil (propylthiouracil), 1-methyl-2-mercaptoimidazole and TAPAZOLE™ (methimazole), NEO-MERCAZOLE™ (carbimazole); beta-adrenergic receptor antagonists such as propranolol and esmolol; Ca²⁺ channel blockers; dexamethasone and iodinated radiological contrast agents such as TELEPAQUE™ (iopanoic acid) and ORAGRAFIN™ (sodium ipodate).

Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, estrogens or conjugated estrogens such as ESTRACE™ (estradiol), ESTINYL™ (ethinyl estradiol), PREMARIN™, ESTRATAB™, ORTHO-EST™, OGEN™ and estropipate (estrone), ESTROVIS™ (quinestrol), ESTRADERM™ (estradiol), DELESTROGEN™ and VALERGEN™ (estradiol valerate), DEPO-ESTRADIOL CYPIONATE™ and ESTROJECT LA™ (estradiol cypionate); antiestrogens such as NOLVADEX™ (tamoxifen), SEROPHENE™ and CLOMID™ (clomiphene); progestins such as DURALUTIN™ (hydroxyprogesterone caproate), MPA™ and DEPO-PROVERA™ (medroxyprogesterone acetate), PROVERA™ and CYCRIN™ (MPA), MEGACE™ (megestrol acetate), NORLUTIN™ (norethindrone), and NORLUTATE™ and AYGESTIN™ (norethindrone acetate); progesterone implants such as NORPLANT SYSTEM™ (subdermal implants of norgestrel); antiprogestins such as RU 486™

(mifepristone); hormonal contraceptives such as ENOVID™ (norethynodrel plus mestranol), PROGESTASERT™ (intrauterine device that releases progesterone), LOESTRIN™, BREVICON™, MODICON™, GENORA™, NELONA™, NORINYL™, OVACON-35™ and OVACON-50™ (ethinyl estradiol/norethindrone),
 5 LEVLEN™, NORDETTE™, TRI-LEVLEN™ and TRIPHASIL-21™ (ethinyl estradiol/levonorgestrel) LO/OVRAL™ and OVRAL™ (ethinyl estradiol/norgestrel), DEMULEN™ (ethinyl estradiol/ethynodiol diacetate), NORINYL™, ORTHO-NOVUM™, NORETHIN™, GENORA™, and NELOVA™ (norethindrone/mestranol), DESOGEN™ and ORTHO-CEPT™ (ethinyl estradiol/desogestrel), ORTHO-
 10 CYCLEN™ and ORTHO-TRICYCLEN™ (ethinyl estradiol/norgestimate), MICRONOR™ and NOR-QD™ (norethindrone), and OVRETTE™ (norgestrel).

Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, testosterone esters such as methenolone acetate and testosterone undecanoate; parenteral and oral androgens such as TESTOJECT-50™
 15 (testosterone), TESTEX™ (testosterone propionate), DELATESTRYL™ (testosterone enanthate), DEPO-TESTOSTERONE™ (testosterone cypionate), DANOCRINE™ (danazol), HALOTESTIN™ (fluoxymesterone), ORETON METHYL™, TESTRED™ and VIRILON™ (methyltestosterone), and OXANDRIN™ (oxandrolone); testosterone transdermal systems such as TESTODERM™; androgen receptor
 20 antagonist and 5-alpha-reductase inhibitors such as ANDROCUR™ (cyproterone acetate), EULEXIN™ (flutamide), and PROSCAR™ (finasteride); adrenocorticotrophic hormone preparations such as CORTROSYN™ (cosyntropin); adrenocortical steroids and their synthetic analogs such as ACLOVATE™ (alclometasone dipropionate), CYCLOCORT™ (amcinonide), BECLOVENT™ and VANCERIL™ (beclomethasone
 25 dipropionate), CELESTONE™ (betamethasone), BENISONE™ and UTICORT™ (betamethasone benzoate), DIPROSONE™ (betamethasone dipropionate), CELESTONE PHOSPHATE™ (betamethasone sodium phosphate), CELESTONE SOLUSPAN™ (betamethasone sodium phosphate and acetate), BETA-VAL™ and VALISONE™ (betamethasone valerate), TEMOVATE™ (clobetasol propionate),
 30 CLODERM™ (clocortolone pivalate), CORTEF™ and HYDROCORTONE™

- (cortisol (hydrocortisone)), HYDROCORTONE ACETATE™ (cortisol (hydrocortisone) acetate), LOCOID™ (cortisol (hydrocortisone) butyrate), HYDROCORTONE PHOSPHATE™ (cortisol (hydrocortisone) sodium phosphate), A-HYDROCORT™ and SOLU CORTEF™ (cortisol (hydrocortisone) sodium succinate), WESTCORT™ (cortisol (hydrocortisone) valerate), CORTISONE ACETATE™ (cortisone acetate), DESOWEN™ and TRIDESILON™ (desonide), TOPICORT™ (desoximetasone), DECADRON™ (dexamethasone), DECADRON LA™ (dexamethasone acetate), DECADRON PHOSPHATE™ and HEXADROL PHOSPHATE™ (dexamethasone sodium phosphate), FLORONE™ and
- 10 MAXIFLOR™ (diflorasone diacetate), FLORINEF ACETATE™ (fludrocortisone acetate), AEROBID™ and NASALIDE™ (flunisolide), FLUONID™ and SYNALAR™ (fluocinolone acetonide), LIDEX™ (fluocinonide), FLUOR-OP™ and FML™ (fluorometholone), CORDRAN™ (flurandrenolide), HALOG™ (halcinonide), HMS LIZUIFILM™ (medrysone), MEDROL™ (methylprednisolone), DEPO-
- 15 MEDROL™ and MEDROL ACETATE™ (methylprednisone acetate), A-METHAPRED™ and SOLUMEDROL™ (methylprednisolone sodium succinate), ELOCON™ (mometasone furoate), HALDRONE™ (paramethasone acetate), DELTA-CORTEF™ (prednisolone), ECONOPRED™ (prednisolone acetate), HYDELTRASOL™ (prednisolone sodium phosphate), HYDELTRA-T.B.A™
- 20 (prednisolone tebutate), DELTASONE™ (prednisone), ARISTOCORT™ and KENACORT™ (triamcinolone), KENALOG™ (triamcinolone acetonide), ARISTOCORT™ and KENACORT DIACETATE™ (triamcinolone diacetate), and ARISTOSPAN™ (triamcinolone hexacetonide); inhibitors of biosynthesis and action of adrenocortical steroids such as CYTADREN™ (aminoglutethimide), NIZORAL™
- 25 (ketoconazole), MODRASTANE™ (trilostane), and METOPIRONE™ (metyrapone); bovine, porcine or human insulin or mixtures thereof; insulin analogs; recombinant human insulin such as HUMULIN™ and NOVOLIN™; oral hypoglycemic agents such as ORAMIDE™ and ORINASE™ (tolbutamide), DIABINESE™
- (chlorpropamide), TOLAMIDE™ and TOLINASE™ (tolazamide), DYMELOS™
- 30 (acetohexamide), glibenclamide, MICRONASE™, DIBETA™ and GLYNASE™

(glyburide), GLUCOTROL™ (glipizide), and DIAMICRON™ (gliclazide), GLUCOPHAGE™ (metformin), ciglitazone, pioglitazone, and alpha-glucosidase inhibitors; bovine or porcine glucagon; somatostatins such as SANDOSTATIN™ (octreotide); and diazoxides such as PROGLYCEM™ (diazoxide).

5 In one embodiment, the Therapeutics of the invention are administered in combination with treatments for uterine motility disorders. Treatments for uterine motility disorders include, but are not limited to, estrogen drugs such as conjugated estrogens (e.g., PREMARIN® and ESTRATAB®), estradiols (e.g., CLIMARA® and ALORA®), estropipate, and chlorotrianisene; progestin drugs (e.g., AMEN®
10 (medroxyprogesterone), MICRONOR® (norethidrone acetate), PROMETRIUM® progesterone, and megestrol acetate); and estrogen/progesterone combination therapies such as, for example, conjugated estrogens/medroxyprogesterone (e.g., PREMPRO™ and PREMPHASE®) and norethindrone acetate/ethinyl estsradiol (e.g., FEMHRT™).

15 In an additional embodiment, the Therapeutics of the invention are administered in combination with drugs effective in treating iron deficiency and hypochromic anemias, including but not limited to, ferrous sulfate (iron sulfate, FEOSOL™), ferrous fumarate (e.g., FEOSTAT™), ferrous gluconate (e.g., FERGON™), polysaccharide-iron complex (e.g., NIFEREX™), iron dextran
20 injection (e.g., INFED™), cupric sulfate, pyroxidine, riboflavin, Vitamin B₁₂, cyancobalamin injection (e.g., REDISOL™, RUBRAMIN PC™), hydroxocobalamin, folic acid (e.g., FOLVITE™), leucovorin (folinic acid, 5-CHOH4PteGlu, citrovorum factor) or WELLCOVORIN (Calcium salt of leucovorin), transferrin or ferritin.

 In certain embodiments, the Therapeutics of the invention are administered in
25 combination with agents used to treat psychiatric disorders. Psychiatric drugs that may be administered with the Therapeutics of the invention include, but are not limited to, antipsychotic agents (e.g., chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozide, quetiapine, risperidone, thioridazine, thiothixene,
30 trifluoperazine, and triflupromazine), antimanic agents (e.g., carbamazepine, divalproex sodium, lithium carbonate, and lithium citrate), antidepressants (e.g.,

amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine), antianxiety agents (e.g., alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam, 5 halazepam, lorazepam, oxazepam, and prazepam), and stimulants (e.g., d-amphetamine, methylphenidate, and pemoline).

In other embodiments, the Therapeutics of the invention are administered in combination with agents used to treat neurological disorders. Neurological agents 10 that may be administered with the Therapeutics of the invention include, but are not limited to, antiepileptic agents (e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, divalproex sodium, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, diazepam, lorazepam, and clonazepam), antiparkinsonian agents (e.g., 15 levodopa/carbidopa, selegiline, amantidine, bromocriptine, pergolide, ropinirole, pramipexole, bengtropine; biperiden; ethopropazine; procyclidine; trihexyphenidyl, tolcapone), and ALS therapeutics (e.g. riluzole).

In another embodiment, Therapeutics of the invention are administered in combination with vasodilating agents and/or calcium channel blocking agents. 20 Vasodilating agents that may be administered with the Therapeutics of the invention include, but are not limited to, Angiotensin Converting Enzyme (ACE) inhibitors (e.g., papaverine, isoxsuprine, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril,trandolapril, and nylidrin), and nitrates (e.g., isosorbide dinitrate, isosorbide mononitrate, and 25 nitroglycerin). Examples of calcium channel blocking agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to amlodipine, bepridil, diltiazem, felodipine, flunarizine, isradipine, nifedipine, nimodipine, and verapamil.

In additional embodiments, the Therapeutics of the invention are administered . 30 in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 24: Method of Treating Decreased Levels of the Polypeptide

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy-Ex Vivo

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the

gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

- 5 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.
- 10 If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.
- 15 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention

- 20 Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650,
- 25 published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

- 30 Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be

operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1

mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3×10^6 cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to
5 construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one
10 non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-
15 digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 $\mu\text{g/ml}$. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is
20 performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 μF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

25 Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a
30 further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts

now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 28: Method of Treatment Using Gene Therapy - In Vivo

5 Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter
10 or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318
15 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The
20 polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or
25 precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

30 The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in

the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to
5 provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and
10 connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of
15 the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely
20 differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg
25 body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the
30 condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an

aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

5 The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

10 Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the
15 knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A
20 time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper
25 dosages and other treatment parameters in humans and other animals using naked DNA.

Example 29: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals.
30 Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a

specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e.,
5 polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus
10 mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science
15 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

20 Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

25 The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and
30 activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the

particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the

transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

Example 30: Knock-Out Animals.

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (*i.e.*,

- animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.
- 10 The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or
- 15 intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and

20 Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

25 example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological

30 function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

Example 31: Production of an Antibody**Hybridoma Technology**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and

therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Isolation Of Antibody Fragments Directed polypeptide(s) of the invention From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10⁹ E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture

incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication
5 WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative
10 supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and
15 concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10¹³ transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immuntubes (Nunc) are coated overnight in PBS
20 with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10¹³ TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20
25 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose
30 and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification

with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect *E. coli* HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the

detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3 H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell

representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+,
5 CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the
10 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 33: T Cell Proliferation Assay

15 Proliferation assay for Resting PBLs.

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 °C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then washed
20 three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of
25 supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0.1 microcuries of ³H-thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and incorporation of ³H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation.
30 Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

Alternatively, a proliferation assay on resting PBL (peripheral blood lymphocytes) is measured by the up-take of ^3H -thymidine. The assay is performed as follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2×10^4 cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2 (*), IFN γ , TNF α , IL-10 and TR2. In addition to the control supernatants, recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of ^3H -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ^3H -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

(*) The amount of the control cytokines IL-2, IFN γ , TNF α and IL-10 produced in each transfection varies between 300pg to 5ng/ml.

25 **Costimulation assay.**

A costimulation assay on resting PBL (peripheral blood lymphocytes) is performed in the presence of immobilized antibodies to CD3 and CD28. The use of antibodies specific for the invariant regions of CD3 mimic the induction of T cell activation that would occur through stimulation of the T cell receptor by an antigen. Cross-linking of the TCR (first signal) in the absence of a costimulatory signal (second signal) causes very low induction of proliferation and will eventually result in a state of "anergy", which is characterized by the absence of growth and inability to

produce cytokines. The addition of a costimulatory signal such as an antibody to CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on activated APCs, results in enhancement of T cell responses including cell survival and production of IL-2. Therefore this type of assay allows to detect both positive and negative effects caused by addition of supernatants expressing the proteins of interest on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with 100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2×10^4 cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFN γ , TNF α , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of ^3H -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ^3H -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

Costimulation assay: IFN γ and IL-2 ELISA.

The assay is performed as follows. Twenty-four well plates are coated with either 300ng/ml or 600ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San

Diego, CA) in a final volume of 500ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the costimulation assay. The assay is performed in the pre-coated twenty-four well plate using 1×10^5 cells/well in a final volume of 900ul. The supernatants (293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 300ul are added to 600ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only(negative control), IL-2, IFN γ , IL-12 and IL-18. In addition to the control supernatants recombinant human IL-2 (all cytokines were purchased from R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml, IL-12 at a final concentration of 1ng/ml and IL-18 at a final concentration of 50ng/ml are also used. Controls and unknown samples are tested in duplicate. Supernatant samples (250ul) are collected 2 days and 5 days after the beginning of the assay. ELISAs to test for IFN γ and IL-2 secretion are performed using kits purchased from R & D Systems, (Minneapolis, MN). Results are expressed as an average of duplicate samples plus or minus standard error.

Proliferation assay for preactivated-resting T cells.

A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would

have an effect on a naïve T cell. Therefore the use of this type of cells might enable to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve) T cells.

The assay is performed as follows. PBMC are isolated by F/H gradient
5 centrifugation from human peripheral blood, and are cultured in 10% FCS (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the presence of 2 µg/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5 ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are
10 washed and rested in starvation medium (1% FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate using 2×10^4 cells/well in a final volume of 200 µl. The supernatants (e.g., CHO or
15 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60 µl are added to 140 µl of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2, IFN , TNF , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 at a final concentration of 10 ng/ml is
20 also used. After 24 hours of culture, each well is pulsed with 1 µCi of ^3H -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ^3H -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

The studies described in this example test activity of polypeptides of the
25 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

5 Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid
10 change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC γ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3
15 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

20 Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to
25 measure the IL-12 release as follows. Dendritic cells (10^6 /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with
30 the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other
5 costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes
10 are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

15

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or
20 activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal
25 elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating
30 factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free

medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before

5 FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through

10 the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the

15 invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

20 Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol

25 red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H_2O_2 produced by the macrophages, a standard curve

30 of a H_2O_2 solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies

to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 35: Biological Effects of Polypeptides of the Invention

5 Astrocyte and Neuronal Assays:

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

25

Fibroblast and endothelial cell assays:

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000

30

cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released. Subsequently, MPP⁺ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP⁺ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate:

ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989).

- 5 Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

- 10 Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for
- 15 20 dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

- Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.
- 25

- The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.
- 30

Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells

5 On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at 2.5×10^4 cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and
10 positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

 An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

15 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20 **Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

 For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was
25 performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF₁₆₅ or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to
30 wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is

subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
5 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell
Proliferation Stimulatory Effect**

10 HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining
15 Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the
20 BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

25 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 39: Stimulation of Endothelial Migration

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

5 Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate
10 concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber, 2.5×10^5 cells suspended in 50 ul M199 containing 1%
15 FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO₂ to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by
20 counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.


The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
25 invention.

Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells

Nitric oxide released by the vascular endothelium is believed to be a mediator of
30 vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after
 5 reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the
 10 following equation:



The standard calibration curve is obtained by adding graded concentrations of KNO_2 (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and H_2SO_4 . The specificity of the Iso-NO electrode to NO is previously determined by
 15 measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2
 20 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per 1×10^6 endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

25 The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis

Another step in angiogenesis is cord formation, marked by differentiation of
5 endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a
10 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an
15 additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also
20 utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.
25

Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The
30 ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cello tape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse

In vivo angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the

Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug
5 are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 44: Rescue of Ischemia in Rabbit Lower Limb Model

15 To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb
20 is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid
25 containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1
30 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow

during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

Example 45: Effect of Polypeptides of the Invention on Vasodilation

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as $p < 0.05$ vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 46: Rat Ischemic Skin Flap Model

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

Ischemic skin

Ischemic skin wounds

Normal wounds

The experimental protocol includes:

5 Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).

 An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).

 Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.

10 Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
15 invention.

Example 47: Peripheral Arterial Disease Model

 Angiogenic therapy using a polypeptide of the invention is a novel therapeutic
20 strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

 One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.

 A polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered
25 intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.

 The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

 The studies described in this example tested activity of a polypeptide of the
30 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 48: Ischemic Myocardial Disease Model

5 A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

10 A polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

15 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 49: Rat Corneal Wound Healing Model

20

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

Making a 1-1.5 mm long incision from the center of cornea into the stromal layer. Inserting a spatula below the lip of the incision facing the outer corner of the eye. Making
25 a pocket (its base is 1-1.5 mm from the edge of the eye). Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

30 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

5 *Diabetic db+/db+ Mouse Model.*

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is
 10 dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal
 15 heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al. Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375
 20 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*,
 25 *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of*
 30 *Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The

animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional
5 Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01
10 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The
15 wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily
20 measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups
25 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.
30 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50

mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus

microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a
5 blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 51: Lymphadema Animal Model

15 The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and
20 histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed
25 with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of
30 dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are

used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca²⁺ comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control
5 legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon
10 sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

15

Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules
20 (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium
25 determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- α), a potent proinflammatory cytokine, is a
30 stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- α induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- α treated ECs when co-stimulated with a member of the FGF family of proteins.

5 To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂.

HUVECs are seeded in 96-well plates at concentrations of 1×10^4 cells/well in EGM
10 medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

15 Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 μ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are
20 aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca⁺⁺ and Mg⁺⁺) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-
25 1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with
30 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the

ExtrAvidin-Alkaline Phosphatase in glycine buffer: $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$. 5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPN reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

10 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

15 **Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation**

This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

20 It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an

inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells
5 are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5×10^5 cells/ml. During this time, 100 μ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that
10 can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10 μ l of prepared cytokines, 50 μ l SID (supernatants at 1:2 dilution = 50 μ l) and
20 μ l of diluted cells are added to the media which is already present in the wells to
15 allow for a final total volume of 100 μ l. The plates are then placed in a 37°C/5% CO₂ incubator for five days.

Eighteen hours before the assay is harvested, 0.5 μ Ci/well of [3H] Thymidine is added in a 10 μ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat
20 using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined
25 via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene
30 therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected

to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the $\alpha_5\beta_1$ and $\alpha_4\beta_1$ integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of $0.2 \mu\text{g}/\text{cm}^2$. Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem

cells is to be expected. Gene products are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5% CO₂, 7% O₂, and 88% N₂) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

If a particular gene product is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone

marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell

5 **Proliferation**

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF α stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 μ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 μ g/ml hEGF, 5mg/ml insulin, 1 μ g/ml hFGF, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNF α is added to a final concentration of 2ng/ml

(NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO₂ until day 5.

Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in
5 the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100
10 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash
15 buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled
20 Streptavidin 1:1000 in Assay buffer, and add 100 µl/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

Add 100 µl/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

25 A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and
30 angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vasculargenesis, both of the blood

vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1

(VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 μ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10 μ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 (10^0) > $10^{-0.5}$ > 10^{-1} > $10^{-1.5}$. 5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-

conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

Example 57: Alamar Blue Endothelial Cells Proliferation Assay

- 5 This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue
- 10 Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and
- 15 Angiostatin or TSP-1 are included as a known inhibitory controls.

- Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of
- 20 interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The
- 25 plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

- Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical
- 30 reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and

inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides).

Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM[®], density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to 2×10^6 cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2×10^5 cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 μ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 μ g/ml; anti-CD4 mAb (R&D

Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 µg/ml. Cells are cultured for 7-8 days at 37°C in 5% CO₂, and 1 µCi of [³H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, the specification and sequence listing of U.S. Provisional Application Serial No. 60/232,104 filed September 12, 2000 is hereby incorporated by reference in its entirety.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL (PCT Rule 13bis)			
A. The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 66.			
B. IDENTIFICATION OF DEPOSIT		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit 09 June 2000		Accession Number PTA-2076	
C. ADDITIONAL INDICATIONS (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer Jerol R. McDowell International Appl Processing Div. (703) 305-8639		Authorized officer	

ATCC Deposit No. PTA-2076

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: 2076

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates⁴ occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID
10 NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID
20 NO:X, having biological activity;
- (f) a polynucleotide which is a variant of SEQ ID NO:X;
- (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ
ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

25

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

30

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15 (g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

30 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.
17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.
18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or absence of a mutation in the
10 polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
19. A method of diagnosing a pathological condition or a susceptibility to
15 a pathological condition in a subject comprising:
- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the
20 polypeptide.
20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
- (a) contacting the polypeptide of claim 11 with a binding partner; and
25 (b) determining whether the binding partner effects an activity of the polypeptide.
21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.
22. A method of identifying an activity in a biological assay, wherein the
30 method comprises:
- (a) expressing SEQ ID NO:X in a cell;

- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

- 5 23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 22 human secreted proteins

<130> PS727PCT

<150> 60/232,104

<151> 2000-09-12

<160> 121

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tcccccaaaa	acccaaggac	accctcatga	120
tctcccggac	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcagg	tctccaacaa	agccctccca	acccccatcg	360
agaaaaccat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgaggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctc	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

<212> DNA

<213> Artificial Sequence

<220>

<221> Primer_Bind

<223> Synthetic sequence with 4 tandem copies of the GAS binding site found in the IRF1 promoter (Rothman et al., Immunity 1:457-468 (1994)), 18 nucleotides complementary to the SV40 early promoter, and a Xho I restriction site.

<400> 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> Primer_Bind

<223> Synthetic sequence complementary to the SV40 promoter; includes a Hind III restriction site.

<400> 4

gcggcaagct ttttgcaaag cctagggc 27

<210> 5

<211> 271

<212> DNA

<213> Artificial Sequence

<220>

<221> Protein_Bind

<223> Synthetic promoter for use in biological assays; includes GAS binding sites found in the IRF1 promoter (Rothman et al., Immunity 1:457-468 (1994)).

<400> 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120
gcccctaact ccgcccagtt ccgcccattc tccgcccacat ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctatc cagaagtagt gaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<221> Primer_Bind

<223> Synthetic primer complementary to human genomic EGR-1 promoter sequence (Sakamoto et al., Oncogene 6:867-871 (1991)); includes a Xho I restriction site.

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<221> Primer_Bind

<223> Synthetic primer complementary to human genomic EGR-1 promoter sequence (Sakamoto et al., Oncogene 6:867-871 (1991)); includes a Hind III restriction site.

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c

31

<210> 8

<211> 12

<212> DNA

<213> Homo sapiens

<400> 8

ggggactttc cc

12

<210> 9

<211> 73

<212> DNA

<213> Artificial Sequence

<220>

<221> Primer_Bind

<223> Synthetic primer with 4 tandem copies of the NF-KB binding site (GGGGACTTTCCC), 18 nucleotides complementary to the 5' end of the SV40 early promoter sequence, and a XhoI restriction site.

<400> 9

gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg
ccatctcaat tag

60

73

<210> 10

<211> 256

<212> DNA

<213> Artificial Sequence

<220>

<221> Protein_Bind

<223> Synthetic promoter for use in biological assays; includes NF-KB binding sites.

<400> 10

ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct
caattagtca gcaaccatag tcccgccct aactccgcc atcccgcgcc taactccgcc
cagttccgcc cattotccgc cccatggctg actaattttt tttatttatg cagaggccga
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg
cttttgcaaa aagctt

60

120

180

240

256

<210> 11

<211> 1698

<212> DNA

<213> Homo sapiens

<400> 11

ccacgcgtcc	gccggagtga	gcgcgacat	catgtccatg	ctcgtggtct	ttctcttget	60
gtgggggtgc	acctggggcc	cagtgcaga	agcagccata	ttttatgaga	cgcagcccag	120
cctgtgggca	gagtcgcaat	cactgctgaa	acccttgccc	aatgtgacgc	tgacgtgcca	180
ggcccgccctg	gagactccag	acttccagct	gttcaagaat	gggggtggccc	aggagcctgt	240
gcaccttgac	tcacctgcca	tcaagcacca	gttctctgctg	acgggtgaca	cccaggcccg	300
ctaccgctgc	cgctcgggct	tgtccacagg	atggaccagg	ctgagcaagc	tcctggagct	360
gacagggcca	aagtccttgc	ctgctccctg	gctctcgatg	gcgccagtgt	cctggatcac	420
ccccggcctg	aaaacaacag	cagtgtgccg	agggtgtgctg	cgggggtgtga	cttttctgct	480
gaggcgggag	ggcgaccatg	agtttctgga	ggtgcctgag	ggccaggagg	atgtggaggc	540
cacctttcca	gtccatcagc	ctggcaacta	cagctgcagc	taccggaccg	atggggaagg	600
cgcctctctct	gagcccagcg	ctactgtgac	cattgaggag	ctcgtgcac	caccaccgcc	660
tgtgctgatg	caccatggag	agtcctccca	ggtcctgcac	cctggcaaca	aggtagacct	720
cacctgcgtg	gctcccctga	gtggagtggg	cttcagcta	cggcgcgggg	agaaagagct	780
gctggtaccc	aggagcagca	ccagcccaga	tcgcatcttc	tttcacctga	acgcggtggc	840
cctgggggat	ggaggtcact	acacctgccg	ctaccggctg	catgacaacc	aaaacggctg	900
gtccggggac	agcgcgcccg	tcgagctgat	tctgagcgat	gagacgctgc	ccgcgcggga	960
gttctccccg	gagccggagt	ccggcagggc	cttgcggctg	cgggtgcctgg	cgccccctgga	1020
gggcgcgcgc	ttcgccctgg	tgcgcgagga	caggggcggg	cgccgcgtgc	accgtttcca	1080
gagccccgt	gggaccgagg	cgctcttcga	gctgcacaac	atttccgtgg	ctgactccgc	1140
caactacagc	tgcgtctacg	tggacctgaa	gccgccttcc	gggggctccg	cgcccagcga	1200
gcgcttgagg	ctgcacgtgg	acggaccccc	tcccaggcct	cagctccggg	cgacgtggag	1260
tggggcggtc	ctggcgggcc	gagatgccgt	cctgcgctgc	gagggaccca	tccccgacgt	1320
caccttcgag	ctgctgcgcg	aggcgagagc	gaaggccgtg	aagacgggtcc	gcaccccgcg	1380
ggcgcgcggc	aacctcgagc	tgatcttcgt	ggggccccag	cacgcgggca	actacagggtg	1440
ccgctaccgc	tcctgggtgc	cccacacctt	cgaatcggag	ctcagcgacc	ctgtggagct	1500
cctggtggca	gaaagctgat	gcagccgcgg	gcccagggtg	ctgttgggtg	cctcagaagt	1560
gccggggatt	ctggactggc	tccctccctc	cctgttgtag	cacaaggccg	gggtctctg	1620
ggggctggag	aagcctccct	cattcctccc	aggaattaat	aaatgtgaag	agagctctgt	1680
ttaaaaaaaa	aaaaaaaaa					1698

<210> 12

<211> 1489

<212> DNA

<213> Homo sapiens

<400> 12

gtcgaccac	gcgtccggcc	ggagggacga	tgagctgcgc	ggggcgggcg	ggccctgccc	60
ggctcgccgc	ctgagccctg	ctgacctgca	gcctgtggcc	ggcacgggca	gacaacgcga	120
gccaggagta	ctacacagcg	ctcatcaacg	tgacggtgca	ggagcccggc	cgccggcgccc	180
cgctcacgtt	tcgcatcgac	cgcgggcgct	acgggcttga	ctcccccaag	gccgaggtcc	240
gcggccagg	gctggcgccg	ctgcccctcc	acggagtgtc	tgatcatctg	ggctgtgatc	300
cacaaacccg	gttctttgtc	cctcctaata	tcaaacagtg	gattgccttg	ctgcagaggg	360
gaaactgcac	gtttaaagag	aaaatatcac	gggcccgttt	ccacaatgca	gttgcgttag	420
tcactctaaa	taataaatcc	aaagaggagc	cagttaccat	gactcatcca	ggcactggag	480
atattattgc	tgtcatgata	acagaattga	gggtaagga	tattttgagt	tatctggaga	540
aaaacatctc	tgtacaaatg	acaatagctg	ttggaactcg	aatgccaccg	aagaacttca	600
gccgtggctc	tctagtcttc	gtgtcaatat	cctttattgt	tttgatgatt	atttcttcag	660
catggctcat	attctacttc	attcagaaga	tcaggtagac	aatgacgcgc	gacaggaacc	720
agcgtcgtct	cggagatgca	gccaaagaa	ccatcagtaa	attgacaacc	aggacagtaa	780
agaaggggtga	caaggaaact	gaccagact	ttgatcattg	tgcagtctgc	atagagagct	840
ataagcagaa	tgatgtcgtc	cgaattctcc	cctgcaagca	tgttttccac	aatcctgctg	900
tggtaccctg	gcttagtgaa	cattgtacct	gtcctatgtg	caaacttaat	atattgaagg	960
ccctgggaat	tgtgcccgaat	ttgccatgta	ctgataacgt	agcattcgat	atggaaaggc	1020
tcaccagaac	ccaagctggt	aaccgaagat	cagccctcgg	cgacctcgcc	ggcgacaact	1080
cccttggcct	tgagccactt	cgaacttcgg	ggatctcacc	tcttctctcag	gatggggagc	1140
tcactccgag	aacaggagaa	atcaacattg	cagtaacaaa	agaatggttt	attattgcca	1200
gttttggcct	cctcagtgcc	ctcacactct	gtcagtagat	catcagagcc	acagctagct	1260

tgaatgctaa	tgaggtagaa	tggttttgaa	gaagaaaaaa	cctgctttct	gactgatttt	1320
gccttgaagg	aaaaaagaac	ctatttttgt	gcattcattta	ccaatcatgc	cacacaagca	1380
tttatTTTTA	gtacatttta	ttttttcata	aaattgctaa	tgccaaagct	ttgtatttaa	1440
agaaataaat	aataaaataa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1489

<210> 13

<211> 979

<212> DNA

<213> Homo sapiens

<400> 13

ctcatgtggg	gagatgagcg	tctttctcct	gggaccgaag	agggaaacaag	acggagaagg	60
aagaggcggg	gctgcgactg	tccccagcgt	actgccgggc	tgccgggtcc	ctgctctggg	120
tacttctctg	ctttcggggc	tctcgtctag	aagctgcagc	ttggcctgtc	tcacctctac	180
acagaggggc	tgctggcgcc	tgacggaaaa	aggtccacac	accgatggc	cggcccgggg	240
tggaacgtgc	tgctactgct	gctgctgctg	ctgctgctgg	ggtccatggc	agggatatgg	300
ccacagaaga	agttgaacct	gtcccataag	ggcatcgggg	agccatgcgg	gagacacgag	360
gagtgccaga	gcaactgctg	taccatcaac	agcctggccc	cacacacgct	ctgcacccct	420
aagaccatct	tcttgacgtg	cctgccctgg	aggaagccca	atgggtacag	atgctcgcac	480
gactcagagt	gccagagcag	ctgctgcgtc	cgcaacaaca	gcccgcagga	gttgtgcacg	540
ccccaaagcg	tcttctcgca	gtgtgtgccc	tggcgcaagc	ccaacggcga	cttctgcagc	600
agccatcarg	agtgtcacag	ccagtgcgtc	atccagctga	gggagtacag	ccccttcgcg	660
tgcatctccc	ggaccgggat	cctggcccag	tgctgcctcc	tgtgatgtga	gctcgaacct	720
gggcgcgagg	gaccggcctg	ggccctggga	tggttcacga	ggaccgcgtt	gcgcgggggc	780
tggttccagc	ggaagcttcc	cttacggttt	gtgctgctgt	ttctggggct	ctgaaaatct	840
gtgggaactg	aaaggctgtg	accagcctgg	tggcgcgaag	tgtctgtgag	aacaaatccc	900
aggcactggg	gtgtagcctg	attgttaaac	atcmataaag	gctcctggcc	gactgaaaaa	960
aaaaaaaaaa	aaaactcga					979

<210> 14

<211> 1093

<212> DNA

<213> Homo sapiens

<400> 14

ggcacgagtg	gactccagcg	gtggcttctt	gatgctgcgc	ggtccccac	tccctacatc	60
agaatgcata	ccgcataccg	actccagcgg	tggtgctcta	cctgcacgct	gttgccaagt	120
ccaagctacc	atactcctgc	ctgagctatg	acaacagcct	cctcactgat	ctcccccttc	180
ttccctttgc	ctctccagc	tcatttttca	cagtgtagaa	tgacattttg	tttgtttgtt	240
ttgttttgtt	tgagatggag	tctcgtcttg	ttgccagggg	tgagatgcag	cgggtgcgatc	300
tcggctcact	gcaacctcca	cctcccgggt	tcaagcggat	tctcgtgcct	cagcctcctg	360
agtagctggg	attacaggca	tgaccacca	tgcccggata	atttttgtat	ttttagtaga	420
gatgggggtt	cactatgttg	gccaggctgg	tctcgaacac	ctgacctcgt	gggccacccg	480
cctcggcctc	ccaaagcact	gggattacag	gcgtgagcca	cccggcctgg	cctagaatga	540
cttttaaaag	atcaaatata	atcaggtcac	tcctttgctt	acaacgcagt	gcgttttagag	600
gtacacccca	tgtctccaca	gggcatacag	catccgattt	aatctggatc	cattccggcg	660
ccttctcttc	ccagtcaccc	agaggggccc	aaccccgggc	gccctttctt	cctcaaagt	720
cctcggctct	ataccgtgcc	tggttctttt	ctctttctct	ctgcctggaa	cattccttct	780
ttcccccttt	gtcttgccca	ctcctgttta	cccttcaagt	ttcaagttca	tgctactgtc	840
tcagagagg	tttctgtg	tcgccctgtt	tctctcagga	agccttgctc	ttttccatca	900
tgccctctaat	cacagcttat	aatcggatat	ttatttctgt	gtctacagtc	ttgccctgcc	960
agactgtatg	ccccatgtgg	gcaggcgctc	atgattgttt	ctgattgttt	cacgcagtgt	1020
gctaaccacg	agcctggggc	caaagctagt	tagtactcaa	tacacaatgc	attgaaaaaa	1080
aaaaaaaaaa	aaa					1093

<210> 15
 <211> 2642
 <212> DNA
 <213> Homo sapiens

<400> 15
 ggacagagggc gcgtctcaaa aggatgggtgc gcctggcggc cgagctgctg ctgctgctgg 60
 ggctgctgct gctcacgctg cacatcacccg tgctgcgcgg ctcgggagcc gccgacgggc 120
 ccgacgcggc cgcggggcaac gccagccaag cccagctgca gaataacctc aacgtgggaa 180
 gtgacaccac atcagaaacc agcttttctc tctccaaaga agcaccaagg gagcatctgg 240
 accaccaggc tgcacaccaa ccttcccca gaccgcgatt ccgacaagag acggggcacc 300
 cttcattgca aagagatttc cccagatcct ttctccttga tctaccaaac tttccagatc 360
 tttccaaagc tgatatcaat gggcagaatc caaatatcca ggtcaccata gaggtggctg 420
 acggtcctga ctctgaagca gataaagatc agcatccgga gaataagccc agctggtcag 480
 tcccatcccc cgactggcgg gcctgggtggc agaggctccct gtccctggcc agggcaaaaca 540
 gcggggacca ggactacaag tacgacagta cctcagacga cagcaacttc ctcaaccccc 600
 ccaggggggtg ggaccataca gccccaggcc accggacttt tgaaaccaa gatcagccag 660
 aatatgattc cacagatggc gagggtgact ggagtctctg gtctgtctgc agcgtcacct 720
 gcgggaacgg caaccagaaa cggaccgggt cttgtggcta cgcgtgact gcaacagaat 780
 cgaggacctg tgacctcca aactgccag gaattgaaga cacttttagg acagctgcca 840
 ccgaagttag tctgcttgcg ggaagcgagg agtttaatgc caccaaactg tttgaagttg 900
 acacagacag ctgtgagcgc tggatgagct gcaaaagega gttcttaaag aagtacatgc 960
 acaaggtgat gaatgacctg cccagctgcc cctgctccta cccactgag gtggcctaca 1020
 gcacggccga catcttcgac cgcataaagc gcaaggactt ccgctggaag gacgccagcg 1080
 ggcccaagga gaagctggag atctacaagc ccactgccc gtactgcatc cgtccatgc 1140
 tgtccctgga gagcaccacg ctggcggcac agcactgctg ctacggcgac aacatgcagc 1200
 tcatcaccaag gggcaaggcg gcgggcacgc ccaacctcat cagcaccgag ttctccgagg 1260
 agctccacta caaggtggac gtccctgccc ggattatctg caagggtgac tggagcaggt 1320
 ataacgaggg ccggcctccc aacaacggac agaagtgcac agagagcccc tcggacgagg 1380
 actacatcaa gcagttccaa gaggccaggg aatattaaag agactgggat gaggtggagg 1440
 acgctgcttc tggttctgga gcacacacgt gctgcactga cgtgccgact ggcgccgaga 1500
 ccttcatagc tgcggtcgtg tatatttgta tataccacat gagtatttct catacattac 1560
 gctaggggag aagtgccctt ggggagcgat gtgggcagaa ggatggggac aacttggaag 1620
 agctccttga aagtgccctt ggggagcgat gtgggcagaa ggatggggac aacttggaag 1680
 ccagaagaag aacctggaag ccacagtggg tgcgactcaa ttcacaccg gatccagagt 1740
 ttcaaagaga ggcaaaggcg gaaagagact gaggttgtaa acgttataag cagtttttat 1800
 atataactta ttaatacaaa atgtgactta attaaagcga accttttctc tggagttgtg 1860
 gtgaaactaa tcagctctgt gagagatcag aaagaaagag acttagggaa gtggaagaga 1920
 aagggaatth tggaaattht ttcttttaaaa ataattgcaat ggaaatatat caaaacatgt 1980
 aaacgcccac cttaaaccaa atgttattht gtcatgaggc accttgctgg agtctcagat 2040
 tccaaaagtc tcttcttcag actgggtagg gaatatgata ttttagggac aaagctgagg 2100
 actggtttta aataggcttht aaaataaaa atcaatatta tcataatgct atcattctgc 2160
 taaacggccc caaaacagta gaatttctgc tcatgtccta gcaggttcag aagactgcag 2220
 ccaagttcag atgtaaaaa aagaagtagc acttttccaa aggaaaacaa caaaacaaat 2280
 gggaaaaaga taatggaccg catthtcacct atttttaata tatttttaaca attttttcat 2340
 ctaccaatat atccccata aataaatata aaaggggggg agggtaaatc tggggaatct 2400
 tagtttttta tgttttaaga aaacaaaaaa aactgcatta tttttgtaaa gtattttattg 2460
 agtcacggat tattgtgcat caagcaattg ttaatatgac ctggtcctat ggggtagaac 2520
 ttaggaaaaa taaagttggt tcttattcaa tattttactt tgcaaaatth tagtaaaaga 2580
 gagtataata taaaatcata ataaaagggt aaaaaaaaa aaaaaaaaa aaaaaaaaa 2640
 aa 2642

<210> 16
 <211> 695
 <212> DNA
 <213> Homo sapiens

<400> 16
acgcgtccga ggcgagagcc ctgggatgca ccggccagag gccatgctgc tgctgctcac 60
gcttgccctc ctggggggcc ccacctgggc agggaagatg tatggccctg gaggaggcaa 120
gtatttcagc accactgaag actacgacca tgaatcaca gggctgcggg tgtctgtagg 180
tcttctcctg gtgaaaagtg tccagggtgaa acttgagac tcttgggacg tgaaactggg 240
agccttaggt gggaataccc aggaagtcac cctgcagcca ggcaataca tcacaaaagt 300
ctttgtcgcc ttccaagctt tctccgggg tatggtcatg tacaccagca aggaccgcta 360
tttctatttt gggaaagctt atggccagat ctctctgcc taccacagcc aagaggggca 420
ggtgctggtg ggcattctatg gccagtatca actccttggc atcaagagca ttggctttga 480
atggaattat ccactagagg agccgaccac tgagccacca gttaattctca catactcagc 540
aaactcaccc gtgggtcgct aggggtgggt atggggccat ccgagctgag gccatctgtg 600
tggtggtggc tgatggtact ggagtaactg agtggggacg ctgaatctga atccaccaat 660
aaataaagct tctgcagaaa aaaaaaaaaa aaaaa 695

<210> 17
<211> 2521
<212> DNA
<213> Homo sapiens

<400> 17
ggcacgagct gaggtccagc cctcgtgaac tgatctgcgg ctgcactcaa ccttctcgcc 60
agtctcagga tgaggtggcc ttgccccacc tcaaagcctg ctctccacc tgtgctctgg 120
agccacctct gccagcatcg ctggggccctc accccagcct ctaccttgct ctgctggctc 180
ttgctcttca acctaggaac gtgcttgagc ttttctcatc ttaaacaaaa caacaataac 240
agcaacacaa gcaaaatctc ctttgaccct gcattccctct gttgggttat catcagctta 300
tcattcccac ctttcccatc aaaacatctc aaaagagtag tctacactca acactctcca 360
tttctcact accctcttac tctcaacct gctgcaattt gacattcacc cccagagttg 420
ctttgacctc ctaattacca aatcagtgagg ccctgtcag tctctgtgtc tgctgcattg 480
atgctgttta ccacccctc ctcaaaaaat gcctgtgctt attactagtt cctataaagt 540
gctgaaaccc aaatctgtct agccctggcc cctcccccaa gattcagcct cctgtactcg 600
actacatgtc agacatctcc ccttggtatg cccacaggca ccttactgtg accaaaagag 660
aattggtcgt ctcatgcccc atctcaactc taaagtgate ttctctctct gtccctatc 720
tcacttggtg gcggcaccat ctaccctgtc ctggtgactc tcgaatactt cccaaatctg 780
agggttttgt ttgccgtgtc tacttccctt agtgtctctc tccctctatc agactaagct 840
tttcaagggc aaggactcta catcagctgt ccgtgcctca gcacaccaca caagtctagg 900
caccaaacag gcctcagtaa atgtcgttga attgaaccgt gctctgctct ctcatccca 960
gcagtgtgtt ccttggtggg agctgacca gtgcctgggg aatgaatgaa gtgggagtct 1020
ggatgccaaag accctcttag tccctgatcc ccctattgag tccaaaagtc tttctttaac 1080
cctgatggca tttgggacac agaggatatt gtaaggtttt aaaagtggct ttgtagacaa 1140
agtcatgcaa ggcaagactt ccaggagtgt gaactgaaca gccacattgc cagatgtgtg 1200
ctccagacta gaagtgtgtt ggatgggttg gcaattggga ggagaaccaa aagggcctgg 1260
atgagtcaga gtttcaagag gaggcatttg aacaattcaa gcaggagaaa gaataaagca 1320
agtttcaaag tccagaagga acatggcatg tgtatataat gggagggagg gagtgaagaag 1380
agcagcatgg agaggtttgg ataggtggcc ttcaaggtag tttccaatcc taagtgcctg 1440
cagagtggaa gctgctggtc tcggagaagt ctggaccaca gagatcttct cccaacccaa 1500
gcataaccga gggatgcgac acatgccggc agtaacagcg gctcacttgg catcttcaaa 1560
gccatggggc agggcctgcc agacgaggag caggagaagc tgctgcgcat ctgttccatt 1620
tataccaga gtggagaaag cagcctggtg caggagggtc ctgaggcctc cccatttggg 1680
aagtctccat atacactaga cagcctgtat tggagcgtca agccagccag ctccagcttc 1740
gggtctgaag caaaggccca gcaacaggag gagcagggca gtgttaatga tgtcaaggaa 1800
gaggagaagg aggagaaaga ggtcttgcca gaccaggtag aggaggagga agaaaatgat 1860
gaccaagagg aggaagagga ggaagaagat gatgaagatg atgaagagga agacagaatg 1920
gaggtggggc ctttctctac agggcaagag tccccactg ccgagaatgc taggcttctg 1980
gcccagaaaa gaggagcttt gcagggtctc gcatggcagg ttagctcaga agacgtgcga 2040
tgggacacat tccccctagg ccgaatgcca ggtcagaccg aggaccagc agagctcatg 2100
ctggagaatt atgacaccat gtatcttttg gaccagcctg tgctagagca gcggctggaa 2160
ccctcaacat gcaagactga caccttgggc ctgagctgtg gtgtcggcag tggcaactgc 2220

agcaacagca	gcagcagcaa	cttcgagggc	cttctctgga	gccaggggca	gctgcatggg	2280
ctcaaaactg	gcctgcagct	cttctgatgg	ccatccctgg	tgcaagtgtt	catccagccg	2340
tgccagggca	acagcccacc	ccctagtaca	actgatgctc	cctgagacaa	cctgggagac	2400
agcctggatc	agccacatca	actcagttgt	ccaccacagg	ggaattttga	atgtcttttg	2460
tttttgtttt	gttttgaaaa	ataataaaca	ggcaactgta	aaaaaaaaaa	aaaaaaaaaa	2520
a						2521

<210> 18

<211> 1276

<212> DNA

<213> Homo sapiens

<400> 18

tcccgggtcg	acccacgcga	accgcgagcg	cgtggggccg	kctgtgcaca	tcccaggaca	60
ggagcccctg	accgcgtcca	tgctggctgc	ggcgcccctg	catgagcaaa	agcagatgat	120
tggcacctgt	tatcttgtct	taaaacgctg	gtcagactgg	atggctcctga	gctttcttcc	180
actgctgctg	tcctgtgact	ttgaggggag	cgtctctacc	cccttatcca	tgatgtccac	240
accagctgg	ctggcaagat	cacgggcatg	ctgctggaga	ttgacaactc	rgagctgttg	300
ctcatgctgg	agtctccaga	atccctccat	gccaaagatag	acgaggcagt	ggccgtgctg	360
caggcacacc	aggctatgga	gcagccgaag	gcgtacatgc	actgaaacca	gatttcagct	420
taaaatgcca	ccagagagacc	aagttcattc	tgtcaactga	tctccagcac	ctggcccaga	480
gacggaaagt	acaaagacta	gtaaaataca	tccttgccct	taaggagcta	agtacccaaa	540
acctgtaatc	catcttgagt	caccagagta	cggttgctca	gaaacagcag	tggtgcggtg	600
gaaagggcat	caaccctgcg	atccggacaa	gtcactccat	ccctctgatc	atgcgtgcc	660
acctaccaca	tgaggatata	acttcataga	cttgctggaa	gggttcattg	tgttagcctg	720
ttccctgagc	tctcttcgtg	atcaagaaga	ctgatcagat	aatcaagag	acttgcccaa	780
aattacctag	gaaatctgta	gcagcagcag	aaccaaactc	cggtccttgc	taaactctaga	840
taccaggcta	gcttttctat	ggacccagaa	ttaaccata	caaatgtaca	agcttttcca	900
gaccagctgg	ggtgagatga	atgaaaatgg	cagcaacatc	aatacctcag	cttcttcagc	960
aacttcatca	agtaaggctg	ccatgaggaa	gtgggcctaa	aggagagttt	tctagaacaa	1020
agaagggggc	aaaggagtgg	cttgaaactg	caaaaagtgc	agacaaaaaa	aaaaaaaaaa	1080
agaatgaaat	ctggagagga	tgtgaggaga	ggtctagcaa	aatgattaaa	aatttgagct	1140
tagcatcaaa	gtcaaacaga	tccatattca	aatcgtggct	cttccatgtc	ttcactatgt	1200
aaccccgagg	gagccaattt	aactctcttg	gactcctcct	ttctaagcat	tttatccaca	1260
gggccataat	aaagat					1276

<210> 19

<211> 1215

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (907)

<223> n equals a,t,g, or c

<400> 19

gcatttacia	gcacttcagc	gccactttgg	catatgtgaa	actctccaag	gtactgaact	60
tctatgtggc	taatgcagat	gactccagca	agactgaact	gctttttgct	gcgttgaaag	120
ccttgaagta	cttgtttaga	ttcatcatcc	aatcccgagt	gctctacttg	aggtaatggt	180
aactgcagtg	aagatgttta	gattatcagc	tgctactctg	tgtgcttttt	ccctcactct	240
gcacagtggg	gttcagctct	gtgagcagtt	agtctcttaga	attgccttat	ttcagaactg	300
cagggctgaa	gatggatttg	ggctgcgtgt	ctgttgagga	agactcatga	gaagtttttg	360
tagatcagca	aaattctggg	gcagtaatga	cctcaggact	tggggaagca	gattcctgtg	420
gaaagattgt	acctaataca	gcagatgact	tcatgacaat	attgagtgtg	caaacttagg	480
atcatgatct	gctgtcgcta	gcagaagcag	cagtcactct	aggggaggtg	ttgcctgaga	540

tgagtgtttc	cttgttgaca	ctgtgcttag	ctacctgggc	aactaagcac	tagagacagg	600
aytattccct	gtttggattt	ctagcataac	agttccatca	aamacagaag	aaactgcaaa	660
agagcaagta	cctttgcagg	gaacattcac	aaccccgatg	actttcctac	ccttcagaaa	720
tagctgtatt	tcacaaactgt	taaaattttt	ttctaaggaa	gaaagaaaag	gtttgtagaa	780
ttgagcatat	gtattttttaa	aagaaacttt	attgaaaaaa	ataaaattaa	aggcaaacaa	840
cctgcaaaaa	ggttacatat	agtacagatg	aaagtttaat	agctttttctc	agttaaagct	900
tttatanatc	aataaagaaa	tgataaatag	ccctaattgga	aaacaaaaac	aggtaattta	960
caaaaagaaa	acttaaattgg	tcaataaact	ttttaaaaaa	tttcataacta	tcaaaagaat	1020
tttgatacag	acgcacacac	atgcgatgcac	acacacacca	tctttttacct	atacatttga	1080
aaaagattag	acatcttttgt	ccttgatgag	attgggcaaa	aattgggtcct	gtatttcagt	1140
tttgatgcta	atggagatat	aaattcttca	ggatagaaat	agatagtcctg	aataaaacca	1200
aaaaaaaaaa	aaaag					1215

<210> 20

<211> 1629

<212> DNA

<213> Homo sapiens

<400> 20

accagtatat	gtgcaaagct	ggtacgcctg	caggtaccgg	tccggaattc	ccgggtcgac	60
ccacgcgtcc	gggttgtgtc	acggaacggc	agggccgcct	ttaggcttac	atccctggaa	120
ctcccacctc	cacagaccgc	tccgggtgct	gaaagtccac	ggatgctatc	cctggtcaaa	180
tcagaggctt	gtccagccgg	aagccctgag	ggcagctgtt	cccactggct	ctgctgacct	240
tgtgccttgg	acggctgtcc	tcagcgaggg	gccgtgcacc	cgctcctgag	cagcgccatg	300
ggcctgctgg	ccttcctgaa	gacccagttc	gtgctgcacc	tgctggctgg	ctttgtcttc	360
gtggtgagtg	gtctgggtcat	caayttsgtc	cagctgtgca	cgctggcgct	ctggccgggtc	420
agcaagcagc	tctaccgcgc	cctcaactgc	cgcctcgctc	actcactctg	gagccaactg	480
gtcatgtctg	tggagtgggtg	gtcctgcacg	gagtgtagac	tgttcacgga	ccaggccacg	540
gtagagcgct	ttgggaagga	gcacgcagtc	atcatcctca	accacaactt	cgagatcgac	600
ttcctctgtg	ggtggaccat	gtgtgagcgc	ttcggagtgc	tggggagctc	caaggctctc	660
gctaagaagg	agctgctcta	cgtgccccctc	atcggctgga	cgtgggtactt	tctggagatt	720
gtgttctgca	agcggaagtg	ggaggaggac	cgggacaccg	tggtcgaagg	gctgaggcgc	780
ctgtcggact	accccgagta	catgtgggtt	ctcctgtact	gcgagggggac	gcgcttcacg	840
gagaccaagc	accgcgttag	catggagggtg	gcggctgcta	aggggcttcc	tgtcctcaag	900
taccacctgc	tgccgcggac	caagggtctc	accaccgcag	tcaagtgcct	ccgggggaca	960
gtcgcagctg	tctatgatgt	aaccctgaac	ttcagaggaa	acaagaacct	gtccctgctg	1020
gggatcctct	acgggaagaa	gtacgaggcg	gacatgtgcg	tgaggagatt	tcctctggaa	1080
gacatcccgc	tggatgaaaa	ggaagcagct	cagtggcttc	ataaactgta	ccaggagaag	1140
gacgcgtcc	aggagatata	taatcagaag	ggcatgtttc	caggggagca	gtttaagcct	1200
gcccggaggc	cgtggaccct	cctgaacttc	ctgtcctggg	ccaccattct	cctgtctccc	1260
ctcttcagtt	ttgtcttggg	cgtctttgcc	agcggatcac	ctctcctgat	cctgactttc	1320
ttgggggttg	tgggagcagc	ttcctttgga	gttcgcagac	tgataggagt	aactgagata	1380
gaaaaaggct	ccagctacgg	aaaccaagag	tttaagaaaa	aggaataatt	aatggctgtg	1440
actgaacaca	cgcggccctg	acgggtggtat	ccagttaact	caaaaccaac	acacagagtg	1500
caggaaaaga	caattagaaa	ctatttttct	tattaactgg	tgactaatat	taacaaaact	1560
tgagccaaga	gtaaagaatt	cagaaggcca	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1620
ggcggccgc						1629

<210> 21

<211> 1015

<212> DNA

<213> Homo sapiens

<400> 21

tgcacccacg	cgctccgggg	cctccaaggc	cctgctccca	gtgggcgcct	atgaagtctt	60
cgcccgagg	gcgggtgggtg	cgggtgcagc	tcggggcctg	ctgcctggag	atgaggacgc	120

tggtcgagct	cgggccctgg	gctggggact	ttgggcctga	cctgctgctc	accctgctct	180
tcttgctctt	cctgggcgcac	gggggtcacct	tggacggggc	ctcgggccaac	cccactgtgt	240
ccctgcagga	gttcctcatg	gccgagcagt	ctctgcctgg	cacgctgttg	aagctggcgg	300
cacaggggct	gggcatgcag	gccgcctgca	ccctgatgcg	cctctgctgg	gcctgggagc	360
tcagtgcact	gcacctgctg	cagagcctca	tggcccagag	ctgcagctcg	gccctgcgca	420
catccgtgcc	ccacggggcg	cttttgagg	ccgcctgcac	cttttgtttc	catctgaccc	480
tcttgcacct	gcggcacagt	cctccggcct	acagcggggc	tgctgtggct	ctgttggtca	540
ccgtcacggc	ctacacggcc	gggcccttca	cgtctgcctt	cttcaacct	gccctggccg	600
cctctgtgac	ctttgcctgc	tcggacacac	cttactggag	tacgtgcagg	tgtactggct	660
gggcccctctg	acagggatgg	tcctggctgt	gctgctgcac	cagggccgcc	ttccccgcct	720
tttccagagg	aacctgttct	acggccagaa	gaacaagtac	cgagcacccc	gagggaagcc	780
ggccccggcc	tcaggggaca	cccagacccc	tgcaaagggg	tccagtgtcc	gggagcctgg	840
gcgcagtggt	gttgaggggc	cacattccag	ctgagtggcc	ttgctctgtg	tgagccccgt	900
gcgagggccc	tgcttgtagc	tggaccttgg	aaccttctgt	agctaagagg	gaatcctggc	960
ccctcccca	gaagccattt	gtcaataaac	catttctaag	aaaaaaaaaa	aaaaa	1015

<210> 22

<211> 1240

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1225)

<223> n equals a,t,g, or c

<400> 22

gtgaaacgcc	tgggctcaag	ctgattcacc	tgccctccacc	tcccacagtg	ctgggattac	60
aaacatgatc	ccccacgccc	agccaacaca	aaacttctga	tgctctgttt	tctcatctgt	120
gaactggagc	taaggctaag	tggctgtgtc	gtttaataag	agtttgaatc	agatggcctg	180
gcatgaagag	tcactggcct	gagagaatgt	caggggcatt	tgtaaatgtg	taaagggctg	240
aaaaatcctg	agggattatt	attattgcta	ttgttgttat	tattcacaga	cacatccaac	300
agccattgtc	tgccctccta	tctgtcatgc	tttctgcacg	agcgtcagcc	tgagcttcaa	360
tctgtgtgta	tatctgcagc	ttacgtcctt	gccacccctc	cagaacccag	tttcatcctt	420
gtaggttttt	ccgaagcagg	atttgcacaa	gtggcgtgtt	ttcttaagta	tttattttgc	480
aggccattta	ctcggcatgg	ctattttttac	agtgggtaag	gagcaaggct	aaaaataact	540
tagctcataa	ccagacaggt	tctgcatttg	acattttacgt	ggaattcatt	tgcatctcat	600
ttgttcgcct	ttctgtttta	caggtagaat	gtaagaaaagc	tcagccgaaa	gaagtcatgt	660
tcccacctgg	gacaagagggc	cgggcccggg	gactgcctta	caccatggac	gcgttcatgc	720
ttggcatggg	gatgctgggt	gagtctggac	aggaccgcag	gtcaccatgg	actgggaggg	780
ctatggaggc	ctctactccc	aactgggtca	cctaccagtg	gggcaaactg	cttcaccttt	840
ctaagcctca	gtttccttgt	ctgtagatga	ggatgataat	tccccgttcc	aagacagttg	900
tgatgattaa	gtgtgggtgt	gtgtgtgtgc	atgcatgtgt	gtgtgtgtgt	gtgtgtttgt	960
atttataata	ttgccccatg	cctggccttat	aggatatgtt	agactatttt	ctctcttttc	1020
catctccttc	ctcaaaaagaa	ggaaaagtcc	ccctctattg	cctcagccct	ctcatctgag	1080
tgggagttct	taagatgtaa	ggactcctgg	ctgacttgac	ttgtgtgggc	taaggctacg	1140
ttttctaaaa	ctkgggagag	gaggggaagt	gtaagggtgg	gcgataatcc	tgtctattta	1200
aatgattaac	atttttctct	tgggntatca	aaatttgcac			1240

<210> 23

<211> 569

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (353)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (444)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (480)

<223> n equals a,t,g, or c

<400> 23

tcgacccacg	cgcccggtgg	cagcgggggc	tgatggaagt	gcagtggggg	ctggagaggg	60
caccctactg	tatccagcat	gctccaaggc	cacagctctg	tgttccaggc	cttgctgggg	120
accttcttca	cctgggggat	gacagcagct	ggggcagctc	tcgtgttcgt	attctctagt	180
ggacagaggg	ggatcttaga	tggaagtctt	ggctttgctg	caggggtcat	gttggcagct	240
tcctattggt	ctcttctggc	cccagcagtt	gagatggcca	cgctctctgg	gggcttcggg	300
gcctttgcct	tcttccctgt	ggctgttggc	ttcacccttg	gagcggcttt	tgntactttg	360
gctgacctcc	tgatgcctca	cttgggtgca	gcagaagacc	cccagacggc	cctggcamtg	420
aacttcggct	ctacgttgat	gaanaagaag	tctgatcctg	agggccccgc	gctgctcttn	480
cctgagagtg	aacttttcat	ccggataggt	agactggctt	ctttcagcag	ctctttgctg	540
caacactgac	tgagtcaggc	cattatgac				569

<210> 24

<211> 1254

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1036)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1069)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1100)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1165)

<223> n equals a,t,g, or c

<400> 24

gcgtccggag	agctacctag	tcaacctgtc	tctcaatgac	aacgatggct	ccagtggggc	60
ttcagaccag	gataccctgg	ctcctctgcc	tgggggccacc	ccctggcccc	tgctgcccac	120
tttctcctac	cagtaccctg	ccccacaccc	ctacagcccg	cagcctccac	cctaccatga	180
gctttcatct	tacacctatg	gtgggggag	tgccagcagc	cagcatagtg	agggcagccg	240
gagcagtggg	tcgacacgga	gtgatggggg	ggcaggggcg	acggggaggc	ccgaggagcg	300
ggcccccgag	tccaagtccg	gcagtggcag	tgagtctgag	ccctccagcc	gagggggcag	360

ccttcggcgg	ggtggggaag	caagtgggac	tagcgatggg	ggccctcctc	catccagagg	420
ctcaactggg	ggtgcccccta	atctccgagc	ccaccagggg	ctccatccct	atggaccgcc	480
ccctggcatg	gccctcccct	acaaccccat	gatgggtggc	atgatgcccc	cacctccacc	540
tccagtccct	ccagcagtg	agcctccggg	ggccctcca	gtcagagacc	tgggctctgt	600
gccccagaa	ctgacagcca	gccgccaaag	cttccatggc	catgggcaat	cccagcgagt	660
tctttgtgga	tggtatgtag	ccactgtgg	ggccaggctg	ggccggggcg	tcctgggtgtg	720
tgactgggtg	tcctggccgt	catgtgcttg	ctcttacagt	gcctgggctc	agcctaccag	780
ctgctgccat	acaggagatt	gtggccactg	tgactctcac	cagcagtgcc	tggttccctc	840
cccttcctc	aggggtagac	aagggacctt	tgattatttt	tagctttgtt	ttttataag	900
cctttttggg	ggttaaaata	gagtttctta	catttttggg	acttttttaa	taggcatttc	960
ctcttttata	tgaagaattc	ccatccattg	ggccctttt	aacccagaa	tgtgacctcc	1020
tcctccagtt	acccanagcc	ctgccgtttg	cagggttggg	ggtggtcanc	ggtaccccg	1080
ggttaggcat	cctagacagn	agcctgagga	agctgggaga	tttgggcat	gtagctgcct	1140
ttgttactct	atttatttta	gtcanttgta	taaaacacca	aataaagcaa	tagaggcaaa	1200
aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaa	1254

<210> 25

<211> 1984

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (598)

<223> n equals a,t,g, or c

<400> 25

ccaagctcga	aattaaccct	cactaaaggg	aacaaaagct	ggagctccac	cgcggtggcg	60
gccgctctag	aactagtgga	tccccgggc	tgcaggaatt	cggcacgagg	cggccctctg	120
cgctacgcg	gtcacctaca	cagcgatgta	cgtgactctc	gtgttccgcg	tgaagggtc	180
cgccctggc	aaacccctgc	tctgcctggc	cttgctgtgc	ccggccttcc	tgggtggcgt	240
ggtccgcgtg	gccgagtacc	gaaaccactg	gtcggacgtg	ctggctggct	tcctgacagg	300
ggcgcccatc	gccacctttt	tggtcacctg	cgttggtgcat	aactttcaga	gccggccacc	360
ctctggccga	aggctctctc	cccagagtgc	ctaccctcgc	ctgcctgggc	ctcagtttcc	420
acatctgcac	aatgggggtg	accatccctg	ccctgctggc	tgccaggagc	ggctgtgagt	480
cttcaggcgt	ggatgcagcc	tgggggaagc	cataggggcg	tttcacaggc	ctggccttca	540
ccatggcggg	agggagaccg	catctgaaga	ggagttttct	catcatcccc	tgctttgnct	600
tcgtggagtc	ggtgctgctg	ggcattgkga	tcctccaggg	ccccagccat	gtgttcgtcg	660
ccccgtgtgc	cccgctcctg	attgaggtct	gagccgagcg	ccttgccctc	gcccctacc	720
ctgccagcgc	ccacccccag	ccaggggccc	tcgccttctc	cccctggacc	tggggggcca	780
ggcgggggtg	gtggacgtgg	ccggaagctg	ctgctgccca	cggccctgct	gcgggacctg	840
tacaccctga	gtggactcta	tccctcccc	ttccaccggg	acaacttcag	cccttacctg	900
tttgccagcc	gtgaccacct	gctgtgaggg	ccgaccaccc	accagaatc	tgccaggtcc	960
ccacttcttc	cctgccacgc	gtgtgtgtgc	gtgtgccacg	tgagtgccaa	agtccccctgc	1020
cccccaagcc	agccagaccc	agacattaga	agatggctag	aaggacattt	aggagacatc	1080
tgctctctctg	gccctctgag	atatcccgat	gggcacaaat	ggaagggtgcg	cacttgcccc	1140
tactattgcc	cttttaaggg	ccaaagcttg	acccatttgg	ccattgcctg	gctaatgaga	1200
acccctgggt	ctcagaattt	taacccaaag	gagttggctc	caaccaatgg	gagccttccc	1260
ctcacttctt	agaatctctc	tgcaagaggg	caactccagc	cagtgttcag	cgactgaaca	1320
gccaatagga	gcccttgggt	tcagaattt	ctagagtggg	tgggcatgat	tcagtgcaat	1380
gggggaccgc	ccgtgtctaa	gcattgtgcaa	aggagaggag	ggagatgagg	tcattgtttg	1440
tcattgagtc	ttctctcaga	atcagcgagc	ccagctgtag	gggtggggggc	aggctcccc	1500
atggcagggt	ccttggggta	ccccttttcc	tctcagcccc	tcctgtgtgtg	cggcctctcc	1560
acctctcacc	cactctctcc	taatccccct	cttaagtagg	gcttgcccca	cttcagaggt	1620
tttgggggtc	aggggtgctg	gtctccccct	gcctgtgccc	aggatcatcc	aaaccccttct	1680
gttattttatt	agggctgtgg	gaagggtttt	tcttctttt	cttggaaacct	gcccctgttc	1740
ttcacactgc	cccccatgcc	tcagcctcat	acagatgtgc	catcatgggg	ggcatgggtg	1800

gagcagaggg	gctccctcac	cccgggcagg	caaaggcagt	gggtagagga	ggcactgccc	1860
ccctttcctg	ccccctcctc	atctttaata	aagacctggc	ttctcatctt	taataaagac	1920
ctgtttgtaa	cagaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1980
aaaa						1984

<210> 26
 <211> 2100
 <212> DNA
 <213> Homo sapiens

<400> 26						
ggttccaaac	agcagttagg	tcagcagtc	gctcagccga	ggcagctctg	ttcatggcgt	60
tctcgaagct	cttggagcaa	gccggaggcg	tgggcctctt	ccagaccctg	caggtgctca	120
ccttcatect	cccctgcctc	atgatacctt	cccagatgct	cctggagaa	ttctcagccg	180
ccatcccagg	ccaccgatgc	tggacacaca	tgctggacaa	tggctctgcg	gtttccacaa	240
acatgacccc	caaggccctt	ctgaccatct	ccatcccggc	aggccccaac	cagggggccc	300
accagtgcg	ccgcttccgc	cagccacagt	ggcagctctt	ggacccaat	gccacggcca	360
ccagctggag	cgaagctgac	acggagccgt	gtgtggacgg	ctgggtctat	gaccgcagcg	420
tcttcacctc	caccatcgtg	gccaagtggg	acctgggtgtg	cagctcccag	ggcttgaagc	480
ccctaascca	gtccatctty	atgkccggga	tcttgggtggg	ctcctttatc	tggggcctcc	540
tctcctaccg	gtttgsgagg	aagccgatgc	tagactgggtg	ctgectgcag	ttggccgtgg	600
cgggcaccag	caccatcttc	gccccaacat	tcgtcatcta	ctgcggcctg	cggttcgtgg	660
ccgcttttgg	gatggccggc	atctttctga	gttcaactgac	actgatgggtg	gagtggacca	720
cgaccagcag	gagggcggtc	accatgacgg	tggtgggatg	tgcccttcagc	gcaggccagg	780
cggcgctggg	cggcctggcc	tttgccctgc	gggactggag	gactctccag	ctggcagcat	840
cagtgcctct	ctttgccatc	tccttgatat	cctgggtggct	gccagaatcc	gcccgtgggc	900
tgattattaa	gggcaaacca	gaccaagcac	ttcaggagct	cagaaagggtg	gccaggataa	960
atggccacaa	ggaggccaag	aacctgacca	tagaggtgct	gatgtccagc	gtgaaggagg	1020
agggtggcctc	tgcaaaaggag	ccgcggctcg	tgctggacct	gttctgcgtg	cccgtgctcc	1080
gctggaggag	ctgcgccatg	ctggtggtga	atcttctctc	attgatctcc	tactatgggc	1140
tggtcttcga	cctgcagagc	ctggggcctg	acatcttctc	cctccaggcc	ctcttcgggg	1200
ccgtggactt	cctgggcccgg	gccaccactg	ccctcttgct	cagtttccct	ggccgcgcga	1260
ccatccaggc	gggttcccag	gccatgggcg	gcctcgccat	tctagccaac	atgctgggtgc	1320
cgcaagtgcg	gatgacagca	gatggcattc	tgcatacagt	gggcccggctg	ggggctatga	1380
tgggtccctc	gacccatgatg	agccgcgaag	ccctgcccct	gctgcctcct	ctcctctatg	1440
gcgttatctc	cattgcttcc	agcctgggtg	tgctgttctt	cctcccggag	accaggggac	1500
ttccgctccc	tgacactatc	caggacctgg	agagccagaa	atcaacagca	gcccagggca	1560
accggcaaga	ggccgtcact	gtggaaagta	cctcgctcta	gaaattgtgc	ctgcatggag	1620
cccccttagt	caaagactcc	tggaaaggag	ttgcctcttc	tccaatcaga	gcgtggaggc	1680
gagttggggc	acttcaaggg	cctggcatgg	cagaggccag	gcagccgtgg	ccgagtggac	1740
agcgtggcgg	tctgctgtgg	ctgaaggcag	cttccacagc	tcactcctct	tctccctgcc	1800
ctgatcagat	tccccacctt	acccggggcc	tacaggagcc	tgtgcagatg	gccatgcccc	1860
accaataacg	agacgggttc	cctccctttc	cctgccaggc	tcattgtctt	acaccttcac	1920
tcagccacgc	caaccagaga	ctgggttcca	atctcaccac	accacataca	gagccctcat	1980
ctgtgaaatg	agaatgatca	cgtgaccac	ccccagggc	aggtatcagg	gtgaactgat	2040
cttagcaccg	gccaaataaa	tggaacctgc	tgagagagct	gccagaaaaa	aaaaaaaaaa	2100

<210> 27
 <211> 1136
 <212> DNA
 <213> Homo sapiens

<400> 27						
gtgaaaggca	ggtctctact	gtcctgcacc	aagccctgag	caagagccag	acattactgg	60
agcaacatca	gcagtgtttg	agagagggaac	aacagaacag	tgctgtgcta	gaagacttgt	120
tggaaaacat	ggaggcagac	acctttgcaa	ccctgtgcag	ccaggagctg	agactggcat	180

cgtacctggc	gaggatggcc	atggtgcccc	gggccacgct	tcgccggctc	ctgagtgtgg	240
tactgcccac	agcctcacag	cctcagctgc	tggccctgct	ggattcggcc	accgagagac	300
atgtggacca	tgcagctgag	agcgatggcg	gagcggagca	ggccgacgtg	ggcaggcgga	360
ggaaacacca	gagctggtgg	caagccttag	atggc aaact	gcgaggagat	ctgataagca	420
gaggattaga	aaagatgctg	tgggcccgc	agagaaagca	gagcatatta	aagaagacat	480
gtctccctct	cagagagagg	atgatattct	ctggaaaagg	aagttggcca	cacctgtcac	540
tggagcccat	tggcgaactg	ggccctgtac	ccattgtagg	ggcagaaacc	attgatctat	600
taaacacagg	agagaagctc	tttatattca	gaaatccaaa	ggagccagag	atctcactga	660
cgttcctcca	ggaaaaagaa	gacctttttg	aatgcccaaa	aggccatgag	ggccttgggc	720
atggactagc	ccaagggaaa	gacctgcggg	agcatatgaa	aagagaaggg	atgattttct	780
cctgcccgc	ggtgtaaatg	tgtttataat	gcacaactcg	caaataataa	ttgcacatgc	840
agaaggcaca	gaccccgtag	cgcattgcaa	cttgaggaga	ctcggtttaa	tcttgtctca	900
tgaatttcca	gatggcccac	tctcttccat	atcacaaagg	cataaacact	ccttctttca	960
gcccacctc	cccaggcccc	tggaggagac	ccccaccctg	caatccacac	cccctcctct	1020
gctgcagaag	ctatggtctg	tggtgtgaca	gccagattct	ctactcttat	gttttgtatt	1080
tgttacatat	tctattttta	taaagggaat	ttaaaaaat	aaaaaaaaa	aaaaaa	1136

<210> 28

<211> 2279

<212> DNA

<213> Homo sapiens

<400> 28

ccacgcgtcc	ggatttggac	ctttttcgag	tttggatggg	agtgtggaca	gggcgggttag	60
ggggctgggc	ccagggtcatg	tttcagtttc	taagccaggg	gttttactgt	ggagtaggac	120
tgtttactcg	ttttcttaag	ctgctgggtg	ctttgctgct	cctggctctg	gccctctttt	180
tgggctttct	acagttggga	tggcgggttc	tgggtgggact	aggtagaccg	ttaggctgga	240
gggataaggc	tacctggctc	ttctcttggc	tggattctcc	agccttgacg	cgttgcttga	300
ctctgctgag	agatagcagg	ccatggcagc	ggctggtaag	aatagttcag	tggggctggc	360
tggagttgcc	ttgggtcaag	cagaatatta	ataggcaggg	gaatgcacct	gtagctagtg	420
ggcgctactg	ccagcctgaa	gaggaaagtgg	ctcgactctt	gacctgggct	ggggttcctg	480
aggatgagct	aaaccctttc	catgtactgg	gggttgaggc	cacagcatca	gatgttgaa	540
tgaagaaggc	ctatagacag	ctggcagtga	tggttcatcc	tgacaaaaat	catcatcccc	600
gggtgagga	ggccttcaag	gttttgcgag	cagcttggga	cattgtcagc	aatgctgaaa	660
agcgaagga	gtatgagatg	aaacgaatgg	cagagaatga	gctgagcccg	tcagtaaatg	720
agtttctgtc	caagctgcaa	gatgacctca	aggaggcaat	gaatactatg	atgtgtagcc	780
gatgcccaag	aaagcatagg	aggtttgaaa	tggaccggga	acctaagagt	gccagatact	840
gtgctgagtg	taataggctg	catcctgctg	aggaaaggaga	cttttgggca	gagtcaagca	900
tgttgggcct	caagatcacc	tactttgcac	tgatggatgg	aaagggtgat	gacatcacac	960
agtgggctgg	atgccagcgt	gtaggtatct	cccagatac	ccacagagtc	ccctatcaca	1020
tctcatttgg	ttctcggatt	ccaggcacca	gagggcgcca	gagagccacc	ccagatgccc	1080
ctcctgctga	tcttcaggat	ttcttgagtc	ggatctttca	agtaccccc	gggcagatgc	1140
ccaatgggaa	cttctttgca	gctcctcagc	ctgcccctgg	agccgctgca	gcctctaagc	1200
ccaacagcac	agtacccaag	ggagaagcca	aaccttaagc	gcggaagaaa	gtgaggaggc	1260
ccttccaacg	ttgatgcccc	ttctctttcc	tcaaatcaat	gtcaggaggat	caaaagggct	1320
gtagcacagg	atggagtttg	atttatccct	cctccccc	cacctaggaa	ctgaatcttt	1380
ttctttttat	tttttgagat	ggagtcttgc	tctgttgccc	agctggagtg	cagtgggtgtg	1440
atctcagctt	actgcaacct	ctgtctcccc	ggttcaagca	attctcccat	ctcagccctcc	1500
tgagttagctg	ggattacagg	cacacaccac	cacacctggc	ccagctaatt	cttttttgta	1560
tttttagtag	agacgggggtt	tcaccatggt	gccaggctg	gtctcgaaat	cctgagctca	1620
ggtgatccac	ccgtcttggc	ctcccaaagt	gctggattac	aggcataagc	cactgtgccc	1680
ggcctgaatc	ttgtcttttg	acaataccaa	agaaataggg	ggtagctaga	gtaaagaacc	1740
tagggcctgg	acctgggctg	gacagtgtat	cccttttaggt	gtgggaactg	ggtatttccc	1800
tggggctctg	atgcctttgt	cttgtcattt	gctttttagg	cagatgacac	tttttcccac	1860
ccttttaaa	ctacaagtct	atcttctttc	ttgacctatt	tcaggaggga	gccctctcct	1920
ttatcctgat	ataatattta	aaagacagaa	caagaaagca	tgtagcccta	atgataggag	1980
attatcgcat	agagttcaga	gactggaaac	tgaattttcc	ctcgactttc	actttgtggg	2040

taaatcaccc	aatttttaggc	tctttttctgc	aaggatggcc	aaaattaatc	attttttaaaa	2100
agtagattca	tgcccactgc	ccttgggtga	gggggaagaa	tacgggggtt	cccagaagcc	2160
cccattgtgat	ccaagggttt	gtattttttt	tttaagtttg	ttcatatttg	tatgtacatg	2220
actattttaa	gccaggggat	tatctttcta	taaatgtata	actggcaaaa	aaaaaaaaa	2279

<210> 29

<211> 1593

<212> DNA

<213> Homo sapiens

<400> 29

ccacgcgtcc	gctcgcgagt	ggcgggcatg	agagtaaact	gcggaaggct	gccagcgggt	60
tctagtcatt	gttggagttg	ttctcttctg	ccgcagggtc	tcgacgagat	tggcgcccg	120
tcgcttactt	ggcgggtgca	atggcgcttt	tccgatgcgt	gtggagcgtg	ctgagtgcct	180
tgggaaagtc	cggatcggac	ctctgcgcgg	gctgtggaag	tcgactgcgc	tctcctttca	240
gttttgcgta	tgtaccgaga	tgtttttcat	ccaccgcgaa	tagttaccca	aagaagcctc	300
tgacttcata	tgttcgggtt	tctaaagaac	agctacccat	atttaaagct	cagaacccag	360
atgcaaaaaa	ttcagaacta	attagaaaaa	tcgcccact	atggagggaa	cttctctgatt	420
cagagaaaaa	aatatatgaa	gatgcttaca	gggcagactg	gcaggcatat	aaagaagaga	480
taaacagaat	tcaagaacag	ttaactccaa	gtcagattgt	atctttggaa	aaagaaatcc	540
agcaaaaacg	tttaaaaaag	aaagcattaa	taaaaaaaag	agagttaaca	atgcttgga	600
aaccgaaaag	acctcgcctc	gcttataaca	tttttatagc	tgaaagggtc	caggaaaacta	660
aggatgggtac	atcacaggta	aagctgaaga	ctataaatga	aaactggaaa	aatctgtcta	720
gttctcaaaa	gcaagtatat	attcagcttg	ctaagtatga	taaaattcgt	tattataatg	780
aatgaaatc	ttgggaagaa	cagatgatgg	aagttggacg	aaaggatcct	ctacgtcgca	840
cagtaaaagca	ccaacgaaaa	gtcgaccctg	aggagtattg	aaatagaaga	ttgagttatg	900
ttcataatgg	atagacacaa	gaaaccaatt	aggtctcaat	acctgaagct	attgaaaatt	960
agaaaggata	aagttgggtg	acattttata	tttaattcct	tttttcttta	gcccattggac	1020
ttttctgcca	gttcaatata	ttttgtatta	gtatcttgct	ttggaaaacc	caaagagata	1080
aaaagttcat	gcgaaattta	ttttgtgtta	aggaactact	gaggatccaa	ataatccatg	1140
aatgcagca	gtgaatcatt	ttacctttga	ttaaggtaaa	tcagactgtg	aagttttttt	1200
atacttgatg	actggaagga	gtatttttgt	ttccttatat	atatatggag	tcaggagttt	1260
catatgcaaa	agtgctccaa	attgtagaag	tcatagtgtc	ctctgatata	attgtacatt	1320
ttagaaaagc	gcccataatt	catctaagta	aattccactt	cctaggtgta	attcacatat	1380
tcagagttga	tggttgtaca	tacaaggaat	tgctgatttc	aattgcagtt	ttttataaaa	1440
aggatggaga	gattttataaa	ccttttcctc	attgcctttt	tcccagagta	aaaacagaga	1500
aattatgtac	caaattctatg	catattgttt	tatactgcat	agaataaaga	ttttaaatgt	1560
ttcctaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa			1593

<210> 30

<211> 2666

<212> DNA

<213> Homo sapiens

<400> 30

ccacgcgtcc	gccaatgttg	aaagactttt	caaattctatt	gttgggtggt	ctctgtgact	60
atgttcttgg	agaagctgaa	tatcttctct	tgagagagcc	aggccatgta	gcactaagca	120
acgacacagt	gtatgtggat	ttccagtatt	ttgatgggtc	taatgggaca	ctgaggaatg	180
tatctgtcct	gctgttggag	gccaacacca	atcagactgt	aactaccaag	tacctcttga	240
ccaaccagtc	ccagggaaca	ctaaagtttg	agtgtctcta	tttcaaggag	gctggtgact	300
actggttcac	aatgactcca	gaagcaacag	acaacagcac	tccattcccc	tgggtggaga	360
aaagtgcctt	tctgaagggtg	gaatggcctg	tctttcacgt	tgacttgaat	aggagtgcc	420
aggcagcaga	aggcaccttc	caagtgggcc	tatttaccag	tcaaccactg	tgcccgtttc	480
ctgtggacaa	gcccacatt	gtagtggatg	tcattcttcac	caacagtcct	cctgaggcaa	540
gaagaaattc	aagacagccg	ctggaaataa	gaaccagcaa	aaggacagaa	cttgctcaag	600
gtcagtgggt	tgagtttggc	tgtgcaccct	tggggccaga	agcctatgtc	accgtggtgc	660

tgaagctgct	tgggcgagac	tcagtcatta	cctccacagg	acccattgac	ctggcccaga	720
aatttggata	caaactgggtg	atggtgccag	aactcacatg	tgagtccggg	gtagagggtga	780
cagtgtctgcc	tccaccatgc	accttcgtcc	aaggagtggt	cactgtcttc	aaggaggccc	840
ccagataccc	tggaagagg	accattcact	tggctgaaaa	cagcctgccc	tggaagagag	900
gaggacaatt	tttaactgta	ctttgtttga	catggggaag	aataagtact	gctttgactt	960
tggaatttca	agcagaagcc	atTTTTctgc	aaaggaggag	tgcatgctaa	ttcagagaaa	1020
tacagctttc	cagccatcca	gcccctctcc	tcttcagccc	caggggtccag	tgaagtccaa	1080
caacatcgtg	actgtcactg	gtatatcctt	gtgcttggtc	atcatcattg	ccactgtgct	1140
catcacgctg	tggaaggagt	tcggccgccc	agccaagtgc	agcacacctg	ctcgacacaa	1200
ctccatccac	tccccagct	tcgggaagaa	ctcgagcag	gagaatatct	gcgagctgag	1260
cgagcagcgc	gggagcttct	cggatggggg	agacgggccc	acggggagtc	caggggacac	1320
aggcatccct	ctgacctaca	ggcggagcgg	gccgtacct	cccaggatg	atgcctctgg	1380
cagcgagagc	ttccagtcca	acgcccagaa	gataatccca	cctctgttca	gctaccgcct	1440
tgcccagcag	cagttaaagg	agatgaaaa	gaaaggtctg	acggaaacta	ccaaagtgtg	1500
tcacgtgtct	cagagtcccc	tgacagacac	tgccattgat	gcggccccc	gcgtccctt	1560
agatttggaa	agcccgaag	aagctgcagc	aaacaagttc	cggatcaaat	ccccatttcc	1620
ggagcagccc	gcggtcagtg	ccggggaag	gcctccctcc	aggetggatc	taaatgtgac	1680
tcaggccagt	tgtgccataa	gccccagcca	gactctgatc	cgcaagtcac	aggcaaggca	1740
cgtgggcagc	agagggggcc	cgtccgaaag	gagccatgcc	aggaacgccc	atttcaggag	1800
gacagcgagt	ttccatgaag	ccaggcaggc	ccggccgttc	cgagagagga	gcagtgtccac	1860
tctgactcca	cggcaggccc	ctgcctacag	ctctaggacg	cggacctgcg	agcaggcaga	1920
ggacagattt	aggcctcaga	gtcgaggtgc	ccacctgttt	cctgaaaaac	tggagcattt	1980
ccaagaggca	agtggaaacc	gtggtccatt	aaacctctc	cctaaatcct	acactttggg	2040
gcagcccttg	aggaaaccag	accttgggga	tcaccaggca	ggattagtgg	ccggaattga	2100
gagaacagag	ccccacagag	ctcgtcgggg	accgtccccc	agtcacaaga	gtgtctcaag	2160
gaagcagctc	tctcccatat	ccccaaaga	taactaccag	aggggtcagtt	ctctgagccc	2220
ttctcagtgt	agaaaagaca	agtgtcaaag	cttccccact	cacctgagt	ttgccttcta	2280
tgacaatacg	tcgtttggcc	tcactgaggc	tgagcagagg	atgctggacc	tcccaggata	2340
ttttgggtca	aatgaagagg	atgaaaccac	aagtacactt	agcgtggaga	agctggtgat	2400
ctagactgag	aatcagcctg	agctttacac	agctggggtc	tgctactcgc	gttttgtaga	2460
cttttgtgta	actatttgtg	ccgtaggaca	gaatgtgagg	aggaagtaac	acacagagga	2520
ggatgtgtgt	gtatgcatgt	gtttgaattc	acaaggaaga	aattatttat	cttgagcttt	2580
ttcctttgtt	attcaatttc	tattgattta	ttagtaataa	caatgataat	aaaatgtaaa	2640
tgagcaaaaa	aaaaaaaaaa	aaaagg				2666

<210> 31
 <211> 2701
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> SITE
 <222> (634)
 <223> n equals a,t,g, or c

<400> 31						
aaggtttaaa	gataccatgt	tttcttttat	tttagagtta	aaaactcacc	acttaaacag	60
tctccagggt	atcaaacaga	actagttatt	cagttgggtt	gggtgggtgg	agaaccacca	120
caacaaataa	ccagcctggc	agtcaattct	tctatggac	tggtgggttt	tggaattgc	180
aatggcattg	ctatggttga	ctacctccag	aaagcagtgc	tgctcaacct	gggcactatt	240
gaattatatg	gctctaata	tccttatcgg	agagaacccc	gatctcctcg	taaatctcga	300
cagccttcag	gagccggtct	gtgtgatatt	agtgaaggga	ctgttggtcc	agaggatcgc	360
tgcaaatctc	caacctctgc	aaagatgtca	aggaagttaa	gcttacctac	tgacctaaag	420
cctgatttag	atgtaaagga	taactccttt	agccgatcac	ggagttcaag	tgtaacaagc	480
attgacaaag	aatcccagga	agcgatctcc	gctcttcatt	tctgtgaaac	gtttactcga	540
aagacggact	cgtcccttcc	cccttgcttr	tggttggaag	caacgctagg	aacagtgcct	600
gtcattgcac	tgaaccttcc	cccaggggga	gagnawwaac	ttcttcagcc	agtaattgtg	660

tctccaagt	gtactatatt	gagggttaaaa	ggtgcaatct	tgagaatggc	atctctggat	720
accacaggct	gcttaataacc	acctgcgat	gaacctgga	gagagcaca	tgcttcctgaa	780
gaaaaagacg	aaaaggaraa	awtgaaaaaa	cggcggcctg	tctcagatc	cccctcctct	840
tctcaggaaa	ttagtgaaaa	ccagtatgca	gtgatatggt	ctgaaaagca	agcaaaaagta	900
atctcactgc	caaccagaa	ctgtgcttat	aagcaaaata	ttacagagac	ctcgtttggt	960
cttcgtggag	atattgtagc	attgagtaac	agtatctgcc	ttgctgttt	ctgtgccaat	1020
ggacatatata	tgacttttag	tttgccaagt	ttaagacctc	tggtgggtgt	gtattacttg	1080
ccccttacca	atatgcgggt	agccagaacg	ttctgcttta	ccaacaatgg	acaagcatta	1140
taccttgttt	cacctacaga	aatccagaga	cttacttata	gtcaagagac	ctgtgaaaat	1200
cttcaggaaa	tggtgggtga	actcttcact	cctgtagaaa	cacctgaagc	accaaacagg	1260
ggattcttta	aaggcttatt	tggagggtgt	gcacaactct	ttgacagaga	agaactattt	1320
ggagaatcgt	cctcaggaaa	ggcttcaagg	agccttgac	agcatattcc	tggccctggt	1380
ggcattgaag	gcgtaaaagg	ggcagcatct	ggagtgtgtg	gtgaattagc	acgagccagg	1440
ctggcactag	atgaaagagg	gcagaaactt	ggcgatctgg	aagaaagaac	tgcggccatg	1500
ttatcaagt	cagagtcatt	ttctaacaat	gctcatgaga	ttatgttgaa	atacaaagat	1560
aagaagtggg	accagttctg	acaaccagaa	tccaataagt	ccaacttcag	ccagaaggaa	1620
aaaagttttc	cattttttatt	acattcttta	ggaaagttaa	cgttaaaggg	atgttcgtca	1680
ctgaatactg	ttcttttcta	gcacagtcac	gcactgtttt	acctcagtc	tggtggcttta	1740
actgaggagt	gttcacacgc	actcgaaatg	gagtatatgg	tggtgtccag	ttatgagttg	1800
accatttggt	aattaaacag	gtcacacgtg	acagatgaag	aaaccaaggg	ggctgctgag	1860
gagacctggg	gcagggacta	atcctggatc	attcctgtat	taaaactttca	tatgccaaaa	1920
gggtttgtgc	cgtttttatct	gccatcagtg	tttgacctgt	ttagggcaga	ggcaataagt	1980
cagaagtctt	gaagttgaaa	tagttatatg	tgtgtcattg	gactggatta	taaacagctg	2040
tcttggaact	tccctctctt	aacactgact	ggatcatcag	atcattagtg	aaaaagaaac	2100
aaattgtttg	ttatcatctc	tttagacaga	taagctgaat	ggtgggcttt	aaataataaa	2160
aacatacaca	tagttgactt	gtgtatgagc	tactcttgga	ttcttggtat	tatagacttg	2220
tatttagttc	atattttgtc	aaaagcaaaa	caagaagata	catcactttt	cattgaaaag	2280
aaaagtgtag	agtcagactg	aattgtctat	cattctggga	gtttccatgt	agtggctatg	2340
cagtgtggaa	agtgagaaaa	acctccattg	tgggtgaggag	aataacttcaa	tgcccttggt	2400
ccttgttctc	attaattcag	ctaaagggtg	atttgaccaa	aataatgctg	gttaaatttg	2460
tagaaatgtt	gaaattggct	gtgtttttaa	ttttgcttga	atgtttataa	aatgtttaac	2520
caaatgtacc	tttgattctt	ttaattaaaa	ttgcttaaaa	aaaaactttc	attatttcag	2580
taaaatgctc	agctcccttt	tcaaaatgcc	ctttattttg	taactgttcc	aatacactca	2640
ggtgatgagc	caattaaatg	gtagtgcaca	tgctattcgc	atgggaaaat	tacaagcatc	2700
t						2701

<210> 32
 <211> 528
 <212> DNA
 <213> Homo sapiens

<400> 32						
ccacgcgtcc	gcacagactc	tcctggcccc	ctgtcctttt	ggaaagaaga	cagggatgaa	60
atataatcaa	gcaattaaac	acccccatca	tcaccaagaa	caacagtatc	aacaagaaga	120
acagggacaa	caaaaccac	ggatgaaaca	ttcctttctc	agctcagatc	ttatctggtg	180
cgttctctct	ctgctctgtc	ttgggtgtgt	gttttagagaa	acatggacaa	cgctgttttg	240
aagaacaggg	cttcccagga	atcaacaatg	cccaagaagg	aagggattgt	agaaatagct	300
taaccctttc	atttaccac	gtggaattg	aagcccaggg	aaggggaagg	accggtcgtg	360
gaagggagag	ccatcagcag	aaagagaccc	tgagatcttc	gcctgggatt	cccagggaag	420
ccagcccag	ctgattcaca	gaataaatgc	atgcaaacct	tgctatcaat	aaattacaca	480
tgcacttacg	taaaacacat	aaaaaaaaaa	aaaaaaaaaa	aaaaaagg		528

<210> 33
 <211> 1710
 <212> DNA
 <213> Homo sapiens

<220>

<221> SITE

<222> (1026)

<223> n equals a,t,g, or c

<400> 33

tcgacccacg	cgctccgccg	agtgagcgcg	accatcatgt	ccatgctcgt	ggtcttttctc	60
ttgctgtggg	gtgtcacctg	gggcccagtg	acagaagcag	ccatatttta	tgagacgcag	120
cccagcctgt	gggcagagtc	cgaatcactg	ctgaaaccct	tggccaatgt	gacgctgacg	180
tgccaggccc	gcctggagac	tccagacttc	cagctgttca	agaatggggt	ggcccaggag	240
cctgtgcacc	ttgactcacc	tgccatcaag	caccagttcc	tgctgacggg	tgacacccag	300
ggccgctacc	gctgccgctc	gggcttgtcc	acaggatgga	cccagctgag	caagctcctg	360
gagctgacag	ggccaaagtc	cttgccctgct	ccctggctct	cgatggcgcc	agtgtccttg	420
atcacccccg	gcctgaaaac	aacagcagtg	tgccgaggtg	tgctgcgggg	tgtgactttt	480
ctgctgaggg	gggagggcga	ccatgagttt	ctggaggtgc	ctgaggccca	ggaggatgtg	540
gaggccacct	ttccagtcca	tcagcctggc	aactacagct	gcagctaccg	gaccgatggg	600
gaaggcgccc	tctctgagcc	cagcgetact	gtgaccattg	aggagctcgc	tgacccacca	660
ccgcctgtgc	tgatgcacca	tggagagtcc	tcccaggtcc	tgcaccctgg	caacaagggtg	720
accctcacct	gcgtggctcc	cctgagtggg	gtggacttcc	agctacggcg	cggggagaaa	780
gagctgctgg	taccaggag	cagcaccagc	ccagatcgca	tcttctttca	cctgaacgcg	840
gtggccctgg	gggatggagg	tactacacc	tgccgctacc	ggctgcatga	caaccaaacc	900
ggctggtccg	gggacagcgc	gccggtcgag	ctgattctga	gcgatgagac	gctgcccgcg	960
ccggagttct	ccccggagcc	ggagtccggc	agggccctgc	ggctgcgggtg	cctggcgccc	1020
ctggangggc	cgcswttcgc	cctggtgcgc	gaggacaggg	gcgggcgcgc	cgtgcaccgt	1080
ttccagagcc	ccgctgggac	cgaggcgctc	ttcgagctgc	acaacatttc	cgtggctgac	1140
tccgccaaact	acagctgcgt	ctacgtggac	ctgaagccgc	ctttcggggg	ctccgcgccc	1200
agcgagcgct	tggagctgca	cgtggacgga	ccccctccca	ggcctcagct	ccgggcgacg	1260
tggagtgggg	cggtcctggc	gggcccagat	gccgtcctgc	gctgcgaggg	acccatcccc	1320
gacgtcacct	tcgagctgct	gcgcgagggc	gagacgaagg	ccgtgaagac	ggtccgcacc	1380
cccggggccc	cggcgaacct	cgagctgata	ttcgtggggc	cccagcacgc	cggcaactac	1440
aggtgccgct	accgctcctg	ggtgccccac	accttcgaat	cggagctcag	cgacctctgt	1500
gagctcctgg	tggcagaaaag	ctgatgcagc	cgccggccca	gggtgctgtt	ggtgtcctca	1560
gaagtgccgg	ggattctgga	ctggctccct	ccccctctgt	tgacgacaaa	ggccgggggtc	1620
tctggggggc	tggagaagcc	tccctcattc	ctcccaggaa	ttaataaatg	tgaagagagc	1680
tctgtttaaa	aaaaaaaaaa	aaggcgggcc				1710

<210> 34

<211> 1546

<212> DNA

<213> Homo sapiens

<400> 34

agcgtccgcc	ggccccggaa	cccgggtccgc	gagcagcggc	ggctgccgga	gggacgatga	60
gctgcgcggg	gcgggcgggc	cctgcccggc	tcgccgcgct	agccctgctg	acctgcagcc	120
tgtggccggc	acgggcagac	aacgcgagcc	aggagtacta	cacagcgctc	atcaacgtga	180
cgggtgcagga	gccccggcgc	ggcgccccgc	tcacgtttcg	catcgaccgc	gggcgctacg	240
ggcttgactc	ccccaggcc	gaggtccgcg	gccagggtgt	ggcgccgctg	ccccctccacg	300
gagttgctga	tcattctggc	tgtgatccac	aaaccgggtt	ctttgtccct	cctaataatca	360
aacagtggat	tgcccttgctg	cagaggggaa	actgcacgtt	ttaaagagaaa	atatcacggg	420
ccgctttcca	caatgcagtt	gctgtagtca	tctacaataa	taaatccaaa	gaggagccag	480
ttaccatgac	tcattccaggc	actggagata	ttattgctgt	catgataaca	gaattgaggg	540
gtaaggatat	tttgagttat	ctggagaaaa	acatctctgt	acaaatgaca	atagctgttg	600
gaactcgaat	gccaccgaag	aacttcagcc	gtggctctct	agtcttcgtg	tcaatatcct	660
ttattgtttt	gatgatatt	tcttcagcat	ggctcatatt	ctacttcatt	cagaagatca	720
ggtacacaaa	tgacgcgcgac	aggaaccagc	gtcgtctcgg	agatgcagcc	aagaaagcca	780
tcagtaaatt	gacaaccagg	acagtaaaga	aggggtgacaa	ggaaactgac	ccagactttg	840

atcattgtgc	agtctgcata	gagagctata	agcagaatga	tgctgtccga	attctcccct	900
gcaagcatgt	tttccacaaa	tcctgcgtgg	atccctggct	tagtgaacat	tgtacctgtc	960
ctatgtgcaa	acttaatata	ttgaaggccc	tggaattgt	gccgaatttg	ccatgtactg	1020
ataacgtagc	attcgatatg	gaaaggctca	ccagaaccca	agctgttaac	cgaagatcag	1080
ccctcggcga	cctcgcgggc	gacaactccc	ttggccttga	gccacttcga	acttcggggg	1140
tctcacctct	tcctcaggat	ggggagctca	ctccgagaac	aggagaaatc	aacattgcag	1200
taacaaaaga	atggtttatt	attgccagtt	ttggcctcct	cagtgccttc	acactctgct	1260
acatgatcat	cagagccaca	gctagcttga	atgctaata	ggtagaatgg	ttttgaagaa	1320
gaaaaaacct	gctttctgac	tgattttgct	ttgaaggaaa	aaagaaccta	tttttgatga	1380
tcatttacca	atcatgccac	acaagcattt	atttttagta	cattttattt	tttcataaaa	1440
ttgctaata	caaagctttg	tattaaaaga	aataataaat	aaaataaaaa	aaaaaaaaaa	1500
actcgagggg	gggcccgtac	ccaattcgcc	ctatagttag	cgattc		1546

<210> 35

<211> 1604

<212> DNA

<213> Homo sapiens

<400> 35

ccatgcctgg	cctattctgg	tctctttaac	tctctcctct	ttatttctct	tctctctctg	60
tacacttttc	ctgggtgggc	tcattccattc	ctttgctttt	tcataccatt	tatttggttaa	120
tgattcccac	atttatattat	gcacttggag	agctcacagg	aatctcagaa	actgatgagg	180
tacaattctg	aaccctcagt	ctcttccctt	taaacccttc	tttttctcta	ctttaatttt	240
tctaaagagt	gtcttgctat	gttgcccagg	ctgggtctcca	actcaagtga	tcctcctgcc	300
gcagctctcc	gaagtgtctg	gattactgac	atgagccacc	acactcagcc	ctttaaacct	360
ttccctggcc	tttcccatag	ctgggtgaagg	acacctccat	ccattccacg	cagttgtctca	420
aagcagaaat	tttcagtga	agtctttagt	ctgcgcctgc	ccccactccc	tacatcagaa	480
cgcacccctc	atctggactc	cagcgggtggc	ttcttgatgc	tgccgggtcc	cccactccct	540
acatcagaat	gcaccccgca	tccagactcc	agcgggtggyg	ctctacctgc	acgctgttgc	600
caagtccaag	ctaccatact	cctgcctgag	ctatgacaac	agcctcctca	ctgatctccc	660
ctttcttccc	tttgctcctt	ccagctcatt	tttcacagt	tagaatgaca	ttttgtttgt	720
ttgttttgg	ttgtttgrga	tggagtctcg	ctctgttgcc	cagggtggag	tgcagcgggtg	780
cgatctggcc	tcactgcaac	ctccacctcc	cgggttcrgg	cggattctcg	tgctcagcc	840
tcctgagtag	ctgggattrc	aggcatgcac	caccatgccc	ggataatttt	tgtrttttta	900
gtararatgg	ggtttcactr	tgttggcagg	ctgggtctga	acacctgact	cgtggtccac	960
ccgcmctggc	ctcccaaagc	actgggatwa	caggcgtgag	ccacccggcc	tgccctagaa	1020
tgacttttaa	aagatcaa	taaatacagg	cactcctttg	cttacaacgc	agtgcgttta	1080
gaggtacacc	ccatgtctcc	acagggcata	cagcatccga	tttaactctg	atccattccg	1140
gcgccttcct	ctcccagtc	cccagagggc	cccaaccccg	gcggcccttt	cttccctcaa	1200
tgctctcgcc	tctataccgt	gcctgggtct	tttctctttc	tctctgcctg	gaasattcct	1260
tctttcccct	tttgtcttgc	ccactcctgt	ttacccttca	agtttcaagt	tcatgtcact	1320
gtctcagaga	ggttttccctg	tgctcgcctt	gtttctctca	ggaagccttg	ctcttttcca	1380
tcatgcctct	aatcacagct	tataatcgga	tatttatctt	tgtgtctaca	gtcttgccct	1440
gccagactgt	awgccccatg	tgggcaggcg	ctcatgattg	tttctgattg	tttcacgcct	1500
gctgctaacc	cagagcctgg	gcccacagct	agttagtact	caataaacia	tgcatgtgaa	1560
aaaaaaaaaa	aaggcgggcc	gctctagagg	atccaagctt	acgt		1604

<210> 36

<211> 757

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (705)

<223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (715)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (716)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (752)
 <223> n equals a,t,g, or c

<400> 36
 ggcgcgctctc aaaaggatgg tgcgcctggc ggccgagctg ctgctgctgc tggggctgct 60
 gctgctcacg ctgcacatca ccgtgctgcg cggctcggga gccgccgacg ggcccgcacg 120
 ggccgcgggc aacgccagcc aagcccagct gcagaataac ctcaacgtgg gaagtgcacac 180
 cacatcagaa accagctttt ctctctccaa agaagcacca agggagcatc tggaccacca 240
 ggctgcacac caacccttcc ccagaccgcg attccgacaa gagacggggc acccttcatt 300
 gcaaagagat ttcccagat cctttctcct tgatctacca aactttccag atctttccaa 360
 agctgatatc aatgggcaga atccaaatat ccaggtcacc atagaggtag tcgacgggtcc 420
 tgactctgaa gcagataaag atcagcatcc ggagaataag ccagctgggt cagtcccatc 480
 ccccgactgg cgggcctggg ggcagaggtc cctgtccttg gccagggcaa acagcggggg 540
 ccaggactac cagtacgaca gtacctcaga cgacagcaac ttcctcaacc ccccagggg 600
 gtgggaccat acagsgccag gccaccggga cttttgaaac cmaagatcaa gccagaatat 660
 gattcacaga tggcgagggt gactggagtc tctggctgkc tgcancggca cctgnnggga 720
 acgggaacca gaaacggacc cgggcttggg gntaccc 757

<210> 37
 <211> 807
 <212> DNA
 <213> Homo sapiens

<400> 37
 tttttttttt ttttttcacc ttttattatg attttattat atactctctt ttactagaat 60
 tttgcaaagt aaaatattga ataagaacca actttatttt tcctaagttc taccocatag 120
 gaccagggtca tattaacaat tgcttgatgc acaataatcc gtgactcaat aaatacttta 180
 caaaaaataat gcagtttttt ttgttttctt aaaacataaa aaaytaagat tcccagatt 240
 gaccctcccc cccttttata tttattttatt ggggatatat tggtagatga aaaaattgtt 300
 aaaatagtat taaaataggt gaaatgcggt ccattatctt tttccattt gttttgttgt 360
 tttccttttg aaaagtgcta cttcttgttt ttacatctga acttggctgc agtcttctga 420
 acctgctagg acatgagcag aaattctact gttttggggc cgttttagcag aatgatagca 480
 ttatgataat attgatcttt tattttaaaag cctattttaa accagtcctc agctttgtcc 540
 ctaaaatatc atattoccta ccagctctga agaagagact tttggaatct gagactccag 600
 caaggtgcct catgaccaa taacatttgg ttttaaggtag gcgtttacat gttttgatat 660
 atttccattg cattattttt aaagaaataa attccaaaat tccctttctc ttccacttcc 720
 ctaagtctct tcttttctga tctctcacag acgtgattag tttcaccaca actccagaga 780
 aaagggttacg sttaattagk caccttt 807

<210> 38
 <211> 1518
 <212> DNA
 <213> Homo sapiens

<400> 38
 gggaagagcc ccacggccag ctccctctctg ttccctctggc ggccctctgc ttcttctcttc 60
 tggatggggg cccagggggc aggagagtat aaaggcgatg tggagggtgc ccggcacaac 120
 cagacgccca gtcacaggcg agagccctgg gatgcaccgg ccagaggcca tgctgctgct 180
 gctcacgctt gccctctctg ggggccccac ctgggcaggg aagatgtatg gccctggagg 240
 aggcaagtat ttcagacca ctgaagacta cgaccatgaa atcacagggc tgcgggtgtc 300
 tgtaggtctt ctccctggtga aaagatttct ggaaggagtt atttatgagt gaagagctgg 360
 agaatccatt cgcaaaactga tgcataaaag tgattagcaa gagaaagtgt tgagacaaaa 420
 cagagaagct gagaggccag aaacctctac ccaggacgct gagctcctgg cggatccgat 480
 gagtccctcc aggacaccgt ccacctggg atgaaggcag aggagttgga aggaggcgag 540
 gccgtcacgg gacaacagga ccctatgaag gtgggcccac agcaaaagga gagatgatc 600
 tagagcatcc agtcttctag ggcagcaaaa caacctaaat tttctaagag gccaccacgc 660
 tgagggtgcc cccgggragg gctraggcgt cagggtgacg gctccaytgc cmaytyacct 720
 ggcacctyaa agcccytctc ytccatgggg tgctcctgac agccacctcc agggcaggcg 780
 agtggcgctg ggacaaaaggc tggcccgact gcgccccacc caagcagacg gtccttcccc 840
 cagacctggc gccaaaactgg agtgaaagcc cgaccaccgt gtctcacagg gaaactgaca 900
 ccagatgcga acttccaaat ggatccctyc ctgcaagtgt ggastggcgc taccaggcac 960
 tgctytggsc atgctcttaa gacacaggca gaggcgctgs ccaccacgct kgcgacggsc 1020
 tcaaagcccc tgttcatgcc tgggacagcg cccaaggacc ttgctcatgc ytgggacagg 1080
 ccccaggggc cccactggct gcagtcagca gcgggcaggg tgggtggggga aggtatggac 1140
 actccgtggg ccggagctgg gagaacaagg cctattattg gacacctggt ggccatggca 1200
 accacacaag gatgcctgag actgaaaatc tgtgggcttc aaggagctcc agctcttgca 1260
 ctggctgagt cacagtgact atataactct tactccact tttgggacac tttttgagag 1320
 ggacagggat cctatctaac tacacgggat agacatcgcc caagaccgtc ctgagcaagc 1380
 ctggacgctg tgacctaac gatgaagggtg tcccgcagac aatgtccggg gcaggcacca 1440
 tgctctccca acctaccaca gccagatgtt tttgtaaaga acaataaaaa tgaattacta 1500
 gaaaagcaac ggcacgag 1518

<210> 39
 <211> 696
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (623)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (652)
 <223> n equals a,t,g, or c

<400> 39
 gctgagggtc agccctctgt aactgatctg cggctgcact caaccttctc gccagtctca 60
 ggatgagggt gccttgcccc acctcaaagc ctgctctctc acctgtgtctc tggagccacc 120
 tctgccagca tcgctggggc ctcaccccag cctctacctt gctctgtctg ctcttgctct 180
 tcaacctagg aacgtgcctg agctttttctc atcttaaaaca aaacaacaat aacagcaaca 240
 caagcaaaaat ctcccttgac cctgcatccc tctgttgggt tatcatcagc ttatcatctc 300
 cacccttccc atcaaaacat ctcaaaagag tagtctacac tcaacactct ccatttctc 360
 actaccctct tactcctcaa cctgctgcaa tttgacattc acccccagag ttgctttgac 420
 ctctaatta ccaaatcagt gggcccttgt cagtctctgt gtctgctgca ttgatgctgt 480
 ttaccacccc ctctcaaaa aatgcctgtg cttattacta gttcctataa agtgcaggaa 540
 acccaaatct gtctagcctg gggccccctc cccaagattt caggcctcct gttactcgga 600
 ttacatgttc aggacatctc ccntgggatg gggcccacag ggggaacctt antgtgggac 660
 caaaggggga tttgggtcgt cttcaggtcc cctttt 696

<210> 40
 <211> 1397
 <212> DNA
 <213> Homo sapiens

<400> 40
 tttttttttt tttttttttt tttttttttt tttacagttg cctgtttatt attttttcaaa 60
 acaaaacaaa aacaaaagac attcaaaatt cccctgtggg ggacaactga gttgatgtgg 120
 ctgatccagg ctgtctccca ggttgtctca gggagcatca gttgtactag ggggtgggct 180
 gttgccctgg cacggctgga tgaacacttg caccagggat ggccatcaga agagctgcag 240
 gccagttttg agcccatgca gctgcccctg gctccagaga aggccctcga agttgctgct 300
 gctgctgttg ctgcagttgc cactgcccgc accacagctc aggcccaagg tgtcagtcctt 360
 gcatgttgag ggttccagcc gctgctctag cacaggctgg tccaaaagat acatgggtgtc 420
 ataattctcc agcatgagct ctgctgggtc ctcggtctga cctggcattc ggcttagggg 480
 aaatgtgtcc catcgcacgt cttctgagct aacctgccat gcagagccct gcaaagctcc 540
 tcttttctgg gccagaagcc tagcattctc ggcagtgggg gactcttgcc ctgtagagaa 600
 aggcccccacc tccattctgt ctctctcttc atcatcttca tcatcttcat cctctctctc 660
 ctctctctgg tcatcatttt ctctctcttc ctctacctgg tctggcaaga cctctttctc 720
 ctctctctcc tcttcttgga catcattaac actgccctgc tctctctgtt gctgggcctt 780
 tgcttcagac ccgaagctgg agctggctgg cttgacgctc caatacaggc tgtctagtgt 840
 atatggagac ttcccaatgg gggaggcctc agagccctcc tgcaccaggc tgttttctcc 900
 actctgggta taaatggaac agatgcgcag cagcttctcc tgctcctcgt ctggcaggcc 960
 ctgccccatg gctttgaaga tgatccgaag gagttggggg ctggcccagc aagggtgagcc 1020
 caagcaggac tcaaccatcc ggggccagtc aaggaggcgg gacagattga acagcctcca 1080
 gccccttctt gcttccact ggctgcaga aaatcggcga gcattccgtc cagtcttggt 1140
 gttggccacg atcagttcaa cggctccatc gaggatgtag gtaggccgga tcccgtgat 1200
 ccccaaggct ggcagttcag agagcatcct ctccaatagg gcctgcgtga agttctggga 1260
 gtgcaggccc ctgagcaggg gctgccagaa ctgagagaac ggctttggca ccaggacgtc 1320
 attcaagtcc acgtttttgt gtgactttgg gtagtacctt cccctctctg gacctcagcg 1380
 gacgcgtggg tcgaccc 1397

<210> 41
 <211> 1323
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (24)
 <223> n equals a,t,g, or c

<400> 41
 tcccgggtcg acccacgcga accncggacg cgtggggcgg ketgtgcaca tcccaggaca 60
 ggagcccctg accgcgtcca tgctggctgc ggcgcccctg catgagcaaa agcagatgat 120
 tggcacctgt tatcttgtct taaaacgctg gtcagactgg atggctctga gctttcttcc 180
 actgctgctg tctgtgact ttgaggggag cgtctctacc cccttatcca tgatgtccac 240
 acccagctgg ctggcaagat cacgggcatg ctgctggaga ttgacaactc rgagctgttg 300
 ctcatgctgg agtctccaga atccctccat gccaatag acgaggcagt ggccgtgctg 360
 caggcacacc aggtatgga gcagccgaag gcgtacatgc actgaaacca gatttcagct 420
 taaaatgccca ccagagacc aagttcattc tgtcaactga tctccagcac ctggcccaga 480
 gacggaaagt acaaagacta gtaaaataca tcttgccct taaggagcta agtaccacaaa 540
 acctgtaatc catcttgagt caccagagta cggttgctca gaaacagcag tggtgccgtg 600
 gaaagggcat caaccctgcg atccggacaa gtcactccat ccctctgatc atgcgtgccc 660
 acctaccaca tgaggatata acttcataga cttgtggaa gggttcattg tgttagcctg 720
 ttccctgagc tctcttctgt atcaagaaga ctgatcagat aaatcaagag acttgcccaa 780

aattacctag	gaaatctgta	gcagcagcag	aaccaaactc	cggtccttgc	taaactctaga	840
taccaggcta	gcttttctat	ggacccagaa	ttaaccata	caaagtaca	agcttttcca	900
gaccagctgg	ggtgagatga	atgaaaatgg	cagcaacatc	aatacctcag	cttcttcagc	960
aacttcatca	agtaaggctg	ccatgaggaa	gtgggcctaa	aggagagttt	tctagaacaa	1020
agaagggggc	aaaggagtg	cttgaaaactg	caaaaagtgc	agacaaaaaa	aaaaaaaaaa	1080
agaatgaaat	ctggagagga	tgtgaggaga	ggtctagcaa	aatgattaaa	aatttggact	1140
tagcatcaaa	gtcaaacaga	tccatattca	aatcgtgggc	tcttccatgt	cttcactatg	1200
taaccccag	gggagccaat	ttaactctct	tggactcctc	ctttctaagc	attttatcca	1260
cagggccata	ataaagatca	aaggagatcg	tgtctaaaaa	aaaaaaaaaa	aaaaaagaa	1320
ttc						1323

<210> 42

<211> 813

<212> DNA

<213> Homo sapiens

<400> 42

gcatttacaa	gcacttcagc	gccactttgg	catatgtgaa	actctccaag	gtactgaact	60
tctatgtggc	taatgcagat	gactccagca	agactgaact	gctttttgct	gcgttgaaag	120
ccttgaagta	cttgtttaga	ttcatcatcc	aatcccaggt	gctctacttg	aggtaatggt	180
aactgcagtg	aagatgttta	gattatcagc	tgtcactctg	tgtgcttttt	ccctcactct	240
gcacagtggt	gttcagctct	gtgagcagtt	agttcttaga	attgccttat	ttcagaactg	300
cagggtcgaa	gatggatttg	ggctgcgtgt	ctgttgagga	agactcatga	gaagtttttg	360
tagatcagca	aaattctggg	gcagtaatga	cctcaggact	tggggaagca	gattcctgtg	420
gaaagattgt	acctaataca	gcagatgact	tcatgacaat	attgagtgtg	caaacttagg	480
atcatgatct	gctgtcgcta	gcagaagcag	cagtcactct	aggggaggtg	ttgcctgaga	540
tgagtgkttc	cttgttgaca	ctgtgcttag	ctacctgggc	aactaagcac	tagagacagg	600
aytattccct	gtttggattt	ctagcataac	agktccatca	aaaacagaag	aaactgcama	660
agagcaagta	cctttgcagg	gaacattcac	aaccccagtg	actttcctac	ccttcagaaa	720
tagctgtatt	yccaaactgt	taamattttt	ttctaaggaa	gaaagaaaag	gtttgtagaa	780
ttgagcatat	gtatttttaa	aagaaacttt	att			813

<210> 43

<211> 817

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (644)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (747)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (756)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (772)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (798)

<223> n equals a,t,g, or c

<400> 43

accagtata	gtgcaaagct	ggtacgcctg	caggtaccgg	tccggaattc	ccgggtcgac	60
ccacgcgtcc	gggttggtgc	acggaacggc	agggccgcct	ttaggcttac	atccctggaa	120
ctccacacctc	cacagaccgc	tccgggtgct	gaaagtccac	ggatgctatc	cctgggtcaaa	180
tcagaggctt	gtccagccgg	aagccctgag	ggcagctgtt	cccaactggct	ctgctgacct	240
tgtgccttgg	acggctgtcc	tcagcgaggg	gccgtgcacc	cgctcctgag	cagcgccatg	300
ggcctgctgg	ccttcctgaa	gacccagttc	gtgctgcacc	tgctggctcg	ctttgtcttc	360
gtggtgagtg	gtctggtcat	caacttcgtc	cagctgtgca	cgctggcgct	ctggccgggtc	420
agcaagcagc	tctaccgccc	cctcaactgc	cgctcgcct	actcactctg	gagccaactg	480
gtcatgctgc	tggagtgggtg	gtcctgcacg	gagtgtacac	tgttcacgga	ccaggccacg	540
gtagagcgct	ttgggaagga	gcacgcaatc	atcatcctya	accacaactt	cgagatcgac	600
ttcctctgtg	ggtggaccat	gtgtgagcgc	ttcggaatgc	tggngagctc	caagggtcct	660
cgctaagaag	gagcttgctc	tacgtgcccc	ttaatcgggc	ctggacgtgg	tacttttctg	720
ggaagattgg	ggttctggca	aagcggnaaa	ttgggnaagg	agggaccggg	gnacaaccgg	780
ggggtcggaa	agggcctnga	aaggcgccct	ggtccgg			817

<210> 44

<211> 643

<212> DNA

<213> Homo sapiens

<400> 44

gcggccgccc	tttttttttt	tttttttttt	tttttttttt	ggccttctga	attctttact	60
cttggctcaa	gttttgtaa	tattagtcac	cagttaataa	gaaaaatagt	ttctaattgt	120
cttttctgc	actctgtgtg	ttggttttga	gttaactgga	taccaccgtc	aggccgcgtg	180
tgttcagtca	cagccattaa	ttattccttt	ttcttaaact	cttggtttcc	gtagctggag	240
cctttttcta	tctcagttac	tcctatcagt	ctgcgaactc	caaaggaagc	tgctcccaca	300
aacccaaga	aagtcaggat	caggagaggt	gatccgctgg	caaagacgcc	caagacaaaa	360
ctgaagaggg	gagacaggag	aatggtggcc	caggacagga	agttcaggag	ggtccacggc	420
ctccgggcag	gcttaaactg	ctcccctgga	aacatgccct	tctgattata	tatctcctgg	480
agcgcgtcct	tctcctggta	cagtttatga	agccactgag	ctgcttccct	ttcatccacg	540
cgggatgtct	tccagaggaa	atctcctcac	gcacatgtcc	gcctcgtact	tcttcccgtg	600
gaggatcccc	agcagggacg	ggttcttgtt	tcctctgaag	ttc		643

<210> 45

<211> 1006

<212> DNA

<213> Homo sapiens

<400> 45

gcgkgcctyc	aaggccctgc	tcccagtggg	cgcctatgaa	gtcttcgccc	gggaggcggt	60
gggtgcgggt	gcagctcggt	gcctgctgcc	tggagatgag	gacgctggtc	gagctcgggc	120
cctgggctgg	ggactttggg	cctgacctgc	tgctcaccct	gctcttctctg	ctcttctctg	180
cgacgggggt	caccttgagc	ggggcctcgg	ccaacccac	tgtgtccctg	caggagtcc	240
tcatggccga	gcagtctctg	cctggcacgc	tgttgaagct	ggcggcacag	gggctgggca	300
tgagggcgc	ctgcacctg	aygcgcctct	gctgggcctg	ggagctcagt	gacctgcacc	360
tgctgcagag	cctcatggcc	cagagctgca	gctcggccct	gcgcacatcc	gtgccccacg	420
gggcgcttkt	ggaggccgcc	tgcacctttt	gtttccatct	gacctcctg	cacctgcggc	480
acagtcctcc	sgcctacagc	gggcygctg	tggctctgtt	ggtcaccgtc	ayggcctaca	540
cggccggccc	ttacgtctgc	ttcttcaacc	ctgccctggc	cgctctgtga	cctttgcctg	600

ctcgggacac	accttactgg	agtacgtgca	ggtgtactgg	ctgggccctc	tgacagggat	660
ggtcctggct	gtgctgctgc	accagggccg	cttccccrcc	ttttccagag	gaacctgttc	720
tacggccaga	agaacaagta	ccgagcacc	cgagggaagc	cggccccggc	ctyaggggac	780
accagaccc	ctgcaaaggg	gtccagtgtc	cgggagcctg	ggcgagtggt	tggtgagggg	840
ccacattoca	gctgagtggc	cttgcctctgt	gtgagccccg	tgcgagggcc	ctgcttgtag	900
ctggaccctg	gaaccttctg	tagctaagag	ggaatcctgg	ccccctcccc	agaagccatt	960
tgtcaataaa	ccattttctaa	gaaaaaaaaa	aaaaaagggc	ggccgc		1006

<210> 46

<211> 647

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (525)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (578)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (581)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (620)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (629)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (630)

<223> n equals a,t,g, or c

<400> 46

gtgaaacgcc	tgggctcaag	ctgattcacc	tgctccacc	tcccacagt	ctgggattac	60
aaacatgac	ccccacgccc	agccaacaca	aaacttctga	tgctctgttt	tctcatctgt	120
gaactggagc	taaggctaag	tggctgtgtc	gtttaataag	agtttgaatc	agatggcctg	180
gcatgaagag	tactggcct	gagagaatgt	caggggcatt	tgtaaatgtg	taaagggtg	240
aaaaatcctg	agggattatt	attattgcta	ttgttggtat	tattcacaga	cacatycaac	300
agccattgtc	tgctccetta	tctgtcatgc	tttctgcacg	agcgtcagcc	tgagcttcaa	360
tctgtgtgta	tatctgcagc	ttacgtcctt	gcacccctcc	agaaccaggt	ttcatccttg	420
taggtttttc	craagcagga	tttgcaaacg	tggcgtgttt	tcttaagtat	ttattttgca	480
ggccatttac	tcggcatggc	tatttttaca	gtgggtaagg	agcanggcta	aaaataactt	540
agctcataac	cagacagggt	ctgcatttga	cattacgngg	nattcatattg	catcccattt	600
ggtcgccctt	ctggttaacn	ggtagaatnn	aagaaagctc	acccgaa		647

<210> 47
 <211> 1321
 <212> DNA
 <213> Homo sapiens

<400> 47
 gcaataaag agtaaaacag gctattttaa acatccattt aaatgcaa atttgatatcc 60
 caagagaaaa atgttaataca tttaaataga caggattatc gccaccctt accacttccc 120
 tcctctccca agtttttagaa aacgtagcct tagcccacac aagtcaagtc agccaggagt 180
 ccttacatct taaraactcc cactcagatg agagggtga ggcagataga gggggacttt 240
 tccttctttt gaggaaggag atggaaaaga gagaaaatag tctaacatat cctataagcc 300
 aggcatgggg caatattata aatacaaaaca cacacacaca cacacacaca tgcattgcaca 360
 cacacacacc cacacttaat catcacaact gtcttggaac ggggaattat catcctcatc 420
 tacagacaag gaaactgagg cttagaaagg tgaagcagtt tgccccactg gtaggtgacc 480
 cagttgggag tagaggcctc catagccctc ccagtcctat gtgacctgcg gtctgttcca 540
 gactcaccca gcattcccat gccaaagcatg aacgcgtcca tgggtgaagg cagtccccgg 600
 gcccgccctc ttgtcccagg tgggaacatg acttctttcg gctgagcttt cttacattct 660
 accattttat tattgatttc atggaaatga atctcacaga ctttctccac aacatcttca 720
 ttctcaaaag tgacaaagcc aaacctctcg tgctgttg tagttttatc aaacatcagc 780
 attgcatctt ccaccttgcm aaactretcg aaatattgct ttacatcttc cactactgtg 840
 ttgcagata accgcctac aaatatcttc ttgttcttg tgacctctt gggttgcgct 900
 cgacgaggaa atgcaacttt ggggtcaatc gtcttggaat ctaactcatg gtggggctga 960
 cctaatactt tatctacact tgctgggtct gcgaacgtga cgaaaccgaa gcctctggag 1020
 cgtttcgtag tgggatctct catgaccata cattctctaa tttctccaaa tttgctaaaa 1080
 tagtctctaa ggctatctgg tgaggtctgc cagctcagtc caccgataaa cattttaccg 1140
 gggctgtgct gggagtcgtt ggcgtgccc gaggtgcctt ggctccatt tgcctccata 1200
 tctgagcccc cccgcccccc ccccccaaa aaaccaagcc ccacagcgat cggagcggag 1260
 cggcgcccg ctcgagccc cgagatctcc gtccctctc cccctctctc ctcccccccg 1320
 c 1321

<210> 48
 <211> 725
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (642)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (694)
 <223> n equals a,t,g, or c

<400> 48
 gttctaaaat atgacccccg ggctgcaaga attcgcacag gaaaattggc agcgggggct 60
 gatggaagtg cagtgggggc tggagagggc accctagtga gttggctttt ctctccttcg 120
 tgcccttttg ttgggtcga ggcgggggt cggaggccat caggacaaga gtgtgggact 180
 tggaaaggga gccacctgga gcttggaagg ggctgtatcc agcatgctcc aaggccacag 240
 ctctgtgttc caggccttgc tggggacctg cttcacctgg gggatgacag cagctggggc 300
 agctctcgtg ttctgtattct ctagtggaca gaggcggatc tttagatggaa gtcttggtt 360
 tgctgcaggg gtcatgttg cagcttccta ttggtctctt ctggccccag cagttgagat 420
 ggccacgtcc tctgggggct tcggtgcctt tgctctctc cctgtggctg ttggcttcac 480
 ccttgagcgc gcttttgtct acttggtgta cctctgatg cctcacttgg gtgcagcaga 540
 agacccccag acggccctgg cactgaactt cggctctacg ttgatgaaga agaagtctga 600
 tcctgagggt cagcgctgc tcttccctga gaggatctat cngatagaca agagtgaaga 660

tgggtgaggca tatcagagaa agaaggcggc agcnactggc cttccagagg gtcctgctgt 720
 cccct 725

<210> 49
 <211> 869
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (765)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (800)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (847)
 <223> n equals a,t,g, or c

<400> 49
 ggacaagcca tgtgccagac ctagtcaacc tgtctctcaa tgacaacgat ggctccagtg 60
 gggcttcaga ccaggatacc ctggtcctc tgccctggggc caccctctgg cccctgctgc 120
 ccactttctc ctaccagtac cctgcccac accctacag cccgcagcct ccaccctacc 180
 atgagctttc atcttacacc tatgggtggg gcagtggcag cagccagcat agtgagggca 240
 gccggagcag tgggtcgaca cggagtgat ggggggcagg gcgcacgggg aggcccgagg 300
 agcgggcccc cgagtcgaag tccggcagtg gcagtgagtc tgagccctcc agccgagggg 360
 gcagccttcg gcgggtggg gaagcaagt ggactagcga tgggggccct cctccatcca 420
 gaggctcaac tgggggtgcc cctaattctc gagcccaccc agggctccat ccctatggac 480
 cgccccctgg catggccctc ccctacaacc ccatgatggt ggtcatgatg cccccacctc 540
 cacctccagt cctccagca gtgcagcctc cggggggccc tccagtcaga gacctgggt 600
 ctgtgcccc agaactgaca gccagccgcc aaagcttcca catggccatg ggcaatccca 660
 gcgagttctt tgtggatgtt atgtagcca ctgtggggcc aggytgggcc gggcgctcct 720
 ggtgtgtgac tgggtgtcct ggccgtcatg tgcttgctct tacantgcct gggctcaagc 780
 ctaccagctg ctgcatacan gagattgtgg gccactgtga ctcttcacca agcatgcctg 840
 gttcctnccc cccttcctt caagggta 869

<210> 50
 <211> 692
 <212> DNA
 <213> Homo sapiens

<400> 50
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tgagtttgcc 60
 tctattgctt tatgtggtgt ttatataaag tgactaaaat aaatagagta acaaaggcag 120
 ctacatggcc caaatctccc agcttctcctca ggctgctgtc taggatgcct accccgggg 180
 taccgctgac caccccaac cctgcaaagg gcagggtgt gggtaactgg aggaggaggt 240
 cacattctgg ggttagaagg ggcccaatgg atgggaattc ttcataaaa agaggaaatg 300
 cctattaaaa aagtcccaaa aatgtaagaa actctatttt aacccccaaa aaggcttata 360
 aaaaaacaaa gctaaaaata atcaaaggtc cctgtctac ccctgagggg agggggagga 420
 accaggcact gctgggtgaga gtcacagtgg ccacaatctc ctgtatggca gcagctggta 480
 ggctgagccc aggcactgta agagcaagca catgacggcc aggcacccca gtcacacacc 540
 aggagcggcc ggcccagcct ggcccacag tgggctacat aacatccaca aagaactcgc 600

tgggattgcc catggscatg tggaagctca tggatatggtg gaggctgcgg gctgtagggg 660
 tgtggggcaa ggtactggtc agagaaagtg gg 692

<210> 51
 <211> 465
 <212> DNA
 <213> Homo sapiens

<400> 51
 gggggccctc tgcgcctacg cggtcaccta cacagcgatg tacgtgactc tcgtgttcg 60
 cgtgaagggc tccgcctgg tcaaaccctc gctctgctg gccttgctgt gcccgccctt 120
 cctgggtggc gtggtcccg tggccgagta ccgaaaccac tggtcggacg tgctggctgg 180
 cttcctgaca ggggcgcca tcgccacctt tttggtcacc tgcgttggtc ataactttca 240
 garccggcca ccctctggcc gaargctctc tccccaragt gcctaccctc gcctgcctgg 300
 gcctyagttt ccacatctgc acaatggggg tgaccatccc tgccctgctg gctgcaggag 360
 cggctgtgag tcttcagcgt ggatgcagcc tgggggaagc catagggcag ctttcacagg 420
 cctggcctta ccatgggcgg gagggagacc gcatccgaag aggag 465

<210> 52
 <211> 546
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (478)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (524)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (538)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (541)
 <223> n equals a,t,g, or c

<400> 52
 ggttccaaac agcagttagg tcagcagtc gctcagccga ggcagctctg ttcattggcgt 60
 tctcgaagct cttggagcaa gccggaggcg tgggcctctt ccagaccctg caggtgctca 120
 ccttcacatc cccctgcctc atgatacctt ccagatgct cctggagaac ttctcagccg 180
 ccatcccagg ccaccgatgc tggacacaca tgetggacaa tggctctgcg gtttcacaa 240
 acatgacccc caaggccctt ctgaccatct ccatcccgcc agggcccaac cagggggccc 300
 accagtgcg ccgcttcgcs cagccacagt ggcagctctt ggaccccaat gccacggcca 360
 ccagctggag cgaagctgac acggagccgt gtgtggacgg ctgggtctat gamcggagg 420
 cttcacctcc accatcgtgg ccaagtggga cctggtgtgc agctccaagg cttgaagncc 480
 cctaaccagt ccatctttat ggcggggatc ctgggtgggc tccnttatct gggggctnct 540
 nttcta 546

<210> 53
 <211> 1861
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1255)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1412)
 <223> n equals a,t,g, or c

<400> 53
 agctctgctc ctcagtcttc tccctgtctg aagaggagct gctcaggatg aggcaggagg 60
 tccatggctg ctttgcctcag atggacagga gcttggccct cccaagatc cgggcccag 120
 ttctgctgca gcaatttcag actgctggc gagaagcaga gttcgtgaag ctggaccagg 180
 ccgtggctgc ccctgagctg cagcaacagt ccaaggtgag aaagtcacgg tccaagagta 240
 aaagcaaggg agagcttctg aagaagtgc tcaagacaa aattcacctc tgtgaggaaac 300
 aggcctctga agacctggg gaaaagggtc gaggtgaatt gctgcgggag agagtgcagc 360
 ggatggaggc acaggaggga ggctttgcac agtcgcttgt tgctctgcag ttccagaagg 420
 cgtcccgggt gaccgagact ctgtcggcct acaccgccct cctcagcatc caggacttgc 480
 tcctggaaga gctgagtgc tctgagatgc tgaccaagtc ggcctgcaca cagatcctgg 540
 agtcgcacag ccgggagctc caggagtgg agaggaaagt ggaggaccag ctggtgcagc 600
 aggaggcag ccagcagcag caggccctgg cgagctggca gcagtgggtg gccgatgggc 660
 ccgggattct gaacgaacct ggggagggtg attctgaaag gcaggtctct actgtcctgc 720
 accaagccct gagcaagagc cagacattac tggagcaaca tcagcagtgt ttgagagagg 780
 aacaacagaa cagtgtcgtg ctagaagact tgttggaata catggaggca gacacctttg 840
 caacctgtg cagccaggag ctgagactgg catcgtacct ggcgaggatg gccatggtgc 900
 ccggggccac gcttcgccgg ctctgagtg tggactgcc cacagcctca cagcctcagc 960
 tgctggccct gctggattcg gccaccgaga gacatgtgga ccatgcagct gagagcgatg 1020
 gcggagcggg ccaggccgac gtgggcaggc ggaggaaaca ccagagctgg tggcaagcct 1080
 tagatggcaa actgcgagga gatctgataa gcagaggatt agaaaagatg ctgtgggccc 1140
 gcaagagaaa gcagagcata ttaaagaaga catgtctccc tctcagagag aggatgatat 1200
 tctctggaag aggaagttgg ccacacctgt cactggagcc cattgsgaa ctggnccttg 1260
 taccattgt aggggcagaa accattgac tattaacac aggagagaag ctctttatat 1320
 tcagaaatcc aaaggagcca gagatctcac tgcacgttcc tccaggaaa aagaagaact 1380
 ttttgaatgc caaaaaggcc atgaggcct tnggcagga ctagcccaag ggaaagacct 1440
 gcgggascac ctgaagagag aaggatgat tttctcctgc ccgccggtgt ttgtgtgttt 1500
 ataatgcaca actcgcaaat ataaattgca catgcagaag gcacagacc cgtagcgcat 1560
 gccaaacttg agggactcgg tttaattctg tctcatgaat ttccagatgg cccactctct 1620
 tccatatcac aaggacataa acactccttc tttcagccc acctcccag ggccctggag 1680
 gagaccccca ccctgcaatc cacaccccat cctctgctgc agaagctatg gtctgtgtgg 1740
 tgacagccag attctctact cttatgttt gtatttgta catattctat ttttataaag 1800
 ggaatttaaa aaaataaatg tgttttgac aaaaataaaa aaaaaaaaaa aaaaaaaaaa 1860
 a 1861

<210> 54
 <211> 884
 <212> DNA
 <213> Homo sapiens

<400> 54
 atcccagtc cctggctgac atcggtggg tcggaaacga agtcaggcag ataagcgcaa 60
 aggcctggga ttgtggggag ccgaggaaat atgtcaactt ggacaggcag gcttttgggtg 120

gctgattgaa	ctgctgggtat	tgggtgggaga	gtacgtagaa	acttgtggcc	atctcatcta	180
tgctgcagg	caactgaaaa	gcagtgattt	ggaccttttt	cgagtttga	tgggagtgtg	240
gacagggcgg	ttagggggct	gggccaggt	catgtttcag	tttctaagcc	aggggtttta	300
ctgtggagta	ggactgttta	ctcgttttct	taagctgctg	ggtgctttgc	tgctcctggc	360
tctggccctc	tttttgggct	ttctacagtt	gggatggcgg	tttctggtgg	gactaggtga	420
ccggttaggc	tggagggata	aggctacctg	gctcttctct	tggctggatt	ctccagcctt	480
gcagcggtgc	ttgactctgc	tgagagatag	caggccatgg	cagcggtgg	taagaatagt	540
tcagtggggc	tggctggagt	tgcttgggt	caagcagaat	attaataggc	aggggaatgc	600
acctgtagct	agtgggcgct	actgccagcc	tgaagaggaa	gtggctcgac	tcttgaccat	660
ggctgggggt	cctgaggatg	agctaaaccc	tttccatgta	ctgggggttg	aggccacagc	720
atcagatgtt	gaactgaaga	aggcctatag	acagctggca	gtgatggttc	atcctgacaa	780
aaatcatcat	ccccgggctg	aggaggcctt	caaggttttt	gcgagcagct	tggggacatt	840
gtcagcaatg	ctgaaaaagc	gaaagggagt	atggagattg	aaac		884

<210> 55
 <211> 572
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (504)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (526)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (541)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (554)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (558)
 <223> n equals a,t,g, or c

<400> 55						
gggtcgaccc	acgcgtccgc	tgcgagtg	cgggcatgag	agtaaaactgc	ggaaggctgc	60
cagcgggttc	tagtcattgt	tggagttgtt	ctcttggtgc	gcaggcttcg	acgagattgg	120
cgccgggtcg	cttacttggc	gggtgcaatg	gcgcttttcc	gatgcgtgtg	gagcgtgctg	180
agtgccctgg	gaaagtccgg	atcggacctc	tgcgcgggct	gtggaagtgc	actgcgtctc	240
cctttcagtt	ttgcgtatgt	accgagatgt	ttttcatcca	ccgcgaatag	ttacccaaag	300
aagcctctga	cttcatatgt	tgggttttct	aaagaacagc	taccatatt	taaagctcag	360
aaccagatg	caaaaaattc	agaactaatt	agaaaaatcg	cccaaytatg	gagggaactt	420
cctgattcag	agaaaaaaat	atatgaagat	gcttacaggg	cagacttggc	agggcataca	480
aagaaagaga	taaacagaat	tcangaacca	ggttaacctc	caagtnagat	tggtttcttt	540
ngaaaaaaga	aatncagnca	aaaacggttt	aa			572

<210> 56
 <211> 464
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (439)
 <223> n equals a,t,g, or c

<400> 56
 gccaatgttg aaagactttt caaatctatt gttggtggta ctctgtgact atgtttcttgg 60
 agaagctgaa tatcttctct tgagagagcc aggccatgta gcactaagca acgacacagt 120
 gtatgtggat ttccagtatt ttgatggkgc taatgggaca ctgaggaatg tatctgtcct 180
 gctgttgag gccaacacca atcagactgt aactaccaag tacctcctga ccaaccagtc 240
 ccaggaaca ctaaagtttg agtgcttcta tttcaaggag gctggtgact actggttcac 300
 aatgactcca gaagcaacag acaacagcac tccattcccc tgggtgggaga aaagtgcctt 360
 tctgaagggtg gaatggcctg tctttcacgt tgacttgaat aggagtgccaggcagcaga 420
 aggcaccttc caagtgggnc tatttaccag tcaaccactg tgcc 464

<210> 57
 <211> 729
 <212> DNA
 <213> Homo sapiens

<400> 57
 tttttttttt tttttttgct cwtttacatt ttattatcat tattagtaat aaaccaataa 60
 aaactgaata acaaaggaaa aagctcaaga taaataattt cttccttgtg aattcaaaca 120
 catgcacaca cacacatcct cctctgtgtg tgttacttcc tctcacatt ctgtcctacg 180
 gtacaaatag ttacacaaaa gtctacaaaa cgcgagtagc agaccccagc tgtgttaagc 240
 tcaggctgat tctcagtccta gatcaccagc ttctccacgc taagtgtact tgtggtttca 300
 tcctcttcat ttgacccaaa atatcctggg aggtccagca tcctctgctc agcctcagtg 360
 aggccaaacg acgtattgtc atagaaggca aactcaggtg gagtggggaa gctttgacac 420
 ttgtcttttc tacactgaga agggctcaga gaactgacct tctggtagt atctttgggg 480
 gatgtgggag aagactactt ccttgagata ctctgtgtgac tgggggacgg tccccgasga 540
 gctctgtggg gctctgttct ctcaattcck gccactaatc ctgcttggg atcccccaagg 600
 tctggtttcc tcaagggctg ccccaaagt taggatttag ggagagggt taatggacca 660
 cgggttccac ttgccycttg gaaatgctcc agtttttcag gaaacagggt ggcacctcga 720
 cctcgtgcc 729

<210> 58
 <211> 1325
 <212> DNA
 <213> Homo sapiens

<400> 58
 cggattgtcc tgtggacctt attcctgcac tttattctgt tggagctaga cagaaacgctc 60
 aaggttacag caaaaaggaa tggcccatca gcgagggtaa ttggggcttg ggtgctcaaa 120
 gttaccaga aataattatt acagggcatg ctgatgggtc agttaagttc tgggatgctt 180
 ctgcaataac tctacaagta ttatataagc taaagacatc taaagtattt gaaaagtcac 240
 gaaataaaga tgacaggcca aacacagaca ttgtagatga agatccat atgccattcaga 300
 tcatctcctg gtgtccagaa agtagaatgc tgtgcatcgc tggagtttca gctcatgtca 360
 ttatttatag attcagcaag caggaagtaa tcacagaagt cattccgatg cttgaagttc 420
 gattattata tgagataaat gatgtggaaa ctccggaggg tgagcagcca ccacctttgc 480
 caacacccgt gggaggggtcc aaccctcagc ccattccctc tcagtctcat ccattaccca 540
 gtacagcttc atctgatggg cttcgtgata atgtaccttg tttaaaagtt aaaaactcac 600

cacttaaaca	gtctccaggt	tatcaaacag	aactagttat	tcarttggtt	tgggtgggtg	660
gagaaccacc	acamcaaata	accagcctgg	cagtcaattc	ttcctatgga	ctggtgggtt	720
ttggcaattg	caatggcatt	gctatggttg	actacctcca	gaaagcagtg	ctgctcaacc	780
tgggcactat	tgaattatat	ggctctaata	atccttatcg	gagagaaccc	cgatctcctc	840
gtaaattctc	acagccttca	ggagccggtc	tgtgtgatat	tagtgaagg	actgttggtc	900
cagaggatcg	ctgcaaactc	ccaacctctg	gttcttcatc	accacacaat	tcagatgatg	960
aacaaaaaat	gaataatttt	atagaaaagg	caaagatrtc	aaggaaagta	agcttaccta	1020
ctgacctaaa	gcctgattta	gatgtaaagg	ataactcctt	tagccgatca	cggagttcaa	1080
gtgtacaagc	attgacaaag	aatcccgaga	agcgatctcc	gctcttcatt	tctgtgaacg	1140
tttactcgaa	agacggactc	gtccccttcc	ccttgtctgt	gggttggaac	acgctaggga	1200
acagtgcctg	tcattgcact	gaaaccttcc	cccaggggga	gagcaaagac	ttcttcagcc	1260
agtaattgtg	tctccaagtg	gtactatatt	gagggttaaaa	ggtgcaatct	tgaggatggg	1320
cattt						1325

<210> 59

<211> 2878

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (811)

<223> n equals a,t,g, or c

<400> 59

ggtagcggtc	ccgaattccc	gggtcgaccc	acgcgtccgg	aagttcgatt	attatatgag	60
ataaatgatg	tggaaactcc	ggaggggtgag	cagccaccac	ctttgccaac	accogtggga	120
gggtccaacc	ctcagcccat	ccctcctcag	tctcatccat	ctaccagtag	cagttcatct	180
gatgggcttc	gtgataatgt	accttggtta	aaagttaaaa	actcaccact	taaacagtct	240
ccaggttata	aaacagaact	agttattcag	ttggtttggg	tgggtggaga	accaccacaa	300
caataaacca	gcctggcagt	caattcttcc	tatggactgg	tgggttttgg	caattgcaat	360
ggcatttgcta	tggttgacta	cctccagaaa	gcagtgtctg	tcaacctggg	cactattgaa	420
ttatatggct	ctaatgatcc	ttatcggaga	gaaccccgat	ctcctcgtaa	atctcgacag	480
ccttcaggag	ccggtctgtg	tgatattagt	gaagggactg	ttgttccaga	ggatcgctgc	540
aaatctccaa	cctctgcaaa	gatgtcaagg	aagttaagct	tacctactga	cctaaagcct	600
gatttagatg	taaaggataa	ctcctttagc	cgatcacgga	gttcaagtgt	aacaagcatt	660
gacaaagaat	cccagagaagc	gatctccgct	cttctattct	gtgaaacggt	tactcgaaag	720
acggactcgt	cccttcccc	ttgtctatgg	tttggaacaa	cgctaggaac	agtgttctgc	780
attgactga	accttcccc	agggggagak	nawwaacttc	ttcagccagt	aattgtgtct	840
ccaagtggta	ctatatgtag	gttaaaaagg	gcaatcttga	gaatggcatt	tctggatacc	900
acaggtcgtc	taataccacc	tgcgtatgaa	ccctggagag	agcacaatgt	tctgaagaa	960
aaagacgaaa	aggaraaaawt	gaaaaaacgg	cggcctgtct	cagtatcccc	ctcctcttct	1020
caggaaatta	gtgaaaacca	gtatgcagtg	atatgttctg	aaaagcaagc	aaaagtaatc	1080
tcactgccaa	cccagaactg	tgcttataag	caaaatatta	cagagacctc	gtttgtgctt	1140
cgtggagata	ttgtagcatt	gagtaacagt	atctgccttg	cctgtttctg	tgccaatgga	1200
catataatga	cttttagttt	gccaagttaa	agacctctgt	tggrtggtga	ttacttgccc	1260
cttaccaata	tgcggrrtagc	cagaacgttc	tgctttacca	acaatggaca	agcattatac	1320
cttgtttcac	ctacagaaat	ccagagactt	acttatagtc	aagagacctg	tgaaaatctt	1380
caggaaatgt	tgggtgaact	cttcactcct	gtagaacac	ctgaagcacc	aaacagggga	1440
ttctttaaag	tcttatttgg	aggtgggtgca	caatctcttg	acagagaaga	actatttggg	1500
gaatcgctct	caggaaaggc	ttcaaggagc	cttgacacgc	atattcctgg	ccctgggtggc	1560
attgaaggcg	taaaaggggc	agcatctgga	gttgttggtg	aattagcacg	agccaggtcg	1620
gcactagatg	aaagagggca	gaaacttggt	gatctggaag	aaagaactgc	ggccatgtta	1680
tcaagtgcag	agtcattttc	taaacatgct	catgagatta	tgttgaaata	caaagataag	1740
aagtgggtacc	agttctgaca	accagaatcc	aataagtcga	acttcagcca	gaaggaaaaa	1800
agttttccat	ttttattaca	ttcttttaga	aagtttaacgt	ttaaaggatg	ttcgtcactg	1860
aatactgttc	tttcttagca	cagtcagtga	ctgttttacc	tcagtcagtgt	ggctttaact	1920

```

gaggagtgtt cacacgcact cgaaatggag tatatggtgt gtgccagtta tgagttgacc 1980
atttgggaat taaacaggtc acacgtgaca gatgaagaaa ccaagggggc tgctgaggag 2040
acctggtgca gggactaatc ctggatcatt cctgtattaa actttcatat gccaaaaggg 2100
tttgtgccgt tttatctgcc atcagtgttt gacctgttta gggcagaggc aataagtcag 2160
aagtcttgaa gttgaaatag ttatatgtgt gtcattggac tggattataa acagctgtct 2220
tggaactttcc ctctcttaac actgactggt catcagtatc attagtgaag aagaaacaaa 2280
ttgtttgtta tcatctcttt agacagataa gctgaatggt gggctttaaa taataaaaac 2340
atacacatag ttgactttgt tatgagctac tcttggattc ttgttattat agacttgtat 2400
ttagttcata ttttgtcaaa agcaaaacaa gaagatacat cacttttcat tgaagagaaa 2460
agtgtagagc atgactgaat tgctcatcat tctgggagtt tccatgtagt ggctatgcag 2520
tgtggaagt gagaaaaacc tccattgtgg tgaggagaat acttcaatgt cccttgctct 2580
tgttctcatt aattcagcta aaggtggatt tgaccaaatt aatgctggtt aaattttag 2640
aaatgttgaa attggctgtg ttttaaattt tgcttgaatt tttataaaat gtttaaccaa 2700
atgtaccttt gcattcttta attaaaattg cttaaaaaaa aactttcatt atttcagtaa 2760
aatgctcagc tcccttttca aaatgccctt tatttgcata ctgttccaat acactcaggt 2820
gatgagccaa ttaaatggta gtgcacatgc tattcgcata ggaaaattac aagcatct 2878

```

<210> 60

<211> 510

<212> DNA

<213> Homo sapiens

<400> 60

```

gcacagactc tcctggcccc ctgtcctttt ggaaagaaga cagggatgaa atataatcaa 60
gcaattaacc acccccatca tcaccaagaa caacagtatc aacaagaaga acaggggacaa 120
caaaacccac ggatgaaaca ttctttcttc agctcagatc ttatctggtg cgttctctct 180
ctgctctgtc ttggtgtgtg gtttagagaa acatggacaa cgctgttttg aagaacaggg 240
cttcccagga atcaacaatg cccaagaagg aagggtattg agaaatagct taaccctttc 300
atttaccaac gtggaaattg aagcccaggg aagggaaggg accggtcgtg gaaggagag 360
ccatcagcag aaagagaccc tgagatcttc gcctgggatt cccaggaagt ccagcccag 420
ctgattcaca gaataaatgc atgcaaacct tgctatcaat aaattacaca tgcacttacg 480
taaaacmcaa aaaaaaaaaa aaaaaaaaaa 510

```

<210> 61

<211> 495

<212> PRT

<213> Homo sapiens

<400> 61

```

Met Ser Met Leu Val Val Phe Leu Leu Leu Trp Gly Val Thr Trp Gly
  1             5             10             15

Pro Val Thr Glu Ala Ala Ile Phe Tyr Glu Thr Gln Pro Ser Leu Trp
          20             25             30

Ala Glu Ser Glu Ser Leu Leu Lys Pro Leu Ala Asn Val Thr Leu Thr
          35             40             45

Cys Gln Ala Arg Leu Glu Thr Pro Asp Phe Gln Leu Phe Lys Asn Gly
          50             55             60

Val Ala Gln Glu Pro Val His Leu Asp Ser Pro Ala Ile Lys His Gln
          65             70             75             80

Phe Leu Leu Thr Gly Asp Thr Gln Gly Arg Tyr Arg Cys Arg Ser Gly
          85             90             95

```

Leu Ser Thr Gly Trp Thr Gln Leu Ser Lys Leu Leu Glu Leu Thr Gly
 100 105 110
 Pro Lys Ser Leu Pro Ala Pro Trp Leu Ser Met Ala Pro Val Ser Trp
 115 120 125
 Ile Thr Pro Gly Leu Lys Thr Thr Ala Val Cys Arg Gly Val Leu Arg
 130 135 140
 Gly Val Thr Phe Leu Leu Arg Arg Glu Gly Asp His Glu Phe Leu Glu
 145 150 155 160
 Val Pro Glu Gly Gln Glu Asp Val Glu Ala Thr Phe Pro Val His Gln
 165 170 175
 Pro Gly Asn Tyr Ser Cys Ser Tyr Arg Thr Asp Gly Glu Gly Ala Leu
 180 185 190
 Ser Glu Pro Ser Ala Thr Val Thr Ile Glu Glu Leu Ala Ala Pro Pro
 195 200 205
 Pro Pro Val Leu Met His His Gly Glu Ser Ser Gln Val Leu His Pro
 210 215 220
 Gly Asn Lys Val Thr Leu Thr Cys Val Ala Pro Leu Ser Gly Val Asp
 225 230 235 240
 Phe Gln Leu Arg Arg Gly Glu Lys Glu Leu Leu Val Pro Arg Ser Ser
 245 250 255
 Thr Ser Pro Asp Arg Ile Phe Phe His Leu Asn Ala Val Ala Leu Gly
 260 265 270
 Asp Gly Gly His Tyr Thr Cys Arg Tyr Arg Leu His Asp Asn Gln Asn
 275 280 285
 Gly Trp Ser Gly Asp Ser Ala Pro Val Glu Leu Ile Leu Ser Asp Glu
 290 295 300
 Thr Leu Pro Ala Pro Glu Phe Ser Pro Glu Pro Glu Ser Gly Arg Ala
 305 310 315 320
 Leu Arg Leu Arg Cys Leu Ala Pro Leu Glu Gly Ala Arg Phe Ala Leu
 325 330 335
 Val Arg Glu Asp Arg Gly Gly Arg Arg Val His Arg Phe Gln Ser Pro
 340 345 350
 Ala Gly Thr Glu Ala Leu Phe Glu Leu His Asn Ile Ser Val Ala Asp
 355 360 365
 Ser Ala Asn Tyr Ser Cys Val Tyr Val Asp Leu Lys Pro Pro Phe Gly
 370 375 380
 Gly Ser Ala Pro Ser Glu Arg Leu Glu Leu His Val Asp Gly Pro Pro
 385 390 395 400

35

Pro Arg Pro Gln Leu Arg Ala Thr Trp Ser Gly Ala Val Leu Ala Gly
 405 410 415

Arg Asp Ala Val Leu Arg Cys Glu Gly Pro Ile Pro Asp Val Thr Phe
 420 425 430

Glu Leu Leu Arg Glu Gly Glu Thr Lys Ala Val Lys Thr Val Arg Thr
 435 440 445

Pro Gly Ala Ala Ala Asn Leu Glu Leu Ile Phe Val Gly Pro Gln His
 450 455 460

Ala Gly Asn Tyr Arg Cys Arg Tyr Arg Ser Trp Val Pro His Thr Phe
 465 470 475 480

Glu Ser Glu Leu Ser Asp Pro Val Glu Leu Leu Val Ala Glu Ser
 485 490 495

<210> 62
 <211> 419
 <212> PRT
 <213> Homo sapiens

<400> 62
 Met Ser Cys Ala Gly Arg Ala Gly Pro Ala Arg Leu Ala Ala Leu Ala
 1 5 10 15

Leu Leu Thr Cys Ser Leu Trp Pro Ala Arg Ala Asp Asn Ala Ser Gln
 20 25 30

Glu Tyr Tyr Thr Ala Leu Ile Asn Val Thr Val Gln Glu Pro Gly Arg
 35 40 45

Gly Ala Pro Leu Thr Phe Arg Ile Asp Arg Gly Arg Tyr Gly Leu Asp
 50 55 60

Ser Pro Lys Ala Glu Val Arg Gly Gln Val Leu Ala Pro Leu Pro Leu
 65 70 75 80

His Gly Val Ala Asp His Leu Gly Cys Asp Pro Gln Thr Arg Phe Phe
 85 90 95

Val Pro Pro Asn Ile Lys Gln Trp Ile Ala Leu Leu Gln Arg Gly Asn
 100 105 110

Cys Thr Phe Lys Glu Lys Ile Ser Arg Ala Ala Phe His Asn Ala Val
 115 120 125

Ala Val Val Ile Tyr Asn Asn Lys Ser Lys Glu Glu Pro Val Thr Met
 130 135 140

Thr His Pro Gly Thr Gly Asp Ile Ile Ala Val Met Ile Thr Glu Leu
 145 150 155 160

Arg Gly Lys Asp Ile Leu Ser Tyr Leu Glu Lys Asn Ile Ser Val Gln
 165 170 175

36

Met Thr Ile Ala Val Gly Thr Arg Met Pro Pro Lys Asn Phe Ser Arg
180 185 190

Gly Ser Leu Val Phe Val Ser Ile Ser Phe Ile Val Leu Met Ile Ile
195 200 205

Ser Ser Ala Trp Leu Ile Phe Tyr Phe Ile Gln Lys Ile Arg Tyr Thr
210 215 220

Asn Ala Arg Asp Arg Asn Gln Arg Arg Leu Gly Asp Ala Ala Lys Lys
225 230 235 240

Ala Ile Ser Lys Leu Thr Thr Arg Thr Val Lys Lys Gly Asp Lys Glu
245 250 255

Thr Asp Pro Asp Phe Asp His Cys Ala Val Cys Ile Glu Ser Tyr Lys
260 265 270

Gln Asn Asp Val Val Arg Ile Leu Pro Cys Lys His Val Phe His Lys
275 280 285

Ser Cys Val Asp Pro Trp Leu Ser Glu His Cys Thr Cys Pro Met Cys
290 295 300

Lys Leu Asn Ile Leu Lys Ala Leu Gly Ile Val Pro Asn Leu Pro Cys
305 310 315 320

Thr Asp Asn Val Ala Phe Asp Met Glu Arg Leu Thr Arg Thr Gln Ala
325 330 335

Val Asn Arg Arg Ser Ala Leu Gly Asp Leu Ala Gly Asp Asn Ser Leu
340 345 350

Gly Leu Glu Pro Leu Arg Thr Ser Gly Ile Ser Pro Leu Pro Gln Asp
355 360 365

Gly Glu Leu Thr Pro Arg Thr Gly Glu Ile Asn Ile Ala Val Thr Lys
370 375 380

Glu Trp Phe Ile Ile Ala Ser Phe Gly Leu Leu Ser Ala Leu Thr Leu
385 390 395 400

Cys Tyr Met Ile Ile Arg Ala Thr Ala Ser Leu Asn Ala Asn Glu Val
405 410 415

Glu Trp Phe

<210> 63

<211> 159

<212> PRT

<213> Homo sapiens

<400> 63

Met Ala Gly Pro Gly Trp Thr Leu Leu Leu Leu Leu Leu Leu Leu
1 5 10 15

37

Leu Leu Gly Ser Met Ala Gly Tyr Gly Pro Gln Lys Lys Leu Asn Leu
 20 25 30
 Ser His Lys Gly Ile Gly Glu Pro Cys Gly Arg His Glu Glu Cys Gln
 35 40 45
 Ser Asn Cys Cys Thr Ile Asn Ser Leu Ala Pro His Thr Leu Cys Thr
 50 55 60
 Pro Lys Thr Ile Phe Leu Gln Cys Leu Pro Trp Arg Lys Pro Asn Gly
 65 70 75 80
 Tyr Arg Cys Ser His Asp Ser Glu Cys Gln Ser Ser Cys Cys Val Arg
 85 90 95
 Asn Asn Ser Pro Gln Glu Leu Cys Thr Pro Gln Ser Val Phe Leu Gln
 100 105 110
 Cys Val Pro Trp Arg Lys Pro Asn Gly Asp Phe Cys Ser Ser His Gln
 115 120 125
 Glu Cys His Ser Gln Cys Cys Ile Gln Leu Arg Glu Tyr Ser Pro Phe
 130 135 140
 Arg Cys Ile Pro Arg Thr Gly Ile Leu Ala Gln Cys Leu Pro Leu
 145 150 155

<210> 64

<211> 122

<212> PRT

<213> Homo sapiens

<400> 64

Met Thr Thr Ala Ser Ser Leu Ile Ser Pro Phe Phe Pro Leu Pro Pro
 1 5 10 15
 Pro Ala His Phe Ser Gln Cys Arg Met Thr Phe Cys Leu Phe Val Leu
 20 25 30
 Phe Cys Leu Arg Trp Ser Leu Ala Leu Leu Pro Arg Val Glu Cys Ser
 35 40 45
 Gly Ala Ile Ser Ala His Cys Asn Leu His Leu Pro Gly Ser Ser Gly
 50 55 60
 Phe Ser Cys Leu Ser Leu Leu Ser Ser Trp Asp Tyr Arg His Ala Pro
 65 70 75 80
 Pro Cys Pro Asp Asn Phe Cys Ile Phe Ser Arg Asp Gly Val Ser Leu
 85 90 95
 Cys Trp Pro Gly Trp Ser Arg Thr Pro Asp Leu Val Val His Pro Pro
 100 105 110
 Arg Pro Pro Lys Ala Leu Gly Leu Gln Ala
 115 120

<210> 65
 <211> 464
 <212> PRT
 <213> Homo sapiens

<400> 65

```

Met Val Arg Leu Ala Ala Glu Leu Leu Leu Leu Gly Leu Leu Leu
  1           5           10           15

Leu Thr Leu His Ile Thr Val Leu Arg Gly Ser Gly Ala Ala Asp Gly
          20           25           30

Pro Asp Ala Ala Ala Gly Asn Ala Ser Gln Ala Gln Leu Gln Asn Asn
      35           40           45

Leu Asn Val Gly Ser Asp Thr Thr Ser Glu Thr Ser Phe Ser Leu Ser
      50           55           60

Lys Glu Ala Pro Arg Glu His Leu Asp His Gln Ala Ala His Gln Pro
      65           70           75           80

Phe Pro Arg Pro Arg Phe Arg Gln Glu Thr Gly His Pro Ser Leu Gln
          85           90           95

Arg Asp Phe Pro Arg Ser Phe Leu Leu Asp Leu Pro Asn Phe Pro Asp
      100           105           110

Leu Ser Lys Ala Asp Ile Asn Gly Gln Asn Pro Asn Ile Gln Val Thr
      115           120           125

Ile Glu Val Val Asp Gly Pro Asp Ser Glu Ala Asp Lys Asp Gln His
      130           135           140

Pro Glu Asn Lys Pro Ser Trp Ser Val Pro Ser Pro Asp Trp Arg Ala
      145           150           155           160

Trp Trp Gln Arg Ser Leu Ser Leu Ala Arg Ala Asn Ser Gly Asp Gln
          165           170           175

Asp Tyr Lys Tyr Asp Ser Thr Ser Asp Asp Ser Asn Phe Leu Asn Pro
          180           185           190

Pro Arg Gly Trp Asp His Thr Ala Pro Gly His Arg Thr Phe Glu Thr
          195           200           205

Lys Asp Gln Pro Glu Tyr Asp Ser Thr Asp Gly Glu Gly Asp Trp Ser
          210           215           220

Leu Trp Ser Val Cys Ser Val Thr Cys Gly Asn Gly Asn Gln Lys Arg
      225           230           235           240

Thr Arg Ser Cys Gly Tyr Ala Cys Thr Ala Thr Glu Ser Arg Thr Cys
          245           250           255

Asp Arg Pro Asn Cys Pro Gly Ile Glu Asp Thr Phe Arg Thr Ala Ala
          260           265           270

```

Thr Glu Val Ser Leu Leu Ala Gly Ser Glu Glu Phe Asn Ala Thr Lys
 275 280 285
 Leu Phe Glu Val Asp Thr Asp Ser Cys Glu Arg Trp Met Ser Cys Lys
 290 295 300
 Ser Glu Phe Leu Lys Lys Tyr Met His Lys Val Met Asn Asp Leu Pro
 305 310 315 320
 Ser Cys Pro Cys Ser Tyr Pro Thr Glu Val Ala Tyr Ser Thr Ala Asp
 325 330 335
 Ile Phe Asp Arg Ile Lys Arg Lys Asp Phe Arg Trp Lys Asp Ala Ser
 340 345 350
 Gly Pro Lys Glu Lys Leu Glu Ile Tyr Lys Pro Thr Ala Arg Tyr Cys
 355 360 365
 Ile Arg Ser Met Leu Ser Leu Glu Ser Thr Thr Leu Ala Ala Gln His
 370 375 380
 Cys Cys Tyr Gly Asp Asn Met Gln Leu Ile Thr Arg Gly Lys Gly Ala
 385 390 395 400
 Gly Thr Pro Asn Leu Ile Ser Thr Glu Phe Ser Ala Glu Leu His Tyr
 405 410 415
 Lys Val Asp Val Leu Pro Trp Ile Ile Cys Lys Gly Asp Trp Ser Arg
 420 425 430
 Tyr Asn Glu Ala Arg Pro Pro Asn Asn Gly Gln Lys Cys Thr Glu Ser
 435 440 445
 Pro Ser Asp Glu Asp Tyr Ile Lys Gln Phe Gln Glu Ala Arg Glu Tyr
 450 455 460

<210> 66

<211> 178

<212> PRT

<213> Homo sapiens

<400> 66

Met His Arg Pro Glu Ala Met Leu Leu Leu Leu Thr Leu Ala Leu Leu
 1 5 10 15
 Gly Gly Pro Thr Trp Ala Gly Lys Met Tyr Gly Pro Gly Gly Gly Lys
 20 25 30
 Tyr Phe Ser Thr Thr Glu Asp Tyr Asp His Glu Ile Thr Gly Leu Arg
 35 40 45
 Val Ser Val Gly Leu Leu Leu Val Lys Ser Val Gln Val Lys Leu Gly
 50 55 60

40

Asp Ser Trp Asp Val Lys Leu Gly Ala Leu Gly Gly Asn Thr Gln Glu
 65 70 75 80
 Val Thr Leu Gln Pro Gly Glu Tyr Ile Thr Lys Val Phe Val Ala Phe
 85 90 95
 Gln Ala Phe Leu Arg Gly Met Val Met Tyr Thr Ser Lys Asp Arg Tyr
 100 105 110
 Phe Tyr Phe Gly Lys Leu Asp Gly Gln Ile Ser Ser Ala Tyr Pro Ser
 115 120 125
 Gln Glu Gly Gln Val Leu Val Gly Ile Tyr Gly Gln Tyr Gln Leu Leu
 130 135 140
 Gly Ile Lys Ser Ile Gly Phe Glu Trp Asn Tyr Pro Leu Glu Glu Pro
 145 150 155 160
 Thr Thr Glu Pro Pro Val Asn Leu Thr Tyr Ser Ala Asn Ser Pro Val
 165 170 175
 Gly Arg

<210> 67
 <211> 110
 <212> PRT
 <213> Homo sapiens

<400> 67
 Met Arg Trp Pro Cys Pro Thr Ser Lys Pro Ala Pro Pro Pro Val Leu
 1 5 10 15
 Trp Ser His Leu Cys Gln His Arg Trp Gly Leu Thr Pro Ala Ser Thr
 20 25 30
 Leu Leu Cys Trp Leu Leu Leu Phe Asn Leu Gly Thr Cys Leu Ser Phe
 35 40 45
 Ser His Leu Lys Gln Asn Asn Asn Asn Ser Asn Thr Ser Lys Ile Ser
 50 55 60
 Phe Asp Pro Ala Ser Leu Cys Trp Val Ile Ile Ser Leu Ser Phe Pro
 65 70 75 80
 Pro Phe Pro Ser Lys His Leu Lys Arg Val Val Tyr Thr Gln His Ser
 85 90 95
 Pro Phe Pro His Tyr Pro Leu Thr Pro Gln Pro Ala Ala Ile
 100 105 110

<210> 68
 <211> 86
 <212> PRT
 <213> Homo sapiens

41

<220>

<221> SITE

<222> (71)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 68

Met Leu Ala Ala Ala Pro Leu His Glu Gln Lys Gln Met Ile Gly Thr
 1 5 10 15

Cys Tyr Leu Val Leu Lys Arg Trp Ser Asp Trp Met Val Leu Ser Phe
 20 25 30

Leu Pro Leu Leu Leu Ser Cys Asp Phe Glu Gly Ser Val Ser Thr Pro
 35 40 45

Leu Ser Met Met Ser Thr Pro Ser Trp Leu Ala Arg Ser Arg Ala Cys
 50 55 60

Cys Trp Arg Leu Thr Thr Xaa Ser Cys Cys Ser Cys Trp Ser Leu Gln
 65 70 75 80

Asn Pro Ser Met Pro Arg
 85

<210> 69

<211> 86

<212> PRT

<213> Homo sapiens

<400> 69

Met Leu Thr Ala Val Lys Met Phe Arg Leu Ser Ala Val Thr Leu Cys
 1 5 10 15

Ala Phe Ser Leu Thr Leu His Ser Gly Val Gln Leu Cys Glu Gln Leu
 20 25 30

Val Leu Arg Ile Ala Leu Phe Gln Asn Cys Arg Ala Glu Asp Gly Phe
 35 40 45

Gly Leu Arg Val Cys Trp Arg Arg Leu Met Arg Ser Phe Cys Arg Ser
 50 55 60

Ala Lys Phe Trp Gly Ser Asn Asp Leu Arg Thr Trp Gly Ser Arg Phe
 65 70 75 80

Leu Trp Lys Asp Cys Thr
 85

<210> 70

<211> 376

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 70

Met	Gly	Leu	Leu	Ala	Phe	Leu	Lys	Thr	Gln	Phe	Val	Leu	His	Leu	Leu	1	5	10	15
Val	Gly	Phe	Val	Phe	Val	Val	Ser	Gly	Leu	Val	Ile	Asn	Xaa	Val	Gln	20	25	30	
Leu	Cys	Thr	Leu	Ala	Leu	Trp	Pro	Val	Ser	Lys	Gln	Leu	Tyr	Arg	Arg	35	40	45	
Leu	Asn	Cys	Arg	Leu	Ala	Tyr	Ser	Leu	Trp	Ser	Gln	Leu	Val	Met	Leu	50	55	60	
Leu	Glu	Trp	Trp	Ser	Cys	Thr	Glu	Cys	Thr	Leu	Phe	Thr	Asp	Gln	Ala	65	70	75	80
Thr	Val	Glu	Arg	Phe	Gly	Lys	Glu	His	Ala	Val	Ile	Ile	Leu	Asn	His	85	90	95	
Asn	Phe	Glu	Ile	Asp	Phe	Leu	Cys	Gly	Trp	Thr	Met	Cys	Glu	Arg	Phe	100	105	110	
Gly	Val	Leu	Gly	Ser	Ser	Lys	Val	Leu	Ala	Lys	Lys	Glu	Leu	Leu	Tyr	115	120	125	
Val	Pro	Leu	Ile	Gly	Trp	Thr	Trp	Tyr	Phe	Leu	Glu	Ile	Val	Phe	Cys	130	135	140	
Lys	Arg	Lys	Trp	Glu	Glu	Asp	Arg	Asp	Thr	Val	Val	Glu	Gly	Leu	Arg	145	150	155	160
Arg	Leu	Ser	Asp	Tyr	Pro	Glu	Tyr	Met	Trp	Phe	Leu	Leu	Tyr	Cys	Glu	165	170	175	
Gly	Thr	Arg	Phe	Thr	Glu	Thr	Lys	His	Arg	Val	Ser	Met	Glu	Val	Ala	180	185	190	
Ala	Ala	Lys	Gly	Leu	Pro	Val	Leu	Lys	Tyr	His	Leu	Leu	Pro	Arg	Thr	195	200	205	
Lys	Gly	Phe	Thr	Thr	Ala	Val	Lys	Cys	Leu	Arg	Gly	Thr	Val	Ala	Ala	210	215	220	
Val	Tyr	Asp	Val	Thr	Leu	Asn	Phe	Arg	Gly	Asn	Lys	Asn	Pro	Ser	Leu	225	230	235	240
Leu	Gly	Ile	Leu	Tyr	Gly	Lys	Lys	Tyr	Glu	Ala	Asp	Met	Cys	Val	Arg	245	250	255	
Arg	Phe	Pro	Leu	Glu	Asp	Ile	Pro	Leu	Asp	Glu	Lys	Glu	Ala	Ala	Gln	260	265	270	
Trp	Leu	His	Lys	Leu	Tyr	Gln	Glu	Lys	Asp	Ala	Leu	Gln	Glu	Ile	Tyr	275	280	285	
Asn	Gln	Lys	Gly	Met	Phe	Pro	Gly	Glu	Gln	Phe	Lys	Pro	Ala	Arg	Arg				

43

290 295 300
 Pro Trp Thr Leu Leu Asn Phe Leu Ser Trp Ala Thr Ile Leu Leu Ser
 305 310 315 320
 Pro Leu Phe Ser Phe Val Leu Gly Val Phe Ala Ser Gly Ser Pro Leu
 325 330 335
 Leu Ile Leu Thr Phe Leu Gly Phe Val Gly Ala Ala Ser Phe Gly Val
 340 345 350
 Arg Arg Leu Ile Gly Val Thr Glu Ile Glu Lys Gly Ser Ser Tyr Gly
 355 360 365
 Asn Gln Glu Phe Lys Lys Lys Glu
 370 375

<210> 71

<211> 186

<212> PRT

<213> Homo sapiens

<400> 71

Met Arg Thr Leu Val Glu Leu Gly Pro Trp Ala Gly Asp Phe Gly Pro
 1 5 10 15
 Asp Leu Leu Leu Thr Leu Leu Phe Leu Leu Phe Leu Ala His Gly Val
 20 25 30
 Thr Leu Asp Gly Ala Ser Ala Asn Pro Thr Val Ser Leu Gln Glu Phe
 35 40 45
 Leu Met Ala Glu Gln Ser Leu Pro Gly Thr Leu Leu Lys Leu Ala Ala
 50 55 60
 Gln Gly Leu Gly Met Gln Ala Ala Cys Thr Leu Met Arg Leu Cys Trp
 65 70 75 80
 Ala Trp Glu Leu Ser Asp Leu His Leu Leu Gln Ser Leu Met Ala Gln
 85 90 95
 Ser Cys Ser Ser Ala Leu Arg Thr Ser Val Pro His Gly Ala Leu Leu
 100 105 110
 Glu Ala Ala Cys Thr Phe Cys Phe His Leu Thr Leu Leu His Leu Arg
 115 120 125
 His Ser Pro Pro Ala Tyr Ser Gly Pro Ala Val Ala Leu Leu Val Thr
 130 135 140
 Val Thr Ala Tyr Thr Ala Gly Pro Phe Thr Ser Ala Phe Phe Asn Pro
 145 150 155 160
 Ala Leu Ala Ala Ser Val Thr Phe Ala Cys Ser Asp Thr Pro Tyr Trp
 165 170 175
 Ser Thr Cys Arg Cys Thr Gly Trp Ala Leu

44

180

185

<210> 72
 <211> 97
 <212> PRT
 <213> Homo sapiens

<400> 72
 Met Cys Lys Gly Leu Lys Asn Pro Glu Gly Leu Leu Leu Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Phe Thr Asp Thr Ser Asn Ser His Cys Leu Pro Pro Tyr
 20 25 30
 Leu Ser Cys Phe Leu His Glu Arg Gln Pro Glu Leu Gln Ser Val Cys
 35 40 45
 Ile Ser Ala Ala Tyr Val Leu Ala Thr Pro Pro Glu Pro Ser Phe Ile
 50 55 60
 Leu Val Gly Phe Ser Glu Ala Gly Phe Ala Gln Val Ala Cys Phe Leu
 65 70 75 80
 Lys Tyr Leu Phe Cys Arg Pro Phe Thr Arg His Gly Tyr Phe Tyr Ser
 85 90 95

Gly

<210> 73
 <211> 156
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (92)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (114)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (122)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (134)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 73
 Met Leu Gln Gly His Ser Ser Val Phe Gln Ala Leu Leu Gly Thr Phe

1						5						10						15
Phe	Thr	Trp	Gly	Met	Thr	Ala	Ala	Gly	Ala	Ala	Leu	Val	Phe	Val	Phe			
			20				25						30					
Ser	Ser	Gly	Gln	Arg	Arg	Ile	Leu	Asp	Gly	Ser	Leu	Gly	Phe	Ala	Ala			
35						40						45						
Gly	Val	Met	Leu	Ala	Ala	Ser	Tyr	Trp	Ser	Leu	Leu	Ala	Pro	Ala	Val			
50						55						60						
Glu	Met	Ala	Thr	Ser	Ser	Gly	Gly	Phe	Gly	Ala	Phe	Ala	Phe	Phe	Pro			
65				70						75			80					
Val	Ala	Val	Gly	Phe	Thr	Leu	Gly	Ala	Ala	Phe	Xaa	Tyr	Leu	Ala	Asp			
			85						90			95						
Leu	Leu	Met	Pro	His	Leu	Gly	Ala	Ala	Glu	Asp	Pro	Gln	Thr	Ala	Leu			
			100			105						110						
Ala	Xaa	Asn	Phe	Gly	Ser	Thr	Leu	Met	Xaa	Lys	Lys	Ser	Asp	Pro	Glu			
115						120						125						
Gly	Pro	Ala	Leu	Leu	Xaa	Pro	Glu	Ser	Glu	Leu	Phe	Ile	Arg	Ile	Gly			
130						135						140						
Arg	Leu	Ala	Ser	Phe	Ser	Ser	Ser	Leu	Leu	Gln	His							
145				150						155								

```
<210> 74
<211> 158
<212> PRT
<213> Homo sapiens
```

```

<400> 74
Met Thr Thr Met Ala Pro Val Gly Leu Gln Thr Arg Ile Pro Trp Leu
  1              5              10              15

Leu Cys Leu Gly Pro Pro Pro Gly Pro Cys Cys Pro Leu Ser Pro Thr
    20              25              30

Ser Thr Leu Pro His Thr Pro Thr Ala Arg Ser Leu His Pro Thr Met
    35              40              45

Ser Phe His Leu Thr Pro Met Val Gly Ala Val Pro Ala Ala Ser Ile
    50              55              60

Val Arg Ala Ala Gly Ala Val Gly Arg His Gly Val Met Gly Gly Gln
    65              70              75              80

Gly Ala Arg Gly Gly Pro Arg Ser Gly Pro Pro Ser Pro Ser Pro Ala
    85              90              95

Val Ala Val Ser Leu Ser Pro Pro Ala Glu Gly Ala Ala Phe Gly Gly
    100              105              110

Val Gly Lys Gln Val Gly Leu Ala Met Gly Ala Leu Leu His Pro Glu

```

46

115 120 125
 Ala Gln Leu Gly Val Pro Leu Ile Ser Glu Pro Thr Gln Gly Ser Ile
 130 135 140
 Pro Met Asp Arg Pro Leu Ala Trp Pro Ser Pro Thr Thr Pro
 145 150 155

<210> 75
 <211> 110
 <212> PRT
 <213> Homo sapiens

<400> 75
 Met Tyr Val Thr Leu Val Phe Arg Val Lys Gly Ser Arg Leu Val Lys
 1 5 10 15
 Pro Ser Leu Cys Leu Ala Leu Leu Cys Pro Ala Phe Leu Val Gly Val
 20 25 30
 Val Arg Val Ala Glu Tyr Arg Asn His Trp Ser Asp Val Leu Ala Gly
 35 40 45
 Phe Leu Thr Gly Ala Ala Ile Ala Thr Phe Leu Val Thr Cys Val Val
 50 55 60
 His Asn Phe Gln Ser Arg Pro Pro Ser Gly Arg Arg Leu Ser Pro Gln
 65 70 75 80
 Ser Ala Tyr Pro Arg Leu Pro Gly Pro Gln Phe Pro His Leu His Asn
 85 90 95
 Gly Gly Asp His Pro Cys Pro Ala Gly Cys Gln Glu Arg Leu
 100 105 110

<210> 76
 <211> 515
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (145)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (151)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (168)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 76

47

Met	Ala	Phe	Ser	Lys	Leu	Leu	Glu	Gln	Ala	Gly	Gly	Val	Gly	Leu	Phe	1	5	10	15
Gln	Thr	Leu	Gln	Val	Leu	Thr	Phe	Ile	Leu	Pro	Cys	Leu	Met	Ile	Pro	20	25	30	
Ser	Gln	Met	Leu	Leu	Glu	Asn	Phe	Ser	Ala	Ala	Ile	Pro	Gly	His	Arg	35	40	45	
Cys	Trp	Thr	His	Met	Leu	Asp	Asn	Gly	Ser	Ala	Val	Ser	Thr	Asn	Met	50	55	60	
Thr	Pro	Lys	Ala	Leu	Leu	Thr	Ile	Ser	Ile	Pro	Pro	Gly	Pro	Asn	Gln	65	70	75	80
Gly	Pro	His	Gln	Cys	Arg	Arg	Phe	Arg	Gln	Pro	Gln	Trp	Gln	Leu	Leu	85	90	95	
Asp	Pro	Asn	Ala	Thr	Ala	Thr	Ser	Trp	Ser	Glu	Ala	Asp	Thr	Glu	Pro	100	105	110	
Cys	Val	Asp	Gly	Trp	Val	Tyr	Asp	Arg	Ser	Val	Phe	Thr	Ser	Thr	Ile	115	120	125	
Val	Ala	Lys	Trp	Asp	Leu	Val	Cys	Ser	Ser	Gln	Gly	Leu	Lys	Pro	Leu	130	135	140	
Xaa	Gln	Ser	Ile	Phe	Met	Xaa	Gly	Ile	Leu	Val	Gly	Ser	Phe	Ile	Trp	145	150	155	160
Gly	Leu	Leu	Ser	Tyr	Arg	Phe	Xaa	Arg	Lys	Pro	Met	Leu	Ser	Trp	Cys	165	170	175	
Cys	Leu	Gln	Leu	Ala	Val	Ala	Gly	Thr	Ser	Thr	Ile	Phe	Ala	Pro	Thr	180	185	190	
Phe	Val	Ile	Tyr	Cys	Gly	Leu	Arg	Phe	Val	Ala	Ala	Phe	Gly	Met	Ala	195	200	205	
Gly	Ile	Phe	Leu	Ser	Ser	Leu	Thr	Leu	Met	Val	Glu	Trp	Thr	Thr	Thr	210	215	220	
Ser	Arg	Arg	Ala	Val	Thr	Met	Thr	Val	Val	Gly	Cys	Ala	Phe	Ser	Ala	225	230	235	240
Gly	Gln	Ala	Ala	Leu	Gly	Gly	Leu	Ala	Phe	Ala	Leu	Arg	Asp	Trp	Arg	245	250	255	
Thr	Leu	Gln	Leu	Ala	Ala	Ser	Val	Pro	Phe	Phe	Ala	Ile	Ser	Leu	Ile	260	265	270	
Ser	Trp	Trp	Leu	Pro	Glu	Ser	Ala	Arg	Trp	Leu	Ile	Ile	Lys	Gly	Lys	275	280	285	
Pro	Asp	Gln	Ala	Leu	Gln	Glu	Leu	Arg	Lys	Val	Ala	Arg	Ile	Asn	Gly	290	295	300	
His	Lys	Glu	Ala	Lys	Asn	Leu	Thr	Ile	Glu	Val	Leu	Met	Ser	Ser	Val				

48

305 310 315 320
 Lys Glu Glu Val Ala Ser Ala Lys Glu Pro Arg Ser Val Leu Asp Leu
 325 330 335
 Phe Cys Val Pro Val Leu Arg Trp Arg Ser Cys Ala Met Leu Val Val
 340 345 350
 Asn Phe Ser Leu Leu Ile Ser Tyr Tyr Gly Leu Val Phe Asp Leu Gln
 355 360 365
 Ser Leu Gly Arg Asp Ile Phe Leu Leu Gln Ala Leu Phe Gly Ala Val
 370 375 380
 Asp Phe Leu Gly Arg Ala Thr Thr Ala Leu Leu Leu Ser Phe Leu Gly
 385 390 395 400
 Arg Arg Thr Ile Gln Ala Gly Ser Gln Ala Met Gly Gly Leu Ala Ile
 405 410 415
 Leu Ala Asn Met Leu Val Pro Gln Val Arg Met Thr Ala Asp Gly Ile
 420 425 430
 Leu His Thr Val Gly Arg Leu Gly Ala Met Met Gly Pro Leu Ile Leu
 435 440 445
 Met Ser Arg Gln Ala Leu Pro Leu Leu Pro Pro Leu Leu Tyr Gly Val
 450 455 460
 Ile Ser Ile Ala Ser Ser Leu Val Val Leu Phe Phe Leu Pro Glu Thr
 465 470 475 480
 Gln Gly Leu Pro Leu Pro Asp Thr Ile Gln Asp Leu Glu Ser Gln Lys
 485 490 495
 Ser Thr Ala Ala Gln Gly Asn Arg Gln Glu Ala Val Thr Val Glu Ser
 500 505 510
 Thr Ser Leu
 515

<210> .77

<211> 200

<212> PRT

<213> Homo sapiens

<400> 77

Met Ala Met Val Pro Gly Ala Thr Leu Arg Arg Leu Leu Ser Val Val
 1 5 10 15
 Leu Pro Thr Ala Ser Gln Pro Gln Leu Leu Ala Leu Leu Asp Ser Ala
 20 25 30
 Thr Glu Arg His Val Asp His Ala Ala Glu Ser Asp Gly Gly Ala Glu
 35 40 45
 Gln Ala Asp Val Gly Arg Arg Arg Lys His Gln Ser Trp Trp Gln Ala

49

50 55 60
 Leu Asp Gly Lys Leu Arg Gly Asp Leu Ile Ser Arg Gly Leu Glu Lys
 65 70 75 80
 Met Leu Trp Ala Arg Lys Arg Lys Gln Ser Ile Leu Lys Lys Thr Cys
 85 90 95
 Leu Pro Leu Arg Glu Arg Met Ile Phe Ser Gly Lys Gly Ser Trp Pro
 100 105 110
 His Leu Ser Leu Glu Pro Ile Gly Glu Leu Gly Pro Val Pro Ile Val
 115 120 125
 Gly Ala Glu Thr Ile Asp Leu Leu Asn Thr Gly Glu Lys Leu Phe Ile
 130 135 140
 Phe Arg Asn Pro Lys Glu Pro Glu Ile Ser Leu Thr Phe Leu Gln Glu
 145 150 155 160
 Lys Glu Asp Leu Phe Glu Cys Pro Lys Gly His Glu Gly Leu Gly His
 165 170 175
 Gly Leu Ala Gln Gly Lys Asp Leu Arg Glu His Met Lys Arg Glu Gly
 180 185 190
 Met Ile Phe Ser Cys Pro Pro Val
 195 200

<210> 78

<211> 412

<212> PRT

<213> Homo sapiens

<400> 78

Met Gly Val Trp Thr Gly Arg Leu Gly Gly Trp Ala Gln Val Met Phe
 1 5 10 15
 Gln Phe Leu Ser Gln Gly Phe Tyr Cys Gly Val Gly Leu Phe Thr Arg
 20 25 30
 Phe Leu Lys Leu Leu Gly Ala Leu Leu Leu Leu Ala Leu Ala Leu Phe
 35 40 45
 Leu Gly Phe Leu Gln Leu Gly Trp Arg Phe Leu Val Gly Leu Gly Asp
 50 55 60
 Arg Leu Gly Trp Arg Asp Lys Ala Thr Trp Leu Phe Ser Trp Leu Asp
 65 70 75 80
 Ser Pro Ala Leu Gln Arg Cys Leu Thr Leu Leu Arg Asp Ser Arg Pro
 85 90 95
 Trp Gln Arg Leu Val Arg Ile Val Gln Trp Gly Trp Leu Glu Leu Pro
 100 105 110
 Trp Val Lys Gln Asn Ile Asn Arg Gln Gly Asn Ala Pro Val Ala Ser

50

115	120	125
Gly Arg Tyr Cys Gln Pro Glu Glu Glu Val Ala Arg Leu Leu Thr Met		
130	135	140
Ala Gly Val Pro Glu Asp Glu Leu Asn Pro Phe His Val Leu Gly Val		
145	150	155
Glu Ala Thr Ala Ser Asp Val Glu Leu Lys Lys Ala Tyr Arg Gln Leu		
	165	170
Ala Val Met Val His Pro Asp Lys Asn His His Pro Arg Ala Glu Glu		
	180	185
Ala Phe Lys Val Leu Arg Ala Ala Trp Asp Ile Val Ser Asn Ala Glu		
	195	200
Lys Arg Lys Glu Tyr Glu Met Lys Arg Met Ala Glu Asn Glu Leu Ser		
	210	215
Arg Ser Val Asn Glu Phe Leu Ser Lys Leu Gln Asp Asp Leu Lys Glu		
	225	230
Ala Met Asn Thr Met Met Cys Ser Arg Cys Gln Gly Lys His Arg Arg		
	245	250
Phe Glu Met Asp Arg Glu Pro Lys Ser Ala Arg Tyr Cys Ala Glu Cys		
	260	265
Asn Arg Leu His Pro Ala Glu Glu Gly Asp Phe Trp Ala Glu Ser Ser		
	275	280
Met Leu Gly Leu Lys Ile Thr Tyr Phe Ala Leu Met Asp Gly Lys Val		
	290	295
Tyr Asp Ile Thr Gln Trp Ala Gly Cys Gln Arg Val Gly Ile Ser Pro		
	305	310
Asp Thr His Arg Val Pro Tyr His Ile Ser Phe Gly Ser Arg Ile Pro		
	325	330
Gly Thr Arg Gly Arg Gln Arg Ala Thr Pro Asp Ala Pro Pro Ala Asp		
	340	345
Leu Gln Asp Phe Leu Ser Arg Ile Phe Gln Val Pro Pro Gly Gln Met		
	355	360
Pro Asn Gly Asn Phe Phe Ala Ala Pro Gln Pro Ala Pro Gly Ala Ala		
	370	375
Ala Ala Ser Lys Pro Asn Ser Thr Val Pro Lys Gly Glu Ala Lys Pro		
	385	390
Lys Arg Arg Lys Lys Val Arg Arg Pro Phe Gln Arg		
	405	410

<210> 79

51

<211> 246

<212> PRT

<213> Homo sapiens

<400> 79

```

Met Ala Leu Phe Arg Cys Val Trp Ser Val Leu Ser Ala Leu Gly Lys
  1           5           10           15

Ser Gly Ser Asp Leu Cys Ala Gly Cys Gly Ser Arg Leu Arg Ser Pro
      20           25           30

Phe Ser Phe Ala Tyr Val Pro Arg Cys Phe Ser Ser Thr Ala Asn Ser
      35           40           45

Tyr Pro Lys Lys Pro Leu Thr Ser Tyr Val Arg Phe Ser Lys Glu Gln
      50           55           60

Leu Pro Ile Phe Lys Ala Gln Asn Pro Asp Ala Lys Asn Ser Glu Leu
      65           70           75           80

Ile Arg Lys Ile Ala Gln Leu Trp Arg Glu Leu Pro Asp Ser Glu Lys
      85           90           95

Lys Ile Tyr Glu Asp Ala Tyr Arg Ala Asp Trp Gln Ala Tyr Lys Glu
      100          105          110

Glu Ile Asn Arg Ile Gln Glu Gln Leu Thr Pro Ser Gln Ile Val Ser
      115          120          125

Leu Glu Lys Glu Ile Gln Gln Lys Arg Leu Lys Lys Lys Ala Leu Ile
      130          135          140

Lys Lys Arg Glu Leu Thr Met Leu Gly Lys Pro Lys Arg Pro Arg Ser
      145          150          155          160

Ala Tyr Asn Ile Phe Ile Ala Glu Arg Phe Gln Glu Thr Lys Asp Gly
      165          170          175

Thr Ser Gln Val Lys Leu Lys Thr Ile Asn Glu Asn Trp Lys Asn Leu
      180          185          190

Ser Ser Ser Gln Lys Gln Val Tyr Ile Gln Leu Ala Asn Asp Asp Lys
      195          200          205

Ile Arg Tyr Tyr Asn Glu Met Lys Ser Trp Glu Glu Gln Met Met Glu
      210          215          220

Val Gly Arg Lys Asp Leu Leu Arg Arg Thr Val Lys His Gln Arg Lys
      225          230          235          240

Val Asp Pro Glu Glu Tyr
      245

```

<210> 80

<211> 490

<212> PRT

<213> Homo sapiens

52

<400> 80
Met Gly Lys Asn Lys Tyr Cys Phe Asp Phe Gly Ile Ser Ser Arg Ser
1 5 10 15
His Phe Ser Ala Lys Glu Glu Cys Met Leu Ile Gln Arg Asn Thr Ala
20 25 30
Phe Gln Pro Ser Ser Pro Ser Pro Leu Gln Pro Gln Gly Pro Val Lys
35 40 45
Ser Asn Asn Ile Val Thr Val Thr Gly Ile Ser Leu Cys Leu Phe Ile
50 55 60
Ile Ile Ala Thr Val Leu Ile Thr Leu Trp Arg Arg Phe Gly Arg Pro
65 70 75 80
Ala Lys Cys Ser Thr Pro Ala Arg His Asn Ser Ile His Ser Pro Ser
85 90 95
Phe Arg Lys Asn Ser Asp Glu Glu Asn Ile Cys Glu Leu Ser Glu Gln
100 105 110
Arg Gly Ser Phe Ser Asp Gly Gly Asp Gly Pro Thr Gly Ser Pro Gly
115 120 125
Asp Thr Gly Ile Pro Leu Thr Tyr Arg Arg Ser Gly Pro Val Pro Pro
130 135 140
Glu Asp Asp Ala Ser Gly Ser Glu Ser Phe Gln Ser Asn Ala Gln Lys
145 150 155 160
Ile Ile Pro Pro Leu Phe Ser Tyr Arg Leu Ala Gln Gln Gln Leu Lys
165 170 175
Glu Met Lys Lys Lys Gly Leu Thr Glu Thr Thr Lys Val Tyr His Val
180 185 190
Ser Gln Ser Pro Leu Thr Asp Thr Ala Ile Asp Ala Ala Pro Ser Ala
195 200 205
Pro Leu Asp Leu Glu Ser Pro Glu Glu Ala Ala Ala Asn Lys Phe Arg
210 215 220
Ile Lys Ser Pro Phe Pro Glu Gln Pro Ala Val Ser Ala Gly Glu Arg
225 230 235 240
Pro Pro Ser Arg Leu Asp Leu Asn Val Thr Gln Ala Ser Cys Ala Ile
245 250 255
Ser Pro Ser Gln Thr Leu Ile Arg Lys Ser Gln Ala Arg His Val Gly
260 265 270
Ser Arg Gly Gly Pro Ser Glu Arg Ser His Ala Arg Asn Ala His Phe
275 280 285
Arg Arg Thr Ala Ser Phe His Glu Ala Arg Gln Ala Arg Pro Phe Arg
290 295 300

Glu Arg Ser Met Ser Thr Leu Thr Pro Arg Gln Ala Pro Ala Tyr Ser
 305 310 315 320
 Ser Arg Thr Arg Thr Cys Glu Gln Ala Glu Asp Arg Phe Arg Pro Gln
 325 330 335
 Ser Arg Gly Ala His Leu Phe Pro Glu Lys Leu Glu His Phe Gln Glu
 340 345 350
 Ala Ser Gly Thr Arg Gly Pro Leu Asn Pro Leu Pro Lys Ser Tyr Thr
 355 360 365
 Leu Gly Gln Pro Leu Arg Lys Pro Asp Leu Gly Asp His Gln Ala Gly
 370 375 380
 Leu Val Ala Gly Ile Glu Arg Thr Glu Pro His Arg Ala Arg Arg Gly
 385 390 395 400
 Pro Ser Pro Ser His Lys Ser Val Ser Arg Lys Gln Ser Ser Pro Ile
 405 410 415
 Ser Pro Lys Asp Asn Tyr Gln Arg Val Ser Ser Leu Ser Pro Ser Gln
 420 425 430
 Cys Arg Lys Asp Lys Cys Gln Ser Phe Pro Thr His Pro Glu Phe Ala
 435 440 445
 Phe Tyr Asp Asn Thr Ser Phe Gly Leu Thr Glu Ala Glu Gln Arg Met
 450 455 460
 Leu Asp Leu Pro Gly Tyr Phe Gly Ser Asn Glu Glu Asp Glu Thr Thr
 465 470 475 480
 Ser Thr Leu Ser Val Glu Lys Leu Val Ile
 485 490

<210> 81

<211> 81

<212> PRT

<213> Homo sapiens

<400> 81

Met Asp Trp Trp Phe Leu Ala Ile Ala Met Ala Leu Leu Trp Leu Thr
 1 5 10 15
 Thr Ser Arg Lys Gln Cys Cys Ser Thr Trp Ala Leu Leu Asn Tyr Met
 20 25 30
 Ala Leu Met Ile Leu Ile Gly Glu Asn Pro Asp Leu Leu Val Asn Leu
 35 40 45
 Asp Ser Leu Gln Glu Pro Val Cys Val Ile Leu Val Lys Gly Leu Leu
 50 55 60
 Phe Gln Arg Ile Ala Ala Asn Leu Gln Pro Leu Gln Arg Cys Gln Gly
 65 70 75 80

Ser

<210> 82

<211> 49

<212> PRT

<213> Homo sapiens

<400> 82

Met Lys His Ser Phe Leu Ser Ser Asp Leu Ile Trp Cys Val Leu Ser
 1 5 10 15

Leu Leu Cys Leu Gly Val Trp Phe Arg Glu Thr Trp Thr Thr Leu Phe
 20 25 30

Gly Arg Thr Gly Leu Pro Arg Asn Gln Gln Cys Pro Arg Arg Lys Gly
 35 40 45

Leu

<210> 83

<211> 495

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (330)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (333)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 83

Met Ser Met Leu Val Val Phe Leu Leu Leu Trp Gly Val Thr Trp Gly
 1 5 10 15

Pro Val Thr Glu Ala Ala Ile Phe Tyr Glu Thr Gln Pro Ser Leu Trp
 20 25 30

Ala Glu Ser Glu Ser Leu Leu Lys Pro Leu Ala Asn Val Thr Leu Thr
 35 40 45

Cys Gln Ala Arg Leu Glu Thr Pro Asp Phe Gln Leu Phe Lys Asn Gly
 50 55 60

Val Ala Gln Glu Pro Val His Leu Asp Ser Pro Ala Ile Lys His Gln
 65 70 75 80

Phe Leu Leu Thr Gly Asp Thr Gln Gly Arg Tyr Arg Cys Arg Ser Gly
 85 90 95

Leu Ser Thr Gly Trp Thr Gln Leu Ser Lys Leu Leu Glu Leu Thr Gly
 100 105 110
 Pro Lys Ser Leu Pro Ala Pro Trp Leu Ser Met Ala Pro Val Ser Trp
 115 120 125
 Ile Thr Pro Gly Leu Lys Thr Thr Ala Val Cys Arg Gly Val Leu Arg
 130 135 140
 Gly Val Thr Phe Leu Leu Arg Arg Glu Gly Asp His Glu Phe Leu Glu
 145 150 155 160
 Val Pro Glu Ala Gln Glu Asp Val Glu Ala Thr Phe Pro Val His Gln
 165 170 175
 Pro Gly Asn Tyr Ser Cys Ser Tyr Arg Thr Asp Gly Glu Gly Ala Leu
 180 185 190
 Ser Glu Pro Ser Ala Thr Val Thr Ile Glu Glu Leu Ala Ala Pro Pro
 195 200 205
 Pro Pro Val Leu Met His His Gly Glu Ser Ser Gln Val Leu His Pro
 210 215 220
 Gly Asn Lys Val Thr Leu Thr Cys Val Ala Pro Leu Ser Gly Val Asp
 225 230 235 240
 Phe Gln Leu Arg Arg Gly Glu Lys Glu Leu Leu Val Pro Arg Ser Ser
 245 250 255
 Thr Ser Pro Asp Arg Ile Phe Phe His Leu Asn Ala Val Ala Leu Gly
 260 265 270
 Asp Gly Gly His Tyr Thr Cys Arg Tyr Arg Leu His Asp Asn Gln Asn
 275 280 285
 Gly Trp Ser Gly Asp Ser Ala Pro Val Glu Leu Ile Leu Ser Asp Glu
 290 295 300
 Thr Leu Pro Ala Pro Glu Phe Ser Pro Glu Pro Glu Ser Gly Arg Ala
 305 310 315 320
 Leu Arg Leu Arg Cys Leu Ala Pro Leu Xaa Gly Ala Xaa Phe Ala Leu
 325 330 335
 Val Arg Glu Asp Arg Gly Gly Arg Arg Val His Arg Phe Gln Ser Pro
 340 345 350
 Ala Gly Thr Glu Ala Leu Phe Glu Leu His Asn Ile Ser Val Ala Asp
 355 360 365
 Ser Ala Asn Tyr Ser Cys Val Tyr Val Asp Leu Lys Pro Pro Phe Gly
 370 375 380
 Gly Ser Ala Pro Ser Glu Arg Leu Glu Leu His Val Asp Gly Pro Pro
 385 390 395 400
 Pro Arg Pro Gln Leu Arg Ala Thr Trp Ser Gly Ala Val Leu Ala Gly

56

405 410 415
 Arg Asp Ala Val Leu Arg Cys Glu Gly Pro Ile Pro Asp Val Thr Phe
 420 425 430
 Glu Leu Leu Arg Glu Gly Glu Thr Lys Ala Val Lys Thr Val Arg Thr
 435 440 445
 Pro Gly Ala Ala Ala Asn Leu Glu Leu Ile Phe Val Gly Pro Gln His
 450 455 460
 Ala Gly Asn Tyr Arg Cys Arg Tyr Arg Ser Trp Val Pro His Thr Phe
 465 470 475 480
 Glu Ser Glu Leu Ser Asp Pro Val Glu Leu Leu Val Ala Glu Ser
 485 490 495

 <210> 84
 <211> 419
 <212> PRT
 <213> Homo sapiens

 <400> 84
 Met Ser Cys Ala Gly Arg Ala Gly Pro Ala Arg Leu Ala Ala Leu Ala
 1 5 10 15
 Leu Leu Thr Cys Ser Leu Trp Pro Ala Arg Ala Asp Asn Ala Ser Gln
 20 25 30
 Glu Tyr Tyr Thr Ala Leu Ile Asn Val Thr Val Gln Glu Pro Gly Arg
 35 40 45
 Gly Ala Pro Leu Thr Phe Arg Ile Asp Arg Gly Arg Tyr Gly Leu Asp
 50 55 60
 Ser Pro Lys Ala Glu Val Arg Gly Gln Val Leu Ala Pro Leu Pro Leu
 65 70 75 80
 His Gly Val Ala Asp His Leu Gly Cys Asp Pro Gln Thr Arg Phe Phe
 85 90 95
 Val Pro Pro Asn Ile Lys Gln Trp Ile Ala Leu Leu Gln Arg Gly Asn
 100 105 110
 Cys Thr Phe Lys Glu Lys Ile Ser Arg Ala Ala Phe His Asn Ala Val
 115 120 125
 Ala Val Val Ile Tyr Asn Asn Lys Ser Lys Glu Glu Pro Val Thr Met
 130 135 140
 Thr His Pro Gly Thr Gly Asp Ile Ile Ala Val Met Ile Thr Glu Leu
 145 150 155 160
 Arg Gly Lys Asp Ile Leu Ser Tyr Leu Glu Lys Asn Ile Ser Val Gln
 165 170 175
 Met Thr Ile Ala Val Gly Thr Arg Met Pro Pro Lys Asn Phe Ser Arg

57

	180		185		190
Gly Ser Leu Val Phe Val Ser Ile Ser Phe Ile Val Leu Met Ile Ile	195	200	205		
Ser Ser Ala Trp Leu Ile Phe Tyr Phe Ile Gln Lys Ile Arg Tyr Thr	210	215	220		
Asn Ala Arg Asp Arg Asn Gln Arg Arg Leu Gly Asp Ala Ala Lys Lys	225	230	235	240	
Ala Ile Ser Lys Leu Thr Thr Arg Thr Val Lys Lys Gly Asp Lys Glu	245	250	255		
Thr Asp Pro Asp Phe Asp His Cys Ala Val Cys Ile Glu Ser Tyr Lys	260	265	270		
Gln Asn Asp Val Val Arg Ile Leu Pro Cys Lys His Val Phe His Lys	275	280	285		
Ser Cys Val Asp Pro Trp Leu Ser Glu His Cys Thr Cys Pro Met Cys	290	295	300		
Lys Leu Asn Ile Leu Lys Ala Leu Gly Ile Val Pro Asn Leu Pro Cys	305	310	315	320	
Thr Asp Asn Val Ala Phe Asp Met Glu Arg Leu Thr Arg Thr Gln Ala	325	330	335		
Val Asn Arg Arg Ser Ala Leu Gly Asp Leu Ala Gly Asp Asn Ser Leu	340	345	350		
Gly Leu Glu Pro Leu Arg Thr Ser Gly Ile Ser Pro Leu Pro Gln Asp	355	360	365		
Gly Glu Leu Thr Pro Arg Thr Gly Glu Ile Asn Ile Ala Val Thr Lys	370	375	380		
Glu Trp Phe Ile Ile Ala Ser Phe Gly Leu Leu Ser Ala Leu Thr Leu	385	390	395	400	
Cys Tyr Met Ile Ile Arg Ala Thr Ala Ser Leu Asn Ala Asn Glu Val	405	410	415		

Glu Trp Phe

<210> 85

<211> 112

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (52)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (64)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (67)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (68)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 85
 Met Thr Phe Cys Leu Phe Val Leu Phe Cys Leu Xaa Trp Ser Leu Ala
 1 5 10 15
 Leu Leu Pro Arg Val Glu Cys Ser Gly Ala Ile Ser Ala His Cys Asn
 20 25 30
 Leu His Leu Pro Gly Ser Gly Gly Phe Ser Cys Leu Ser Leu Leu Ser
 35 40 45
 Ser Trp Asp Xaa Arg His Ala Pro Pro Cys Pro Asp Asn Phe Cys Xaa
 50 55 60
 Phe Ser Xaa Xaa Gly Val Ser Leu Cys Trp Gln Ala Gly Leu Glu His
 65 70 75 80
 Leu Thr Arg Gly Pro Pro Ala Ser Ala Ser Gln Ser Thr Gly Ile Thr
 85 90 95
 Gly Val Ser His Pro Ala Trp Pro Arg Met Thr Phe Lys Arg Ser Asn
 100 105 110

<210> 86
 <211> 206
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (200)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 86
 Met Val Arg Leu Ala Ala Glu Leu Leu Leu Leu Gly Leu Leu Leu

59

1 5 10 15
 Leu Thr Leu His Ile Thr Val Leu Arg Gly Ser Gly Ala Ala Asp Gly
 20 25 30
 Pro Asp Ala Ala Ala Gly Asn Ala Ser Gln Ala Gln Leu Gln Asn Asn
 35 40 45
 Leu Asn Val Gly Ser Asp Thr Thr Ser Glu Thr Ser Phe Ser Leu Ser
 50 55 60
 Lys Glu Ala Pro Arg Glu His Leu Asp His Gln Ala Ala His Gln Pro
 65 70 75 80
 Phe Pro Arg Pro Arg Phe Arg Gln Glu Thr Gly His Pro Ser Leu Gln
 85 90 95
 Arg Asp Phe Pro Arg Ser Phe Leu Leu Asp Leu Pro Asn Phe Pro Asp
 100 105 110
 Leu Ser Lys Ala Asp Ile Asn Gly Gln Asn Pro Asn Ile Gln Val Thr
 115 120 125
 Ile Glu Val Val Asp Gly Pro Asp Ser Glu Ala Asp Lys Asp Gln His
 130 135 140
 Pro Glu Asn Lys Pro Ser Trp Ser Val Pro Ser Pro Asp Trp Arg Ala
 145 150 155 160
 Trp Trp Gln Arg Ser Leu Ser Leu Ala Arg Ala Asn Ser Gly Asp Gln
 165 170 175
 Asp Tyr Gln Tyr Asp Ser Thr Ser Asp Asp Ser Asn Phe Leu Asn Pro
 180 185 190
 Pro Arg Gly Trp Asp His Thr Xaa Pro Gly His Arg Asp Phe
 195 200 205

<210> 87

<211> 107

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (52)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 87

His Phe Ser Lys Gly Lys Gln Gln Asn Lys Trp Glu Lys Asp Asn Gly
 1 5 10 15
 Pro His Phe Thr Tyr Phe Asn Thr Ile Leu Thr Ile Phe Ser Ser Thr
 20 25 30
 Asn Ile Ser Pro Ile Asn Lys Tyr Lys Arg Gly Gly Gly Ser Ile Trp
 35 40 45

60

Gly Ile Leu Xaa Phe Tyr Val Leu Arg Lys Gln Lys Lys Leu His Tyr
 50 55 60

Phe Cys Lys Val Phe Ile Glu Ser Arg Ile Ile Val His Gln Ala Ile
 65 70 75 80

Val Asn Met Thr Trp Ser Tyr Gly Val Glu Leu Arg Lys Asn Lys Val
 85 90 95

Gly Ser Tyr Ser Ile Phe Tyr Phe Ala Lys Phe
 100 105

<210> 88

<211> 66

<212> PRT

<213> Homo sapiens

<400> 88

Met His Arg Pro Glu Ala Met Leu Leu Leu Thr Leu Ala Leu Leu
 1 5 10 15

Gly Gly Pro Thr Trp Ala Gly Lys Met Tyr Gly Pro Gly Gly Gly Lys
 20 25 30

Tyr Phe Ser Thr Thr Glu Asp Tyr Asp His Glu Ile Thr Gly Leu Arg
 35 40 45

Val Ser Val Gly Leu Leu Leu Val Lys Arg Phe Leu Glu Gly Val Ile
 50 55 60

Tyr Glu
 65

<210> 89

<211> 110

<212> PRT

<213> Homo sapiens

<400> 89

Met Arg Trp Pro Cys Pro Thr Ser Lys Pro Ala Pro Pro Val Leu
 1 5 10 15

Trp Ser His Leu Cys Gln His Arg Trp Gly Leu Thr Pro Ala Ser Thr
 20 25 30

Leu Leu Cys Trp Leu Leu Leu Phe Asn Leu Gly Thr Cys Leu Ser Phe
 35 40 45

Ser His Leu Lys Gln Asn Asn Asn Asn Ser Asn Thr Ser Lys Ile Ser
 50 55 60

Phe Asp Pro Ala Ser Leu Cys Trp Val Ile Ile Ser Leu Ser Phe Pro
 65 70 75 80

Pro Phe Pro Ser Lys His Leu Lys Arg Val Val Tyr Thr Gln His Ser

61

	85		90		95
Pro Phe Pro His Tyr Pro Leu Thr Pro Gln Pro Ala Ala Ile					
	100		105		110

<210> 90
 <211> 382
 <212> PRT
 <213> Homo sapiens

<400> 90
Gly Pro Glu Arg Gly Arg Tyr Tyr Pro Lys Ser His Lys Asn Val Asp
1 5 10 15
Leu Asn Asp Val Leu Val Pro Lys Pro Phe Ser Gln Phe Trp Gln Pro
20 25 30
Leu Leu Arg Gly Leu His Ser Gln Asn Phe Thr Gln Ala Leu Leu Glu
35 40 45
Arg Met Leu Ser Glu Leu Pro Ala Leu Gly Ile Ser Gly Ile Arg Pro
50 55 60
Thr Tyr Ile Leu Arg Trp Thr Val Glu Leu Ile Val Ala Asn Thr Lys
65 70 75 80
Thr Gly Arg Asn Ala Arg Arg Phe Ser Ala Gly Gln Trp Glu Ala Arg
85 90 95
Arg Gly Trp Arg Leu Phe Asn Cys Ser Ala Ser Leu Asp Trp Pro Arg
100 105 110
Met Val Glu Ser Cys Leu Gly Ser Pro Cys Trp Ala Ser Pro Gln Leu
115 120 125
Leu Arg Ile Ile Phe Lys Ala Met Gly Gln Gly Leu Pro Asp Glu Glu
130 135 140
Gln Glu Lys Leu Leu Arg Ile Cys Ser Ile Tyr Thr Gln Ser Gly Glu
145 150 155 160
Asn Ser Leu Val Gln Glu Gly Ser Glu Ala Ser Pro Ile Gly Lys Ser
165 170 175
Pro Tyr Thr Leu Asp Ser Leu Tyr Trp Ser Val Lys Pro Ala Ser Ser
180 185 190
Ser Phe Gly Ser Glu Ala Lys Ala Gln Gln Gln Glu Glu Gln Gly Ser
195 200 205
Val Asn Asp Val Lys Glu Glu Glu Lys Glu Glu Lys Glu Val Leu Pro
210 215 220
Asp Gln Val Glu Glu Glu Glu Glu Asn Asp Asp Gln Glu Glu Glu Glu
225 230 235 240
Glu Asp Glu Asp Asp Glu Asp Asp Glu Glu Glu Asp Arg Met Glu Val

62

245										250					255				
Gly	Pro	Phe	Ser	Thr	Gly	Gln	Glu	Ser	Pro	Thr	Ala	Glu	Asn	Ala	Arg				
260								265				270							
Leu	Leu	Ala	Gln	Lys	Arg	Gly	Ala	Leu	Gln	Gly	Ser	Ala	Trp	Gln	Val				
275								280				285							
Ser	Ser	Glu	Asp	Val	Arg	Trp	Asp	Thr	Phe	Pro	Leu	Gly	Arg	Met	Pro				
290												300							
Gly	Gln	Thr	Glu	Asp	Pro	Ala	Glu	Leu	Met	Leu	Glu	Asn	Tyr	Asp	Thr				
305												315							
Met	Tyr	Leu	Leu	Asp	Gln	Pro	Val	Leu	Glu	Gln	Arg	Leu	Glu	Pro	Ser				
				325								335							
Thr	Cys	Lys	Thr	Asp	Thr	Leu	Gly	Leu	Ser	Cys	Gly	Val	Gly	Ser	Gly				
				340								350							
Asn	Cys	Ser	Asn	Ser	Ser	Ser	Ser	Asn	Phe	Glu	Gly	Leu	Leu	Trp	Ser				
355								360				365							
Gln	Gly	Gln	Leu	His	Gly	Leu	Lys	Thr	Gly	Leu	Gln	Leu	Phe						
370								375				380							

<210> 91

<211> 86

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (71)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 91

[illegible]

<210> 92

63

<211> 86
 <212> PRT
 <213> Homo sapiens

<400> 92
 Met Leu Thr Ala Val Lys Met Phe Arg Leu Ser Ala Val Thr Leu Cys
 1 5 10 15
 Ala Phe Ser Leu Thr Leu His Ser Gly Val Gln Leu Cys Glu Gln Leu
 20 25 30
 Val Leu Arg Ile Ala Leu Phe Gln Asn Cys Arg Ala Glu Asp Gly Phe
 35 40 45
 Gly Leu Arg Val Cys Trp Arg Arg Leu Met Arg Ser Phe Cys Arg Ser
 50 55 60
 Ala Lys Phe Trp Gly Ser Asn Asp Leu Arg Thr Trp Gly Ser Arg Phe
 65 70 75 80
 Leu Trp Lys Asp Cys Thr
 85

<210> 93
 <211> 122
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (116)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 93
 Met Gly Leu Leu Ala Phe Leu Lys Thr Gln Phe Val Leu His Leu Leu
 1 5 10 15
 Val Gly Phe Val Phe Val Val Ser Gly Leu Val Ile Asn Phe Val Gln
 20 25 30
 Leu Cys Thr Leu Ala Leu Trp Pro Val Ser Lys Gln Leu Tyr Arg Arg
 35 40 45
 Leu Asn Cys Arg Leu Ala Tyr Ser Leu Trp Ser Gln Leu Val Met Leu
 50 55 60
 Leu Glu Trp Trp Ser Cys Thr Glu Cys Thr Leu Phe Thr Asp Gln Ala
 65 70 75 80
 Thr Val Glu Arg Phe Gly Lys Glu His Ala Ile Ile Ile Leu Asn His
 85 90 95
 Asn Phe Glu Ile Asp Phe Leu Cys Gly Trp Thr Met Cys Glu Arg Phe
 100 105 110
 Gly Met Leu Xaa Ser Ser Lys Gly Pro Arg
 115 120

64

<210> 94
 <211> 121
 <212> PRT
 <213> Homo sapiens

<400> 94
 Gly Asp Phe Leu Trp Lys Thr Ser Arg Val Asp Glu Lys Glu Ala Ala
 1 5 10 15
 Gln Trp Leu His Lys Leu Tyr Gln Glu Lys Asp Ala Leu Gln Glu Ile
 20 25 30
 Tyr Asn Gln Lys Gly Met Phe Pro Gly Glu Gln Phe Lys Pro Ala Arg
 35 40 45
 Arg Pro Trp Thr Leu Leu Asn Phe Leu Ser Trp Ala Thr Ile Leu Leu
 50 55 60
 Ser Pro Leu Phe Ser Phe Val Leu Gly Val Phe Ala Ser Gly Ser Pro
 65 70 75 80
 Leu Leu Ile Leu Thr Phe Leu Gly Phe Val Gly Ala Ala Ser Phe Gly
 85 90 95
 Val Arg Arg Leu Ile Gly Val Thr Glu Ile Glu Lys Gly Ser Ser Tyr
 100 105 110
 Gly Asn Gln Glu Phe Lys Lys Lys Glu
 115 120

<210> 95
 <211> 164
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (76)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (112)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (146)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 95
 Met Arg Thr Leu Val Glu Leu Gly Pro Trp Ala Gly Asp Phe Gly Pro
 1 5 10 15
 Asp Leu Leu Leu Thr Leu Leu Phe Leu Leu Phe Leu Ala His Gly Val

65

20	25	30
Thr Leu Asp Gly Ala Ser Ala Asn Pro Thr Val Ser Leu Gln Glu Phe		
35	40	45
Leu Met Ala Glu Gln Ser Leu Pro Gly Thr Leu Leu Lys Leu Ala Ala		
50	55	60
Gln Gly Leu Gly Met Gln Ala Ala Cys Thr Leu Xaa Arg Leu Cys Trp		
65	70	75
Ala Trp Glu Leu Ser Asp Leu His Leu Leu Gln Ser Leu Met Ala Gln		
85	90	95
Ser Cys Ser Ser Ala Leu Arg Thr Ser Val Pro His Gly Ala Leu Xaa		
100	105	110
Glu Ala Ala Cys Thr Phe Cys Phe His Leu Thr Leu Leu His Leu Arg		
115	120	125
His Ser Pro Pro Ala Tyr Ser Gly Pro Ala Val Ala Leu Leu Val Thr		
130	135	140
Val Xaa Ala Tyr Thr Ala Gly Pro Tyr Val Cys Phe Phe Asn Pro Ala		
145	150	155
160		
Leu Ala Ala Leu		

<210> 96

<211> 65

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (24)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 96

Met Cys Lys Gly Leu Lys Asn Pro Glu Gly Leu Leu Leu Leu Leu		
1	5	10
15		
Leu Leu Leu Phe Thr Asp Thr Xaa Asn Ser His Cys Leu Pro Pro Tyr		
20	25	30
Leu Ser Cys Phe Leu His Glu Arg Gln Pro Glu Leu Gln Ser Val Cys		
35	40	45
Ile Ser Ala Ala Tyr Val Leu Ala Pro Leu Gln Asn Pro Val Ser Ser		
50	55	60
Leu		
65		

<210> 97

<211> 299
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (172)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (174)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 97

Gly	Gly	Glu	Glu	Glu	Gly	Glu	Glu	Gly	Ala	Glu	Ile	Ser	Gly	Leu	Gly	1	5	10	15
Ala	Gly	Arg	Arg	Ser	Ala	Pro	Ile	Ala	Val	Gly	Leu	Gly	Phe	Leu	Gly	20	25	30	
Val	Gly	Gly	Arg	Gly	Gly	Ser	Asp	Met	Glu	Ala	Asn	Gly	Ser	Gln	Gly	35	40	45	
Thr	Ser	Gly	Ser	Ala	Asn	Asp	Ser	Gln	His	Asp	Pro	Gly	Lys	Met	Phe	50	55	60	
Ile	Gly	Gly	Leu	Ser	Trp	Gln	Thr	Ser	Pro	Asp	Ser	Leu	Arg	Asp	Tyr	65	70	75	80
Phe	Ser	Lys	Phe	Gly	Glu	Ile	Arg	Glu	Cys	Met	Val	Met	Arg	Asp	Pro	85	90	95	
Thr	Thr	Lys	Arg	Ser	Arg	Gly	Phe	Gly	Phe	Val	Thr	Phe	Ala	Asp	Pro	100	105	110	
Ala	Ser	Val	Asp	Lys	Val	Leu	Gly	Gln	Pro	His	His	Glu	Leu	Asp	Ser	115	120	125	
Lys	Thr	Ile	Asp	Pro	Lys	Val	Ala	Phe	Pro	Arg	Arg	Ala	Gln	Pro	Lys	130	135	140	
Met	Val	Thr	Arg	Thr	Lys	Lys	Ile	Phe	Val	Gly	Gly	Leu	Ser	Ala	Asn	145	150	155	160
Thr	Val	Val	Glu	Asp	Val	Lys	Gln	Tyr	Phe	Glu	Xaa	Phe	Xaa	Lys	Val	165	170	175	
Glu	Asp	Ala	Met	Leu	Met	Phe	Asp	Lys	Thr	Thr	Asn	Arg	His	Arg	Gly	180	185	190	
Phe	Gly	Phe	Val	Thr	Phe	Glu	Asn	Glu	Asp	Val	Val	Glu	Lys	Val	Cys	195	200	205	
Glu	Ile	His	Phe	His	Glu	Ile	Asn	Asn	Lys	Met	Val	Glu	Cys	Lys	Lys	210	215	220	
Ala	Gln	Pro	Lys	Glu	Val	Met	Phe	Pro	Pro	Gly	Thr	Arg	Gly	Arg	Ala				

225					230					235					240
Arg	Gly	Leu	Pro	Tyr	Thr	Met	Asp	Ala	Phe	Met	Leu	Gly	Mét	Gly	Met
				245					250					255	
Leu	Gly	Glu	Ser	Gly	Gln	Asp	Arg	Arg	Ser	Pro	Trp	Thr	Gly	Arg	Ala
			260					265					270		
Met	Glu	Ala	Ser	Thr	Pro	Asn	Trp	Val	Thr	Tyr	Gln	Trp	Gly	Lys	Leu
		275					280					285			
Leu	His	Leu	Ser	Lys	Pro	Gln	Phe	Pro	Cys	Leu					
290						295									

```
<210> 98
<211> 167
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (140)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 98

Met Leu Gln Gly His Ser Ser Val Phe Gln Ala Leu Leu Gly Thr Phe
1 5 10 15

Phe Thr Trp Gly Met Thr Ala Ala Gly Ala Ala Leu Val Phe Val Phe
20 25 30

Ser Ser Gly Gln Arg Arg Ile Leu Asp Gly Ser Leu Gly Phe Ala Ala
35 40 45

Gly Val Met Leu Ala Ala Ser Tyr Trp Ser Leu Leu Ala Pro Ala Val
50 55 60

Glu Met Ala Thr Ser Ser Gly Gly Phe Gly Ala Phe Ala Phe Phe Pro
65 70 75 80

Val Ala Val Gly Phe Thr Leu Gly Ala Ala Phe Val Tyr Leu Ala Asp
85 90 95

Leu Leu Met Pro His Leu Gly Ala Ala Glu Asp Pro Gln Thr Ala Leu
100 105 110

Ala Leu Asn Phe Gly Ser Thr Leu Met Lys Lys Lys Ser Asp Pro Glu
115 120 125

Gly His Ala Leu Leu Phe Pro Glu Arg Ile His Xaa Ile Asp Lys Ser
130 135 140

Glu Asn Gly Glu Ala Tyr Gln Arg Lys Lys Ala Ala Ala Thr Gly Leu
145 150 155 160

Pro Glu Gly Pro Ala Val Pro
165

<210> 99
 <211> 158
 <212> PRT
 <213> Homo sapiens

<400> 99
 Met Thr Thr Met Ala Pro Val Gly Leu Gln Thr Arg Ile Pro Trp Leu
 1 5 10 15
 Leu Cys Leu Gly Pro Pro Pro Gly Pro Cys Cys Pro Leu Ser Pro Thr
 20 25 30
 Ser Thr Leu Pro His Thr Pro Thr Ala Arg Ser Leu His Pro Thr Met
 35 40 45
 Ser Phe His Leu Thr Pro Met Val Gly Ala Val Pro Ala Ala Ser Ile
 50 55 60
 Val Arg Ala Ala Gly Ala Val Gly Arg His Gly Val Met Gly Gly Gln
 65 70 75 80
 Gly Ala Arg Gly Gly Pro Arg Ser Gly Pro Pro Ser Pro Ser Pro Ala
 85 90 95
 Val Ala Val Ser Leu Ser Pro Pro Ala Glu Gly Ala Ala Phe Gly Gly
 100 105 110
 Val Gly Lys Gln Val Gly Leu Ala Met Gly Ala Leu Leu His Pro Glu
 115 120 125
 Ala Gln Leu Gly Val Pro Leu Ile Ser Glu Pro Thr Gln Gly Ser Ile
 130 135 140
 Pro Met Asp Arg Pro Leu Ala Trp Pro Ser Pro Thr Thr Pro
 145 150 155

<210> 100
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (26)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 100
 Pro Thr Phe Ser Asp Gln Tyr Leu Ala Pro His Pro Tyr Ser Pro Gln
 1 5 10 15
 Pro Pro Pro Tyr His Glu Leu Pro His Xaa His Gly Gln Ser Gln Arg
 20 25 30
 Val Leu Cys Gly Cys Tyr Val Ala His Cys Gly Ala Arg Leu Gly Arg
 35 40 45

69

Ala Leu Leu Val Cys Asp Trp Val Ser Trp Pro Ser Cys Ala Cys Ser
 50 55 60

Tyr Ser Ala Trp Ala Gln Pro Thr Ser Cys Cys His Thr Gly Asp Cys
 65 70 75 80

Gly His Cys Asp Ser His Gln Gln Cys Leu Val Pro Pro Pro Ser Leu
 85 90 95

Arg Gly Arg Gln Gly Thr Phe Asp Tyr Phe
 100 105

<210> 101

<211> 142

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (69)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (76)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (90)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (108)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 101

Met Tyr Val Thr Leu Val Phe Arg Val Lys Gly Ser Arg Leu Val Lys
 1 5 10 15

Pro Ser Leu Cys Leu Ala Leu Leu Cys Pro Ala Phe Leu Val Gly Val
 20 25 30

Val Arg Val Ala Glu Tyr Arg Asn His Trp Ser Asp Val Leu Ala Gly
 35 40 45

Phe Leu Thr Gly Ala Ala Ile Ala Thr Phe Leu Val Thr Cys Val Val
 50 55 60

His Asn Phe Gln Xaa Arg Pro Pro Ser Gly Arg Xaa Leu Ser Pro Gln
 65 70 75 80

Ser Ala Tyr Pro Arg Leu Pro Gly Pro Xaa Phe Pro His Leu His Asn
 85 90 95

70

Gly Gly Asp His Pro Cys Pro Ala Gly Cys Arg Xaa Gly Cys Glu Ser
 100 105 110

Ser Ala Trp Met Gln Pro Gly Gly Ser His Arg Ala Ala Phe Thr Gly
 115 120 125

Leu Ala Leu Pro Trp Ala Gly Gly Arg Pro His Pro Lys Arg
 130 135 140

<210> 102

<211> 143

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (120)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (142)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 102

Met Ala Phe Ser Lys Leu Leu Glu Gln Ala Gly Gly Val Gly Leu Phe
 1 5 10 15

Gln Thr Leu Gln Val Leu Thr Phe Ile Leu Pro Cys Leu Met Ile Pro
 20 25 30

Ser Gln Met Leu Leu Glu Asn Phe Ser Ala Ala Ile Pro Gly His Arg
 35 40 45

Cys Trp Thr His Met Leu Asp Asn Gly Ser Ala Val Ser Thr Asn Met
 50 55 60

Thr Pro Lys Ala Leu Leu Thr Ile Ser Ile Pro Pro Gly Pro Asn Gln
 65 70 75 80

Gly Pro His Gln Cys Arg Arg Phe Arg Gln Pro Gln Trp Gln Leu Leu
 85 90 95

Asp Pro Asn Ala Thr Ala Thr Ser Trp Ser Glu Ala Asp Thr Glu Pro
 100 105 110

Cys Val Asp Gly Trp Val Tyr Xaa Arg Arg Ser Ser Pro Pro Ser
 115 120 125

Trp Pro Ser Gly Thr Trp Cys Ala Ala Pro Arg Leu Glu Xaa Pro
 130 135 140

<210> 103

<211> 178

<212> PRT

<213> Homo sapiens

<220>
 <221> SITE
 <222> (123)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (175)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 103
 Met Ala Met Val Pro Gly Ala Thr Leu Arg Arg Leu Leu Ser Val Val
 1 5 10 15
 Leu Pro Thr Ala Ser Gln Pro Gln Leu Leu Ala Leu Leu Asp Ser Ala
 20 25 30
 Thr Glu Arg His Val Asp His Ala Ala Glu Ser Asp Gly Gly Ala Glu
 35 40 45
 Gln Ala Asp Val Gly Arg Arg Arg Lys His Gln Ser Trp Trp Gln Ala
 50 55 60
 Leu Asp Gly Lys Leu Arg Gly Asp Leu Ile Ser Arg Gly Leu Glu Lys
 65 70 75 80
 Met Leu Trp Ala Arg Lys Arg Lys Gln Ser Ile Leu Lys Lys Thr Cys
 85 90 95
 Leu Pro Leu Arg Glu Arg Met Ile Phe Ser Gly Lys Gly Ser Trp Pro
 100 105 110
 His Leu Ser Leu Glu Pro Ile Gly Glu Leu Xaa Pro Val Pro Ile Val
 115 120 125
 Gly Ala Glu Thr Ile Asp Leu Leu Asn Thr Gly Glu Lys Leu Phe Ile
 130 135 140
 Phe Arg Asn Pro Lys Glu Pro Glu Ile Ser Leu His Val Pro Pro Arg
 145 150 155 160
 Lys Lys Lys Asn Phe Leu Asn Ala Lys Lys Ala Met Arg Ala Xaa Gly
 165 170 175
 Met Asp

<210> 104
 <211> 204
 <212> PRT
 <213> Homo sapiens

<400> 104
 Met Phe Gln Phe Leu Ser Gln Gly Phe Tyr Cys Gly Val Gly Leu Phe
 1 5 10 15

72

Thr Arg Phe Leu Lys Leu Leu Gly Ala Leu Leu Leu Leu Ala Leu Ala
 20 25 30
 Leu Phe Leu Gly Phe Leu Gln Leu Gly Trp Arg Phe Leu Val Gly Leu
 35 40 45
 Gly Asp Arg Leu Gly Trp Arg Asp Lys Ala Thr Trp Leu Phe Ser Trp
 50 55 60
 Leu Asp Ser Pro Ala Leu Gln Arg Cys Leu Thr Leu Leu Arg Asp Ser
 65 70 75 80
 Arg Pro Trp Gln Arg Leu Val Arg Ile Val Gln Trp Gly Trp Leu Glu
 85 90 95
 Leu Pro Trp Val Lys Gln Asn Ile Asn Arg Gln Gly Asn Ala Pro Val
 100 105 110
 Ala Ser Gly Arg Tyr Cys Gln Pro Glu Glu Glu Val Ala Arg Leu Leu
 115 120 125
 Thr Met Ala Gly Val Pro Glu Asp Glu Leu Asn Pro Phe His Val Leu
 130 135 140
 Gly Val Glu Ala Thr Ala Ser Asp Val Glu Leu Lys Lys Ala Tyr Arg
 145 150 155 160
 Gln Leu Ala Val Met Val His Pro Asp Lys Asn His His Pro Arg Ala
 165 170 175
 Glu Glu Ala Phe Lys Val Phe Ala Ser Ser Leu Gly Thr Leu Ser Ala
 180 185 190
 Met Leu Lys Lys Arg Lys Gly Val Trp Arg Leu Lys
 195 200

<210> 105

<211> 122

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (119)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 105

Met Ala Leu Phe Arg Cys Val Trp Ser Val Leu Ser Ala Leu Gly Lys
 1 5 10 15
 Ser Gly Ser Asp Leu Cys Ala Gly Cys Gly Ser Arg Leu Arg Ser Pro
 20 25 30
 Phe Ser Phe Ala Tyr Val Pro Arg Cys Phe Ser Ser Thr Ala Asn Ser
 35 40 45
 Tyr Pro Lys Lys Pro Leu Thr Ser Tyr Val Arg Phe Ser Lys Glu Gln

73

50 55 60
 Leu Pro Ile Phe Lys Ala Gln Asn Pro Asp Ala Lys Asn Ser Glu Leu
 65 70 75 80
 Ile Arg Lys Ile Ala Gln Leu Trp Arg Glu Leu Pro Asp Ser Glu Lys
 85 90 95
 Lys Ile Tyr Glu Asp Ala Tyr Arg Ala Asp Leu Ala Gly His Thr Lys
 100 105 110
 Lys Glu Ile Asn Arg Ile Xaa Glu Pro Gly
 115 120

<210> 106
 <211> 153
 <212> PRT
 <213> Homo sapiens

<400> 106
 Met Leu Lys Asp Phe Ser Asn Leu Leu Leu Val Val Leu Cys Asp Tyr
 1 5 10 15
 Val Leu Gly Glu Ala Glu Tyr Leu Leu Leu Arg Glu Pro Gly His Val
 20 25 30
 Ala Leu Ser Asn Asp Thr Val Tyr Val Asp Phe Gln Tyr Phe Asp Gly
 35 40 45
 Ala Asn Gly Thr Leu Arg Asn Val Ser Val Leu Leu Leu Glu Ala Asn
 50 55 60
 Thr Asn Gln Thr Val Thr Thr Lys Tyr Leu Leu Thr Asn Gln Ser Gln
 65 70 75 80
 Gly Thr Leu Lys Phe Glu Cys Phe Tyr Phe Lys Glu Ala Gly Asp Tyr
 85 90 95
 Trp Phe Thr Met Thr Pro Glu Ala Thr Asp Asn Ser Thr Pro Phe Pro
 100 105 110
 Trp Trp Glu Lys Ser Ala Phe Leu Lys Val Glu Trp Pro Val Phe His
 115 120 125
 Val Asp Leu Asn Arg Ser Ala Lys Ala Ala Glu Gly Thr Phe Gln Val
 130 135 140
 Gly Leu Phe Thr Ser Gln Pro Leu Cys
 145 150

<210> 107
 <211> 78
 <212> PRT
 <213> Homo sapiens

<400> 107

74

Ser Ser Pro Thr Ser Pro Lys Asp Asn Tyr Gln Arg Val Ser Ser Leu
 1 5 10 15
 Ser Pro Ser Gln Cys Arg Lys Asp Lys Cys Gln Ser Phe Pro Thr His
 20 25 30
 Pro Glu Phe Ala Phe Tyr Asp Asn Thr Ser Phe Gly Leu Thr Glu Ala
 35 40 45
 Glu Gln Arg Met Leu Asp Leu Pro Gly Tyr Phe Gly Ser Asn Glu Glu
 50 55 60
 Asp Glu Thr Thr Ser Thr Leu Ser Val Glu Lys Leu Val Ile
 65 70 75

<210> 108
 <211> 88
 <212> PRT
 <213> Homo sapiens

<400> 108
 Met Asp Trp Trp Phe Leu Ala Ile Ala Met Ala Leu Leu Trp Leu Thr
 1 5 10 15
 Thr Ser Arg Lys Gln Cys Cys Ser Thr Trp Ala Leu Leu Asn Tyr Met
 20 25 30
 Ala Leu Met Ile Leu Ile Gly Glu Asn Pro Asp Leu Leu Val Asn Leu
 35 40 45
 Asp Ser Leu Gln Glu Pro Val Cys Val Ile Leu Val Lys Gly Leu Leu
 50 55 60
 Phe Gln Arg Ile Ala Ala Asn Leu Gln Pro Leu Val Leu His His His
 65 70 75 80
 Thr Ile Gln Met Met Asn Lys Lys
 85

<210> 109
 <211> 81
 <212> PRT
 <213> Homo sapiens

<400> 109
 Met Asp Trp Trp Phe Leu Ala Ile Ala Met Ala Leu Leu Trp Leu Thr
 1 5 10 15
 Thr Ser Arg Lys Gln Cys Cys Ser Thr Trp Ala Leu Leu Asn Tyr Met
 20 25 30
 Ala Leu Met Ile Leu Ile Gly Glu Asn Pro Asp Leu Leu Val Asn Leu
 35 40 45
 Asp Ser Leu Gln Glu Pro Val Cys Val Ile Leu Val Lys Gly Leu Leu
 50 55 60

75

Phe Gln Arg Ile Ala Ala Asn Leu Gln Pro Leu Gln Arg Cys Gln Gly
 65 70 75 80

Ser

<210> 110
 <211> 49
 <212> PRT
 <213> Homo sapiens

<400> 110
 Met Lys His Ser Phe Leu Ser Ser Asp Leu Ile Trp Cys Val Leu Ser
 1 5 10 15

Leu Leu Cys Leu Gly Val Trp Phe Arg Glu Thr Trp Thr Thr Leu Phe
 20 25 30

Gly Arg Thr Gly Leu Pro Arg Asn Gln Gln Cys Pro Arg Arg Lys Gly
 35 40 45

Leu

<210> 111
 <211> 112
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (8)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (14)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (97)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 111
 Pro Gly Ser Thr His Ala Asn Xaa Gly Arg Val Gly Pro Xaa Val His
 1 5 10 15

Ile Pro Gly Gln Glu Pro Leu Thr Ala Ser Met Leu Ala Ala Ala Pro
 20 25 30

Leu His Glu Gln Lys Gln Met Ile Gly Thr Cys Tyr Leu Val Leu Lys
 35 40 45

Arg Trp Ser Asp Trp Met Val Leu Ser Phe Leu Pro Leu Leu Leu Ser

76

50 55 60
 Cys Asp Phe Glu Gly Ser Val Ser Thr Pro Leu Ser Met Met Ser Thr
 65 70 75 80
 Pro Ser Trp Leu Ala Arg Ser Arg Ala Cys Cys Trp Arg Leu Thr Thr
 85 90 95
 Xaa Ser Cys Cys Ser Cys Trp Ser Leu Gln Asn Pro Ser Met Pro Arg
 100 105 110

<210> 112
 <211> 98
 <212> PRT
 <213> Homo sapiens

<400> 112
 Ile His His Pro Ile Pro Ser Ala Leu Leu Glu Val Met Leu Thr Ala
 1 5 10 15
 Val Lys Met Phe Arg Leu Ser Ala Val Thr Leu Cys Ala Phe Ser Leu
 20 25 30
 Thr Leu His Ser Gly Val Gln Leu Cys Glu Gln Leu Val Leu Arg Ile
 35 40 45
 Ala Leu Phe Gln Asn Cys Arg Ala Glu Asp Gly Phe Gly Leu Arg Val
 50 55 60
 Cys Trp Arg Arg Leu Met Arg Ser Phe Cys Arg Ser Ala Lys Phe Trp
 65 70 75 80
 Gly Ser Asn Asp Leu Arg Thr Trp Gly Ser Arg Phe Leu Trp Lys Asp
 85 90 95
 Cys Thr

<210> 113
 <211> 293
 <212> PRT
 <213> Homo sapiens

<400> 113
 Arg Pro Glu Ser Tyr Leu Val Asn Leu Ser Leu Asn Asp Asn Asp Gly
 1 5 10 15
 Ser Ser Gly Ala Ser Asp Gln Asp Thr Leu Ala Pro Leu Pro Gly Ala
 20 25 30
 Thr Pro Trp Pro Leu Leu Pro Thr Phe Ser Tyr Gln Tyr Pro Ala Pro
 35 40 45

77

His Pro Tyr Ser Pro Gln Pro Pro Pro Tyr His Glu Leu Ser Ser Tyr
 50 55 60
 Thr Tyr Gly Gly Gly Ser Ala Ser Ser Gln His Ser Glu Gly Ser Arg
 65 70 75 80
 Ser Ser Gly Ser Thr Arg Ser Asp Gly Gly Ala Gly Arg Thr Gly Arg
 85 90 95
 Pro Glu Glu Arg Ala Pro Glu Ser Lys Ser Gly Ser Gly Ser Glu Ser
 100 105 110
 Glu Pro Ser Ser Arg Gly Gly Ser Leu Arg Arg Gly Gly Glu Ala Ser
 115 120 125
 Gly Thr Ser Asp Gly Gly Pro Pro Pro Ser Arg Gly Ser Thr Gly Gly
 130 135 140
 Ala Pro Asn Leu Arg Ala His Pro Gly Leu His Pro Tyr Gly Pro Pro
 145 150 155 160
 Pro Gly Met Ala Leu Pro Tyr Asn Pro Met Met Val Val Met Met Pro
 165 170 175
 Pro Pro Pro Pro Pro Val Pro Pro Ala Val Gln Pro Pro Gly Ala Pro
 180 185 190
 Pro Val Arg Asp Leu Gly Ser Val Pro Pro Glu Leu Thr Ala Ser Arg
 195 200 205
 Gln Ser Phe His Gly His Gly Gln Ser Gln Arg Val Leu Cys Gly Cys
 210 215 220
 Tyr Val Ala His Cys Gly Ala Arg Leu Gly Arg Ala Leu Leu Val Cys
 225 230 235 240
 Asp Trp Val Ser Trp Pro Ser Cys Ala Cys Ser Tyr Ser Ala Trp Ala
 245 250 255
 Gln Pro Thr Ser Cys Cys His Thr Gly Asp Cys Gly His Cys Asp Ser
 260 265 270
 His Gln Gln Cys Leu Val Pro Pro Pro Ser Leu Arg Gly Arg Gln Gly
 275 280 285
 Thr Phe Asp Tyr Phe
 290

<210> 114

<211> 72

<212> PRT

<213> Homo sapiens

<400> 114

Tyr Ala Val Thr Tyr Thr Ala Met Tyr Val Thr Leu Val Phe Arg Val
 1 5 10 15

78

Lys Gly Ser Arg Leu Val Lys Pro Ser Leu Cys Leu Ala Leu Leu Cys
 20 25 30
 Pro Ala Phe Leu Val Gly Val Val Arg Val Ala Glu Tyr Arg Asn His
 35 40 45
 Trp Ser Asp Val Leu Ala Gly Phe Leu Thr Gly Ala Ala Ile Ala Thr
 50 55 60
 Phe Leu Val Thr Cys Val Val His
 65 70

<210> 115
 <211> 82
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (81)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 115
 Ala Ala Leu Cys Ala Tyr Ala Val Thr Tyr Thr Ala Met Tyr Val Thr
 1 5 10 15
 Leu Val Phe Arg Val Lys Gly Ser Arg Leu Val Lys Pro Ser Leu Cys
 20 25 30
 Leu Ala Leu Leu Cys Pro Ala Phe Leu Val Gly Val Val Arg Val Ala
 35 40 45
 Glu Tyr Arg Asn His Trp Ser Asp Val Leu Ala Gly Phe Leu Thr Gly
 50 55 60
 Ala Ala Ile Ala Thr Phe Leu Val Thr Cys Val Val His Asn Phe Gln
 65 70 75 80
 Xaa Arg

<210> 116
 <211> 154
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (81)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (88)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (102)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (120)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 116
 Ala Ala Leu Cys Ala Tyr Ala Val Thr Tyr Thr Ala Met Tyr Val Thr
 1 5 10 15
 Leu Val Phe Arg Val Lys Gly Ser Arg Leu Val Lys Pro Ser Leu Cys
 20 25 30
 Leu Ala Leu Leu Cys Pro Ala Phe Leu Val Gly Val Val Arg Val Ala
 35 40 45
 Glu Tyr Arg Asn His Trp Ser Asp Val Leu Ala Gly Phe Leu Thr Gly
 50 55 60
 Ala Ala Ile Ala Thr Phe Leu Val Thr Cys Val Val His Asn Phe Gln
 65 70 75 80
 Xaa Arg Pro Pro Ser Gly Arg Xaa Leu Ser Pro Gln Ser Ala Tyr Pro
 85 90 95
 Arg Leu Pro Gly Pro Xaa Phe Pro His Leu His Asn Gly Gly Asp His
 100 105 110
 Pro Cys Pro Ala Gly Cys Arg Xaa Gly Cys Glu Ser Ser Ala Trp Met
 115 120 125
 Gln Pro Gly Gly Ser His Arg Ala Ala Phe Thr Gly Leu Ala Leu Pro
 130 135 140
 Trp Ala Gly Gly Arg Pro His Pro Lys Arg
 145 150

<210> 117
 <211> 120
 <212> PRT
 <213> Homo sapiens

<400> 117
 Met Ala Phe Ser Lys Leu Leu Glu Gln Ala Gly Gly Val Gly Leu Phe
 1 5 10 15
 Gln Thr Leu Gln Val Leu Thr Phe Ile Leu Pro Cys Leu Met Ile Pro
 20 25 30
 Ser Gln Met Leu Leu Glu Asn Phe Ser Ala Ala Ile Pro Gly His Arg
 35 40 45
 Cys Trp Thr His Met Leu Asp Asn Gly Ser Ala Val Ser Thr Asn Met

80

50 55 60
 Thr Pro Lys Ala Leu Leu Thr Ile Ser Ile Pro Pro Gly Pro Asn Gln
 65 70 75 80
 Gly Pro His Gln Cys Arg Arg Phe Arg Gln Pro Gln Trp Gln Leu Leu
 85 90 95
 Asp Pro Asn Ala Thr Ala Thr Ser Trp Ser Glu Ala Asp Thr Glu Pro
 100 105 110
 Cys Val Asp Gly Trp Val Tyr Asp
 115 120

<210> 118

<211> 458

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (403)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (455)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 118

Met Arg Gln Glu Val His Gly Cys Phe Ala Gln Met Asp Arg Ser Leu
 1 5 10 15
 Ala Leu Pro Lys Ile Arg Ala Arg Val Leu Leu Gln Gln Phe Gln Thr
 20 25 30
 Ala Trp Arg Glu Ala Glu Phe Val Lys Leu Asp Gln Ala Val Ala Ala
 35 40 45
 Pro Glu Leu Gln Gln Gln Ser Lys Val Arg Lys Ser Arg Ser Lys Ser
 50 55 60
 Lys Ser Lys Gly Glu Leu Leu Lys Lys Cys Ile Glu Asp Lys Ile His
 65 70 75 80
 Leu Cys Glu Glu Gln Ala Ser Glu Asp Leu Val Glu Lys Val Arg Gly
 85 90 95
 Glu Leu Leu Arg Glu Arg Val Gln Arg Met Glu Ala Gln Glu Gly Gly
 100 105 110
 Phe Ala Gln Ser Leu Val Ala Leu Gln Phe Gln Lys Ala Ser Arg Val
 115 120 125
 Thr Glu Thr Leu Ser Ala Tyr Thr Ala Leu Leu Ser Ile Gln Asp Leu
 130 135 140

Leu Leu Glu Glu Leu Ser Ala Ser Glu Met Leu Thr Lys Ser Ala Cys
 145 150 155 160
 Thr Gln Ile Leu Glu Ser His Ser Arg Glu Leu Gln Glu Leu Glu Arg
 165 170 175
 Lys Leu Glu Asp Gln Leu Val Gln Gln Glu Ala Ala Gln Gln Gln Gln
 180 185 190
 Ala Leu Ala Ser Trp Gln Gln Trp Val Ala Asp Gly Pro Gly Ile Leu
 195 200 205
 Asn Glu Pro Gly Glu Val Asp Ser Glu Arg Gln Val Ser Thr Val Leu
 210 215 220
 His Gln Ala Leu Ser Lys Ser Gln Thr Leu Leu Glu Gln His Gln Gln
 225 230 235 240
 Cys Leu Arg Glu Glu Gln Gln Asn Ser Val Val Leu Glu Asp Leu Leu
 245 250 255
 Glu Asn Met Glu Ala Asp Thr Phe Ala Thr Leu Cys Ser Gln Glu Leu
 260 265 270
 Arg Leu Ala Ser Tyr Leu Ala Arg Met Ala Met Val Pro Gly Ala Thr
 275 280 285
 Leu Arg Arg Leu Leu Ser Val Val Leu Pro Thr Ala Ser Gln Pro Gln
 290 295 300
 Leu Leu Ala Leu Leu Asp Ser Ala Thr Glu Arg His Val Asp His Ala
 305 310 315 320
 Ala Glu Ser Asp Gly Gly Ala Glu Gln Ala Asp Val Gly Arg Arg Arg
 325 330 335
 Lys His Gln Ser Trp Trp Gln Ala Leu Asp Gly Lys Leu Arg Gly Asp
 340 345 350
 Leu Ile Ser Arg Gly Leu Glu Lys Met Leu Trp Ala Arg Lys Arg Lys
 355 360 365
 Gln Ser Ile Leu Lys Lys Thr Cys Leu Pro Leu Arg Glu Arg Met Ile
 370 375 380
 Phe Ser Gly Lys Gly Ser Trp Pro His Leu Ser Leu Glu Pro Ile Gly
 385 390 395 400
 Glu Leu Xaa Pro Val Pro Ile Val Gly Ala Glu Thr Ile Asp Leu Leu
 405 410 415
 Asn Thr Gly Glu Lys Leu Phe Ile Phe Arg Asn Pro Lys Glu Pro Glu
 420 425 430
 Ile Ser Leu His Val Pro Pro Arg Lys Lys Lys Asn Phe Leu Asn Ala
 435 440 445
 Lys Lys Ala Met Arg Ala Xaa Gly Met Asp

450

455

<210> 119

<211> 331

<212> PRT

<213> Homo sapiens

<400> 119

```

Met Leu Lys Asp Phe Ser Asn Leu Leu Leu Val Val Leu Cys Asp Tyr
  1              5              10              15

Val Leu Gly Glu Ala Glu Tyr Leu Leu Leu Arg Glu Pro Gly His Val
      20              25              30

Ala Leu Ser Asn Asp Thr Val Tyr Val Asp Phe Gln Tyr Phe Asp Gly
      35              40              45

Ala Asn Gly Thr Leu Arg Asn Val Ser Val Leu Leu Leu Glu Ala Asn
      50              55              60

Thr Asn Gln Thr Val Thr Thr Lys Tyr Leu Leu Thr Asn Gln Ser Gln
      65              70              75              80

Gly Thr Leu Lys Phe Glu Cys Phe Tyr Phe Lys Glu Ala Gly Asp Tyr
      85              90              95

Trp Phe Thr Met Thr Pro Glu Ala Thr Asp Asn Ser Thr Pro Phe Pro
      100              105              110

Trp Trp Glu Lys Ser Ala Phe Leu Lys Val Glu Trp Pro Val Phe His
      115              120              125

Val Asp Leu Asn Arg Ser Ala Lys Ala Ala Glu Gly Thr Phe Gln Val
      130              135              140

Gly Leu Phe Thr Ser Gln Pro Leu Cys Pro Phe Pro Val Asp Lys Pro
      145              150              155              160

Asn Ile Val Val Asp Val Ile Phe Thr Asn Ser Leu Pro Glu Ala Arg
      165              170              175

Arg Asn Ser Arg Gln Pro Leu Glu Ile Arg Thr Ser Lys Arg Thr Glu
      180              185              190

Leu Ala Gln Gly Gln Trp Val Glu Phe Gly Cys Ala Pro Leu Gly Pro
      195              200              205

Glu Ala Tyr Val Thr Val Val Leu Lys Leu Leu Gly Arg Asp Ser Val
      210              215              220

Ile Thr Ser Thr Gly Pro Ile Asp Leu Ala Gln Lys Phe Gly Tyr Lys
      225              230              235              240

Leu Val Met Val Pro Glu Leu Thr Cys Glu Ser Gly Val Glu Val Thr
      245              250              255

Val Leu Pro Pro Pro Cys Thr Phe Val Gln Gly Val Val Thr Val Phe

```

83

260	265	270
Lys Glu Ala Pro Arg Tyr Pro Gly Lys Arg Thr Ile His Leu Ala Glu		
275	280	285
Asn Ser Leu Pro Trp Glu Arg Gly Gly Gln Phe Leu Thr Val Leu Cys		
290	295	300
Leu Thr Trp Gly Arg Ile Ser Thr Ala Leu Thr Leu Ala Phe Gln Ala		
305	310	315
		320
Glu Ala Ile Phe Leu Gln Arg Arg Ser Ala Cys		
325	330	

<210> 120
 <211> 81
 <212> PRT
 <213> Homo sapiens

<400> 120
 Met Asp Trp Trp Phe Leu Ala Ile Ala Met Ala Leu Leu Trp Leu Thr
 1 5 10 15
 Thr Ser Arg Lys Gln Cys Cys Ser Thr Trp Ala Leu Leu Asn Tyr Met
 20 25 30
 Ala Leu Met Ile Leu Ile Gly Glu Asn Pro Asp Leu Leu Val Asn Leu
 35 40 45
 Asp Ser Leu Gln Glu Pro Val Cys Val Ile Leu Val Lys Gly Leu Leu
 50 55 60
 Phe Gln Arg Ile Ala Ala Asn Leu Gln Pro Leu Gln Arg Cys Gln Gly
 65 70 75 80
 Ser

<210> 121
 <211> 462
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (148)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (149)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (204)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (292)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (303)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 121

Met	Val	Asp	Tyr	Leu	Gln	Lys	Ala	Val	Leu	Leu	Asn	Leu	Gly	Thr	Ile	1	5	10	15
Glu	Leu	Tyr	Gly	Ser	Asn	Asp	Pro	Tyr	Arg	Arg	Glu	Pro	Arg	Ser	Pro	20	25	30	
Arg	Lys	Ser	Arg	Gln	Pro	Ser	Gly	Ala	Gly	Leu	Cys	Asp	Ile	Ser	Glu	35	40	45	
Gly	Thr	Val	Val	Pro	Glu	Asp	Arg	Cys	Lys	Ser	Pro	Thr	Ser	Ala	Lys	50	55	60	
Met	Ser	Arg	Lys	Leu	Ser	Leu	Pro	Thr	Asp	Leu	Lys	Pro	Asp	Leu	Asp	65	70	75	80
Val	Lys	Asp	Asn	Ser	Phe	Ser	Arg	Ser	Arg	Ser	Ser	Ser	Val	Thr	Ser	85	90	95	
Ile	Asp	Lys	Glu	Ser	Arg	Glu	Ala	Ile	Ser	Ala	Leu	His	Phe	Cys	Glu	100	105	110	
Thr	Phe	Thr	Arg	Lys	Thr	Asp	Ser	Ser	Pro	Ser	Pro	Cys	Leu	Trp	Val	115	120	125	
Gly	Thr	Thr	Leu	Gly	Thr	Val	Leu	Val	Ile	Ala	Leu	Asn	Leu	Pro	Pro	130	135	140	
Gly	Gly	Glu	Xaa	Xaa	Leu	Leu	Gln	Pro	Val	Ile	Val	Ser	Pro	Ser	Gly	145	150	155	160
Thr	Ile	Leu	Arg	Leu	Lys	Gly	Ala	Ile	Leu	Arg	Met	Ala	Phe	Leu	Asp	165	170	175	
Thr	Thr	Gly	Cys	Leu	Ile	Pro	Pro	Ala	Tyr	Glu	Pro	Trp	Arg	Glu	His	180	185	190	
Asn	Val	Pro	Glu	Glu	Lys	Asp	Glu	Lys	Glu	Lys	Xaa	Lys	Lys	Arg	Arg	195	200	205	
Pro	Val	Ser	Val	Ser	Pro	Ser	Ser	Ser	Gln	Glu	Ile	Ser	Glu	Asn	Gln	210	215	220	
Tyr	Ala	Val	Ile	Cys	Ser	Glu	Lys	Gln	Ala	Lys	Val	Ile	Ser	Leu	Pro	225	230	235	240

Thr Gln Asn Cys Ala Tyr Lys Gln Asn Ile Thr Glu Thr Ser Phe Val
 245 250 255
 Leu Arg Gly Asp Ile Val Ala Leu Ser Asn Ser Ile Cys Leu Ala Cys
 260 265 270
 Phe Cys Ala Asn Gly His Ile Met Thr Phe Ser Leu Pro Ser Leu Arg
 275 280 285
 Pro Leu Leu Xaa Val Tyr Tyr Leu Pro Leu Thr Asn Met Arg Xaa Ala
 290 295 300
 Arg Thr Phe Cys Phe Thr Asn Asn Gly Gln Ala Leu Tyr Leu Val Ser
 305 310 315 320
 Pro Thr Glu Ile Gln Arg Leu Thr Tyr Ser Gln Glu Thr Cys Glu Asn
 325 330 335
 Leu Gln Glu Met Leu Gly Glu Leu Phe Thr Pro Val Glu Thr Pro Glu
 340 345 350
 Ala Pro Asn Arg Gly Phe Phe Lys Gly Leu Phe Gly Gly Gly Ala Gln
 355 360 365
 Ser Leu Asp Arg Glu Glu Leu Phe Gly Glu Ser Ser Ser Gly Lys Ala
 370 375 380
 Ser Arg Ser Leu Ala Gln His Ile Pro Gly Pro Gly Gly Ile Glu Gly
 385 390 395 400
 Val Lys Gly Ala Ala Ser Gly Val Val Gly Glu Leu Ala Arg Ala Arg
 405 410 415
 Leu Ala Leu Asp Glu Arg Gly Gln Lys Leu Gly Asp Leu Glu Glu Arg
 420 425 430
 Thr Ala Ala Met Leu Ser Ser Ala Glu Ser Phe Ser Lys His Ala His
 435 440 445
 Glu Ile Met Leu Lys Tyr Lys Asp Lys Lys Trp Tyr Gln Phe
 450 455 460

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US01/01386

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database: EST; Accession NO: AI499684; NCI/NINDS-CGAP; "NCI_CGAP_Brn25 Homo sapiens cDNA clone, 3 prime similar to alpha 1B-glycoprotein"; 14 April 1999; having 100% sequence identity to SEQ ID NO: 11; vector: pT7T3D-Pac; hostcell: DH10B; see entire document.	1-10, 21
X	Database: SwissProt_39; Accession NO: P04217; ISHIOKA et al.; "Alpha1 B-glycoprotein"; 20 March 1987; having 99.8% sequence identity to SEQ ID NO: 61; see entire document.	1-7, 21

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*I* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 MAY 2001

Date of mailing of the international search report

01 JUN 2001

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RITA MITRA

Telephone No. (703) 308-0196

 JOYCE BRIDGERS
 PARALEGAL SPECIALIST
 CHEMICAL MATRIXX

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/01386

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ISHIOKA et al. Amino acid sequence of human plasma α 1 B-glycoprotein: Homology to the immunoglobulin supergene family. Proc. Natl. Acad. Sci., USA. April 1986, Vol. 83, pages 2363-2367, see complete sequence in Fig. 1, page 2364 and internal homology in the primary structure of alpha B in Fig. 2, page 2365; see entire document.	1-7, 21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/01386

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10, 14, 15, 21 all in part

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/01386

A. CLASSIFICATION OF SUBJECT MATTER: IPC (7):

C07H 21/04, 21/02; C07K 5/00, 14/00; C12Q 1/68; C12N 1/21, 15/63, 15/85, 15/86

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Database: GenEmbl, N_GeneSeq_36, Issued_Patents_NA, EST, A_GeneSeq_36, Issued_Patents_AA, PIR_65, SwissProt_39, SPTREMBL_14.

EAST (Database: USPTO, Derwent, EPO, JPO)

STN (Database: biosis, caplus, cmbase, medline, seiscarch)

Search Terms: alpha-1 B-glycoprotein, immunoglobulin supergene family, polynucleotides

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups 1-50, claims 1-10, 14, 15 and 21, all in part, drawn to an isolated nucleic acid of SEQ ID NO X or a peptide of SEQ ID NO: Y, wherein X and Y are values that correlate to those listed in Table 1, and correspond to one of the cDNA Clone IDs, respectively. For examples,

If group 1 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein X is 11 and Y is 61.

If group 2 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein X is 12 and Y is 62.

Groups 51-100, claims 11, 12 and 16, all in part, each group directed to a peptide of SEQ ID NO: Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 51 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein Y is 61.

If group 52 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein Y is 62.

Groups 101-150 claim 13, in part, drawn to an isolated antibody which binds to a protein with SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 101 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein Y is 61.

If group 102 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein Y is 62.

Groups 151-200, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polypeptide of SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 151 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein Y is 61.

If group 152 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein Y is 62.

Groups 201-250, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01386

condition by administering a polynucleotide of SEQ ID NO X encoding a protein of SEQ ID NO Y, wherein X and Y correlate to one of those listed in Table 1, and correspond to one of the cDNA Clone IDs, respectively. For examples,

If group 201 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein X is 11 and Y is 61.

If group 202 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein X is 12 and Y is 62.

Groups 251-300, claim 18, in part, drawn to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 251 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein X is 11.

If group 252 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein X is 12.

Groups 301-350, claim 19, in part, drawn to a method of diagnosis of an undefined pathological condition by determining the presence or amount of expression of the polypeptide of SEQ ID NO y, wherein y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 301 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein y is 61.

If group 302 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein y is 62.

Groups 351-400, claim 20, in part, drawn to a method of identifying a binding partner to a polypeptide defined by SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 351 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein Y is 61.

If group 352 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein Y is 62.

Groups 401-450, claim 22, in part, drawn to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polypeptide encoded by SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 401 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein X is 11.

If group 402 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein X is 12.

Groups 451-500, claim 23, in part, each group directed to a peptide produced by the method for the identifying a binding partner to a polypeptide defined by SEQ ID NO: Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 451 is elected, this correlates to Gene No 1, cDNA clone ID HLDAB75 of Table 1, wherein Y is 60.

If group 452 is elected, this correlates to Gene No 2, cDNA clone ID HDPGT25, wherein Y is 61.

The inventions listed as Groups 1-500 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The polynucleotides and polypeptides of each of the clones in Table 1 are unrelated, each to the other. The polynucleotide sequences encode structurally distinct polypeptides and do not share a special technical feature. Furthermore, the technical feature that links the DNA, protein, antibody, methods of CDNA clone HLDAB75 (see Table 1) is not a contribution over the prior art. See the various documents cited in the search report. Thus the technical feature of the polynucleotide sequence is not special and the groups are not so linked under PCT Rule 13.1. Additionally the claimed methods produce different products and/or different results which are not coextensive and which do not share the same technical feature.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)